
<html lang="en"     class="pb-page"  data-request-id="d2e690da-9496-4f44-bdeb-15df3ddf50ec"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.5b01171;website:website:acspubs;issue:issue:10.1021/jmcmar.2015.58.issue-23;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery and SAR of Novel and Selective Inhibitors of Urokinase Plasminogen Activator (uPA) with an Imidazo[1,2-a]pyridine Scaffold" /></meta><meta name="dc.Creator" content="Rafaela  Gladysz" /></meta><meta name="dc.Creator" content="Yves  Adriaenssens" /></meta><meta name="dc.Creator" content="Hans  De Winter" /></meta><meta name="dc.Creator" content="Jurgen  Joossens" /></meta><meta name="dc.Creator" content="Anne-Marie  Lambeir" /></meta><meta name="dc.Creator" content="Koen  Augustyns" /></meta><meta name="dc.Creator" content="Pieter  Van der Veken" /></meta><meta name="dc.Description" content="Urokinase plasminogen activator (uPA) is a biomarker and therapeutic target for several cancer types. Its inhibition is regarded as a promising, noncytotoxic approach in cancer therapy by blocking ..." /></meta><meta name="Description" content="Urokinase plasminogen activator (uPA) is a biomarker and therapeutic target for several cancer types. Its inhibition is regarded as a promising, noncytotoxic approach in cancer therapy by blocking ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 1, 2015" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.5b01171" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2015 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01171" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.5b01171" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01171" /></link>
        
    
    

<title>Discovery and SAR of Novel and Selective Inhibitors of Urokinase Plasminogen Activator (uPA) with an Imidazo[1,2-a]pyridine Scaffold | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b01171" /></meta><meta property="og:title" content="Discovery and SAR of Novel and Selective Inhibitors of Urokinase Plasminogen Activator (uPA) with an Imidazo[1,2-a]pyridine Scaffold" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/large/jm-2015-01171e_0021.jpeg" /></meta><meta property="og:description" content="Urokinase plasminogen activator (uPA) is a biomarker and therapeutic target for several cancer types. Its inhibition is regarded as a promising, noncytotoxic approach in cancer therapy by blocking growth and/or metastasis of solid tumors. Earlier, we reported the modified substrate activity screening (MSAS) approach and applied it for the identification of fragments with affinity for uPA’s S1 pocket. Here, these fragments are transformed into a novel class of uPA inhibitors with an imidazo[1,2-a]pyridine scaffold. The SAR for uPA inhibition around this scaffold is explored, and the best compounds in the series have nanomolar uPA affinity and selectivity with respect to the related trypsin-like serine proteases (thrombin, tPA, FXa, plasmin, plasma kallikrein, trypsin, FVIIa). Finally, the approach followed for translating fragments into small molecules with a decorated scaffold architecture is conceptually straightforward and can be expected to be broadly applicable in fragment-based drug design." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.5b01171"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01171">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.5b01171&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.5b01171&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.5b01171&amp;href=/doi/10.1021/acs.jmedchem.5b01171" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2015</span><span class="cit-fg-volume">, 58</span><span class="cit-fg-issue">, 23</span><span class="cit-fg-pageRange">, 9238-9257</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/58/23" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.5b01125" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.5b01188" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery and SAR of Novel and Selective Inhibitors of Urokinase Plasminogen Activator (uPA) with an Imidazo[1,2-<i>a</i>]pyridine Scaffold</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rafaela++Gladysz">Rafaela Gladysz</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yves++Adriaenssens">Yves Adriaenssens</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hans++De+Winter">Hans De Winter</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jurgen++Joossens">Jurgen Joossens</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anne-Marie++Lambeir">Anne-Marie Lambeir</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Koen++Augustyns">Koen Augustyns</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Pieter++Van+der+Veken">Pieter Van der Veken</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Laboratory of Medicinal Chemistry (UAMC), Department of Pharmaceutical Sciences, University of Antwerp (UA), Universiteitsplein 1, B-2610 Wilrijk, Antwerp, Belgium</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Medical Biochemistry, Department of Pharmaceutical Sciences, University of Antwerp, Universiteitsplein 1, B-2610 Wilrijk, Antwerp, Belgium</span></div><div class="corresp-info"><strong>*</strong>Phone: +32-3 265 27 08. E-mail: <a href="/cdn-cgi/l/email-protection#04746d617061762a72656a60617672616f616a4471656a7073617674616a2a6661"><span class="__cf_email__" data-cfemail="17677e726372653961767973726561727c72795762767963607265677279397572">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01171&amp;href=/doi/10.1021%2Facs.jmedchem.5b01171" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2015</span></span><span class="cit-volume">, 58</span><span class="cit-issue">, 23</span><span class="cit-pageRange">, 9238–9257</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 17, 2015</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>24 July 2015</li><li><span class="item_label"><b>Published</b> online</span>1 December 2015</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 December 2015</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.5b01171" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01171</a></div><div class="article_header-article-copyright"><strong>Copyright © 2015 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9238%26pageCount%3D20%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DRafaela%2BGladysz%252C%2BYves%2BAdriaenssens%252C%2BHans%2BDe%2BWinter%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D58%26issueNum%3D23%26contentID%3Dacs.jmedchem.5b01171%26title%3DDiscovery%2Band%2BSAR%2Bof%2BNovel%2Band%2BSelective%2BInhibitors%2Bof%2BUrokinase%2BPlasminogen%2BActivator%2B%2528uPA%2529%2Bwith%2Ban%2BImidazo%255B1%252C2-a%255Dpyridine%2BScaffold%26numPages%3D20%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9257%26publicationDate%3DDecember%2B2015">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.5b01171"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1981</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">20</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.5b01171" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery and SAR of Novel and Selective Inhibitors of Urokinase Plasminogen Activator (uPA) with an Imidazo[1,2-a]pyridine Scaffold&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Rafaela&quot;,&quot;last_name&quot;:&quot;Gladysz&quot;},{&quot;first_name&quot;:&quot;Yves&quot;,&quot;last_name&quot;:&quot;Adriaenssens&quot;},{&quot;first_name&quot;:&quot;Hans&quot;,&quot;last_name&quot;:&quot;De Winter&quot;},{&quot;first_name&quot;:&quot;Jurgen&quot;,&quot;last_name&quot;:&quot;Joossens&quot;},{&quot;first_name&quot;:&quot;Anne-Marie&quot;,&quot;last_name&quot;:&quot;Lambeir&quot;},{&quot;first_name&quot;:&quot;Koen&quot;,&quot;last_name&quot;:&quot;Augustyns&quot;},{&quot;first_name&quot;:&quot;Pieter&quot;,&quot;last_name&quot;:&quot;Van der Veken&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2015&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;01&quot;,&quot;issue&quot;:&quot;23&quot;,&quot;volume&quot;:&quot;58&quot;,&quot;pages&quot;:&quot;9238-9257&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.5b01171&quot;},&quot;abstract&quot;:&quot;Urokinase plasminogen activator (uPA) is a biomarker and therapeutic target for several cancer types. Its inhibition is regarded as a promising, noncytotoxic approach in cancer therapy by blocking growth and/or metastasis of solid tumors. Earlier, we reported the modified substrate activity screening (MSAS) approach and applied it for the identification of fragments with affinity for uPA’s S1 pocket. Here, these fragments are transformed into a novel class of uPA inhibitors with an imidazo[1,2-a]pyridine scaffold. The SAR for uPA inhibition around this scaffold is explored, and the best compounds in the series have nanomolar uPA affinity and selectivity with respect to the related trypsin-like serine proteases (thrombin, tPA, FXa, plasmin, plasma kallikrein, trypsin, FVIIa). Finally, the approach followed for translating fragments into small molecules with a decorated scaffold architecture is conceptually straightforward and can be expected to be broadly applicable in fragment-based drug design.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01171&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01171" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01171&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01171" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01171&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01171" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01171&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01171&amp;href=/doi/10.1021/acs.jmedchem.5b01171" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.5b01171" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.5b01171" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.5b01171%26sid%3Dliteratum%253Aachs%26pmid%3D26575094%26genre%3Darticle%26aulast%3DGladysz%26date%3D2015%26atitle%3DDiscovery%2Band%2BSAR%2Bof%2BNovel%2Band%2BSelective%2BInhibitors%2Bof%2BUrokinase%2BPlasminogen%2BActivator%2B%2528uPA%2529%2Bwith%2Ban%2BImidazo%255B1%252C2-a%255Dpyridine%2BScaffold%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D58%26issue%3D23%26spage%3D9238%26epage%3D9257%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292201" title="Scaffolds">Scaffolds</a>,</li><li><a href="/action/doSearch?ConceptID=290676" title="Substituents">Substituents</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/58/23" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/jmcmar.2015.58.issue-23/20151210/jmcmar.2015.58.issue-23.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/medium/jm-2015-01171e_0021.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/large/jm-2015-01171e_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01171&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Urokinase plasminogen activator (uPA) is a biomarker and therapeutic target for several cancer types. Its inhibition is regarded as a promising, noncytotoxic approach in cancer therapy by blocking growth and/or metastasis of solid tumors. Earlier, we reported the modified substrate activity screening (MSAS) approach and applied it for the identification of fragments with affinity for uPA’s S1 pocket. Here, these fragments are transformed into a novel class of uPA inhibitors with an imidazo[1,2-<i>a</i>]pyridine scaffold. The SAR for uPA inhibition around this scaffold is explored, and the best compounds in the series have nanomolar uPA affinity and selectivity with respect to the related trypsin-like serine proteases (thrombin, tPA, FXa, plasmin, plasma kallikrein, trypsin, FVIIa). Finally, the approach followed for translating fragments into small molecules with a decorated scaffold architecture is conceptually straightforward and can be expected to be broadly applicable in fragment-based drug design.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35463" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35463" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Urokinase plasminogen activator (uPA, urokinase) is a trypsin-like serine protease and a therapeutical target for many cancer types, including breast, ovarian, and pancreatic cancer.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1-3)</a> It is part of an extracellular enzyme system overexpressed in metastasizing solid tumors, comprising the urokinase-type plasminogen activator (uPA), the plasminogen activator inhibitors (PAIs), tissue-type plasminogen activator (tPA), and the uPA receptor (uPAR).<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The uPAR is an important regulator of extracellular matrix (ECM) proteolysis, cell-ECM interactions and cell signaling.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Binding of uPA to its receptor activates the enzyme and triggers a proteolytic cascade through which plasminogen is converted into plasmin. This in turn activates matrix metalloproteases (MMPs), leading to proteolytic degradation of the ECM components.<a onclick="showRef(event, 'ref1 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref4">(1, 4)</a> As a result, tumor cells degrade the surrounding tissue, invade into healthy tissue, and migrate with the bloodstream to form metastasized tumors at distant organs. The uPA system also interacts with a number of relevant molecular-biological systems promoting tumor growth: it can activate growth factors and interacts with proteins involved in cell adhesion and signal transduction (vitronectin, integrins).<a onclick="showRef(event, 'ref2 ref4'); return false;" href="javascript:void(0);" class="ref ref2 ref4">(2, 4)</a></div><div class="NLM_p">Although uPA is a valuable oncology target, clinical development of uPA inhibitors has been problematic. This is most probably related to the doubtful biopharmaceutical performance of compounds developed so far and their insufficient selectivity with respect to other, phylogenetically related trypsin-like proteases. Nonetheless, the field of urokinase inhibitor discovery still produces significant numbers of relevant compounds, mostly small molecules with a competitive, reversible inhibition profile. Wilex’s amidine-based inhibitor WX-UK1 (<b>1a</b>, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) and its orally bioavailable prodrug WX-761 (<b>1b</b>, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) are currently the most advanced products. Interestingly, <b>1a</b> (<i>K</i><sub>i</sub> = 410 nM) and <b>1b</b> are the first inhibitors of uPA in oncology trials worldwide. The latter has successfully completed two clinical phase I trials and recently showed favorable results in randomized phase II trial in patients with locally advanced nonmetastatic pancreatic cancer as well as met its primary objective in phase II trial in patients with HER2 receptor negative metastatic breast cancer (MBC).<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Next to compounds developed by Wilex (<b>1a</b>–<b>b</b>), a significant number of optimized inhibitors of urokinase has been reported, but these have only been investigated in preclinical studies. Pfizer reported 1-isoquinolinylguanidine UK-356,202 (<b>2</b>, <i>K</i><sub>i</sub> = 37 nM) and its sulfonamide derivative UK-371,804 (<b>3</b>, <i>K</i><sub>i</sub> = 10 nM) as potent and selective inhibitors of uPA.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> These compounds were selected for preclinical evaluation for the treatment of chronic dermal ulcers, a condition characterized by high levels of uPA promoting uncontrolled matrix breakdown and inhibition of wound repair. As a result, compound <b>3</b> was demonstrated to inhibit exogenous uPA activity both in human chronic wound fluid in vitro, and in the porcine acute excisional wound model.<a onclick="showRef(event, 'cit6c'); return false;" href="javascript:void(0);" class="ref cit6c">(6c)</a> Besides, according to Barber et al., <b>2</b> has been selected for human clinical trials, but apparently these plans have never materialized for unknown reasons.<a onclick="showRef(event, 'cit6a'); return false;" href="javascript:void(0);" class="ref cit6a">(6a)</a> An amidine based, peptide-derived uPA inhibitor CJ-463 (<b>4</b>, <i>K</i><sub>i</sub> = 20 nM) was found to reduce the number of experimental lung metastases in a fibrosarcoma mouse model as well as primary tumor growth and metastasis formation in murine lung carcinoma model.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> A fragment-based approach by Astex led to the discovery of a mexiletine-derived, low basicity inhibitor of uPA (<b>5</b>, IC<sub>50</sub> = 72 nM) with moderate selectivity against closely related proteases and high oral bioavailability.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Abbott Laboratories developed a series of naphthamidine inhibitors of uPA (compound <b>6</b> as a representative example; <i>K</i><sub>i</sub> = 263 nM) with improved pharmacokinetic properties, as good oral bioavailability and extended half-life in rats.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Additionally, the 4-oxazolidinone analogue UK122 (<b>7</b>) was reported by Zhu and co-workers as a selective inhibitor of uPA with significant potency to inhibit the migratory and invasive capacity of pancreatic cancer cells.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/medium/jm-2015-01171e_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/large/jm-2015-01171e_0001.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Reported inhibitors of uPA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/large/jm-2015-01171e_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01171&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Other approaches have been focusing on discovery of irreversible uPA ligands, antibodies, or peptide-based molecules. Our group described a series of highly potent and selective, irreversible diaryl phosphonate inhibitors of uPA (<b>8a</b>, IC<sub>50</sub> = 3.1 ± 0.5 nM; and <b>8b</b>, IC<sub>50</sub> = 3.4 ± 0.4 nM) with significant antimetastatic activity in a rodent model of breast cancer.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Mazar and co-workers invented a novel therapeutic uPAR antibody ATN-658 demonstrating antitumor effects across a variety of tumor models, including inhibition of invasion, metastasis, and proliferation as well as induction of apoptosis.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Additionally, bicyclic peptide constructs were recently reported as highly potent uPA inhibitors.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Nonetheless, given all the preclinical evidence mentioned, it is remarkable that none of the compounds were developed clinically.</div><div class="NLM_p">This study focuses on the discovery of a novel class of reversible, nonpeptide derived uPA inhibitors with an imidazo[1,2-<i>a</i>]pyridine scaffold. It directly furthers on an earlier publication in which we reported an optimized version of substrate activity screening (SAS), an approach pioneered by Ellman and co-workers for the discovery of fragments with affinity for the active center of enzymes. Our “modified substrate activity screening” (MSAS) approach was validated by identifying several fragment-sized ligands of the uPA S1 pocket.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> As hypothesized in this earlier report, an S1-binding fragment could be transformed into a druglike uPA inhibitor by grafting it onto a suitable scaffold and by further decorating this scaffold with additional affinity-conferring substituents. This hypothesis will be extensively investigated here and corroborated with the preparation of potent uPA inhibitors. Because, to the best of our knowledge, no earlier examples of imidazopyridine inhibitors of urokinase have been reported, evaluation of the inhibitory potencies under the assay conditions of this manuscript will include the reference compounds <b>7</b>, gabexate (<b>9</b>), and amiloride (<b>10</b>) (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/medium/jm-2015-01171e_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/large/jm-2015-01171e_0002.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Inhibitory activities of the reference compounds against uPA determined under the assay conditions of this manuscript.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/large/jm-2015-01171e_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01171&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The S1-binding fragments used in this study were demonstrated in our earlier report to possess high micromolar uPA affinity. Their structures are summarized in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A. It is noteworthy that our earlier publication already included a proof-of-concept example where fragment <b>R</b><sup><b>1b</b></sup> was grafted onto the 3-position of an imidazopyridine scaffold. A comparison of the IC<sub>50</sub> values of the separate and the scaffolded fragment indicated the imidazopyridine system to be a novel, potentially useful scaffold for uPA inhibitors.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/medium/jm-2015-01171e_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/large/jm-2015-01171e_0003.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Overview of the strategy followed for the preparation of potent uPA inhibitors with an imidazopyridine scaffold.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/large/jm-2015-01171e_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01171&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The general strategy that was followed in this study for obtaining potent uPA inhibitors consists of two parts. In the first part (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B, step 1), a set of imidazo[1,2-<i>a</i>]pyridines was prepared, each bearing one of the S1-binding fragments (<b>R</b><sup><b>1a</b>–<b>h</b></sup>). The choice to introduce the S1-binders at the 3-position of the imidazopyridine was mainly governed by practical synthetic considerations (vide infra), although our earlier proof-of-concept work already indicated this to be a viable approach for preparing compounds with appreciable uPA-affinity. Comparison of the target potencies of the monosubstituted scaffolds obtained in this manner was then used to identify the optimal S1-binding substituent. Further optimization (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B, step 2) was achieved by combining the optimal S1-substituent with additional substituents (R<sup>2</sup> and R<sup>3</sup>) on the imidazopyridine ring system. Although we extensively relied on molecular modeling to guide the selection of the R<sup>2</sup> and R<sup>3</sup> substituents, diversification in terms of steric and electronic parameters was an equally important goal.</div><div class="NLM_p">The key step in the preparation of all target compounds of this study is the so-called Groebke–Blackburn–Bienaymé condensation, a variant of the Ugi reaction, reported for the first time in 1998.<a onclick="showRef(event, 'ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17">(15-17)</a> It is based on the three-component coupling of (1) an isocyanide, (2) an aldehyde, and (3) a 2-aminoazine in the presence of a suitable catalyst, usually a Lewis acid or Brønsted acid, to generate fused imidazo[1,2-<i>a</i>]heterocycles in a one-pot transformation. Taking into account the limited number of commercially available isocyanides and their often nonstraightforward synthesis, we considered the latter reaction component the least suited as a source of molecular diversity. As mentioned, this practical consideration was instrumental to reserve the isocyanide-derived R<sup>1</sup> group for the S1-binding fragments identified in the MSAS hits. Conversely, aldehydes are commercially available in abundant numbers. Therefore, the aldehyde-derived R<sup>2</sup>-substituent was deemed an appropriate source of steric and electronic diversity. Finally, we also found the commercial availability of decorated 2-aminopyridines to be rather limited. Nonetheless, a significant number of 2-aminopyridines equipped with functional groups (e.g., carboxylates, halides) that can easily be derivatized using standard chemical transformations were found to be available. This approach was used to generate sufficient diversity in the produced compound series.</div><div class="NLM_p last">On a general level, imidazo[1,2-<i>a</i>]pyridines have already been applied successfully as scaffold moieties in drug discovery, and the Groebke–Blackburn–Bienaymé reaction represents one of the simplest routes for the diversity-oriented synthesis of this pharmacophore. Compounds of this type have been in clinical investigation for various therapeutic targets, resulting in several drugs entering the market, as for instance the hypnotic GABA<sub>A</sub> receptor ligand zolpidem, the selective phosphodiesterase 3 (PDE3) inhibitor olprinone, or the CXC chemokine receptor 4 (CXCR4) antagonist GSK812397.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Our group, to the best of our knowledge, is the first to report the application of an imidazo[1,2-<i>a</i>]pyridine scaffold for the construction of uPA inhibitors. Next to producing novel and potent uPA-inhibitors, this study also discloses a significant amount of structure–activity relationship data for this class of compounds. Finally, the present study also successfully exemplifies a novel strategy for transforming low-affinity fragments into potent, druglike compounds with a decorated scaffold architecture. Theoretically, the same strategy (fragment scaffolding, followed by optimization through diversity-oriented introduction of additional substituents) could be applied for all targets where a fragment-based approach to drug discovery is followed.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85245" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85245" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">First, the set of imidazo[1,2-<i>a</i>]pyridines linked with S1-binding fragments <b>R</b><sup><b>1a</b>–<b>h</b></sup> was synthesized relying on the Groebke–Blackburn–Bienaymé (GBB) reaction (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/medium/jm-2015-01171e_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/large/jm-2015-01171e_0005.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Steps Leading to the Monosubstituted Scaffold-Based Inhibitors <b>14h</b>, <b>15a</b>–<b>g</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/large/jm-2015-01171e_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01171&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) ethyl formate, TEA, 55 °C, 24 h, 55–90%; (b) POCl<sub>3</sub>, DIPA, DCM, 60–85%; (c) pyridin-2-amine, glyoxylic acid monohydrate, HClO<sub>4</sub> (cat.), MeOH, rt, 24 h, 38–66%; (d) TFA/DCM (1:1), rt, 1 h, 95–100%.</p></p></figure><div class="NLM_p">The isocyanides (<b>13a</b>–<b>h</b>) required for this reaction were synthesized from amines <b>11a</b>–<b>h</b> by consecutive formylation and dehydration. The formylation reaction was carried out by refluxing the corresponding amines overnight in ethyl formate and in the presence of triethylamine as previously described by Hartman et al.,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> to afford the desired formamides (<b>12a</b>–<b>h</b>) in 55–90% yield. Dehydration in the presence of POCl<sub>3</sub> led to the formation of the isocyanides (<b>13a</b>–<b>h</b>) in low to moderate yields. Careful optimization of the reaction conditions, including the nature of base and the reaction medium, were therefore necessary. Following the protocol described by Ugi et al., we replaced triethylamine by diisopropylamine, which increased not only the average yields (60–85%) but also purity, making chromatographic purification in some cases avoidable.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Detailed experimental procedures and characterization data for preparation of amines <b>11a</b>–<b>h</b>, formamides <b>12a</b>–<b>h</b>, and isocyanides <b>13a</b>–<b>h</b> can be found in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>.</div><div class="NLM_p">For obtaining the monosubstituted imidazopyridines (R<sup>2</sup> = R<sup>3</sup> = H), the GBB-reaction requires formaldehyde as the aldehyde component. However, the scope of this nonconcerted [4 + 1] cycloaddition is rather limited for formaldehyde.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21, 22)</a> This is due to formation of unstable imines, resulting in poor conversions. Our initial attempts to use formaldehyde hydrate and paraformaldehyde as potential formaldehyde equivalents did not produce satisfactory results and afforded the desired product in poor yields (<30%). Following the protocol reported by Kercher et al.,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> we then applied glyoxylic acid as a formaldehyde equivalent and reacted it with 2-aminopyridine and the set of isocyanides. Glyoxylic acid was indeed found to be an efficient and experimentally more convenient reagent. Further optimization of the original experimental protocol was achieved by using HClO<sub>4</sub> as the catalyst and MeOH as the solvent. This resulted in conditions applicable to all isocyanides that were evaluated and yields for the desired products (<b>14h</b>, <b>15a</b>–<b>g</b>) ranging between 38 and 65% yield. All reactions were completed within 24 h.</div><div class="NLM_p">Evaluation of the uPA inhibitory potency of these monosubstituted imidazo[1,2-<i>a</i>]pyridines revealed that the most potent analogues were guanidinophenyl derivatives <b>15a</b> and <b>15b</b> (bearing fragments <b>R</b><sup><b>1a</b></sup> and <b>R</b><sup><b>1b</b></sup>) (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). These displayed IC<sub>50</sub> values of 9.04 ± 0.62 and 19.39 ± 1.22 μM, respectively. The hypothetical binding modes of these closely related molecules were investigated by docking studies. Results suggested the guanidine side chain of both compounds to interact through hydrogen bonds with Gly-219, Ser-190, and as reasonably expectable, with the anionic carboxylate function of uPA’s Asp189 (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). In addition, a hydrogen bond between the amine nitrogen of the imidazopyridine ring system and the catalytically important Ser-195 is also predicted both in the case of compounds <b>15a</b> and <b>15b</b> (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). A helicopter view of the predicted binding of compound <b>15a</b> within the active site pocket of uPA is given in <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>a, showing complementarity between ligand and pocket. The guanidine moiety of the compound is deeply buried in the active site, while the imidazole nitrogen of the imidazopyridine ring system is pointing into the solvent and not participating in any hydrogen bonding to the protein. The imidazopyridine scaffold in these simulations was found not to contribute to target affinity via directed interactions with the enzyme, although it also does not negatively interfere with binding of <b>15a</b> and <b>15b</b> to the active center.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Biochemical Evaluation of the Monosubstituted Analogues <b>14h</b>, <b>15a</b>–<b>g</b> against uPA</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/medium/jm-2015-01171e_0009.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/medium/jm-2015-01171e_0010.gif" alt="" id="GRAPHIC-d133e685-autogenerated" /></img><div></div></div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/medium/jm-2015-01171e_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/large/jm-2015-01171e_0004.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Predicted binding mode of compounds <b>15a</b> (light brown) and <b>15b</b> (yellow) in the active site of uPA (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2O8W">2O8W</a>). Proposed hydrogen bonds between ligands and labeled protein residues are indicated by yellow dashed lines. Both compounds overlay quite well and show an almost identical binding pattern.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/large/jm-2015-01171e_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01171&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/medium/jm-2015-01171e_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/large/jm-2015-01171e_0023.jpeg" id="GRAPHIC-d133e737-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Helicopter view of uPA’s active site (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2O8W">2O8W</a>) showing the proposed binding mode of compound <b>15a</b> (a), compound <b>25a</b> (b), and compounds <b>25b</b>–<b>f</b> (c). The protein surface is colored white, while the surface generated by residue Ser-195 is colored red, and the surface generated by residues Ser-190, Asp-189, and Gly-219 is colored green. Putative hydrogen bonds are shown as dashed yellow lines. Docking of compound <b>25a</b> (b) reveals an additional hydrogen bond between the ligand and the hydroxyl group of Tyr-151 (colored blue). The R<sup>4</sup> group (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>) of compound <b>25a</b> is colored green and has been docked using idealized geometrical bond and torsion angles.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/large/jm-2015-01171e_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01171&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The significant potency of <b>15a</b> and <b>15b</b> also reflects the ranking of their corresponding S1-fragments <b>R</b><sup><b>1a</b></sup> and <b>R</b><sup><b>1b</b></sup> during the modified SAS (MSAS) experiments mentioned earlier, where both displayed among the highest affinities in the collection of “hits”. For the other inhibitors in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, however, the translation of fragment ranking data into potency of the corresponding imidazopyridine inhibitors seems less straightforward. In general, affinities for compounds <b>14h</b> and <b>15c</b>–<b>g</b> are in the high micromolar range. It is noteworthy that the presence of a guanidinobutyl fragment in <b>15c</b> did not lead to potent inhibition despite this fragment’s resemblance to the arginine side chain that is used by uPA for recognition of its natural substrates. Likewise, the aminoethoxyphenyl fragments present in <b>15d</b> and <b>15e</b> displayed satisfactory potency during our earlier MSAS experiments but did not result in potent imidazopyridine inhibitors. In addition, these fragments also occur in mexiletine analogue and/or its like, and both of them were confirmed as ligands of uPA’s S1 pocket using X-ray crystallography.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Comparable discrepancy is present for the dichlorophenoxy fragment in <b>14h</b>; while this moiety was ranked close to <b>R</b><sup><b>1a</b></sup> and <b>R</b><sup><b>1b</b></sup> in the MSAS experiments, grafting it onto an imidazopyridine scaffold leads to a relatively poor inhibitor. Finally, evaluation data for the aminomethyl-substituted <b>15f</b> and <b>15g</b> also demonstrated these compounds to be weak uPA inhibitors. Taken together, these biochemical evaluation data led to prioritization of <b>15a</b> and <b>15b</b> in the optimization effort. The slightly higher uPA potency, lower molecular weight, and reduced conformational flexibility of <b>15a</b> were decisive for focusing on this compound during optimization by introducing additional substituents on different positions of the monosubstituted scaffold.</div><div class="NLM_p">Optimization of the initial hit <b>15a</b> began with investigating the influence of an additional substituent at the 2-position of the imidazo[1,2-<i>a</i>]pyridine scaffold (compounds <b>17a</b>–<b>k</b>, <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). For preparing these compounds, we reacted 2-aminopyridine and the corresponding isocyanide <b>13a</b> with different commercially available aldehydes (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Selection of the latter was mainly done in a nontarget-biased manner, aiming to cover as much of druglike chemical space as possible by taking steric, electronic and electrostatic parameters into account.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Biochemical Evaluation of the 2-Substituted-3-amino-imidazo[1,2-<i>a</i>]pyridines Set <b>17a</b>–<b>k</b> against uPA</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/medium/jm-2015-01171e_0011.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/medium/jm-2015-01171e_0012.gif" alt="" id="GRAPHIC-d133e858-autogenerated" /></img><div></div></div><figure id="sch2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/medium/jm-2015-01171e_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/large/jm-2015-01171e_0006.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Analogues Modified at the 2-Position <b>17a</b>–<b>k</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/large/jm-2015-01171e_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01171&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) HClO<sub>4</sub> (cat.), MeOH, rt, 24 h, 22–86%; (b) TFA/DCM (1:1), rt, 1 h, 94–100%.</p></p></figure><div class="NLM_p">Preparation of the 2-substituted-3-amino-imidazo[1,2-<i>a</i>]pyridines followed the classical GBB reaction experimental protocol.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Reactions were performed in MeOH and included preformation of the imine intermediate in the presence of a catalytic amount of HClO<sub>4</sub> in order to suppress byproducts formation. Although the applied experimental protocol in most cases gave satisfactory results (60–86% yield), reaction with some aliphatic aldehydes (e.g., propionaldehyde, 2-aminoacetaldehyde, 3-chlorophenylacetaldehyde) led to poor or moderate yields for compounds <b>16d</b>–<b>f</b> (49%, 32%, and 22%, respectively), while 2-methoxyaldehyde and 3-(2,4-dichlorophenyl)propanal failed to react under these conditions. Additionally, two analogues of <b>15b</b> (<b>19a</b> and <b>19b</b>) with a guanidinophenethyl substituent at the 3-position were prepared for comparison of the inhibitory potency (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). Compound <b>19a</b> has an ethyl substituent at the 2-position of the imidazo[1,2-<i>a</i>]pyridine ring, whereas analogue <b>19b</b> is comprising of the imidazo[1,2-<i>a</i>]pyrazine core and carries a 3-chlorophenyl substituent at the 2-position. Preparation of compounds <b>19a</b> and <b>19b</b> involved the previously used GBB reaction protocol affording intermediates <b>18a</b> and <b>18b</b> in moderate yields (54 and 49%, respectively).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Biochemical Evaluation of the C3-Guanidinophenethyl-Substituted Analogues <b>19a</b>, <b>19b</b> against uPA</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/medium/jm-2015-01171e_0013.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/medium/jm-2015-01171e_0014.gif" alt="" id="GRAPHIC-d133e949-autogenerated" /></img><div></div></div><div class="NLM_p">Most of the performed GBB reactions were complete within 24 h. The final step involved a simple Boc deprotection to afford the desired products in quantitative yields in the form of TFA-salts.</div><div class="NLM_p">The uPA potency of the prepared set of 2-substituted analogues was then evaluated (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). In general, most of the compounds within the 2-substituted imidazo[1,2-<i>a</i>]pyridines set displayed reduced uPA affinity. Especially aromatic substituents and sterically demanding aliphatic substituents at the 2-position were not favorable. This detrimental effect is tentatively explained by the computational model used (vide supra), suggesting that sterically demanding substituents at the 2-position increase the internal conformational energy when the compound is in a conformation that is optimal for binding to the uPA S1 pocket. For instance, the 3-pyridyl (<b>17a</b>), 3-fluophenyl (<b>17j</b>), 4-fluophenyl (<b>17k</b>), and 3,5-dichlorophenyl (<b>17h</b>) analogues have IC<sub>50</sub> values ≥100 μM, indicating at least 10-fold decrease in potency in comparison to the initial hit <b>15a</b>. The same is true for the 4-piperidinyl-substituted compound <b>17g</b>, displaying an IC<sub>50</sub> of more than 100 μM. Interestingly, the benzylic substituents in <b>17c</b> and <b>17f</b> caused a relatively less pronounced affinity decrease in comparison to <b>15a</b>, probably due to increased conformational flexibility. Finally, only the aminomethyl-substituted compound <b>17e</b> retained the initial binding affinity with an IC<sub>50</sub> value of 9.30 ± 2.67 μM.</div><div class="NLM_p">The guanidinophenethyl derivatives <b>19a</b>, 1<b>9b</b> followed a grossly comparable potency pattern (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>), although <b>19a</b>’s significant drop in potency compared to <b>15b</b> cannot be readily rationalized by taking only steric factors into account.</div><div class="NLM_p">Before evaluation data for the 2-substituted imidazo[1,2-<i>a</i>]pyridines set were obtained (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>), we decided to explore substitution at the C6–C8 position conserving the 2-pyridyl substituent (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). The reason to conserve the latter was inspired by the practically very straightforward synthesis and purification of the compound.</div><figure id="sch3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/medium/jm-2015-01171e_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/large/jm-2015-01171e_0007.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Analogues <b>22a</b>–<b>i</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/large/jm-2015-01171e_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01171&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) HClO<sub>4</sub> (cat.), MeOH, rt, 24 h, 25–68% (in case of compound <b>21d</b> (i) methyl 2-aminopyridine-4-carboxylate, TBD, DMF, 120 °C, 20 h, 52.5%, (ii) HClO<sub>4</sub> (cat.), MeOH, rt, 24 h, 60%); compound <b>21h</b> (i) methyl 6-aminonicotinate, TBD, DMF, 120 °C, 24 h, 42%, (ii) HClO<sub>4</sub> (cat), MeOH, rt, 24 h, 47%); (b) TFA/DCM (1:1), rt, 1 h, 94–100% (in case of compound <b>22c</b> (i) NaOH (2 M), DCM/MeOH (9:1), 12 h, rt, 69%, (ii) TFA/DCM (1:1), rt, 1 h, 93%).</p></p></figure><div class="NLM_p">Nine additional 2-(3-pyridyl) analogues (<b>22a</b>–<b>i</b>) (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>) were prepared by varying the aminopyridine reaction partner of the GBB reaction. Aminopyridine building blocks were either commercially available or synthesized separately. Accordingly, 2-amino-<i>N</i>-butylisonicotinamide (<b>20a</b>) and 6-amino-<i>N</i>-butylnicotinamide (<b>20b</b>) used for the preparation of compounds <b>22d</b> and <b>22h</b> were synthesized by the aminolysis reaction in the presence of an organocatalyst (1,5,7- triazabicyclo[4.4.0]dec-5-ene, TBD), as reported by Kiesewetter et al.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>, entry 2). Details on the preparation of the latter can be found in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Biochemical Evaluation of the C2 3-Pyridyl Substituted Analogues <b>22a</b>–<b>i</b> against uPA</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/medium/jm-2015-01171e_0015.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/medium/jm-2015-01171e_0016.gif" alt="" id="GRAPHIC-d133e1125-autogenerated" /></img><div></div></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Conditions Applied to Amide Bond Formation</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/medium/jm-2015-01171e_0017.gif" alt="" id="fx5" /></img><div></div></div><div class="NLM_p">It is noteworthy that aminopyridines substituted at the 4- or 5-position (e.g., compounds <b>21d</b> and <b>21i</b>) provided better yields in the GBB reaction (60 and 68%, respectively), whereas 2-aminopyridines substituted at the 3- or 6-position performed worse or failed to react under these conditions. For instance, reaction with 3-methylpyridin-2-amine provided <b>21a</b> only in 25% yield, and 3-(trifluoromethyl)pyridin-2-amine was found not to react at all under these conditions. Replacing the reaction solvent (MeOH) by the non-nucleophilic trifluoroethanol, as originally proposed by Bienaymé et al., still did not afford the desired product.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><div class="NLM_p">The uPA-evaluation results of inhibitors <b>22a</b>–<b>i</b> are presented in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>. These demonstrate that the detrimental effect of the 2-pyridyl substituent on uPA potency, as observed with <b>17a</b>, can be significantly reduced by introducing additional affinity-conferring substituents (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>) on the scaffold. Nonetheless, the position of a substituent was found to have a significant effect on inhibitory activity. Generally, analogues substituted at the 7-position of the imidazopyridine scaffold displayed a higher affinity than compounds bearing a substituent at the 6-position. For instance, the C7 methyl carboxylate moiety in <b>22b</b> caused an increase of binding affinity of almost 1 order of magnitude relative to <b>17a</b>. Replacement of the 7-methyl carboxylate group by an <i>N</i>-butylcarboxamide group in <b>22d</b> leads to a further increase in affinity. On the other hand, introducing the <i>N</i>-butylcarboxamide at the 6-position resulted in analogue <b>22h</b> with a significantly reduced uPA affinity (60.84 ± 3.39 μM) compared to <b>22d</b>. Also compounds with C6 electron-withdrawing groups like trifluoromethyl- and fluoro-substituted analogues <b>22f</b> and <b>22g</b> displayed reduced inhibitory potency (IC<sub>50</sub> ∼ 200 μM and IC<sub>50</sub> = 57.55 ± 6.58 μM, respectively).</div><div class="NLM_p">Again, the more favorable results of the 7-substituted congeners can be tentatively explained by a molecular docking study. <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a> clearly indicates that the 6-position of the imidazopyridine scaffold approaches the surface of the pocket and might therefore be compatible with only very small substituent types. On the contrary, the 7-position is more accessible for attaching alternative substituents.</div><div class="NLM_p">After obtaining the evaluation results, we decided to synthesize a set imidazo[1,2-<i>a</i>]pyridines lacking the 2-pyridyl substituent but with diverse amide groups at the scaffold’s 7-position (compounds <b>25a</b>–<b>f</b>). The <i>N</i>-butylcarboxamide substituent that was already present in <b>22d</b> was included in this series.</div><div class="NLM_p">The synthetic strategy for these molecules involved formation of the required amide substituent via aminolysis of methyl 2-amino-pyridin-4-carboxylate prior to the GBB reaction with glyoxylic acid and isocyanide <b>13a</b> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). Although this strategy does not introduce molecular diversity during the final synthetic step, it was deemed preferable for two reasons. First, the aminolysis reaction was found to require harsh reaction conditions (high temperature and pressure, long reaction times) that were not compatible with the labile di-Boc-protecting groups of the guanidine function, resulting in poor yields of the desired product (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>, entry 1). Second, performing the GBB further on in the synthesis allowed us to reduce the reaction scale and therefore consume less of the synthetically more demanding guanidinophenyl-derived isocyanide <b>13a</b>. Again, the aminolysis was carried out in the presence of TBD. Optimization of the experimental conditions used for preparation of amides <b>20a</b>–<b>b</b> (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>, entry 2) revealed that by reacting methyl 2-aminopyridine-4-carboxylate with a 2-fold excess of the amine component, increasing the catalyst amount (0.3 equiv) and performing the reaction in dry toluene at 110 °C, the desired amides (<b>23a</b>–<b>e</b>) were obtained in very good to excellent yields and without the need of chromatographic purification (exemplified in <a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>, entry 4). The devised protocol does not require protection of the amino group in aminopyridine and was found to be applicable with comparable outcome to methyl 2-aminopyridine-3-carboxylate, methyl 6-aminopyridine-3-carboxylate. Detailed experimental procedures and characterization data for amides <b>23a</b>–<b>e</b> can be found in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. Next to aminolysis, direct coupling of 2-aminopyridine-4-carboxylate with the corresponding amine in DMF in the presence of EDC and HOBt was also tried. However, this also returned the desired amide only in 10% yield (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>, entry 5).</div><figure id="sch4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/medium/jm-2015-01171e_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/large/jm-2015-01171e_0008.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of the Amide-Substituted Analogues <b>25a</b>–<b>f</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/large/jm-2015-01171e_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01171&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) TBD, toluene, 110 °C, 20 h, 86–97% (in case of compound <b>20a</b> TBD, DMF, 120 °C, 20 h, 52.5%); (b) glyoxylic acid monohydrate, isocyanide <b>13a</b>, HClO<sub>4</sub> (cat.), MeOH, rt, 6 h, 42–61%; (c) TFA/DCM (1:1), rt, 1 h, 96–100%.</p></p></figure><div class="NLM_p">The prepared amide-substituted aminopyridines were then reacted with glyoxylic acid and isocyanide <b>13a</b> following the previously used GBB reaction protocol (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). Interestingly, reactions involving 2-aminopyridines with 4-substituent proceeded faster and most of them were complete within 6 h. Products of the three-component coupling (3CC) <b>24a</b>–<b>f</b> were then subjected to a simple Boc deprotection to afford the desired compounds in the form of TFA-salts, or in case of compound <b>25e</b>, HCl-salt. Finally, six analogues (<b>25a</b>–<b>f</b>) were synthesized in moderate yields (42–60%) (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Biochemical Evaluation of the Amide-Substituted Analogues <b>25a</b>–<b>f</b> against uPA</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/medium/jm-2015-01171e_0018.gif" alt="" id="fx6" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/medium/jm-2015-01171e_0019.gif" alt="" id="GRAPHIC-d133e1344-autogenerated" /></img><div></div></div><div class="NLM_p">Affinities of compounds within this series were in the nanomolar range, indicating an optimal substitution pattern for the scaffold-based uPA inhibitors. The most potent analogue <b>25a</b> (IC<sub>50</sub> = 97 ± 10 nM) displays an increase in uPA affinity of about 2 orders of magnitude relative to initial hit <b>15a</b>. Similar potency was demonstrated by the cyclopropylamide-substituted analogue <b>25b</b> (IC<sub>50</sub> = 184 ± 7 nM), whereas the 2-(4-methylpiperazine) ethylamide group in compound <b>25f</b> (IC<sub>50</sub> = 404 ± 20 nM) caused a 4-fold affinity decrease in comparison to <b>25a</b>. The modeling study of the <i>N</i>-butylamide fragment of compound <b>25a</b> in the active site of uPA highlights the available space in this region (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>b). Besides, formation of an additional hydrogen bond between the amide nitrogen of the <i>N</i>-butylamide fragment and the hydroxyl group of Tyr-151 can be observed and could potentially explain the increase in binding affinity that is observed when comparing compound <b>25a</b> with compound <b>15a</b> (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>a,b). The modeling study of compounds <b>25b</b>–<b>f</b> revealed similar interactions occurring in the uPA’s active site (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>c). This additional interaction might also contribute favorably to the compounds’ selectivity with respect to related proteases (vide infra).</div><div class="NLM_p">Kinetic analysis of the identified inhibitors <b>25a</b>–<b>f</b> indicated that these are reversible, tight-binding, slow-dissociating inhibitors of uPA. In addition, selectivity of the most potent analogues for uPA was determined with respect to a panel of closely related proteases (tissue-type plasminogen activator (tPA), thrombin, factor Xa (FXa), plasmin, plasma kallikrein, trypsin, and factor VIIa (FVIIa)). The results are summarized in <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>. Compound <b>15a</b> was found to be at least 10-fold more selective for uPA than for the other assayed enzymes, while the amide-substituted compounds <b>25a</b>–<b>f</b> were found selective over all specified enzymes. High specificity of these compounds for uPA can probably be related to interacting with Tyr in position 151 of uPA (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>b,c). Compound <b>25a</b> demonstrated the best affinity as well as selectivity profile among this set: with an IC<sub>50</sub> > 100 μM for all of the related enzymes, this compound has a uPA selectivity index of more than 10<sup>3</sup>.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Inhibitory Activities against uPA and Related Enzymes (Including the Reference Compounds: <b>7</b>, gabexate (<b>9</b>), amiloride (<b>10</b>))</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="8" align="center" char="±">IC<sub>50</sub> [μM] or % of enzyme inhibition at 100 μM concentration<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char="±">uPA</th><th class="colsep0 rowsep0" align="center">thrombin</th><th class="colsep0 rowsep0" align="center">tPA</th><th class="colsep0 rowsep0" align="center">FXa</th><th class="colsep0 rowsep0" align="center">plasmin</th><th class="colsep0 rowsep0" align="center">plasma kallikrein</th><th class="colsep0 rowsep0" align="center">trypsin</th><th class="colsep0 rowsep0" align="center" char=".">FVIIa</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="char" char="±">8.67 ± 1.12</td><td class="colsep0 rowsep0" align="center">56.1 ± 3.65</td><td class="colsep0 rowsep0" align="center">68.51 ± 5.05</td><td class="colsep0 rowsep0" align="center">6.47 ± 0.58</td><td class="colsep0 rowsep0" align="center">0.34 ± 0.01</td><td class="colsep0 rowsep0" align="center">1.34 ± 0.19</td><td class="colsep0 rowsep0" align="center">3.18 ± 0.17</td><td class="colsep0 rowsep0" align="char" char=".">0%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="char" char="±">0.431 ± 0.017</td><td class="colsep0 rowsep0" align="center">0.687 ± 0.048</td><td class="colsep0 rowsep0" align="center">15.36 ± 0.94</td><td class="colsep0 rowsep0" align="center">4.61 ± 0.54</td><td class="colsep0 rowsep0" align="center">1.55 ± 0.06</td><td class="colsep0 rowsep0" align="center">1.35 ± 0.24</td><td class="colsep0 rowsep0" align="center">7.12 ± 0.13</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="char" char="±">11.98 ± 0.22</td><td class="colsep0 rowsep0" align="center">5.2%</td><td class="colsep0 rowsep0" align="center">1%</td><td class="colsep0 rowsep0" align="center">3.5%</td><td class="colsep0 rowsep0" align="center">0%</td><td class="colsep0 rowsep0" align="center">0%</td><td class="colsep0 rowsep0" align="center">31.76 ± 2.88</td><td class="colsep0 rowsep0" align="char" char=".">7.4%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15a</b></td><td class="colsep0 rowsep0" align="char" char="±">9.04 ± 0.62</td><td class="colsep0 rowsep0" align="center">23%</td><td class="colsep0 rowsep0" align="center">33.6%</td><td class="colsep0 rowsep0" align="center">42%</td><td class="colsep0 rowsep0" align="center">29.8%</td><td class="colsep0 rowsep0" align="center">39.4%</td><td class="colsep0 rowsep0" align="center">114.88 ± 6.78</td><td class="colsep0 rowsep0" align="char" char=".">2.5%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17a</b></td><td class="colsep0 rowsep0" align="char" char="±">250 ± 2.23</td><td class="colsep0 rowsep0" align="center">6.6%</td><td class="colsep0 rowsep0" align="center">9.4%</td><td class="colsep0 rowsep0" align="center">24.6%</td><td class="colsep0 rowsep0" align="center">0%</td><td class="colsep0 rowsep0" align="center">0%</td><td class="colsep0 rowsep0" align="center">3.3%</td><td class="colsep0 rowsep0" align="char" char=".">0%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25a</b></td><td class="colsep0 rowsep0" align="char" char="±">0.097 ± 0.010</td><td class="colsep0 rowsep0" align="center">19.2%</td><td class="colsep0 rowsep0" align="center">8%</td><td class="colsep0 rowsep0" align="center">41.8%</td><td class="colsep0 rowsep0" align="center">13.6%</td><td class="colsep0 rowsep0" align="center">2.8%</td><td class="colsep0 rowsep0" align="center">42.7%</td><td class="colsep0 rowsep0" align="char" char=".">1.4%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25b</b></td><td class="colsep0 rowsep0" align="char" char="±">0.184 ± 0.007</td><td class="colsep0 rowsep0" align="center">8%</td><td class="colsep0 rowsep0" align="center">0%</td><td class="colsep0 rowsep0" align="center">45.4%</td><td class="colsep0 rowsep0" align="center">3.3%</td><td class="colsep0 rowsep0" align="center">0%</td><td class="colsep0 rowsep0" align="center">46%</td><td class="colsep0 rowsep0" align="char" char=".">2.6%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25c</b></td><td class="colsep0 rowsep0" align="char" char="±">0.254 ± 0.016</td><td class="colsep0 rowsep0" align="center">19.5%</td><td class="colsep0 rowsep0" align="center">11.9%</td><td class="colsep0 rowsep0" align="center">45.7%</td><td class="colsep0 rowsep0" align="center">8.3%</td><td class="colsep0 rowsep0" align="center">0%</td><td class="colsep0 rowsep0" align="center">43.2%</td><td class="colsep0 rowsep0" align="char" char=".">4.2%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25d</b></td><td class="colsep0 rowsep0" align="char" char="±">0.174 ± 0.021</td><td class="colsep0 rowsep0" align="center">17.8%</td><td class="colsep0 rowsep0" align="center">11.2%</td><td class="colsep0 rowsep0" align="center">47.8%</td><td class="colsep0 rowsep0" align="center">0%</td><td class="colsep0 rowsep0" align="center">0%</td><td class="colsep0 rowsep0" align="center">37.1%</td><td class="colsep0 rowsep0" align="char" char=".">4%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25e</b></td><td class="colsep0 rowsep0" align="char" char="±">0.366 ± 0.017</td><td class="colsep0 rowsep0" align="center">4.7%</td><td class="colsep0 rowsep0" align="center">0%</td><td class="colsep0 rowsep0" align="center">51.58 ± 2.39</td><td class="colsep0 rowsep0" align="center">15.6%</td><td class="colsep0 rowsep0" align="center">0%</td><td class="colsep0 rowsep0" align="center">43.3%</td><td class="colsep0 rowsep0" align="char" char=".">5%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25f</b></td><td class="colsep0 rowsep0" align="char" char="±">0.404 ± 0.020</td><td class="colsep0 rowsep0" align="center">6.6%</td><td class="colsep0 rowsep0" align="center">2.8%</td><td class="colsep0 rowsep0" align="center">12.2%</td><td class="colsep0 rowsep0" align="center">0%</td><td class="colsep0 rowsep0" align="center">0%</td><td class="colsep0 rowsep0" align="center">32%</td><td class="colsep0 rowsep0" align="char" char=".">2%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="char" char="±">57.49 ± 5.20</td><td class="colsep0 rowsep0" align="center">0%</td><td class="colsep0 rowsep0" align="center">0%</td><td class="colsep0 rowsep0" align="center">0%</td><td class="colsep0 rowsep0" align="center">0%</td><td class="colsep0 rowsep0" align="center">0%</td><td class="colsep0 rowsep0" align="center">38.8%</td><td class="colsep0 rowsep0" align="char" char=".">0%</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last">The IC<sub>50</sub> values and % of enzyme inhibition were determined under the assay conditions of this manuscript.</p></div></div></div><div class="NLM_p last">Besides, because the phenylguanidine (<b>26</b>) fragment is an essential part of the identified inhibitors, we decided to check its contribution to selectivity. Given the fact that no inhibition of thrombin, tPA, FXa, plasmin, plasma kallikrein, and FVIIa was observed at 100 μM concentration of compound <b>26</b>, we can conclude that indeed the phenylguanidine fragment is crucial for selectivity of the identified inhibitors for uPA.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84113" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84113" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In conclusion, we have developed a straightforward synthetic strategy for the synthesis of substituted imidazo[1,2-<i>a</i>]pyridines as efficient and selective uPA inhibitors. To the best of our knowledge, this is the first reported application of an imidazo[1,2-<i>a</i>]pyridine scaffold to the discovery of uPA inhibitors. Compounds <b>25a</b>–<b>f</b> have nanomolar uPA potencies and are among the most selective inhibitors reported to date. The presence of a guanidine group in <b>25a</b>–<b>f</b> might nonetheless be seen as a liability for further development. If required, a prodrug strategy involving the use of a hydroxyguanidine precursor could offer an effective way to overcome bioavailability issues of this kind. Finally, this study presents a novel and efficient strategy for transforming low-affinity fragments into potent, druglike compounds with a decorated scaffold architecture. The same strategy can be readily applied to inhibitor discovery for other enzyme targets.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68745" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68745" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Chemistry</h3><div class="NLM_p">Reagents were obtained from Sigma-Aldrich, Acros, Fluorochem, or Apollo Scientific and were used without further purification. Synthesized compounds were characterized by <sup>1</sup>H NMR, <sup>13</sup>C NMR, and mass spectrometry. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded with a Bruker Avance DRX 400 spectrometer and analyzed by use of MestReNova analytical chemistry software. Chemical shifts are in ppm, and coupling constants are in hertz (Hz). Purities were determined with two diverse UHPLC systems based either on mass detection or on UV detection. All final products have a purity of at least 95%, with the exception of compound <b>15c</b> (purity: 90%). A Waters acquity UPLC system coupled to a Waters TUV detector and a Waters TQD ESI mass spectrometer was used. A Waters Acquity UPLC BEH C18 1.7 μm, 2.1 mm × 50 mm column was used. Solvent A, water with 0.1% formic acid; solvent B, acetonitrile with 0.1% formic acid. Method I: 0.7 mL/min, 0.15 min 95% A, 5% B then in 1.85 min from 95% A, 5% B to 100% B, 0% A, then 0.25 min, 100% B, 0% A, 0.75 min (0.350 mL/min) 95% A, 5% B. Method II (purity method): 0.4 mL/min, 0.15 min 95% A, 5% B then in 4.85 min from 95% A, 5% B to 100% B, 0% A, then 0.25 min, 100% B, 0% A, 0.75 min 95% A, 5% B. The wavelength for UV detection was 254 nm.</div><div class="NLM_p">Where necessary, flash purification was performed with a Biotage ISOLERA One flash system equipped with an internal variable dual-wavelength diode array detector (200–400 nm). SNAP cartridges were used for normal phase purifications KP-Sil (10 g, 25 g, 50 g, flow rate of 10–50 mL/min) and for reversed phase purifications KP-C18-HS (12 g, 30 g, flow rate of 10–30 mL/min). Dry sample loading was done by self-packing samplet cartridges using silica and Celite 545, respectively, for normal and reversed phase purifications. Gradients used varied for each purification.</div><div class="NLM_p">HRMS involved the following: The dry samples were dissolved in 1 mL of methanol to obtain 10 mM stock solutions and next diluted 100-fold with methanol to a final concentration of 10 μM. Then 10 μL of each sample was injected using the CapLC system (Waters, Manchester, UK) and electrosprayed using a standard electrospray source. Samples were injected with an interval of 3 min. Positive ion mode accurate mass spectra were acquired using a Q-TOF II instrument (Waters, Manchester, UK). The mass spectrometer was calibrated prior to use with a 0.2% H<sub>3</sub>PO<sub>4</sub> solution. The spectra were lock-mass-corrected using the known mass of the nearest H<sub>3</sub>PO<sub>4</sub> cluster.</div><div class="NLM_p">Melting points were determined with a Buchi 530 melting point apparatus and are uncorrected.</div><div class="NLM_p">The following section comprises the synthetic procedures and analytical data for intermediates and all final compounds reported in this manuscript. Most of the final products were obtained in the form of TFA salts. All TFA-related resonances are omitted in the <sup>13</sup>C NMR characterization. Additional data, including tables and schemes for the synthesis of intermediates en route to final compounds, can be found in the <a href="/doi/suppl/10.1021/acs.jmedchem.5b01171/suppl_file/jm5b01171_si_001.pdf" class="ext-link">Supporting Information</a>. The experimental procedures for all the steps in the synthesis of several final products are summarized here as the general procedures.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> General Prodecure A (Formamide Synthesis)</h4><div class="NLM_p last">To a round-bottomed flask fitted with a reflux condenser were added the corresponding amine (13.50 mmol) and ethyl formate (20 equiv). The reaction mixture was stirred and heated under reflux while triethylamine (1.5 equiv) was added. After overnight stirring under reflux, the reaction was completed. Subsequently, volatiles were evaporated and the crude product was redissolved in DCM (50 mL). The resulting solution was washed with H<sub>2</sub>O (50 mL) and then with brine (50 mL). The organic phase was separated, dried over anhydrous MgSO<sub>4</sub>, and condensed under reduced pressure. In some cases, further purification was avoidable, otherwise the corresponding formamide was purified using and Isolera purification system with a gradient of 20–100% of EtOAc in heptane, affording the corresponding formamides <b>12a</b>–<b>h</b> in 55–90% yield.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> General Prodecure B (Isocyanide Synthesis)</h4><div class="NLM_p last">To a suspension of formamide (4.08 mmol) in dry DCM (25 mL) was added diisopropylamine (2.7 equiv), and the reaction mixture was stirred at 0 °C under a nitrogen atmosphere. To this solution POCl<sub>3</sub> (1.1 equiv) was slowly added through a syringe, and stirring was continued for 1 h at 0 °C and then for 2 h at rt. After completion of the reaction, a solution of Na<sub>2</sub>CO<sub>3</sub> in water (2 g/20 mL) was slowly added to maintain 25–30 °C. Stirring was continued for 1 h at rt. More water (20 mL) and DCM (50 mL) was added. The organic phase was separated, dried over anhydrous MgSO<sub>4</sub>, and concentrated under reduced pressure. In some cases further purification was avoidable, otherwise the corresponding isocyanide was purified using an Isolera purification system with a gradient of 0–50% of EtOAc in heptane, affording the corresponding isocyanides <b>13a</b>–<b>h</b> in 60–85% yield.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> General Prodecure C (TBD-Catalyzed Aminolysis Reaction)</h4><div class="NLM_p last">To a solution of methyl 2-aminopyridine-4-carboxylate (0.5 g, 3.29 mmol) in dry toluene (10 mL) were added amine (2.2 equiv) and 1,5,7-triazabicyclo[4.4.0]dec-5-ene (TBD) (0.137 g, 0.986 mmol, 0.3 equiv), and the reaction mixture was stirred in a pressure tube at 110 °C for 20 h. After that time, the reaction mixture was cooled down and stirred at ambient temperature for a few hours. The desired product precipitated in the form of white crystals, which were next filtered and washed with cold diethyl ether (3 × 20 mL). The desired amides <b>23a</b>–<b>e</b> were obtained in very good to excellent yields (86–97%) and without the need of chromatographic purification.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> General Prodecure D (Preparation of Substituted Imidazo[1,2-<i>a</i>]pyridines Using the Groebke–Blackburn–Bienaymé (GBB) Reaction)</h4><div class="NLM_p last">To a solution 2-aminoazine (e.g., 1.104 mmol) in MeOH (10 mL), aldehyde (or formaldehyde equivalent: glyoxylic acid monohydrate, 1.5 equiv)) and HClO<sub>4</sub> (cat.) (70% aq solution, 8.48 μL, 0.1 equiv) were added at rt, and the reaction was left stirring for 30 min. After that time, the isonitrile component (1.1 equiv) was introduced, and the reaction mixture was stirred at ambient temperature until it was completed, usually for 5–24 h. After that time, the reaction mixture was concentrated under reduced pressure and the crude product was directly purified using an Isolera purification system with a gradient varying by purification, usually 20–100% of EtOAc in heptane (1.5% TEA). In some cases, reversed phase purification was used and applied gradient of 10–100% of MeOH in water. The general procedure D was used to prepare compounds <b>14a</b>–<b>h</b>, <b>16a</b>–<b>k</b>, <b>18a</b>–<b>b</b>, <b>21a</b>–<b>i</b>, and <b>24a</b>–<b>f</b>.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> General Prodecure E (Standard Procedure for Deprotection of Boc Groups Using TFA/DCM)</h4><div class="NLM_p last">Product of the GBB reaction (0.195 mmol) containing a basic function protected with the Boc group was dissolved in a mixture of DCM (1.5 mL) and TFA (1.5 mL) in a 1:1 ratio, and the reaction mixture was stirred at rt for 1 h. After that time, volatiles were evaporated and the obtained product was washed with diethyl ether (2 × 10 mL), yielding pure final compound in the form of TFA-salt.</div></div><div id="sec4_1_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 1-(4-(Aminomethyl)phenyl)-2,3-di-Boc-guanidine (<b>11a</b>)</h4><div class="NLM_p last">To a solution of 4-(aminomethyl)aniline (0.6 g, 4.91 mmol) in 10% aq acetic acid (40 mL) was added a solution of (<i>Z</i>)-<i>tert</i>-butyl(((<i>tert</i>-butoxycarbonyl)amino)(1<i>H</i>-pyrazol-1-yl)methylene)carbamate (1.68 g, 5.40 mmol) in 1,4-dioxane (40 mL). After overnight stirring at rt, water (100 mL) was added and the mixture was washed with diethyl ether (3 × 60 mL). The aqueous phase was basicified with 2 M NaOH to pH 13 and extracted with ethyl acetate (3 × 75 mL). The combined extract was washed with water (2 × 50 mL), dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to give the expected product <b>11a</b> in a form of white solid (0.46 g, 80%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.65 (s, 1H), 10.31 (s, 1H), 7.56 (d, <i>J</i> = 8.5 Hz, 2H), 7.27 (d, <i>J</i> = 8.5 Hz, 2H), 3.83 (s, 2H), 1.54 (s, 9H), 1.51 (s, 9H). UPLC/MS: <i>t</i><sub>r</sub> 1.94 min, <i>m</i>/<i>z</i> 365.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 1-(4-(Aminoethyl)phenyl)-2,3-di-Boc-guanidine (<b>11b</b>)</h4><div class="NLM_p last">The title compound was prepared from 4-(aminoethyl)aniline (0.3 g, 2.203 mmol) using the same synthetic procedure that was applied to the preparation of 1-(4-(aminomethyl)phenyl)- <i>N</i>,<i>N</i>′-bis-Boc-guanidine (<b>11a</b>), yielding a colorless oil (0.65 g, 78%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.64 (s, 1H), 10.26 (s, 1H), 7.50 (d, <i>J</i> = 8.4 Hz, 2H), 7.15 (d, <i>J</i> = 8.4 Hz, 2H), 3.07–2.86 (m, 2H), 2.72 (t, <i>J</i> = 6.0 Hz, 2H), 1.53 (s, 9H), 1.49 (s, 9H). UPLC/MS: <i>t</i><sub>r</sub> 1.60 min, <i>m</i>/<i>z</i> 379.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 1-(4-Aminobutyl)-2,3-di-Boc-guanidine (<b>11c</b>)</h4><div class="NLM_p last">To a solution of tetramethylenediamine (1.14 mL, 11.34 mmol) in 20:1 mixture of THF (16 mL) and H<sub>2</sub>O (0.8 mL) was added dropwise a solution of <i>N</i>,<i>N</i>′-bis-Boc-methylisothiourea (1.098 g, 3.78 mmol) in THF (10 mL) at 25 °C. After addition, the reaction was heated at 50 °C for 2 h, and then the solvent was evaporated under reduced pressure. The resulting crude was partitioned between DCM and saturated aq NaHCO<sub>3</sub>. The organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to give the desired product (<b>11c</b>) in a form of cloudy oil (1.05 g, 85%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.45 (brs, 1H), 8.30 (s, 1H), 3.44–3.31 (m, 2H), 2.69 (t, <i>J</i> = 6.6 Hz, 2H), 1.63–1.52 (m, 2H), 1.51–1.37 (m, 20H). UPLC/MS: <i>t</i><sub>r</sub> 1.51 min, <i>m</i>/<i>z</i> 331.6 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 3,5-Dichloro-4-(2-(Boc-amino)ethoxy)aniline (<b>11e</b>)</h4><div class="NLM_p">Amine <b>11e</b> was obtained in three synthetic steps from the previously prepared starting material. Step 1: Preparation of <i>N</i>-Cbz-4-amino-2,6-dichlorophenol (standard Cbz-protection procedure). To a suspension of 4-amino-2,6-dichlorophenol (2.2 g, 12.36 mmol) and NaHCO<sub>3</sub> (1.142 g, 13.59 mmol, 1.1 equiv) in THF (20 mL), benzyl chloroformate (1.669 mL, 11.74 mmol) was added dropwise at 0 °C. The reaction was left stirring overnight. After that time, EtOAc (70 mL) was added and the organic layer was extracted with 2 M HCl (50 mL), washed with brine, dried over anhydrous MgSO<sub>4</sub>, and evaporated under reduced pressure. The title compound was purified using an Isolera purification system with a gradient of 0–20% of EtOAc in heptane to afford <i>N</i>-Cbz-4-amino-2,6-dichlorophenol (2 g, 52%).</div><div class="NLM_p">Step 2: Preparation of 3,5-dichloro-<i>N</i>-Cbz-4-(2-(Boc-amino)ethoxy)aniline. To a solution of <i>N</i>-Boc-2-bromoethanamine (2.202 g, 8.84 mmol) in DMF (40 mL), <i>N</i>-Cbz-4-amino-2,6-dichlorophenol (2.3 g, 7.37 mmol) was added. To this reaction mixture, K<sub>2</sub>CO<sub>3</sub> (2.037 g, 14.74 mmol) was added in portions. After 4 h stirring at 60 °C, the reaction was completed. The reaction mixture was quenched with water, and the aqueous phase was extracted with EtOAc (3 × 50 mL). The combined organic extract was washed with water (50 mL), then with brine (50 mL), dried over anhydrous MgSO<sub>4</sub>, and concentrated under reduced pressure to afford a transparent oil. The title compound was purified using an Isolera purification system with a gradient of 0–25% of EtOAc in heptane (1.7 g, 51%).</div><div class="NLM_p last">Step 3: 3,5-Dichloro-4-(2-(Boc-amino)ethoxy)aniline (<b>11e</b>) (standard hydrogenolysis procedure). First, 3,5-dichloro-<i>N</i>-Cbz-4-(2-(Boc-amino)ethoxy)aniline (1.5 g, 3.29 mmol) was dissolved in MeOH (30 mL). After 30 min of bubbling nitrogen gas through the solution, Pd/C (0.631 g, 2.96 mmol) was added, and the reaction was flushed again for 15 min with nitrogen before hydrogen gas was added via a balloon. The reaction was stirred under a hydrogen atmosphere for 50 min. The obtained product was purified using an Isolera purification system with a gradient of 10–100% of EtOAc in heptane to afford the title amine (0.835 g, 75%). The product was directly used in the next step, formamide synthesis.</div></div><div id="sec4_1_5_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> (1<i>R</i>,4<i>R</i>)-4-((Boc-amino)methyl)cyclohexan-1-amine (<b>11g</b>)</h4><div class="NLM_p last">To a solution of (1<i>R</i>,4<i>R</i>)-4-((Boc-amino)methyl)cyclohexane-1-carboxylic acid (2.15 g, 8.36 mmol) in anhydrous THF (25 mL) stirred under a nitrogen atmosphere were added triethylamine (2.329 mL, 16.71 mmol, 2 equiv) and diphenylphosphonic azide (2.7 mL, 12.53 mmol, 1.5 equiv). The reaction mixture was stirred under reflux for 1 h for full conversion of the starting material to occur. The reaction mixture was cooled down, solvent was evaporated under vacuum, and the obtained residue was redissolved in a small amount of THF. The obtained solution was poured into a 2 M NaOH aq (50 mL) and stirred for 1 h at rt. Next, EtOAc (75 mL) was added and the aqueous phase was washed thoroughly with EtOAc (3 × 75 mL). The organic phase was dried over anhydrous MgSO<sub>4</sub> and concentrated under reduced pressure and washed with a small portion of cold diethyl ether (30 mL) to afford the desired amine as a white solid (1.73 g, 82%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 2.81–2.67 (m, 3H), 1.91–1.78 (m, 2H), 1.70–1.58 (m, 2H), 1.37 (s, 9H), 1.30–1.08 (m, 3H), 0.94–0.78 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 155.72, 77.35, 49.51, 45.58, 36.85, 30.67, 28.28, 28.23. UPLC/MS: <i>t</i><sub>r</sub> 1.14 min, <i>m</i>/<i>z</i> 229.1 [M + H]<sup>+</sup>, 457.4 [2M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 2-(2,4-Dichlorophenoxy)ethanamine (<b>11h</b>)</h4><div class="NLM_p last">To a solution of 2,4-dichlorophenol (0.58 g, 3.56 mmol) in DMF (20 mL) were added <i>N</i>-Boc-2-bromoethanamine (0.957 g, 4.27 mmol, 1.2 equiv) and K<sub>2</sub>CO<sub>3</sub> (0.984 g, 7.12 mmol, 2 equiv). After overnight stirring at 60 °C, the reaction was quenched with water and the aqueous phase was extracted with EtOAc (3 × 50 mL). The combined organic extract was washed with water (50 mL), then with brine (50 mL), dried over anhydrous MgSO<sub>4</sub>, and concentrated under reduced pressure to yield the desired product in a form of transparent oil which rapidly crystallized into white solid material (1.02 g, 65.5%). Next, the obtained <i>N</i>-Boc-(2-(2,4-dichlorophenoxy)ethaneamine (1 g, 3.27 mmol) was dissolved in 1:1 mixture of TFA and DCM and the reaction mixture was stirred for 1 h at rt. After that time, volatiles were evaporated under reduced pressure, affording the title amine (<b>11h</b>) in quantitative yield in the form of TFA salt (1.493 g, 100%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.97 (brs, 3H), 7.32 (d, <i>J</i> = 2.5 Hz, 1H), 7.16 (dd, <i>J</i> = 8.8, 2.5 Hz, 1H), 6.82 (d, <i>J</i> = 8.8 Hz, 1H), 4.20 (t, <i>J</i> = 5 Hz, 2H), 3.48–3.37 (m, 2H). UPLC/MS: <i>t</i><sub>r</sub> 1.43 min, <i>m</i>/<i>z</i> 206.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> <i>N</i>-(4-(2,3-Di-Boc-guanidino)benzyl)formamide (<b>12a</b>)</h4><div class="NLM_p last">The title compound was prepared using the general procedure A to afford a white solid in 68% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.61 (s, 1H), 10.29 (s, 1H), 8.17 (s, 1H), 7.53 (d, <i>J</i> = 8.5 Hz, 2H), 7.22 (d, <i>J</i> = 8.4 Hz, 2H), 6.07 (s, 1H), 4.39 (d, <i>J</i> = 5.8 Hz, 2H), 1.53 (s, 9H), 1.48 (s, 9H). UPLC/MS: <i>t</i><sub>r</sub> 2.00 min, <i>m</i>/<i>z</i> 393.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> <i>N</i>-(4-(2,3-Di-Boc-guanidino)phenethyl)formamide (<b>12b</b>)</h4><div class="NLM_p last">The title compound was prepared using the general procedure A to afford a white solid in 55% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.62 (s, 1H), 10.26 (s, 1H), 8.06 (s, 1H), 7.49 (d, <i>J</i> = 8.5 Hz, 2H), 7.14 (d, <i>J</i> = 8.5 Hz, 2H), 5.82 (brs, 1H), 3.51 (q, <i>J</i> = 6.5 Hz, 2H), 2.79 (t, <i>J</i> = 6.7 Hz, 2H), 1.53 (s, 9H), 1.49 (s, 9H). UPLC/MS: <i>t</i><sub>r</sub> 2.16 min, <i>m</i>/<i>z</i> 407.5 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> <i>N</i>-(4-(2,3-Di-Boc-guanidino)butyl)formamide (<b>12c</b>)</h4><div class="NLM_p last">The title compound was prepared using the general procedure A to afford a white solid in 56.7% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.49 (s, 1H), 8.29 (t, <i>J</i> = 5.5 Hz, 1H), 7.99 (s, 1H), 3.31–3.22 (m, 2H), 3.15–3.02 (m, 2H), 1.55–1.30 (m, 22H). UPLC/MS: <i>t</i><sub>r</sub> 1.83 min, <i>m</i>/<i>z</i> 359.6 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> <i>N</i>-(4-(2-(Boc-amino)ethoxy)phenyl)formamide (<b>12d</b>)</h4><div class="NLM_p last">The title compound was prepared using the general procedure A to afford a white solid in 90% yield. <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.01 (s, 1H), 8.19 (d, <i>J</i> = 1.9 Hz, 1H), 7.52–7.45 (m, 2H), 6.98 (t, <i>J</i> = 5.3 Hz, 1H), 6.93–6.85 (m, 2H), 3.91 (t, <i>J</i> = 5.9 Hz, 2H), 3.26 (q, <i>J</i> = 5.8 Hz, 2H), 1.38 (s, 9H). UPLC/MS: <i>t</i><sub>r</sub> 1.54 min, <i>m</i>/<i>z</i> 281.2 [M + H]<sup>+</sup>, 561.4 [2M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> <i>N</i>-(3,5-Dichloro-4-(2-(Boc-amino)ethoxy)phenyl)formamide (<b>12e</b>)</h4><div class="NLM_p last">The title compound was prepared using the general procedure A to afford a yellow solid in 72% yield. The product was directly used in the next step, isocyanide synthesis.</div></div><div id="sec4_1_5_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> <i>N</i>-(4-((Boc-amino)methyl)phenyl)formamide (<b>12f</b>)</h4><div class="NLM_p last">The title compound was prepared using the general procedure A to afford a white solid in 56% yield. <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.13 (s, 1H), 8.24 (s, 1H), 7.51 (d, <i>J</i> = 8.4 Hz, 2H), 7.32 (brs, 1H), 7.17 (d, <i>J</i> = 8.5 Hz, 2H), 4.06 (d, <i>J</i> = 6.1 Hz, 2H), 1.38 (s, 9H). UPLC/MS: <i>t</i><sub>r</sub> 1.51 min, <i>m</i>/<i>z</i> 251.3 [M + H]<sup>+</sup>, 501.3 [2M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> <i>N</i>-((1<i>R</i>,4<i>R</i>)-4-((Boc-amino)methyl)cyclohexyl)formamide (<b>12g</b>)</h4><div class="NLM_p last">The title compound was prepared using the general procedure A to afford a white solid in 57% yield. <sup>1</sup>H NMR (400 MHz, DMSO) δ 7.91 (m, 1H), 6.80 (t, <i>J</i> = 5.6 Hz, 1H), 3.60–3.40 (m, 1H), 2.75 (t, <i>J</i> = 6.3 Hz, 2H), 1.83–1.60 (m, 4H), 1.37 (s, 9H), 1.33–1.02 (m, 3H), 0.98–0.81 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 159.98, 155.70, 77.30, 46.55, 45.77, 37.10, 31.86, 28.95, 28.27. UPLC/MS: <i>t</i><sub>r</sub> 1.45 min, <i>m</i>/<i>z</i> 257.1 [M + H]<sup>+</sup>, 513.4 [2M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> <i>N</i>-(2-(2,4-Dichlorophenoxy)ethyl)formamide (<b>12h</b>)</h4><div class="NLM_p last">The title compound was prepared using the general procedure A to afford a white solid in 62.2% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.18 (s, 1H), 7.30 (s, 1H), 7.12 (d, <i>J</i> = 8.8 Hz, 1H), 6.79 (d, <i>J</i> = 8.8 Hz, 1H), 4.03 (t, <i>J</i> = 5.1 Hz, 2H), 3.68 (q, <i>J</i> = 5.3 Hz, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 161.60, 152.73, 130.00, 127.78, 126.41, 123.70, 114.49, 68.19, 37.37. UPLC/MS: <i>t</i><sub>r</sub> 1.98 min, <i>m</i>/<i>z</i> 234.0 [M + H]<sup>+</sup>, 469.1 [2M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 1-(4-(Isocyanomethyl)phenyl)-2,3-di-Boc-guanidine (<b>13a</b>)</h4><div class="NLM_p last">The title compound was prepared using the general procedure B to afford a white solid in 85% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.63 (s, 1H), 10.39 (s, 1H), 7.66 (d, <i>J</i> = 8.6 Hz, 2H), 7.29 (d, <i>J</i> = 8.7 Hz, 2H), 4.59 (s, 2H), 1.54 (s, 9H), 1.50 (s, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 163.53, 153.61, 153.41, 137.17, 128.53, 127.35, 122.61, 84.01, 79.89, 45.23, 28.28, 28.18. UPLC/MS: <i>t</i><sub>r</sub> 2.44 min, <i>m</i>/<i>z</i> 375.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 1-(4-(2-Isocyanoethyl)phenyl)-2,3-di-Boc-guanidine (<b>13b</b>)</h4><div class="NLM_p last">The title compound was prepared using the general procedure B to afford a white solid in 63% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.63 (s, 1H), 10.33 (s, 1H), 7.57 (d, <i>J</i> = 8.5 Hz, 2H), 7.18 (d, <i>J</i> = 8.5 Hz, 2H), 3.57 (t, <i>J</i> = 7.1 Hz, 2H), 2.95 (t, <i>J</i> = 7.1 Hz, 2H), 1.53 (s, 9H), 1.50 (s, 9H). UPLC/MS: <i>t</i><sub>r</sub> 2.43 min, <i>m</i>/<i>z</i> 389.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 1-(4-Isocyanobutyl)-2,3-di-Boc-guanidine (<b>13c</b>)</h4><div class="NLM_p last">The title compound was prepared using the general procedure B to afford a white solid in 65% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.48 (s, 1H), 8.35 (s, 1H), 3.52–3.38 (m, 4H), 1.80–1.67 (m, 4H), 1.49 (d, <i>J</i> = 1.9 Hz, 18H). UPLC/MS: <i>t</i><sub>r</sub> 2.22 min, <i>m</i>/<i>z</i> 341.6 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 2-(4-Isocyanophenoxy)-<i>N</i>-Boc-ethanamine (<b>13d</b>)</h4><div class="NLM_p last">The title compound was prepared using the general procedure B to afford a white solid in 70% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.33–7.27 (m, 2H), 6.88–6.83 (m, 2H), 4.01 (t, <i>J</i> = 5.2 Hz, 2H), 3.53 (q, <i>J</i> = 5.3 Hz, 2H), 1.44 (s, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 162.92, 158.99, 155.95, 127.93, 119.91, 115.17, 79.85, 67.66, 40.03, 28.49. UPLC/MS: <i>t</i><sub>r</sub> 1.79 min, <i>m</i>/<i>z</i> 263.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 2-(2,6-Dichloro-4-isocyanophenoxy)-<i>N</i>-Boc-ethanamine (<b>13e</b>)</h4><div class="NLM_p last">The title compound was prepared using the general procedure B to afford a white solid in 73% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.36 (s, 2H), 4.11 (t, <i>J</i> = 5.0 Hz, 2H), 3.54 (q, <i>J</i> = 5.2 Hz, 2H), 1.45 (s, 9H).</div></div><div id="sec4_1_5_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 1-(4-Isocyanophenyl)-<i>N</i>-Boc-methanamine (<b>13f</b>)</h4><div class="NLM_p last">The title compound was prepared using the general procedure B to afford a white solid in 68% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.36–7.27 (m, 4H), 4.94 (s, 1H), 4.32 (d, <i>J</i> = 5.7 Hz, 2H), 1.45 (s, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 164.14, 155.97, 140.95, 128.32, 126.69, 80.06, 44.14, 28.49. UPLC/MS: <i>t</i><sub>r</sub> 1.84 min, <i>m</i>/<i>z</i> 233.0 [M + H]<sup>+</sup>, 465.2 [2M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 1-((1<i>R</i>,4<i>R</i>)-4-Isocyanocyclohexyl)-<i>N</i>-Boc-methanamine (<b>13g</b>)</h4><div class="NLM_p last">The title compound was prepared using the general procedure B to afford a white solid in 80% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.59 (brs, 1H), 3.42–3.29 (m, 1H), 2.95 (t, <i>J</i> = 6.5 Hz, 2H), 2.22–2.11 (m, 2H), 1.87–1.71 (m, 2H), 1.63–1.31 (m, 12H), 1.02–0.85 (m, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 156.12, 154.14, 79.38, 52.10, 45.86, 36.99, 32.83, 28.49, 28.22. UPLC/MS: <i>t</i><sub>r</sub> 1.81 min, <i>m</i>/<i>z</i> 239.0 [M + H]<sup>+</sup>, 477.3 [2M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 2,4-Dichloro-1-(2-isocyanoethoxy)benzene (<b>13h</b>)</h4><div class="NLM_p last">The title compound was prepared using the general procedure B to afford a white solid in 60% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.39 (d, <i>J</i> = 2.5 Hz, 1H), 7.20 (dd, <i>J</i> = 8.8, 2.5 Hz, 1H), 6.87 (d, <i>J</i> = 8.8 Hz, 1H), 4.21 (t, <i>J</i> = 5.6 Hz, 2H), 3.84 (t, <i>J</i> = 5.6 Hz, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 159.02, 152.49, 130.52, 127.86, 127.55, 124.79, 115.53, 67.24, 41.28. UPLC/MS: <i>t</i><sub>r</sub> 2.58 min, <i>m</i>/<i>z</i> 216.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 1-(4-((Imidazo[1,2-<i>a</i>]pyridin-3-ylamino)methyl)phenyl)-2,3-di-Boc-guanidine (<b>14a</b>)</h4><div class="NLM_p last">The title compound was prepared according to the general procedure D from pyridin-2-amine, glyoxylic acid monohydrate, and isocyanide <b>13a</b> (0.35 g, 47.5%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.61 (s, 1H), 10.32 (s, 1H), 8.24 (d, <i>J</i> = 6.9 Hz, 1H), 7.56 (d, <i>J</i> = 9.1 Hz, 1H), 7.50–7.35 (m, 3H), 7.26 (d, <i>J</i> = 8.5 Hz, 2H), 7.05 (td, <i>J</i> = 6.9, 1.0 Hz, 1H), 6.83 (s, 1H), 4.20 (s, 2H), 1.54 (s, 9H), 1.43 (s, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 154.39, 138.09, 135.93, 135.14, 132.63, 128.42, 128.19, 123.58, 123.50, 114.55, 114.46, 84.35, 80.14, 49.97, 28.24. UPLC/MS: <i>t</i><sub>r</sub> 1.92 min, <i>m</i>/<i>z</i> 481.4 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 1-(4-((Imidazo[1,2-<i>a</i>]pyridin-3-ylamino)ethyl)phenyl)-2,3-di-Boc-guanidine (<b>14b</b>)</h4><div class="NLM_p last">The title compound was prepared according to the general procedure D from pyridin-2-amine, glyoxylic acid monohydrate, and isocyanide <b>13b</b> (0.40 g, 64%). UPLC/MS: <i>t</i><sub>r</sub> 2.07 min, <i>m</i>/<i>z</i> 495.6 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 1-(4-(Imidazo[1,2-<i>a</i>]pyridin-3-ylamino)butyl)-2,3-di-Boc-guanidine (<b>14c</b>)</h4><div class="NLM_p last">The title compound was prepared according to the general procedure D using pyridin-2-amine, glyoxylic acid monohydrate, and isocyanide <b>13c</b> (0.28 g, 42%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 11.50 (s, 1H), 8.33 (t, <i>J</i> = 5.4 Hz, 1H), 8.13 (d, <i>J</i> = 6.9 Hz, 1H), 7.43 (d, <i>J</i> = 9.1 Hz, 1H), 7.10 (ddd, <i>J</i> = 9.1, 6.6, 1.1 Hz, 1H), 6.95 (s, 1H), 6.87 (td, <i>J</i> = 6.8, 1.0 Hz, 1H), 5.40 (t, <i>J</i> = 5.6 Hz, 1H), 3.37–3.26 (m, 2H), 3.14–3.01 (m, 2H), 1.69–1.51 (m, 4H), 1.43 (s, 9H), 1.33 (s, 9H). UPLC/MS: <i>t</i><sub>r</sub> 1.76 min, <i>m</i>/<i>z</i> 447.6 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> <i>N</i>-(4-(2-(Boc-amino)ethoxy)phenyl)imidazo[1,2-<i>a</i>]pyridin-3-amine (<b>14d</b>)</h4><div class="NLM_p last">The title compound was prepared according to the general procedure D using pyridin-2-amine, glyoxylic acid monohydrate, and isocyanide <b>13d</b> (0.42 g, 65%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.87 (dt, <i>J</i> = 6.8, 1.2 Hz, 1H), 7.62 (dt, <i>J</i> = 9.1, 1.1 Hz, 1H), 7.50 (s, 1H), 7.24–7.18 (m, 1H), 6.83–6.70 (m, 3H), 6.53–6.46 (m, 2H), 5.44 (s, 1H), 4.99 (brs, 1H), 3.93 (t, <i>J</i> = 5.1 Hz, 2H), 3.52–3.44 (m, 2H), 1.44 (s, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 156.04, 152.72, 142.96, 139.25, 127.65, 125.34, 124.30, 123.10, 117.73, 115.97, 115.06, 112.76, 79.63, 67.89, 40.30, 28.53. UPLC/MS: <i>t</i><sub>r</sub> 1.37 min, <i>m</i>/<i>z</i> 369.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> <i>N</i>-(3,5-Dichloro-4-(2-(Boc-amino)ethoxy)phenyl)imidazo[1,2-<i>a</i>]pyridin-3-amine (<b>14e</b>)</h4><div class="NLM_p last">The title compound was prepared according to the general procedure D using pyridin-2-amine, glyoxylic acid monohydrate, and isocyanide <b>13e</b> (0.26 g, 42%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.92 (dt, <i>J</i> = 6.8, 1.1 Hz, 1H), 7.69 (d, <i>J</i> = 9.1 Hz, 1H), 7.54 (s, 1H), 7.34–7.28 (m, 1H), 6.91 (td, <i>J</i> = 6.8, 0.9 Hz, 1H), 6.52 (s, 2H), 5.80 (s, 1H), 5.18 (s, 1H), 4.01 (t, <i>J</i> = 5.0 Hz, 2H), 3.56–3.44 (m, 2H), 1.45 (s, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 156.22, 144.10, 143.91, 142.88, 130.24, 129.99, 125.20, 122.54, 121.73, 118.39, 113.67, 112.94, 79.53, 72.81, 50.92, 28.55. UPLC/MS: <i>t</i><sub>r</sub> 1.55 min, <i>m</i>/<i>z</i> 437.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> <i>N</i>-(4-((Boc-amino)methyl)phenyl)imidazo[1,2-<i>a</i>]pyridin-3-amine (<b>14f</b>)</h4><div class="NLM_p last">The title compound was prepared according to the general procedure D from pyridin-2-amine, glyoxylic acid monohydrate, and isocyanide <b>13f</b> (0.40g, 66%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.00 (s, 1H), 7.95 (d, <i>J</i> = 6.8 Hz, 1H), 7.60 (dt, <i>J</i> = 9.1, 1.0 Hz, 1H), 7.51 (s, 1H), 7.30 (ddd, <i>J</i> = 9.1, 6.7, 1.2 Hz, 1H), 7.23 (t, <i>J</i> = 6.0 Hz, 1H), 7.02 (d, <i>J</i> = 8.4 Hz, 2H), 6.95 (td, <i>J</i> = 6.8, 1.0 Hz, 1H), 6.50 (d, <i>J</i> = 8.4 Hz, 2H), 3.98 (d, <i>J</i> = 6.1 Hz, 2H), 1.37 (s, 9H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 155.68, 144.59, 141.71, 128.28, 126.21, 124.71, 124.10, 123.17, 117.04, 113.08, 112.37, 77.58, 42.91, 28.26. UPLC/MS: <i>t</i><sub>r</sub> 1.38 min, <i>m</i>/<i>z</i> 339.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> <i>N</i>-((1<i>R</i>,4<i>R</i>)-4-((Boc-amino)methyl)cyclohexyl)imidazo[1,2-<i>a</i>]pyridin-3-amine (<b>14g</b>)</h4><div class="NLM_p last">The title compound was prepared according to the general procedure D from pyridin-2-amine, glyoxylic acid monohydrate, and isocyanide <b>13g</b> (0.26 g, 43%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.19 (d, <i>J</i> = 6.9 Hz, 1H), 7.68 (d, <i>J</i> = 9.1 Hz, 1H), 7.42–7.33 (m, 1H), 7.23 (s, 1H), 7.02 (t, <i>J</i> = 6.8 Hz, 1H), 4.62 (brs, 1H), 3.03–2.89 (m, 3H), 2.13–2.04 (m, 2H), 1.86–1.76 (m, 2H), 1.44 (s, 9H), 1.36–1.22 (m, 3H), 1.07–0.92 (m, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 156.22, 140.85, 130.18, 125.13, 122.87, 116.55, 112.71, 79.26, 56.63, 46.43, 37.95, 33.16, 29.28, 28.54. UPLC/MS: <i>t</i><sub>r</sub> 1.42 min, <i>m</i>/<i>z</i> 345.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> <i>N</i>-(2-(2,4-Dichlorophenoxy)ethyl)imidazo[1,2-<i>a</i>]pyridin-3-amine (<b>14h</b>)</h4><div class="NLM_p last">The title compound was prepared according to the general procedure D from pyridin-2-amine, glyoxylic acid monohydrate, and isocyanide <b>13h</b>, yielding a yellow solid (0.25 g, 38%), mp 98–100 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.03 (d, <i>J</i> = 6.9 Hz, 1H), 7.55 (d, <i>J</i> = 9.1 Hz, 1H), 7.40 (d, <i>J</i> = 2.5 Hz, 1H), 7.23–7.17 (m, 2H), 7.15–7.08 (m, 1H), 6.88 (d, <i>J</i> = 8.8 Hz, 1H), 6.80 (td, <i>J</i> = 6.8, 0.9 Hz, 1H), 4.21 (t, <i>J</i> = 5.1 Hz, 2H), 3.60–3.51 (m, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 152.86, 137.39, 132.91, 130.18, 129.52, 127.99, 126.65, 124.04, 123.65, 115.18, 114.59, 114.02, 68.96, 46.18. UPLC/MS: <i>t</i><sub>r</sub> 1.85 min, <i>m</i>/<i>z</i> 322.1 [M + H]<sup>+</sup>, purity 98%. HRMS: mass calculated for C<sub>15</sub>H<sub>14</sub>N<sub>3</sub>OCl<sub>2</sub>, 322.0514; found, 322.0514.</div></div><div id="sec4_1_5_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 1-(4-((Imidazo[1,2-<i>a</i>]pyridin-3-ylamino)methyl)phenyl)guanidine (<b>15a</b>)</h4><div class="NLM_p last">Boc deprotection of compound <b>14a</b> was done using the general procedure E to afford the title compound (<b>15a</b>) as a yellow oil (0.12 g, 98%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 9.98 (s, 1H), 8.63 (d, <i>J</i> = 6.9 Hz, 1H), 7.89–7.75 (m, 2H), 7.59–7.42 (m, 7H), 7.32 (s, 1H), 7.23 (d, <i>J</i> = 8.4 Hz, 2H), 4.41 (s, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 155.86, 136.50, 135.53, 134.50, 133.91, 131.08, 128.89, 124.44, 124.39, 115.90, 112.37, 47.46. UPLC/MS: <i>t</i><sub>r</sub> 0.27 min, <i>m</i>/<i>z</i> 281.2 [M + H]<sup>+</sup>, purity 96%. HRMS: mass calculated for C<sub>15</sub>H<sub>17</sub>N<sub>6</sub>, 281.1515; found, 281.1524.</div></div><div id="sec4_1_5_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 1-(4-(2-(Imidazo[1,2-<i>a</i>]pyridin-3-ylamino)ethyl)phenyl)guanidine (<b>15b</b>)</h4><div class="NLM_p last">Boc deprotection of compound <b>14b</b> was done using the general procedure E to afford the title compound (<b>15b</b>) as an orange oil (0.09 g, 97%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 9.85 (s, 1H), 8.54 (d, <i>J</i> = 6.93, 1H), 7.86–7.76 (m, 2H), 7.50 (s, 1H), 7.47–7.43 (m, 4H), 7.41 (d, <i>J</i> = 8.37, 2H), 7.19 (d, <i>J</i> = 8.37, 2H), 6.39 (brs, 1H), 3.39 (t, <i>J</i> = 7.3 Hz, 2H), 2.97 (t, <i>J</i> = 7.4 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 155.96, 144.01, 137.64, 135.53, 134.14, 133.54, 130.92, 130.11, 124.58, 124.26, 115.80, 112.36, 101.40, 46.18, 34.12. UPLC/MS: <i>t</i><sub>r</sub> 0.28 min, <i>m</i>/<i>z</i> 295.3 [M + H]<sup>+</sup>, purity 95%. HRMS: mass calculated for C<sub>16</sub>H<sub>19</sub>N<sub>6</sub>, 295.1671; found, 295.1679.</div></div><div id="sec4_1_5_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 1-(4-(Imidazo[1,2-<i>a</i>]pyridin-3-ylamino)butyl)guanidine (<b>15c</b>)</h4><div class="NLM_p last">Boc deprotection of compound <b>14c</b> was done using the general procedure E to afford the title compound (<b>15c</b>) as an orange oil (0.10 g, 96%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.57 (d, <i>J</i> = 6.90 Hz, 1H), 7.96–7.67 (m, 4H), 7.44 (td, <i>J</i> = 6.9, 1.2 Hz, 1H), 7.41 (s, 1H), 6.26 (s, 1H), 3.21–3.04 (m, 5H), 1.72–1.53 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 156.93, 135.46, 134.44, 130.85, 124.30, 115.71, 112.32, 100.88, 45.72, 44.26, 26.07, 25.59. UPLC/MS: <i>t</i><sub>r</sub> 0.27 min, <i>m</i>/<i>z</i> 247.2 [M + H]<sup>+</sup>, purity 90%. HRMS: mass calculated for C<sub>12</sub>H<sub>19</sub>N<sub>6</sub>, 247.1671; found, 247.1662.</div></div><div id="sec4_1_5_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> <i>N</i>-(4-(2-Aminoethoxy)phenyl)imidazo[1,2-<i>a</i>]pyridin-3-amine (<b>15d</b>)</h4><div class="NLM_p last">Boc deprotection of compound <b>14d</b> was done using the general procedure E to afford the title compound (<b>15d</b>) as a yellow oil (0.11 g, 100%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.43 (d, <i>J</i> = 6.8 Hz, 1H), 8.11 (brs, 3H), 8.08 (s, 1H), 8.02 (d, <i>J</i> = 9.1 Hz, 1H), 7.97–7.89 (m, 1H), 7.48 (t, <i>J</i> = 6.4 Hz, 1H), 6.89 (d, <i>J</i> = 9.0 Hz, 2H), 6.80 (d, <i>J</i> = 9.0 Hz, 2H), 4.08 (t, <i>J</i> = 5.1 Hz, 2H), 3.20 (q, <i>J</i> = 5.1 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 152.06, 138.21, 137.50, 132.85, 127.05, 125.06, 116.77, 116.05, 115.84, 114.56, 112.95, 64.95, 30.71. UPLC/MS: <i>t</i><sub>r</sub> 0.18 min, <i>m</i>/<i>z</i> 269.0 [M + H]<sup>+</sup>, purity: 97%. HRMS: mass calculated for C<sub>15</sub>H<sub>17</sub>N<sub>4</sub>O: 269.1402; found: 269.1408.</div></div><div id="sec4_1_5_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> <i>N</i>-(4-(2-Aminoethoxy)-3,5-dichlorophenyl)imidazo[1,2-<i>a</i>]pyridin-3-amine (<b>15e</b>)</h4><div class="NLM_p last">Boc deprotection of compound <b>14e</b> was done using the general procedure E to afford the title compound (<b>15e</b>) as a white solid (0.12 g, 97%), mp 195–197 °C. <sup>1</sup>H NMR (400 MHz, MeOD) δ 8.47 (dt, <i>J</i> = 6.9, 1.1 Hz, 1H), 8.07–7.95 (m, 3H), 7.52 (td, <i>J</i> = 6.7, 1.4 Hz, 1H), 6.87 (s, 2H), 4.18 (t, <i>J</i> = 5.1, 2H), 3.38 (t, <i>J</i> = 5.0, 2H). <sup>13</sup>C NMR (101 MHz, MeOD) δ 144.91, 143.93, 140.06, 135.18, 131.21, 126.57, 126.17, 118.66, 118.58, 115.50, 113.92, 70.17, 40.97. UPLC/MS: <i>t</i><sub>r</sub> 0.24 min, <i>m</i>/<i>z</i> 337.0 [M + H]<sup>+</sup>, purity 99%. HRMS: mass calculated for C<sub>15</sub>H<sub>15</sub>N<sub>4</sub>OCl<sub>2</sub>, 337.0623; found, 337.0623.</div></div><div id="sec4_1_5_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> <i>N</i>-(4-(Aminomethyl)phenyl)imidazo[1,2-<i>a</i>]pyridin-3-amine (<b>15f</b>)</h4><div class="NLM_p last">Boc deprotection of compound <b>14f</b> was done using the general procedure E to afford the title compound (<b>15f</b>) as a colorless oil (0.26 g, 95%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.73 (s, 1H), 8.39 (dt, <i>J</i> = 6.8, 1.0 Hz, 1H), 8.24–8.10 (m, 4H), 8.05 (dt, <i>J</i> = 9.1, 1.0 Hz, 1H), 7.97 (ddd, <i>J</i> = 9.0, 6.9, 1.1 Hz, 1H), 7.49 (td, <i>J</i> = 6.9, 1.1 Hz, 1H), 7.30 (d, <i>J</i> = 8.6 Hz, 2H), 6.82 (d, <i>J</i> = 8.6 Hz, 2H), 3.93 (q, <i>J</i> = 5.5 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 144.75, 137.91, 133.10, 130.49, 125.47, 125.20, 124.99, 116.90, 116.47, 114.08, 113.10, 41.93. UPLC/MS: <i>t</i><sub>r</sub> 0.22 min, <i>m</i>/<i>z</i> 239.1 [M + H]<sup>+</sup>, purity 97%. HRMS: mass calculated for C<sub>14</sub>H<sub>15</sub>N<sub>4</sub>, 239.1297; found, 239.1292.</div></div><div id="sec4_1_5_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> <i>N</i>-((1<i>R</i>,4<i>R</i>)-4-(Aminomethyl)cyclohexyl)imidazo[1,2-<i>a</i>]pyridin-3-amine (<b>15g</b>)</h4><div class="NLM_p last">Boc deprotection of compound <b>14g</b> was done using the general procedure E to afford the title compound (<b>15g</b>) as an orange oil (0.10 g, 98%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.60 (d, <i>J</i> = 6.9 Hz, 1H), 8.04–7.82 (m, 5H), 7.81–7.74 (m, 1H), 7.52 (s, 1H), 7.43 (t, <i>J</i> = 6.8 Hz, 1H), 3.22–3.03 (m, 1H), 2.80–2.59 (m, 2H), 2.22–2.02 (m, 2H), 1.92–1.72 (m, 2H), 1.66–1.50 (m, 1H), 1.35–1.19 (m, 2H), 1.15–0.97 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 135.49, 133.05, 130.92, 124.43, 115.75, 112.27, 102.65, 53.49, 44.14, 35.17, 31.49, 28.42. UPLC/MS: <i>t</i><sub>r</sub> 0.25 min, <i>m</i>/<i>z</i> 245.0 [M + H]<sup>+</sup>, 489.3 [2M + H]<sup>+</sup>, purity 98%. HRMS: mass calculated for C<sub>14</sub>H<sub>21</sub>N<sub>4</sub>, 245.1766; found, 245.1775.</div></div><div id="sec4_1_5_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 1,2-Di-Boc-3-(4-(((2-(pyridin-3-yl)imidazo[1,2-<i>a</i>]pyridin-3-yl)amino)methyl)phenyl)guanidine (<b>16a</b>)</h4><div class="NLM_p last">The title compound was prepared according to the general procedure D from pyridin-2-amine, nicotinaldehyde, and isocyanide <b>13a</b> (0.67 g, 72%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 11.40 (s, 1H), 9.96 (s, 1H), 9.30 (d, <i>J</i> = 1.4 Hz, 1H), 8.48 (dd, <i>J</i> = 4.7, 1.4 Hz, 1H), 8.40 (d, <i>J</i> = 8.0 Hz, 1H), 8.24 (d, <i>J</i> = 6.8 Hz, 1H), 7.54–7.38 (m, 4H), 7.28 (d, <i>J</i> = 8.3 Hz, 2H), 7.19 (t, <i>J</i> = 8.1 Hz, 1H), 6.87 (t, <i>J</i> = 6.5 Hz, 1H), 5.45 (t, <i>J</i> = 6.2 Hz, 1H), 4.09 (d, <i>J</i> = 6.1 Hz, 2H), 1.50 (s, 9H), 1.40 (s, 9H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 152.80, 147.71, 147.62, 140.94, 136.23, 135.62, 133.47, 131.87, 130.33, 128.49, 127.21, 124.37, 123.56, 123.37, 122.49, 116.91, 111.64, 83.38, 78.83, 50.76, 27.87, 27.69. UPLC/MS: <i>t</i><sub>r</sub> 1.84 min, <i>m</i>/<i>z</i> 558.5 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 1,2-Di-Boc-3-(4-(((2-(4-ethylphenyl)imidazo[1,2-<i>a</i>]pyridin-3-yl)amino)methyl)phenyl)guanidine (<b>16b</b>)</h4><div class="NLM_p last">The title compound was prepared according to the general procedure D from pyridin-2-amine, 4-ethylbenzaldehyde, and isocyanide <b>13a</b> (0.50 g, 82%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 11.41 (s, 1H), 9.97 (s, 1H), 8.20 (d, <i>J</i> = 6.9 Hz, 1H), 8.06 (d, <i>J</i> = 8.2 Hz, 2H), 7.55–7.37 (m, 3H), 7.38–7.21 (m, 4H), 7.18–7.09 (m, 1H), 6.82 (td, <i>J</i> = 6.8, 1.0 Hz, 1H), 5.27 (t, <i>J</i> = 6.2 Hz, 1H), 4.06 (d, <i>J</i> = 6.2 Hz, 2H), 2.64 (q, <i>J</i> = 7.6 Hz, 2H), 1.51 (s, 9H), 1.40 (s, 9H), 1.22 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 162.69, 152.83, 142.41, 140.38, 136.47, 135.57, 134.53, 132.04, 128.48, 127.75, 126.58, 126.13, 123.70, 123.10, 122.51, 116.65, 111.24, 83.42, 78.82, 50.73, 27.98, 27.92, 27.67, 15.55. UPLC/MS: <i>t</i><sub>r</sub> 2.12 min, <i>m</i>/<i>z</i> 585.6 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 1-(4-(((2-Benzylimidazo[1,2-<i>a</i>]pyridin-3-yl)amino)methyl)phenyl)-2,3-di-Boc-guanidine (<b>16c</b>)</h4><div class="NLM_p last">The title compound was prepared according to the general procedure D from pyridin-2-amine, 2-phenylacetaldehyde, and isocyanide <b>13a</b> (0.40 g, 60%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 11.41 (s, 1H), 9.97 (s, 1H), 8.14 (d, <i>J</i> = 6.8 Hz, 1H), 7.45 (d, <i>J</i> = 8.4 Hz, 2H), 7.38–7.18 (m, 7H), 7.17–7.04 (m, 2H), 6.81 (td, <i>J</i> = 6.7, 1.1 Hz, 1H), 5.13 (t, <i>J</i> = 6.4 Hz, 1H), 3.99 (d, <i>J</i> = 6.5 Hz, 2H), 3.90 (s, 2H), 1.51 (s, 9H), 1.40 (s, 9H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 152.82, 140.63, 140.09, 136.35, 135.54, 128.79, 128.55, 128.03, 126.45, 125.62, 122.85, 122.64, 122.47, 116.40, 110.94, 83.39, 78.80, 51.12, 32.70, 27.90, 27.66. UPLC/MS: <i>t</i><sub>r</sub> 1.94 min, <i>m</i>/<i>z</i> 571.5 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 1,2-Di-Boc-3-(4-(((2-ethylimidazo[1,2-<i>a</i>]pyridin-3-yl)amino)methyl)phenyl)guanidine (<b>16d</b>)</h4><div class="NLM_p last">The title compound was prepared according to the general procedure D from pyridin-2-amine, propionaldehyde, and isocyanide <b>13a</b> (0.30 g, 49%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 11.40 (s, 1H), 9.97 (s, 1H), 8.12 (d, <i>J</i> = 6.8 Hz, 1H), 7.46 (d, <i>J</i> = 8.2 Hz, 2H), 7.38–7.24 (m, 3H), 7.13–7.00 (m, 1H), 6.79 (t, <i>J</i> = 6.7 Hz, 1H), 5.03 (t, <i>J</i> = 6.4 Hz, 1H), 4.03 (d, <i>J</i> = 6.2 Hz, 2H), 2.54 (q, <i>J</i> = 7.6 Hz, 2H), 1.50 (s, 9H), 1.39 (s, 9H), 1.11 (t, <i>J</i> = 7.6 Hz, 3H). UPLC/MS: <i>t</i><sub>r</sub> 1.96 min, <i>m</i>/<i>z</i> 509.5 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 1,2-Di-Boc-3-(4-(((2-((Boc-amino)methyl)imidazo[1,2-<i>a</i>]pyridin-3-yl)amino)methyl)phenyl)guanidine (<b>16e</b>)</h4><div class="NLM_p last">The title compound was prepared according to the general procedure D from pyridin-2-amine, 2-(Boc-amino)acetaldehyde, and isocyanide <b>13a</b> (0.21 g, 32%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.62 (s, 1H), 10.34 (s, 1H), 8.00 (d, <i>J</i> = 6.8 Hz, 1H), 7.57 (d, <i>J</i> = 8.5 Hz, 2H), 7.50 (d, <i>J</i> = 9.0 Hz, 1H), 7.25–7.14 (m, 3H), 6.82 (t, <i>J</i> = 6.7 Hz, 1H), 5.43–5.22 (m, 1H), 4.54–4.33 (m, 1H), 4.17 (d, <i>J</i> = 6.1 Hz, 2H), 4.10 (d, <i>J</i> = 6.5 Hz, 2H), 1.54 (s, 9H), 1.50 (s, 9H), 1.39 (s, 9H). UPLC/MS: <i>t</i><sub>r</sub> 2.02 min, <i>m</i>/<i>z</i> 610.7 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 1-(4-(((2-(3-Chlorobenzyl)imidazo[1,2-<i>a</i>]pyridin-3-yl)amino)methyl)phenyl)-2,3-di-Boc-guanidine (<b>16f</b>)</h4><div class="NLM_p last">The title compound was prepared according to the general procedure D from pyridin-2-amine, 2-(3-chlorophenyl)acetaldehyde, and isocyanide <b>13a</b> (0.14 g, 22%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.61 (s, 1H), 10.33 (s, 1H), 8.09 (d, <i>J</i> = 7.0 Hz, 1H), 7.63–7.50 (m, 3H), 7.37–7.30 (m, 1H), 7.23–7.06 (m, 7H), 6.96 (t, <i>J</i> = 6.7 Hz, 1H), 4.04–3.91 (m, 4H), 3.31 (s, 1H), 1.54 (s, 9H), 1.49 (s, 9H). UPLC/MS: <i>t</i><sub>r</sub> 2.15 min, <i>m</i>/<i>z</i> 605.7 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> 1-(4-(((2-(1-Boc-piperidin-4-yl)imidazo[1,2-<i>a</i>]pyridin-3-yl)amino)methyl)phenyl)-2,3-di-Boc-guanidine (<b>16g</b>)</h4><div class="NLM_p last">The title compound was prepared according to the general procedure D from pyridin-2-amine, 1-Boc-piperidine-4-carbaldehyde, and isocyanide <b>13a</b> (0.35 g, 72%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.62 (s, 1H), 10.34 (s, 1H), 8.05 (d, <i>J</i> = 6.4 Hz, 1H), 7.82–7.66 (m, 1H), 7.63–7.55 (m, 2H), 7.29–7.20 (m, 3H), 6.97–6.82 (m, 1H), 4.10 (d, <i>J</i> = 6.4 Hz, 2H), 3.42–3.18 (m, 1H), 2.93–2.62 (m, 2H), 2.02–1.82 (m, 2H), 1.76–1.65 (m, 2H), 1.61–1.41 (m, 29H). UPLC/MS: <i>t</i><sub>r</sub> 2.16 min, <i>m</i>/<i>z</i> 664.8 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 1-(4-(((2-(3,5-Dichlorophenyl)imidazo[1,2-<i>a</i>]pyridin-3-yl)amino)methyl)phenyl)-2,3-di-Boc-guanidine (<b>16h</b>)</h4><div class="NLM_p last">The title compound was prepared according to the general procedure D from pyridin-2-amine, 3,5-dichlorobenzaldehyde, and isocyanide <b>13a</b> (0.42 g, 86%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.61 (s, 1H), 10.32 (s, 1H), 8.12–8.02 (m, 1H), 7.96 (d, <i>J</i> = 1.9 Hz, 2H), 7.66–7.59 (m, 1H), 7.55–7.48 (m, 2H), 7.30–7.18 (m, 4H), 6.87 (t, <i>J</i> = 6.5 Hz, 1H), 4.15–4.08 (m, 2H), 1.54 (s, 9H), 1.50 (s, 9H). UPLC/MS: <i>t</i><sub>r</sub> 2.29 min, <i>m</i>/<i>z</i> 625.6 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 1,2-Di-Boc-3-(4-(((2-phenylimidazo[1,2-<i>a</i>]pyridin-3-yl)amino)methyl)phenyl)guanidine (<b>16i</b>)</h4><div class="NLM_p last">The title compound was prepared according to the general procedure D from pyridin-2-amine, benzaldehyde, and isocyanide <b>13a</b> (0.14 g, 34%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.61 (s, 1H), 10.30 (s, 1H), 8.13 (d, <i>J</i> = 6.6 Hz, 1H), 8.06–8.00 (m, 2H), 7.94 (brs, 1H), 7.86–7.73 (m, 1H), 7.55–7.41 (m, 4H), 7.40–7.32 (m, 2H), 7.20 (d, <i>J</i> = 8.2 Hz, 2H), 7.01–6.92 (m, 1H), 4.15 (d, <i>J</i> = 5.2 Hz, 2H), 1.54 (s, 9H), 1.50 (s, 9H). UPLC/MS: <i>t</i><sub>r</sub> 2.08 min, <i>m</i>/<i>z</i> 557.5 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 1-(4-(((2-(3-Fluorophenyl)imidazo[1,2-<i>a</i>]pyridin-3-yl)amino)methyl)phenyl)-2,3-di-Boc-guanidine (<b>16j</b>)</h4><div class="NLM_p last">The title compound was prepared according to the general procedure D from pyridin-2-amine, 3-fluorobenzaldehyde, and isocyanide <b>13a</b> (0.36 g, 75%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.63 (s, 1H), 10.32 (s, 1H), 8.01 (d, <i>J</i> = 6.8 Hz, 1H), 7.83–7.72 (m, 2H), 7.65–7.51(m, 3H), 7.45–7.36 (m, 1H), 7.28 (d, <i>J</i> = 8.4 Hz, 2H), 7.18 (ddd, <i>J</i> = 8.9, 6.7, 1.1 Hz, 1H), 7.02 (tdd, <i>J</i> = 8.4, 2.6, 0.9 Hz, 1H), 6.80 (td, <i>J</i> = 6.8, 0.9 Hz, 1H), 4.15 (d, <i>J</i> = 6.1 Hz, 2H), 3.57 (s, 1H), 1.54 (s, 9H), 1.51 (s, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 163.63, 163.3 (d, <i>J</i> = 242.4 Hz), 153.68, 153.46, 136.54, 135.17, 130.38 (d, <i>J</i> = 8.5 Hz), 128.83, 126.13, 122.70 (d, <i>J</i> = 6.3 Hz), 122.64 (d, <i>J</i> = 6.1 Hz), 122.61, 117.24, 114.67 (d, <i>J</i> = 21.5 Hz), 114.02 (d, <i>J</i> = 23.1 Hz), 112.62, 83.97, 79.86, 52.01, 28.34, 28.23. UPLC/MS: <i>t</i><sub>r</sub> 1.97 min, <i>m</i>/<i>z</i> 575.6 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> 1-(4-(((2-(4-Fluorophenyl)imidazo[1,2-<i>a</i>]pyridin-3-yl)amino)methyl)phenyl)-2,3-di-Boc-guanidine (<b>16k</b>)</h4><div class="NLM_p last">The title compound was prepared according to the general procedure D from pyridin-2-amine, 4-fluorobenzaldehyde, and isocyanide <b>13a</b> (0.27 g, 63%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 11.41 (s, 1H), 9.96 (s, 1H), 8.25–8.12 (m, 3H), 7.50–7.40 (m, 3H), 7.34–7.22 (m, 4H), 7.16 (ddd, <i>J</i> = 9.0, 6.6, 1.2 Hz, 1H), 6.84 (td, <i>J</i> = 6.8, 1.1 Hz, 1H), 5.32 (t, <i>J</i> = 6.2 Hz, 1H), 4.06 (d, <i>J</i> = 6.2 Hz, 2H), 1.51 (s, 9H), 1.40 (s, 9H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 161.30 (d, <i>J</i> = 243.9 Hz), 152.83, 152.18, 140.46, 136.35, 135.59, 133.61, 131.07 (d, <i>J</i> = 3.0 Hz), 128.50, 128.46 (d, <i>J</i> = 9.1 Hz), 126.19, 123.98, 123.25, 122.55, 116.72, 115.17 (d, <i>J</i> = 21.1 Hz), 111.37, 83.39, 78.80, 50.69, 27.90, 27.66. UPLC/MS: <i>t</i><sub>r</sub> 1.97 min, <i>m</i>/<i>z</i> 575.6 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> 1-(4-(((2-(Pyridin-3-yl)imidazo[1,2-<i>a</i>]pyridin-3-yl)amino)methyl)phenyl)guanidine (<b>17a</b>)</h4><div class="NLM_p last">Boc deprotection of compound <b>16a</b> was done using the general procedure E to afford the title compound (<b>17a</b>) as a yellow solid (0.30 g, 95%), mp 146 °C. <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.01 (s, 1H), 9.07 (d, <i>J</i> = 1.8 Hz, 1H), 8.68 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H), 8.64 (d, <i>J</i> = 6.8 Hz, 1H), 8.39 (d, <i>J</i> = 8.1 Hz, 1H), 7.91–7.73 (m, 2H), 7.72–7.65 (m, 1H), 7.57 (brs, 4H), 7.39 (t, <i>J</i> = 6.8 Hz, 1H), 7.29 (d, <i>J</i> = 8.4 Hz, 2H), 7.08 (d, <i>J</i> = 8.3 Hz, 2H), 4.17 (s, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 155.85, 147.87, 146.29, 138.05, 137.09, 136.25, 134.51, 131.44, 129.46, 128.29, 125.03, 124.52, 124.15, 115.65, 113.47, 50.10. UPLC/MS: <i>t</i><sub>r</sub> 0.23 min, <i>m</i>/<i>z</i> 358.4 [M + H]<sup>+</sup>, purity 99%. HRMS: mass calculated for C<sub>20</sub>H<sub>20</sub>N<sub>7</sub>, 358.1780; found, 358.1778.</div></div><div id="sec4_1_5_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> 1-(4-(((2-(4-Ethylphenyl)imidazo[1,2-<i>a</i>]pyridin-3-yl)amino)methyl)phenyl)guanidine (<b>17b</b>)</h4><div class="NLM_p last">Boc deprotection of compound <b>16b</b> was done using the general procedure E to afford the title compound (<b>17b</b>) as a yellow solid (0.10 g, 98%), mp 165–166 °C. <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.01 (s, 1H), 8.68 (d, <i>J</i> = 6.8 Hz, 1H), 7.92–7.82 (m, 4H), 7.54 (brs, 4H), 7.49–7.40 (m, 3H), 7.33 (d, <i>J</i> = 8.4 Hz, 2H), 7.12 (d, <i>J</i> = 8.4 Hz, 2H), 5.98 (brs, 1H), 4.16 (s, 2H), 2.70 (q, <i>J</i> = 7.6 Hz, 2H), 1.24 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 155.85, 145.61, 137.07, 136.54, 134.55, 132.63, 129.37, 128.51, 127.35, 127.11, 125.58, 125.19, 124.50, 124.10, 116.44, 112.13, 49.96, 28.03, 15.39. UPLC/MS: <i>t</i><sub>r</sub> 1.12 min, <i>m</i>/<i>z</i> 385.5 [M + H]<sup>+</sup>, 769.8 [2M + H]<sup>+</sup>, purity >99%. HRMS: mass calculated for C<sub>23</sub>H<sub>25</sub>N<sub>6</sub>, 385.2141; found, 385.2139.</div></div><div id="sec4_1_5_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> 1-(4-(((2-Benzylimidazo[1,2-<i>a</i>]pyridin-3-yl)amino)methyl)phenyl)guanidine (<b>17c</b>)</h4><div class="NLM_p last">Boc deprotection of compound <b>16c</b> was done using the general procedure E to afford the title compound (<b>17c</b>) as a white solid (0.31 g, 100%), mp 110 °C. <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.15 (s, 1H), 8.64 (d, <i>J</i> = 6.8 Hz, 1H), 7.92–7.79 (m, 2H), 7.64 (brs, 4H), 7.47 (td, <i>J</i> = 6.8, 1.4 Hz, 1H), 7.41 (d, <i>J</i> = 8.4 Hz, 2H), 7.37–7.12 (m, 7H), 4.18 (s, 2H), 4.07 (s, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 155.90, 137.38, 137.15, 136.28, 134.64, 132.44, 129.51, 128.67, 128.61, 128.34, 126.89, 125.71, 125.25, 124.19, 116.48, 111.97, 50.30, 29.11. UPLC/MS: <i>t</i><sub>r</sub> 0.97 min, <i>m</i>/<i>z</i> 371.4 [M + H]<sup>+</sup>, purity >99%. HRMS: mass calculated for C<sub>22</sub>H<sub>23</sub>N<sub>6</sub>, 371.1984; found, 371.1978.</div></div><div id="sec4_1_5_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> 1-(4-(((2-Ethylimidazo[1,2-<i>a</i>]pyridin-3-yl)amino)methyl)phenyl)guanidine (<b>17d</b>)</h4><div class="NLM_p last">Boc deprotection of compound <b>16d</b> was done using the general procedure E, affording the title compound (<b>17d</b>) as a colorless oil (0.10 g, 98%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.01 (s, 1H), 8.62 (d, <i>J</i> = 6.8 Hz, 1H), 7.90–7.82 (m, 2H), 7.54 (brs, 4H), 7.49–7.43 (m, 1H), 7.40 (d, <i>J</i> = 8.4 Hz, 2H), 7.19 (d, <i>J</i> = 8.4 Hz, 2H), 5.78 (brs, 1H), 4.17 (s, 2H), 2.64 (q, <i>J</i> = 7.6 Hz, 2H), 1.12 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 155.88, 137.50, 135.97, 134.59, 132.08, 129.56, 128.97, 126.98, 125.01, 124.14, 116.39, 111.84, 50.37, 16.82, 12.93. UPLC/MS: <i>t</i><sub>r</sub> 0.24 min, <i>m</i>/<i>z</i> 309.4 [M + H]<sup>+</sup>, purity 96%. HRMS: mass calculated for C<sub>17</sub>H<sub>21</sub>N<sub>6</sub>, 309.1828; found, 309.1812.</div></div><div id="sec4_1_5_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> 1-(4-(((2-(Aminomethyl)imidazo[1,2-<i>a</i>]pyridin-3-yl)amino)methyl)phenyl)guanidine (<b>17e</b>)</h4><div class="NLM_p last">Boc deprotection of compound <b>16e</b> was done using the general procedure E, affording the title compound (<b>17e</b>) as an orange oil (0.08 g, 94%). <sup>1</sup>H NMR (400 MHz, MeOD) δ 8.18 (dt, <i>J</i> = 6.9, 1.2 Hz, 1H), 7.48 (dt, <i>J</i> = 9.1, 1.1 Hz, 1H), 7.44 (d, <i>J</i> = 8.5 Hz, 2H), 7.31 (ddd, <i>J</i> = 9.1, 6.7, 1.3 Hz, 1H), 7.24 (d, <i>J</i> = 8.5 Hz, 2H), 6.93 (td, <i>J</i> = 6.8, 1.1 Hz, 1H), 4.23 (s, 2H), 4.06 (s, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 155.97, 137.57, 137.26, 134.71, 131.03, 130.08, 129.50, 124.85, 124.23, 115.51, 113.54, 50.18, 48.62. UPLC/MS: <i>t</i><sub>r</sub> 0.16 min, <i>m</i>/<i>z</i> 310.3 [M + H]<sup>+</sup>, purity 97%. HRMS: mass calculated for C<sub>16</sub>H<sub>20</sub>N<sub>7</sub>, 310.1780; found, 310.1775.</div></div><div id="sec4_1_5_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> 1-(4-(((2-(3-Chlorobenzyl)imidazo[1,2-<i>a</i>]pyridin-3-yl)amino)methyl)phenyl)guanidine (<b>17f</b>)</h4><div class="NLM_p last">Boc deprotection of compound <b>16f</b> was done using the general procedure E, affording the title compound (<b>17f</b>) as an orange oil (0.09 g, 97%). <sup>1</sup>H NMR (400 MHz, MeOD) δ 8.61 (d, <i>J</i> = 6.8 Hz, 1H), 7.93–7.83 (m, 1H), 7.74 (d, <i>J</i> = 9.0 Hz, 1H), 7.51–7.39 (m, 3H), 7.36–7.07 (m, 6H), 4.27 (s, 2H), 4.09 (s, 2H). <sup>13</sup>C NMR (101 MHz, MeOD) δ 158.01, 140.11, 139.93, 138.63, 135.75, 135.67, 134.05, 131.47, 131.01, 129.90, 129.73, 128.45, 128.17, 128.05, 126.43, 126.27, 117.80, 112.98, 51.99, 30.33. UPLC/MS: <i>t</i><sub>r</sub> 1.24 min, <i>m</i>/<i>z</i> 405.4 [M + H]<sup>+</sup>, purity 98%. HRMS: mass calculated for C<sub>22</sub>H<sub>22</sub>N<sub>6</sub>Cl, 405.1594; found, 405.1602.</div></div><div id="sec4_1_5_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> 1-(4-(((2-(Piperidin-4-yl)imidazo[1,2-<i>a</i>]pyridin-3-yl)amino)methyl)phenyl)guanidine (<b>17g</b>)</h4><div class="NLM_p last">Boc deprotection of compound <b>16g</b> was done using the general procedure E, affording the title compound (<b>17g</b>) as a white solid (0.25 g, 94%), mp 108 °C. <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.28 (s, 1H), 9.13–8.94 (m, 1H), 8.80–8.63 (m, 1H), 8.60 (d, <i>J</i> = 6.8 Hz, 1H), 7.94–7.79 (m, 2H), 7.67 (brs, 4H), 7.50–7.35 (m, 3H), 7.19 (d, <i>J</i> = 8.2 Hz, 2H), 4.18 (s, 2H), 3.46–3.29 (m, 2H), 3.17–3.02 (m, 1H), 3.00–2.84 (m, 2H), 1.99–1.79 (m, 2H), 1.75–1.59 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 155.95, 137.42, 136.72, 134.63, 129.77, 126.92, 125.01, 124.17, 116.22, 112.38, 50.41, 43.03, 29.91, 27.41. UPLC/MS: <i>t</i><sub>r</sub> 0.23 min, <i>m</i>/<i>z</i> 364.4 [M + H]<sup>+</sup>, purity >99%. HRMS: mass calculated for C<sub>20</sub>H<sub>26</sub>N<sub>7</sub>, 364.2250; found, 364.2242.</div></div><div id="sec4_1_5_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> 1-(4-(((2-(3,5-Dichlorophenyl)imidazo[1,2-<i>a</i>]pyridin-3-yl)amino)methyl)phenyl)guanidine (<b>17h</b>)</h4><div class="NLM_p last">Boc deprotection of compound <b>16h</b> was done using the general procedure E, affording the title compound (<b>17h</b>) as a yellow solid (0.19 g, 100%), mp 151–153 °C. <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.03 (s, 1H), 8.58 (d, <i>J</i> = 6.8 Hz, 1H), 8.01 (d, <i>J</i> = 1.9 Hz, 2H), 7.80–7.73 (m, 1H), 7.71–7.62 (m, 2H), 7.57 (brs, 4H), 7.35 (d, <i>J</i> = 8.4 Hz, 2H), 7.27 (t, <i>J</i> = 6.8 Hz, 1H), 7.14 (d, <i>J</i> = 8.4 Hz, 2H), 4.16 (s, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 155.83, 138.41, 137.07, 134.53, 133.27, 130.19, 129.45, 128.22, 127.68, 125.24, 124.77, 123.99, 114.81, 114.15, 50.25. UPLC/MS: <i>t</i><sub>r</sub> 1.29 min, <i>m</i>/<i>z</i> 425.4 [M + H]<sup>+</sup>, purity >99%. HRMS: mass calculated for C<sub>21</sub>H<sub>19</sub>N<sub>6</sub>Cl<sub>2</sub>, 425.1048; found, 425.1059.</div></div><div id="sec4_1_5_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> 1-(4-(((2-Phenylimidazo[1,2-<i>a</i>]pyridin-3-yl)amino)methyl)phenyl)guanidine (<b>17i</b>)</h4><div class="NLM_p last">Boc deprotection of compound <b>16i</b> was done using the general procedure E, affording the title compound (<b>17i</b>) as an orange oil (0.09 g, 97%). <sup>1</sup>H NMR (400 MHz, MeOD) δ 8.69 (dt, <i>J</i> = 6.9, 1.0 Hz, 1H), 7.96–7.89 (m, 1H), 7.87–7.80 (m, 3H), 7.62–7.53 (m, 3H), 7.48 (td, <i>J</i> = 6.9, 1.1 Hz, 1H), 7.28 (d, <i>J</i> = 8.4 Hz, 2H), 7.10 (d, <i>J</i> = 8.4 Hz, 2H), 4.24 (s, 2H). <sup>13</sup>C NMR (101 MHz, MeOD) δ 157.96, 139.42, 138.31, 135.49, 134.47, 131.17, 130.91, 130.36, 128.93, 128.04, 126.28, 118.01, 112.87, 51.34. UPLC/MS: <i>t</i><sub>r</sub> 1.02 min, <i>m</i>/<i>z</i> 357.4 [M + H]<sup>+</sup>, purity: 96%. HRMS: mass calculated for C<sub>21</sub>H<sub>21</sub>N<sub>6</sub>, 357.1828; found, 357.1810.</div></div><div id="sec4_1_5_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> 1-(4-(((2-(3-Fluorophenyl)imidazo[1,2-<i>a</i>]pyridin-3-yl)amino)methyl)phenyl)guanidine (<b>17j</b>)</h4><div class="NLM_p last">Boc deprotection of compound <b>16j</b> was done using the general procedure E, affording the title compound (<b>17j</b>) as a white solid (0.16 g, 96%), mp 153 °C. <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.04 (s, 1H), 8.65 (d, <i>J</i> = 6.8 Hz, 1H), 7.91–7.76 (m, 4H), 7.65–7.59 (m, 1H), 7.57 (brs, 4H), 7.41 (td, <i>J</i> = 6.7, 1.3 Hz, 1H), 7.37–7.29 (m, 3H), 7.11 (d, <i>J</i> = 8.4 Hz, 2H), 6.03 (s, 1H), 4.17 (s, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ, 162.30 (d, <i>J</i> = 243.8 Hz), 155.83, 137.25, 137.05, 134.54, 132.07, 131.13 (d, <i>J</i> = 8.5 Hz), 129.39, 127.92, 125.12, 124.09, 123.34 (d, <i>J</i> = 2.6 Hz), 116.04 (d, <i>J</i> = 20.6 Hz), 113.92 (d, <i>J</i> = 23.8 Hz), 112.86, 50.04. UPLC/MS: <i>t</i><sub>r</sub> 0.99 min, <i>m</i>/<i>z</i> 375.5 [M + H]<sup>+</sup>, purity >99%. HRMS: mass calculated for C<sub>21</sub>H<sub>20</sub>N<sub>6</sub>F, 375.1733; found, 375.1721.</div></div><div id="sec4_1_5_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> 1-(4-(((2-(4-Fluorophenyl)imidazo[1,2-<i>a</i>]pyridin-3-yl)amino)methyl)phenyl)guanidine (<b>17k</b>)</h4><div class="NLM_p last">Boc deprotection of compound <b>16k</b> was done using the general procedure E, affording the title compound (<b>17k</b>) as a light-yellow oil (0.15 g, 95%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.09 (s, 1H), 8.69–8.62 (m, 1H), 8.03–7.93 (m, 2H), 7.90–7.78 (m, 2H), 7.73–7.50 (m, 4H), 7.46–7.37 (m, 3H), 7.31 (d, <i>J</i> = 8.4 Hz, 2H), 7.11 (d, <i>J</i> = 8.4 Hz, 2H), 5.96 (brs, 1H), 4.15 (s, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 162.54 (d, <i>J</i> = 247.8 Hz), 155.92, 137.06, 136.92, 134.59, 132.19, 129.79 (d, <i>J</i> = 8.6 Hz), 129.40, 127.30, 125.32, 125.16, 124.24, 124.09, 116.16, 116.11 (d, <i>J</i> = 21.9 Hz), 112.57, 49.98. UPLC/MS: <i>t</i><sub>r</sub> 0.97 min, <i>m</i>/<i>z</i> 375.3 [M + H]<sup>+</sup>, purity 99%. HRMS: mass calculated for C<sub>21</sub>H<sub>20</sub>N<sub>6</sub>F, 375.1733; found, 375.1751.</div></div><div id="sec4_1_5_60" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> 1-(4-(2-((2-Ethylimidazo[1,2-<i>a</i>]pyridin-3-yl)amino)ethyl)phenyl)-2,3-di-Boc-guanidine (<b>18a</b>)</h4><div class="NLM_p last">The title compound was prepared according to the general procedure D from pyridin-2-amine, 4-propionaldehyde, and isocyanide <b>13b</b> (0.35 g, 54%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 11.43 (s, 1H), 9.94 (s, 1H), 7.96 (d, <i>J</i> = 6.8 Hz, 1H), 7.43 (d, <i>J</i> = 8.4 Hz, 2H), 7.34 (dt, <i>J</i> = 9.0, 1.0 Hz, 1H), 7.20 (d, <i>J</i> = 8.5 Hz, 2H), 7.05 (ddd, <i>J</i> = 9.0, 6.6, 1.3 Hz, 1H), 6.77 (td, <i>J</i> = 6.7, 1.1 Hz, 1H), 4.61 (t, <i>J</i> = 6.2 Hz, 1H), 3.16–3.07 (m, 2H), 2.76 (t, <i>J</i> = 7.5 Hz, 2H), 2.66 (q, <i>J</i> = 7.5 Hz, 2H), 1.50 (s, 9H), 1.39 (s, 9H), 1.21 (t, <i>J</i> = 7.5 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 152.93, 139.90, 138.73, 136.56, 134.58, 128.86, 125.62, 122.85, 122.52, 122.19, 116.24, 110.73, 83.36, 49.75, 36.02, 27.87, 27.67, 19.88, 14.22. UPLC/MS: <i>t</i><sub>r</sub> 2.03 min, <i>m</i>/<i>z</i> 523.6 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_61" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> 1-(4-(2-((2-(3-Chlorophenyl)imidazo[1,2-<i>a</i>]pyrazin-3-yl)amino)ethyl)phenyl)-2,3-di-Boc-guanidine (<b>18b</b>)</h4><div class="NLM_p last">The title compound was prepared according to the general procedure D from pyrazin-2-amine, 3-chlorobenzaldehyde, and isocyanide <b>13b</b> (0.18 g, 49%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.62 (s, 1H), 8.85 (s, 1H), 8.16–8.07 (m, 1H), 7.96–7.90 (m, 1H), 7.79–7.69 (m, 2H), 7.46–7.34 (m, 4H), 7.10 (d, <i>J</i> = 8.3 Hz, 2H), 4.31 (brs, 1H), 3.42–3.32 (m, 2H), 2.83 (t, <i>J</i> = 6.4 Hz, 2H), 1.55 (s, 9H), 1.49 (s, 9H). UPLC/MS: <i>t</i><sub>r</sub> 1.44 min, <i>m</i>/<i>z</i> 606.5 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_62" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> 1-(4-(2-((2-Ethylimidazo[1,2-<i>a</i>]pyridin-3-yl)amino)ethyl)phenyl)guanidine (<b>19a</b>)</h4><div class="NLM_p last">Boc deprotection of compound <b>18a</b> was done using the general procedure E, affording the title compound (<b>19a</b>) as a colorless oil (0.24 g, 98%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.01 (s, 1H), 8.47 (d, <i>J</i> = 6.8 Hz, 1H), 7.90–7.80 (m, 2H), 7.53 (brs, 4H), 7.43 (ddd, <i>J</i> = 6.8, 5.9, 2.2 Hz, 1H), 7.31 (d, <i>J</i> = 8.4 Hz, 2H), 7.15 (d, <i>J</i> = 8.4 Hz, 2H), 3.29–3.16 (m, 2H), 2.92–2.76 (m, 4H), 1.28 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 156.06, 137.67, 135.91, 133.50, 131.91, 129.95, 128.44, 127.39, 124.90, 124.50, 116.27, 111.82, 48.95, 35.77, 16.93, 13.16. UPLC/MS: <i>t</i><sub>r</sub> 0.28 min, <i>m</i>/<i>z</i> 323.4 [M + H]<sup>+</sup>, purity 97%. HRMS: mass calculated for C<sub>18</sub>H<sub>23</sub>N<sub>6</sub>, 323.1984; found, 323.1986.</div></div><div id="sec4_1_5_63" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> 1-(4-(2-((2-(3-Chlorophenyl)imidazo[1,2-<i>a</i>]pyrazin-3-yl)amino)ethyl)phenyl)guanidine (<b>19b</b>)</h4><div class="NLM_p last">Boc deprotection of compound <b>18b</b> was done using the general procedure E, affording the title compound (<b>19b</b>) as a yellow oil (0.12 g, 96%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 9.64 (s, 1H), 8.97 (d, <i>J</i> = 1.3 Hz, 1H), 8.31 (dd, <i>J</i> = 4.7, 1.4 Hz, 1H), 8.10 (t, <i>J</i> = 1.7 Hz, 1H), 8.00 (dt, <i>J</i> = 7.7, 1.3 Hz, 1H), 7.87 (d, <i>J</i> = 4.7 Hz, 1H), 7.48 (t, <i>J</i> = 7.8 Hz, 1H), 7.45–7.40 (m, 1H), 7.34 (brs, 4H), 7.18 (d, <i>J</i> = 8.4 Hz, 2H), 7.07 (d, <i>J</i> = 8.4 Hz, 2H), 5.51 (s, 1H), 3.25 (t, <i>J</i> = 7.1 Hz, 2H), 2.81 (t, <i>J</i> = 7.4 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 155.97, 140.46, 137.52, 135.38, 135.19, 134.91, 133.48, 133.31, 130.64, 130.54, 129.77, 127.93, 126.54, 125.58, 124.58, 116.87, 48.17, 35.92. UPLC/MS: <i>t</i><sub>r</sub> 1.38 min, <i>m</i>/<i>z</i> 406.4 [M + H]<sup>+</sup>, purity 99%. HRMS: mass calculated for C<sub>21</sub>H<sub>21</sub>N<sub>7</sub>Cl, 406.1547; found, 406.1548.</div></div><div id="sec4_1_5_64" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> 2-Amino-<i>N</i>-butylisonicotinamide (<b>20a</b>)</h4><div class="NLM_p last">The title compound was prepared according to the TBD-catalyzed aminolysis reaction. To a solution of methyl 2-aminopyridine-4-carboxylate (0.3 g, 1.972 mmol) in dry DMF (10 mL) were added butan-1-amine (0.391 mL, 3.94 mmol, 2 equiv) and 1,5,7- triazabicyclo[4.4.0]dec-5-ene (TBD) (54.9 mg, 0.394 mmol, 0.2 equiv), and the reaction mixture was stirred in a pressure tube at 120 °C for 20 h. The crude product was purified by an Isolera, using normal phase chromatography and by applying gradient from 0 to 10% of MeOH in EtOAc to afford a white solid (0.20 g, 52.5%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.10 (dd, <i>J</i> = 5.3, 0.5 Hz, 1H), 6.93–6.89 (s, 1H), 6.84 (dd, <i>J</i> = 5.4, 1.4 Hz, 1H), 6.20 (brs, 1H), 3.48–3.38 (m, 2H), 1.64–1.54 (m, 2H), 1.46–1.34 (m, 2H), 0.95 (t, <i>J</i> = 7.3 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 165.97, 158.91, 148.07, 144.47, 110.69, 107.11, 40.02, 31.70, 20.27, 13.89. UPLC/MS: <i>t</i><sub>r</sub> 0.31 min, <i>m</i>/<i>z</i> 194.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_65" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> 6-Amino-<i>N</i>-butylnicotinamide (<b>20b</b>)</h4><div class="NLM_p last">The title compound was prepared according to the TBD-catalyzed aminolysis reaction. To a solution of methyl 6-aminonicotinate (0.3 g, 1.972 mmol) in dry DMF (9 mL) were added butan-1-amine (0.391 mL, 3.94 mmol, 2 equiv) and 1,5,7- triazabicyclo[4.4.0]dec-5-ene (TBD) (54.9 mg, 0.394 mmol, 0.2 equiv), and the reaction mixture was stirred in a pressure tube at 120 °C for 24 h. The crude product was purified by an Isolera, using normal phase chromatography and by applying gradient from 10 to 100% of EtOAc in heptane to 0–15% of MeOH in EtOAc to afford a white solid (0.16 g, 42%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.45 (d, <i>J</i> = 2.3 Hz, 1H), 7.88 (dd, <i>J</i> = 8.6, 2.3 Hz, 1H), 6.50 (dd, <i>J</i> = 8.6, 0.7 Hz, 1H), 5.94 (brs, 1H), 3.48–3.39 (m, 2H), 1.63–1.53 (m, 2H), 1.47–1.35 (m, 2H), 0.95 (t, <i>J</i> = 7.3 Hz, 3H). UPLC/MS: <i>t</i><sub>r</sub> 0.25 min, <i>m</i>/<i>z</i> 194.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_66" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> 1-(4-(((8-Methyl-2-(pyridin-3-yl)imidazo[1,2-<i>a</i>]pyridin-3-yl)amino)methyl)phenyl)-2,3-di-Boc-guanidine (<b>21a</b>)</h4><div class="NLM_p last">The title compound was prepared according to the general procedure D from 3-methylpyridin-2-amine, nicotinaldehyde, and isocyanide <b>13a</b> (0.09 g, 25%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.62 (s, 1H), 10.30 (s, 1H), 9.22 (d, <i>J</i> = 2.0 Hz, 1H), 8.53 (dd, <i>J</i> = 4.8, 1.4 Hz, 1H), 8.32 (d, <i>J</i> = 7.9 Hz, 1H), 7.90 (d, <i>J</i> = 6.8 Hz, 1H), 7.52 (d, <i>J</i> = 8.4 Hz, 2H), 7.37 (ddd, <i>J</i> = 7.9, 4.8, 0.8 Hz, 1H), 7.23 (d, <i>J</i> = 8.3 Hz, 2H), 6.98 (d, <i>J</i> = 6.8 Hz, 1H), 6.73 (t, <i>J</i> = 6.8 Hz, 1H), 4.12 (s, 2H), 2.63 (s, 3H), 1.53 (s, 9H), 1.50 (s, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 153.61, 147.97, 147.91, 142.03, 136.47, 135.30, 135.09, 130.15, 129.42, 128.85, 127.37, 126.70, 124.29, 123.84, 122.52, 120.62, 112.76, 83.93, 79.83, 52.07, 28.24, 16.81. UPLC/MS: <i>t</i><sub>r</sub> 1.95 min, <i>m</i>/<i>z</i> 572.6 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_67" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> Methyl 3-((4-(2,3-Di-Boc-guanidino)benzyl)amino)-2-(pyridin-3-yl)imidazo[1,2-<i>a</i>]pyridine-7-carboxylate (<b>21b</b>)</h4><div class="NLM_p last">The title compound was prepared according to the general procedure D from methyl 2-aminoisonicotinate, nicotinaldehyde, and isocyanide <b>13a</b> (0.40 g, 49%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.61 (brs, 1H), 9.12 (d, <i>J</i> = 1.6 Hz, 1H), 8.52 (dd, <i>J</i> = 4.9, 1.5 Hz, 1H), 8.32 (dt, <i>J</i> = 8.0, 1.9 Hz, 1H), 8.28 (dd, <i>J</i> = 1.5, 0.9 Hz, 1H), 8.03 (dd, <i>J</i> = 7.2, 0.9 Hz, 1H), 7.48 (d, <i>J</i> = 8.5 Hz, 2H), 7.45–7.36 (m, 2H), 7.22 (d, <i>J</i> = 8.5 Hz, 2H), 4.16 (d, <i>J</i> = 5.9 Hz, 2H), 3.96 (s, 3H), 1.59–1.45 (m, 18H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 165.90, 154.42, 153.86, 148.25, 147.68, 140.89, 136.44, 135.97, 135.28, 135.19, 130.26, 128.96, 127.90, 125.90, 124.09, 122.86, 122.16, 120.54, 111.62, 84.08, 80.14, 52.70, 50.96, 28.24. UPLC/MS: <i>t</i><sub>r</sub> 2.08 min, <i>m</i>/<i>z</i> 616.6 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_68" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> 3-((4-(2,3-Di-Boc-guanidino)benzyl)amino)-2-(pyridin-3-yl)imidazo[1,2-<i>a</i>]pyridine-7-carboxylic acid (<b>21c</b>)</h4><div class="NLM_p last">The title compound was prepared by base hydrolysis of an ester function in compound <b>21b</b>. To a solution of compound <b>21b</b> (0.10 g, 0.194 mmol) in a 9:1 mixture of DCM (1.8 mL) and MeOH (0.2 mL) was added a 2 M solution of sodium hydroxide (0.145 mL, 0.291 mmol, 1.5 equiv), and the reaction was left stirring for 12 h at rt. The crude product was purified by an Isolera, using reversed phase chromatography and by applying gradient of 10–100% of MeOH in water to afford a yellow solid (0.08 g, 69%). <sup>1</sup>H NMR (400 MHz, MeOD) δ 9.03 (d, <i>J</i> = 1.7 Hz, 1H), 8.57 (dd, <i>J</i> = 5.0, 1.1 Hz, 1H), 8.52–8.46 (m, 1H), 8.37 (dd, <i>J</i> = 7.2, 0.9 Hz, 1H), 8.21 (dd, <i>J</i> = 1.4, 1.0 Hz, 1H), 7.68 (dd, <i>J</i> = 7.9, 5.0 Hz, 1H), 7.53 (dd, <i>J</i> = 7.2, 1.5 Hz, 1H), 7.33 (d, <i>J</i> = 8.5 Hz, 2H), 7.10 (d, <i>J</i> = 8.5 Hz, 2H), 4.19 (s, 2H), 1.57–1.45 (m, 18H). UPLC/MS: <i>t</i><sub>r</sub> 1.89 min, <i>m</i>/<i>z</i> 602.7 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_69" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> <i>N</i>-Butyl-3-((4-(2,3-di-Boc-guanidino)benzyl)amino)-2-(pyridin-3-yl)imidazo[1,2-<i>a</i>]pyridine-7-carboxamide (<b>21d</b>)</h4><div class="NLM_p last">The title compound was prepared according to the general procedure D from aminopyridine <b>20a</b>, nicotinaldehyde, and isocyanide <b>13a</b> to afford a light-yellow solid (0.41 g, 60%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.61 (s, 1H), 10.29 (s, 1H), 9.26–9.19 (m, 1H), 8.56 (dd, <i>J</i> = 4.9, 1.6 Hz, 1H), 8.36–8.29 (m, 1H), 8.05 (dd, <i>J</i> = 7.1, 0.8 Hz, 1H), 7.98–7.94 (m, 1H), 7.48 (d, <i>J</i> = 8.5 Hz, 2H), 7.42 (ddd, <i>J</i> = 8.0, 4.9, 0.7 Hz, 1H), 7.30 (dd, <i>J</i> = 7.1, 1.6 Hz, 1H), 7.16 (d, <i>J</i> = 8.5 Hz, 2H), 6.67 (t, <i>J</i> = 5.5 Hz, 1H), 4.16–4.06 (m, 2H), 3.98–3.83 (m, 1H), 3.52–3.43 (m, 2H), 1.69–1.58 (m, 2H), 1.54 (s, 9H), 1.50 (s, 9H), 1.46–1.36 (m, 2H), 0.97 (t, <i>J</i> = 7.3 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 165.57, 153.76, 148.17, 147.50, 140.49, 136.59, 135.21, 134.80, 129.70, 128.88, 127.49, 124.15, 122.77, 122.74, 115.47, 111.56, 84.05, 79.85, 52.00, 40.20, 31.77, 28.24, 20.33, 13.94. UPLC/MS: <i>t</i><sub>r</sub> 2.02 min, <i>m</i>/<i>z</i> 657.7 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_70" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> 1,2-Di-Boc-3-(4-(((6-methyl-2-(pyridin-3-yl)imidazo[1,2-<i>a</i>]pyridin-3-yl)amino)methyl)phenyl)guanidine (<b>21e</b>)</h4><div class="NLM_p last">The title compound was prepared according to the general procedure D from 5-methylpyridin-2-amine, nicotinaldehyde, and isocyanide <b>13a</b> to afford a yellow solid (0.17 g, 46%). UPLC/MS: <i>t</i><sub>r</sub> 1.98 min, <i>m</i>/<i>z</i> 572.6 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_71" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> 1,2-Di-Boc-3-(4-(((2-(pyridin-3-yl)-6-(trifluoromethyl)imidazo[1,2-<i>a</i>]pyridin-3-yl)amino)methyl)phenyl)guanidine (<b>21f</b>)</h4><div class="NLM_p last">The title compound was prepared according to the general procedure D from 5-(trifluoromethyl)pyridin-2-amine, nicotinaldehyde, and isocyanide <b>13a</b> to afford a yellow solid (0.13 g, 37%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.61 (s, 1H), 10.30 (brs, 1H), 9.26 (s, 1H), 8.57 (d, <i>J</i> = 4.0 Hz, 1H), 8.38–8.28 (m, 2H), 7.62 (d, <i>J</i> = 9.4 Hz, 1H), 7.53–7.47 (m, 2H), 7.47–7.41 (m, 1H), 7.29 (dd, <i>J</i> = 9.4, 1.8 Hz, 1H), 7.21–7.14 (m, 2H), 4.20–4.13 (m, 2H), 3.77 (t, <i>J</i> = 5.3 Hz, 1H), 1.53 (s, 9H), 1.50 (s, 9H). UPLC/MS: <i>t</i><sub>r</sub> 2.18 min, <i>m</i>/<i>z</i> 626.7 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_72" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> 1-Boc-3-(4-(((6-fluoro-2-(pyridin-3-yl)imidazo[1,2-<i>a</i>]pyridin-3-yl)amino)methyl)phenyl)guanidine (<b>21g</b>)</h4><div class="NLM_p last">The title compound was prepared according to the general procedure D from 5-fluoropyridin-2-amine, nicotinaldehyde, and isocyanide <b>13a</b> and using 2,2,2-trifluoroethanol (8 mL) as a solvent to afford a yellow solid (0.25 g, 65%). <sup>1</sup>H NMR (400 MHz, MeOD) δ 9.06 (dd, <i>J</i> = 2.2, 0.8 Hz, 1H), 8.46 (dd, <i>J</i> = 4.9, 1.6 Hz, 1H), 8.32 (ddd, <i>J</i> = 8.0, 2.2, 1.7 Hz, 1H), 8.21 (ddd, <i>J</i> = 4.2, 2.4, 0.7 Hz, 1H), 7.54–7.45 (m, 2H), 7.31–7.23 (m, 1H), 7.14 (d, <i>J</i> = 8.5 Hz, 2H), 7.04 (d, <i>J</i> = 8.5 Hz, 2H), 4.13 (s, 2H), 1.47 (s, 9H). <sup>13</sup>C NMR (101 MHz, MeOD) δ 153.73, 148.64 (d, <i>J</i> = 3.1 Hz), 140.94, 137.64, 136.39, 135.16, 131.77, 130.68, 129.86, 125.04 (d, <i>J</i> = 32.7 Hz),124.87, 118.64, 118.42 (d, <i>J</i> = 8.9 Hz), 111.04 (d, <i>J</i> = 42.1 Hz), 79.98, 52.05, 28.64. UPLC/MS: <i>t</i><sub>r</sub> 1.28 min, <i>m</i>/<i>z</i> 476.5 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_73" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> <i>N</i>-Butyl-3-((4-(2,3-di-Boc-guanidino)benzyl)amino)-2-(pyridin-3-yl)imidazo[1,2-<i>a</i>]pyridine-6-carboxamide (<b>21h</b>)</h4><div class="NLM_p last">The title compound was prepared according to the general procedure D from aminopyridine <b>20b</b>, nicotinaldehyde, andisocyanide <b>13a</b> to afford a yellow solid (0.23 g, 47%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.67 (s, 1H), 9.43 (d, <i>J</i> = 1.4 Hz, 1H), 9.24 (s, 1H), 8.55 (dd, <i>J</i> = 4.8, 1.5 Hz, 1H), 8.50–8.42 (m, 1H), 7.65 (d, <i>J</i> = 9.5 Hz, 1H), 7.54 (d, <i>J</i> = 9.4 Hz, 1H), 7.41 (dd, <i>J</i> = 7.9, 4.8 Hz, 1H), 7.30 (d, <i>J</i> = 8.3 Hz, 2H), 7.18 (d, <i>J</i> = 8.3 Hz, 2H), 7.04–6.88 (m, 1H), 4.59–4.40 (m, 1H), 4.08 (d, <i>J</i> = 5.6 Hz, 2H), 3.31–3.16 (m, 2H), 1.62–1.47 (m, 11H), 1.45 (s, 9H), 1.41–1.30 (m, 2H), 0.92 (t, <i>J</i> = 7.3 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 164.95, 155.02, 153.40, 148.22, 148.00, 141.87, 136.22, 135.73, 134.69, 130.10, 129.13, 128.29, 125.24, 124.69, 123.92, 123.56, 120.76, 116.29, 84.18, 80.26, 52.47, 40.31, 31.58, 28.29, 28.25, 20.42, 13.97. UPLC/MS: <i>t</i><sub>r</sub> 2.00 min, <i>m</i>/<i>z</i> 657.7 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_74" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> 3-((4-(2,3-Di-Boc-guanidino)benzyl)amino)-2-(pyridin-3-yl)imidazo[1,2-<i>a</i>]pyridine-6-carboxamide (<b>21i</b>)</h4><div class="NLM_p last">The title compound was prepared according to the general procedure D from 6-aminonicotinamide, nicotinaldehyde, and isocyanide <b>13a</b>. The crude product was purified by an Isolera, using reversed phase chromatography and by applying gradient of 10–100% of MeOH in water to afford a yellow solid (0.30 g, 68%). UPLC/MS: <i>t</i><sub>r</sub> 1.76 min, <i>m</i>/<i>z</i> 601.7 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_75" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> 1-(4-(((8-Methyl-2-(pyridin-3-yl)imidazo[1,2-<i>a</i>]pyridin-3-yl)amino)methyl)phenyl)guanidine (<b>22a</b>)</h4><div class="NLM_p last">Boc deprotection of compound <b>21a</b> was done using the general procedure E, affording the title compound (<b>22a</b>) as an orange oil (0.04 g, 99%). <sup>1</sup>H NMR (400 MHz, MeOD) δ 8.77 (brs, 1H), 8.65 (dd, <i>J</i> = 4.9, 1.4 Hz, 1H), 8.57 (d, <i>J</i> = 6.8 Hz, 1H), 8.28–8.23 (m, 1H), 7.73 (d, <i>J</i> = 7.2 Hz, 1H), 7.63 (dd, <i>J</i> = 8.0, 5.0 Hz, 1H), 7.40 (t, <i>J</i> = 7.0 Hz, 1H), 7.21 (d, <i>J</i> = 8.4 Hz, 2H), 7.09 (d, <i>J</i> = 8.4 Hz, 2H), 4.24 (s, 2H), 2.67 (s, 3H). <sup>13</sup>C NMR (101 MHz, MeOD) δ 158.03, 149.97, 148.98, 139.47, 139.41, 138.74, 135.56, 133.41, 130.91, 130.05, 126.35, 125.61, 124.96, 124.79, 123.87, 117.88, 51.42, 15.99. UPLC/MS: <i>t</i><sub>r</sub> 0.26 min, <i>m</i>/<i>z</i> 372.5 [M + H]<sup>+</sup>, purity 98%. HRMS: mass calculated for C<sub>21</sub>H<sub>22</sub>N<sub>7</sub>, 372.1937; found, 372.1935.</div></div><div id="sec4_1_5_76" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> Methyl 3-((4-Guanidinobenzyl)amino)-2-(pyridin-3-yl)imidazo[1,2-<i>a</i>]pyridine-7-carboxylate (<b>22b</b>)</h4><div class="NLM_p last">Boc deprotection of compound <b>21b</b> was done using the general procedure E, affording the title compound (<b>22b</b>) as an orange oil (0.09 g, 94%). <sup>1</sup>H NMR (400 MHz, MeOD) δ 9.13 (brs, 1H), 8.73–8.59 (m, 2H), 8.39 (dd, <i>J</i> = 7.2, 0.7 Hz, 1H), 8.25–8.20 (m, 1H), 7.84–7.73 (m, 1H), 7.53 (dd, <i>J</i> = 7.2, 1.5 Hz, 1H), 7.26 (d, <i>J</i> = 8.4 Hz, 2H), 7.10 (d, <i>J</i> = 8.4 Hz, 2H), 4.26 (s, 2H), 3.98 (s, 3H). UPLC/MS: <i>t</i><sub>r</sub> 1.09 min, <i>m</i>/<i>z</i> 416.5 [M + H]<sup>+</sup>, purity 97%. HRMS: mass calculated for C<sub>22</sub>H<sub>22</sub>N<sub>7</sub>O<sub>2</sub>, 416.1835; found, 416.1846.</div></div><div id="sec4_1_5_77" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> 3-((4-Guanidinobenzyl)amino)-2-(pyridin-3-yl)imidazo[1,2-<i>a</i>]pyridine-7-carboxylic Acid (<b>22c</b>)</h4><div class="NLM_p last">Boc deprotection of compound <b>21c</b> was done using the general procedure E, affording the title compound (<b>22c</b>) as a yellow solid (0.05 g, 93%). <sup>1</sup>H NMR (400 MHz, MeOD) δ 9.12 (brs, 1H), 8.72–8.58 (m, 2H), 8.42 (dd, <i>J</i> = 7.2, 0.7 Hz, 1H), 8.28–8.21 (m, 1H), 7.85–7.75 (m, 1H), 7.58 (dd, <i>J</i> = 7.2, 1.5 Hz, 1H), 7.26 (d, <i>J</i> = 8.4 Hz, 2H), 7.11 (d, <i>J</i> = 8.4 Hz, 2H), 4.27 (s, 2H). <sup>13</sup>C NMR (101 MHz, MeOD) δ 158.01, 157.23, 146.21, 145.55, 140.02, 139.75, 137.59, 137.31, 135.57, 131.09, 126.35, 124.95, 121.19, 118.91, 114.16, 51.83. UPLC/MS: <i>t</i><sub>r</sub> 0.17 min, <i>m</i>/<i>z</i> 402.3 [M + H]<sup>+</sup>, purity 98%. HRMS: mass calculated for C<sub>21</sub>H<sub>20</sub>N<sub>7</sub>O<sub>2</sub>, 402.1678; found, 402.1673.</div></div><div id="sec4_1_5_78" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> <i>N</i>-Butyl-3-((4-guanidinobenzyl)amino)-2-(pyridin-3-yl)imidazo[1,2-<i>a</i>]pyridine-7-carboxamide (<b>22d</b>)</h4><div class="NLM_p last">Boc deprotection of compound <b>21d</b> was done using the general procedure E, affording the title compound (<b>22d</b>) as a light-yellow solid (0.08 g, 100%), mp 148–150 °C. <sup>1</sup>H NMR (400 MHz, DMSO) δ 9.84 (s, 1H), 9.26–9.17 (m, 1H), 8.75 (t, <i>J</i> = 5.5 Hz, 1H), 8.68 (d, <i>J</i> = 4.3 Hz, 1H), 8.61 (d, <i>J</i> = 8.0 Hz, 1H), 8.45 (d, <i>J</i> = 7.1 Hz, 1H), 8.11 (s, 1H), 7.76 (dd, <i>J</i> = 8.0, 5.2 Hz, 1H), 7.55–7.38 (m, 5H), 7.30 (d, <i>J</i> = 8.3 Hz, 2H), 7.09 (d, <i>J</i> = 8.3 Hz, 2H), 5.90 (s, 1H), 4.17 (s, 2H), 3.37–3.23 (m, 2H), 1.60–1.47 (m, 2H), 1.42–1.28 (m, 2H), 0.92 (t, <i>J</i> = 7.3 Hz, 3H). UPLC/MS: <i>t</i><sub>r</sub> 1.13 min, <i>m</i>/<i>z</i> 457.5 [M + H]<sup>+</sup>, purity >99%. HRMS: mass calculated for C<sub>25</sub>H<sub>29</sub>N<sub>8</sub>O, 457.2464; found, 457.2446.</div></div><div id="sec4_1_5_79" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> 1-(4-(((6-Methyl-2-(pyridin-3-yl)imidazo[1,2-<i>a</i>]pyridin-3-yl)amino)methyl)phenyl)guanidine (<b>22e</b>)</h4><div class="NLM_p last">Boc deprotection of compound <b>21e</b> was done using the general procedure E, affording the title compound (<b>22e</b>) as an orange oil (0.07 g, 95%). <sup>1</sup>H NMR (400 MHz, MeOD) δ 8.82 (s, 1H), 8.64 (d, <i>J</i> = 4.5 Hz, 1H), 8.52–8.46 (m, 1H), 8.28–8.20 (m, 1H), 7.87–7.74 (m, 2H), 7.63 (dd, <i>J</i> = 8.0, 5.0 Hz, 1H), 7.25 (d, <i>J</i> = 8.5 Hz, 2H), 7.10 (d, <i>J</i> = 8.5 Hz, 2H), 4.26 (s, 2H), 2.52 (d, <i>J</i> = 0.9 Hz, 3H). <sup>13</sup>C NMR (101 MHz, MeOD) δ 158.03, 149.95, 148.35, 139.43, 138.13, 137.99, 137.33, 135.62, 131.05, 129.50, 128.95, 126.33, 125.81, 124.74, 123.98, 112.80, 51.54, 18.15. UPLC/MS: <i>t</i><sub>r</sub> 0.28 min, <i>m</i>/<i>z</i> 372.4 [M + H]<sup>+</sup>, purity 98%. HRMS: mass calculated for C<sub>21</sub>H<sub>22</sub>N<sub>7</sub>, 372.1937; found, 372.1938.</div></div><div id="sec4_1_5_80" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> 1-(4-(((2-(Pyridin-3-yl)-6-(trifluoromethyl)imidazo[1,2-<i>a</i>]pyridin-3-yl)amino)methyl)phenyl)guanidine (<b>22f</b>)</h4><div class="NLM_p last">Boc deprotection of compound <b>21f</b> was done using the general procedure E, affording the title compound (<b>22f</b>) as a colorless oil (0.08 g, 95%). <sup>1</sup>H NMR (400 MHz, MeOD) δ 9.17 (s, 1H), 8.66 (d, <i>J</i> = 8.2 Hz, 1H), 8.64–8.56 (m, 2H), 7.74 (dd, <i>J</i> = 8.0, 5.2 Hz, 1H), 7.69 (d, <i>J</i> = 9.5 Hz, 1H), 7.52 (dd, <i>J</i> = 9.5, 1.7 Hz, 1H), 7.26 (d, <i>J</i> = 8.4 Hz, 2H), 7.10 (d, <i>J</i> = 8.4 Hz, 2H), 4.24 (s, 2H). UPLC/MS: <i>t</i><sub>r</sub> 1.24 min, <i>m</i>/<i>z</i> 426.5 [M + H]<sup>+</sup>, purity >99%.</div></div><div id="sec4_1_5_81" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> 1-(4-(((6-Fluoro-2-(pyridin-3-yl)imidazo[1,2-<i>a</i>]pyridin-3-yl)amino)methyl)phenyl)guanidine (<b>22g</b>)</h4><div class="NLM_p last">Boc deprotection of compound <b>21g</b> was done using the general procedure E, affording the title compound (<b>22g</b>) as a yellow solid (0.17 g, 96%), mp 141 °C. <sup>1</sup>H NMR (400 MHz, MeOD) δ 9.03 (d, <i>J</i> = 1.7 Hz, 1H), 8.70 (dd, <i>J</i> = 5.3, 1.4 Hz, 1H), 8.68–8.64 (m, 1H), 8.60–8.54 (m, 1H), 7.88–7.72 (m, 3H), 7.26 (d, <i>J</i> = 8.4 Hz, 2H), 7.10 (d, <i>J</i> = 8.4 Hz, 2H), 4.25 (s, 2H). <sup>13</sup>C NMR (101 MHz, MeOD) δ 157.96, 157.35, 154.95, 146.61, 145.43, 140.42, 139.40, 138.42, 135.65, 131.16, 131.01 (d, <i>J</i> = 2.3 Hz), 129.26, 128.06, 126.84, 126.27, 123.85 (d, <i>J</i> = 26.4 Hz), 116.36 (d, <i>J</i> = 8.7 Hz), 113.06 (d, <i>J</i> = 42.6 Hz), 51.58. UPLC/MS: <i>t</i><sub>r</sub> 0.26 min, <i>m</i>/<i>z</i> 376.3 [M + H]<sup>+</sup>, purity >99%. HRMS: mass calculated for C<sub>20</sub>H<sub>19</sub>N<sub>7</sub>F, 376.1686; found, 376.1685.</div></div><div id="sec4_1_5_82" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> <i>N</i>-Butyl-3-((4-guanidinobenzyl)amino)-2-(pyridin-3-yl)imidazo[1,2-<i>a</i>]pyridine-6-carboxamide (<b>22h</b>)</h4><div class="NLM_p last">Boc deprotection of compound <b>21h</b> was done using the general procedure E, affording the title compound (<b>22h</b>) as a yellow oil (0.13 g, 96%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 9.91 (s, 1H), 9.21 (d, <i>J</i> = 1.7 Hz, 1H), 8.82 (s, 1H), 8.75 (t, <i>J</i> = 5.5 Hz, 1H), 8.65 (dd, <i>J</i> = 5.0, 1.3 Hz, 1H), 8.58 (d, <i>J</i> = 8.0 Hz, 1H), 7.85 (d, <i>J</i> = 9.4 Hz, 1H), 7.75–7.66 (m, 2H), 7.53 (brs, 4H), 7.31 (d, <i>J</i> = 8.3 Hz, 2H), 7.10 (d, <i>J</i> = 8.3 Hz, 2H), 4.18 (s, 2H), 3.36–3.25 (m, 2H), 1.59–1.49 (m, 2H), 1.42–1.30 (m, 2H), 0.92 (t, <i>J</i> = 7.3 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 163.53, 155.85, 145.69, 144.78, 140.28, 137.58, 136.99, 134.43, 129.55, 128.91, 125.42, 124.94, 124.19, 120.83, 115.08, 50.71, 40.15, 31.22, 19.69, 13.76. UPLC/MS: <i>t</i><sub>r</sub> 1.12 min, <i>m</i>/<i>z</i> 457.5 [M + H]<sup>+</sup>, purity >99%. HRMS: mass calculated for C<sub>25</sub>H<sub>29</sub>N<sub>8</sub>O, 457.2464; found, 457.2477.</div></div><div id="sec4_1_5_83" class="NLM_sec NLM_sec_level_3"><div id="ac_i104" class="anchor-spacer"></div><h4 class="article-section__title" id="_i104"> 3-((4-Guanidinobenzyl)amino)-2-(pyridin-3-yl)imidazo[1,2-<i>a</i>]pyridine-6-carboxamide (<b>22i</b>)</h4><div class="NLM_p last">Boc deprotection of compound <b>21i</b> was done using the general procedure E, affording the title compound (<b>22i</b>) as an orange oil (0.11 g, 100%). <sup>1</sup>H NMR (400 MHz, MeOD) δ 9.17 (brs, 1H), 8.95 (dd, <i>J</i> = 1.6, 1.0 Hz, 1H), 8.77–8.70 (m, 2H), 8.10 (dd, <i>J</i> = 9.4, 1.7 Hz, 1H), 7.96–7.88 (m, 1H), 7.79 (dd, <i>J</i> = 9.4, 0.9 Hz, 1H), 7.28 (d, <i>J</i> = 8.4 Hz, 2H), 7.11 (d, <i>J</i> = 8.4 Hz, 2H), 4.28 (s, 2H). <sup>13</sup>C NMR (101 MHz, MeOD) δ 167.86, 157.93, 145.44, 144.35, 141.52, 141.47, 139.61, 135.72, 131.22, 131.16, 130.22, 130.01, 127.65, 127.58, 127.35, 126.34, 123.81, 114.99, 52.23. UPLC/MS: <i>t</i><sub>r</sub> 0.17 min, <i>m</i>/<i>z</i> 401.4 [M + H]<sup>+</sup>, purity 98%. HRMS: mass calculated for C<sub>21</sub>H<sub>21</sub>N<sub>8</sub>O, 401.1838; found, 401.1838.</div></div><div id="sec4_1_5_84" class="NLM_sec NLM_sec_level_3"><div id="ac_i105" class="anchor-spacer"></div><h4 class="article-section__title" id="_i105"> 2-Amino-<i>N</i>-cyclopropylisonicotinamide (<b>23a</b>)</h4><div class="NLM_p last">The title compound was prepared according to the general procedure C using cyclopropanamine to afford a white solid (0.51 g, 89%). <sup>1</sup>H NMR (400 MHz, MeOD) δ 7.96 (dd, <i>J</i> = 5.4, 0.8 Hz, 1H), 6.87 (dd, <i>J</i> = 1.5, 0.8 Hz, 1H), 6.84 (dd, <i>J</i> = 5.4, 1.5 Hz, 1H), 2.87–2.79 (m, 1H), 0.84–0.77 (m, 2H), 0.66–0.59 (m, 2H). <sup>13</sup>C NMR (101 MHz, MeOD) δ 170.31, 161.43, 148.75, 145.18, 110.95, 108.14, 23.97, 6.48. UPLC/MS: <i>t</i><sub>r</sub> 0.18 min, <i>m</i>/<i>z</i> 178.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_85" class="NLM_sec NLM_sec_level_3"><div id="ac_i106" class="anchor-spacer"></div><h4 class="article-section__title" id="_i106"> 2-Amino-<i>N</i>-(4-fluorobenzyl)isonicotinamide (<b>23b</b>)</h4><div class="NLM_p last">The title compound was prepared according to the general procedure C using (4-fluorophenyl)methanamine to afford a white solid (0.70 g, 87%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 9.08 (brs, 1H), 8.00 (d, <i>J</i> = 5.1 Hz, 1H), 7.39–7.28 (m, 2H), 7.21–7.09 (m, 2H), 6.89–6.80 (m, 2H), 6.14 (s, 2H), 4.42 (s, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 165.61, 161.18 (d, <i>J</i> = 242.1 Hz), 160.31, 148.35, 142.70, 135.59 (d, <i>J</i> = 3.0 Hz), 129.21 (d, <i>J</i> = 8.1 Hz), 115.01 (d, <i>J</i> = 21.3 Hz), 109.04, 106.08, 41.86. UPLC/MS: <i>t</i><sub>r</sub> 1.09 min, <i>m</i>/<i>z</i> 246.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_86" class="NLM_sec NLM_sec_level_3"><div id="ac_i107" class="anchor-spacer"></div><h4 class="article-section__title" id="_i107"> 2-Amino-<i>N</i>-cyclopentylisonicotinamide (<b>23c</b>)</h4><div class="NLM_p last">The title compound was prepared according to the general procedure C using cyclopentanamine to afford a white solid (0.61 g, 90%). <sup>1</sup>H NMR (400 MHz, MeOD) δ 7.96 (d, <i>J</i> = 5.0, 1H), 6.89–6.83 (m, 2H), 4.28 (p, <i>J</i> = 6.9 Hz, 1H), 2.08–1.95 (m, 2H), 1.83–1.71 (m, 2H), 1.69–1.50 (m, 4H). <sup>13</sup>C NMR (101 MHz, MeOD) δ 168.67, 161.36, 148.66, 145.75, 111.14, 108.23, 53.04, 33.32, 24.93. UPLC/MS: <i>t</i><sub>r</sub> 0.18 min, <i>m</i>/<i>z</i> 206.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_87" class="NLM_sec NLM_sec_level_3"><div id="ac_i108" class="anchor-spacer"></div><h4 class="article-section__title" id="_i108"> 2-Amino-<i>N</i>-(2-hydroxyethyl)isonicotinamide (<b>23d</b>)</h4><div class="NLM_p last">The title compound was prepared according to the general procedure C using 2-aminoethan-1-ol to afford a white solid (0.49 g, 86%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.41 (t, <i>J</i> = 5.5 Hz, 1H), 7.97 (d, <i>J</i> = 5.2 Hz, 1H), 6.84–6.79 (m, 2H), 6.10 (s, 2H), 4.72 (t, <i>J</i> = 5.6 Hz, 1H), 3.49 (q, <i>J</i> = 6.0 Hz, 2H), 3.29 (q, <i>J</i> = 6.1 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 165.65, 160.27, 148.22, 142.95, 109.10, 106.07, 59.59, 42.09. UPLC/MS: <i>t</i><sub>r</sub> 0.17 min, <i>m</i>/<i>z</i> 182.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_88" class="NLM_sec NLM_sec_level_3"><div id="ac_i109" class="anchor-spacer"></div><h4 class="article-section__title" id="_i109"> 2-Amino-<i>N</i>-(2-(4-methylpiperazin-1-yl)ethyl)isonicotinamide (<b>23e</b>)</h4><div class="NLM_p last">The title compound was prepared according to the general procedure C using 2-(4-methylpiperazin-1-yl)ethan-1-amine to afford a white solid (0.45 g, 97%). <sup>1</sup>H NMR (400 MHz, MeOD) δ 7.98 (dd, <i>J</i> = 5.4, 0.7 Hz, 1H), 6.90 (dd, <i>J</i> = 1.5, 0.7 Hz, 1H), 6.87 (dd, <i>J</i> = 5.4, 1.5 Hz, 1H), 3.51 (t, <i>J</i> = 6.8 Hz, 2H), 2.60 (t, <i>J</i> = 6.8 Hz, 2H), 2.57–2.34 (m, 8H), 2.28 (s, 3H). <sup>13</sup>C NMR (101 MHz, MeOD) δ 168.70, 161.47, 148.81, 145.28, 110.89, 108.14, 57.90, 55.65, 53.67, 45.98, 37.95. UPLC/MS: <i>t</i><sub>r</sub> 0.16 min, <i>m</i>/<i>z</i> 264.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_89" class="NLM_sec NLM_sec_level_3"><div id="ac_i110" class="anchor-spacer"></div><h4 class="article-section__title" id="_i110"> <i>N</i>-Butyl-3-((4-(2,3-di-Boc-guanidino)benzyl)amino)imidazo[1,2-<i>a</i>]pyridine-7-carboxamide (<b>24a</b>)</h4><div class="NLM_p last">The title compound was prepared according to the general procedure D from aminopyridine <b>20a</b>, glyoxylic acid monohydrate, and isocyanide <b>13a</b> to afford a light-yellow solid (0.24 g, 42%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.61 (s, 1H), 10.27 (brs, 1H), 8.29 (d, <i>J</i> = 6.7 Hz, 1H), 7.98 (s, 1H), 7.58 (brs, 1H), 7.51 (d, <i>J</i> = 6.8 Hz, 1H), 7.37 (d, <i>J</i> = 8.3 Hz, 2H), 7.21 (d, <i>J</i> = 8.3 Hz, 2H), 6.88 (s, 1H), 5.09 (brs, 1H), 4.12 (s, 2H), 3.52–3.34 (m, 2H), 1.68–1.59 (m, 2H), 1.54 (s, 9H), 1.46–1.32 (m, 11H), 0.92 (t, <i>J</i> = 7.3 Hz, 3H). UPLC/MS: <i>t</i><sub>r</sub> 1.94 min, <i>m</i>/<i>z</i> 580.6 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_90" class="NLM_sec NLM_sec_level_3"><div id="ac_i111" class="anchor-spacer"></div><h4 class="article-section__title" id="_i111"> <i>N</i>-Cyclopropyl-3-((4-(2,3-di-Boc-guanidino)benzyl)amino)imidazo[1,2-<i>a</i>]pyridine-7-carboxamide (<b>24b</b>)</h4><div class="NLM_p last">The title compound was prepared according to the general procedure D from aminopyridine <b>23a</b>, glyoxylic acid monohydrate, and isocyanide <b>13a</b> to afford a light-yellow solid (0.30 g, 48%). UPLC/MS: <i>t</i><sub>r</sub> 1.85 min, <i>m</i>/<i>z</i> 564.6 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_91" class="NLM_sec NLM_sec_level_3"><div id="ac_i112" class="anchor-spacer"></div><h4 class="article-section__title" id="_i112"> 3-((4-(2,3-Di-Boc-guanidino)benzyl)amino)-<i>N</i>-(4-fluorobenzyl)imidazo[1,2-<i>a</i>]pyridine-7-carboxamide (<b>24c</b>)</h4><div class="NLM_p last">The title compound was prepared according to the general procedure D from aminopyridine <b>23b</b>, glyoxylic acid monohydrate, and isocyanide <b>13a</b> to afford a light-yellow solid (0.32 g, 50%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.61 (s, 1H), 10.28 (s, 1H), 8.09–7.98 (m, 2H), 7.50 (d, <i>J</i> = 8.4 Hz, 2H), 7.43–7.30 (m, 5H), 7.03–6.95 (m, 2H), 6.91 (s, 1H), 4.57 (d, <i>J</i> = 5.6 Hz, 2H), 4.23 (s, 2H), 1.54 (s, 9H), 1.39 (s, 9H). UPLC/MS: <i>t</i><sub>r</sub> 1.97 min, <i>m</i>/<i>z</i> 632.6 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_92" class="NLM_sec NLM_sec_level_3"><div id="ac_i113" class="anchor-spacer"></div><h4 class="article-section__title" id="_i113"> <i>N</i>-Cyclopentyl-3-((4-(2,3-di-Boc-guanidino)benzyl)amino)imidazo[1,2-<i>a</i>]pyridine-7-carboxamide (<b>24d</b>)</h4><div class="NLM_p last">The title compound was prepared according to the general procedure D from aminopyridine <b>23c</b>, glyoxylic acid monohydrate, and isocyanide <b>13a</b> to afford a light-yellow solid (0.26 g, 43%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.96 (d, <i>J</i> = 7.2 Hz, 1H), 7.84 (brs, 1H), 7.53 (d, <i>J</i> = 8.5 Hz, 2H), 7.29 (d, <i>J</i> = 8.5 Hz, 2H), 7.23 (dd, <i>J</i> = 7.2, 1.4 Hz, 1H), 7.04 (s, 1H), 4.42–4.30 (m, 1H), 4.22 (s, 2H), 2.14–1.98 (m, 2H), 1.81–1.60 (m, 4H), 1.58–1.49 (m, 11H), 1.46 (s, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 165.68, 163.44, 153.56, 139.62, 136.15, 135.05, 132.75, 129.24, 128.55, 122.83, 122.72, 121.81, 115.79, 110.64, 83.99, 79.88, 51.99, 50.36, 33.17, 33.14, 28.28, 28.20, 24.00. UPLC/MS: <i>t</i><sub>r</sub> 1.91 min, <i>m</i>/<i>z</i> 592.6 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_93" class="NLM_sec NLM_sec_level_3"><div id="ac_i114" class="anchor-spacer"></div><h4 class="article-section__title" id="_i114"> 3-((4-(2,3-Di-Boc-guanidino)benzyl)amino)-<i>N</i>-(2-hydroxyethyl)imidazo[1,2-<i>a</i>]pyridine-7-carboxamide (<b>24e</b>)</h4><div class="NLM_p last">The title compound was prepared according to the general procedure D from aminopyridine <b>23d</b>, glyoxylic acid monohydrate, and isocyanide <b>13a</b> to afford a light-yellow solid (0.38 g, 61%). UPLC/MS: <i>t</i><sub>r</sub> 1.74 min, <i>m</i>/<i>z</i> 568.6 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_94" class="NLM_sec NLM_sec_level_3"><div id="ac_i115" class="anchor-spacer"></div><h4 class="article-section__title" id="_i115"> 3-((4-(2,3-Di-Boc-guanidino)benzyl)amino)-<i>N</i>-(2-(4-methylpiperazin-1-yl)ethyl)imidazo[1,2-<i>a</i>]pyridine-7-carboxamide (<b>24f</b>)</h4><div class="NLM_p last">The title compound was prepared according to the general procedure D from aminopyridine <b>23e</b>, glyoxylic acid monohydrate, and isocyanide <b>13a</b> to afford a light-yellow solid (0.40 g, 58%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.63 (s, 1H), 10.33 (s, 1H), 7.98 (d, <i>J</i> = 5.6 Hz, 1H), 7.89 (brs, 1H), 7.58 (d, <i>J</i> = 8.4 Hz, 2H), 7.36 (d, <i>J</i> = 8.4 Hz, 2H), 7.23–7.16 (m, 1H), 7.10 (s, 1H), 4.32 (d, <i>J</i> = 4.0 Hz, 2H), 3.67–3.50 (m, 2H), 2.96–2.48 (m, 10H), 2.33 (s, 3H), 1.53 (s, 9H), 1.49 (s, 9H). UPLC/MS: <i>t</i><sub>r</sub> 1.58 min, <i>m</i>/<i>z</i> 650.9 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5_95" class="NLM_sec NLM_sec_level_3"><div id="ac_i116" class="anchor-spacer"></div><h4 class="article-section__title" id="_i116"> <i>N</i>-Butyl-3-((4-guanidinobenzyl)amino)imidazo[1,2-<i>a</i>]pyridine-7-carboxamide (<b>25a</b>)</h4><div class="NLM_p last">Boc deprotection of compound <b>24a</b> was done using the general procedure E, affording the title compound (<b>25a</b>) as a yellow oil (0.08 mg, 100%). <sup>1</sup>H NMR (400 MHz, MeOD) δ 8.61 (dd, <i>J</i> = 7.2, 0.7 Hz, 1H), 8.24–8.20 (m, 1H), 7.77 (dd, <i>J</i> = 7.2, 1.6 Hz, 1H), 7.58 (d, <i>J</i> = 8.5 Hz, 2H), 7.32–7.27 (m, 3H), 4.52 (s, 2H), 3.43 (t, <i>J</i> = 7.2 Hz, 2H), 1.69–1.58 (m, 2H), 1.50–1.37 (m, 2H), 0.98 (t, <i>J</i> = 7.4 Hz, 3H). <sup>13</sup>C NMR (101 MHz, MeOD) δ 165.84, 158.08, 138.72, 137.64, 136.82, 136.31, 135.56, 130.33, 126.66, 125.32, 115.16, 112.36, 105.46, 49.35, 41.16, 32.40, 21.17, 14.10. UPLC/MS: <i>t</i><sub>r</sub> 0.62 min, <i>m</i>/<i>z</i> 380.4 [M + H]<sup>+</sup>, purity >99%. HRMS: mass calculated for C<sub>20</sub>H<sub>26</sub>N<sub>7</sub>O, 380.2199; found, 380.2214.</div></div><div id="sec4_1_5_96" class="NLM_sec NLM_sec_level_3"><div id="ac_i117" class="anchor-spacer"></div><h4 class="article-section__title" id="_i117"> <i>N</i>-Cyclopropyl-3-((4-guanidinobenzyl)amino)imidazo[1,2-<i>a</i>]pyridine-7-carboxamide (<b>25b</b>)</h4><div class="NLM_p last">Boc deprotection of compound <b>24b</b> was done using the general procedure E, affording the title compound (<b>25b</b>) as a yellow solid (0.11 mg, 96%), mp 80 °C. <sup>1</sup>H NMR (400 MHz, MeOD) δ 8.61 (d, <i>J</i> = 7.3 Hz, 1H), 8.25–8.18 (m, 1H), 7.76 (dd, <i>J</i> = 7.3, 1.6 Hz, 1H), 7.58 (d, <i>J</i> = 8.5 Hz, 2H), 7.34–7.25 (m, 3H), 4.52 (s, 2H), 2.96–2.87 (m, 1H), 0.89–0.82 (m, 2H), 0.73–0.66 (m, 2H). <sup>13</sup>C NMR (101 MHz, MeOD) δ 167.35, 158.09, 138.70, 137.38, 136.71, 136.37, 135.59, 130.33, 126.67, 125.31, 115.23, 112.34, 105.28, 49.34, 24.38, 6.53. UPLC/MS: <i>t</i><sub>r</sub> 0.26 min, <i>m</i>/<i>z</i> 364.3 [M + H]<sup>+</sup>, purity >99%. HRMS: mass calculated for C<sub>19</sub>H<sub>22</sub>N<sub>7</sub>O, 364.1886; found, 364.1879.</div></div><div id="sec4_1_5_97" class="NLM_sec NLM_sec_level_3"><div id="ac_i118" class="anchor-spacer"></div><h4 class="article-section__title" id="_i118"> <i>N</i>-(4-Fluorobenzyl)-3-((4-guanidinobenzyl)amino)imidazo[1,2-<i>a</i>]pyridine-7-carboxamide (<b>25c</b>)</h4><div class="NLM_p last">Boc deprotection of compound <b>24c</b> was done using the general procedure E, affording the title compound (<b>25c</b>) as a yellow oil (0.08 mg, 97%). <sup>1</sup>H NMR (400 MHz, MeOD) δ 8.62 (dd, <i>J</i> = 7.3, 0.8 Hz, 1H), 8.30–8.21 (m, 1H), 7.80 (dd, <i>J</i> = 7.3, 1.6 Hz, 1H), 7.58 (d, <i>J</i> = 8.4 Hz, 2H), 7.45–7.36 (m, 2H), 7.35–7.24 (m, 3H), 7.12–7.00 (m, 2H), 4.59 (s, 2H), 4.52 (s, 2H). <sup>13</sup>C NMR (101 MHz, MeOD) δ 165.78, 163.58 (d, <i>J</i> = 244.2 Hz), 158.09, 138.70, 137.42, 136.73, 136.40, 135.62 (d, <i>J</i> = 3.4 Hz), 135.59, 130.79 (d, <i>J</i> = 8.2 Hz), 130.33, 126.68, 125.40, 116.23 (d, <i>J</i> = 21.7 Hz), 115.23, 112.49, 105.31, 49.34, 44.24. UPLC/MS: <i>t</i><sub>r</sub> 1.75 min, <i>m</i>/<i>z</i> 432.4 [M + H]<sup>+</sup>, purity >99%. HRMS: mass calculated for C<sub>23</sub>H<sub>23</sub>N<sub>7</sub>OF, 432.1948; found, 432.1956.</div></div><div id="sec4_1_5_98" class="NLM_sec NLM_sec_level_3"><div id="ac_i119" class="anchor-spacer"></div><h4 class="article-section__title" id="_i119"> <i>N</i>-Cyclopentyl-3-((4-guanidinobenzyl)amino)imidazo[1,2-<i>a</i>]pyridine-7-carboxamide (<b>25d</b>)</h4><div class="NLM_p last">Boc deprotection of compound <b>24d</b> was done using the general procedure E, affording the title compound (<b>25d</b>) as a yellow oil (0.09 mg, 100%). <sup>1</sup>H NMR (400 MHz, MeOD) δ 8.61 (dd, <i>J</i> = 7.2, 0.9 Hz, 1H), 8.22 (dd, <i>J</i> = 1.6, 1.0 Hz, 1H), 7.79 (dd, <i>J</i> = 7.2, 1.6 Hz, 1H), 7.59 (d, <i>J</i> = 8.5 Hz, 2H), 7.33–7.26 (m, 3H), 4.52 (s, 2H), 4.40–4.28 (m, 1H), 2.13–2.00 (m, 2H), 1.88–1.74 (m, 2H), 1.72–1.57 (m, 4H). <sup>13</sup>C NMR (101 MHz, MeOD) δ 165.69, 158.09, 138.73, 137.93, 136.76, 136.33, 135.59, 130.34, 126.68, 125.26, 115.43, 112.34, 105.22, 53.56, 49.36, 33.32, 24.96. UPLC/MS: <i>t</i><sub>r</sub> 0.60 min, <i>m</i>/<i>z</i> 392.6 [M + H]<sup>+</sup>, purity >99%). HRMS: mass calculated for C<sub>21</sub>H<sub>26</sub>N<sub>7</sub>O, 392.2199; found, 392.2180.</div></div><div id="sec4_1_5_99" class="NLM_sec NLM_sec_level_3"><div id="ac_i120" class="anchor-spacer"></div><h4 class="article-section__title" id="_i120"> 3-((4-Guanidinobenzyl)amino)-<i>N</i>-(2-hydroxyethyl)imidazo[1,2-<i>a</i>]pyridine-7-carboxamide (<b>25e</b>)</h4><div class="NLM_p last">Boc deprotection of compound <b>24e</b> was done following the standard procedure for deprotection of Boc groups using HCl/dioxane. A solution of HCl/dioxane (4M, 2 mL) was cooled by an ice–water bath under nitrogen gas. Compound <b>24e</b> (65 mg, 0.115 mmol) was added in one portion to this solution, and the reaction mixture was stirred for 2 h at rt. After that time, volatiles were evaporated and the obtained product was washed with diethyl ether (2 × 5 mL), yielding HCl-salt of the title compound <b>25e</b> as a yellow solid (0.05 g, 98%). <sup>1</sup>H NMR (400 MHz, MeOD) δ 8.67 (dd, <i>J</i> = 7.3, 0.8 Hz, 1H), 8.27 (dd, <i>J</i> = 1.5, 0.9 Hz, 1H), 7.81 (dd, <i>J</i> = 7.2, 1.6 Hz, 1H), 7.61 (d, <i>J</i> = 8.5 Hz, 2H), 7.33 (s, 1H), 7.30 (d, <i>J</i> = 8.5 Hz, 2H), 4.53 (s, 2H), 3.75 (t, <i>J</i> = 5.7 Hz, 2H), 3.56 (t, <i>J</i> = 5.7 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 163.21, 156.09, 136.46, 134.71, 134.44, 134.35, 128.94, 124.47, 124.23, 113.67, 111.30, 102.78, 59.41, 47.11, 42.71. UPLC/MS: <i>t</i><sub>r</sub> 0.25 min, <i>m</i>/<i>z</i> 368.4 [M + H]<sup>+</sup>, purity 96%. HRMS: mass calculated for C<sub>18</sub>H<sub>22</sub>N<sub>7</sub>O<sub>2</sub>, 368.1835; found, 368.1823.</div></div><div id="sec4_1_5_100" class="NLM_sec NLM_sec_level_3"><div id="ac_i121" class="anchor-spacer"></div><h4 class="article-section__title" id="_i121"> 3-((4-Guanidinobenzyl)amino)-<i>N</i>-(2-(4-methylpiperazin-1-yl)ethyl)imidazo[1,2-<i>a</i>]pyridine-7-carboxamide (<b>25f</b>)</h4><div class="NLM_p last">Boc deprotection of compound <b>24f</b> was done using the general procedure E, affording the title compound (<b>25f</b>) as an orange oil (0.06, 97%). <sup>1</sup>H NMR (400 MHz, MeOD) δ 8.63 (dd, <i>J</i> = 7.3, 0.9 Hz, 1H), 8.29–8.25 (m, 1H), 7.80 (dd, <i>J</i> = 7.3, 1.6 Hz, 1H), 7.59 (d, <i>J</i> = 8.5 Hz, 2H), 7.32 (s, 1H), 7.30 (d, <i>J</i> = 8.5 Hz, 2H), 4.52 (s, 2H), 3.73 (t, <i>J</i> = 5.9 Hz, 2H), 3.54–3.26 (m, 8H), 3.12 (t, <i>J</i> = 5.9 Hz, 2H), 2.92 (s, 3H). <sup>13</sup>C NMR (101 MHz, MeOD) δ 166.40, 158.08, 138.69, 137.06, 136.67, 136.42, 135.60, 130.33, 126.68, 125.30, 115.27, 112.64, 105.18, 57.27, 53.15, 50.70, 49.31, 43.46, 37.11. UPLC/MS: <i>t</i><sub>r</sub> 0.25 min, <i>m</i>/<i>z</i> 450.6 [M + H]<sup>+</sup>, purity: 97%.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i122" class="anchor-spacer"></div><h3 class="article-section__title" id="_i122"> Biochemistry</h3><div class="NLM_p">Enzymatic assays were performed with use of BioTek microplate reader (Synergy MX). Data collection and analysis were performed using Gen5Microplate Software and Microsoft Excel.</div><div class="NLM_p last">The synthesized imidazo[1,2-<i>a</i>]pyridine derivatives <b>14h</b>, <b>15a</b>–<b>g</b>, <b>17a</b>–<b>k</b>, <b>19a</b>–<b>b</b>, <b>22a</b>–<b>i</b>, and <b>25a</b>–<b>f</b> were evaluated for their inhibitory activity against uPA. Human enzyme, the urokinase plasminogen activator (uPA), was obtained from HYPHEN BioMed. Inhibitor kinetic assays were using urokinase chromogenic substrate BIOPHEN CS-61(44) (pyro-Glu-Gly-Arg-pNA, <i>K</i><sub>m</sub> = 80 μM) purchased from HYPHEN BioMed. The IC<sub>50</sub> values were determined using a spectrophotometric assay. All the experiments were conducted in duplicate in a 50 mM HEPES buffer (Sigma-Aldrich) at pH 8.2 as described in our previous work.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> The readout consisted of the evaluation of uPA-mediated <i>para</i>-nitroaniline release from the chromogenic substrate pyro-Glu-Gly-Arg-pNA at 100 μM concentration.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Enzymatic activity was measured during 5 min at 37 °C. Absorbance was monitored at λ = 405 nM. All compounds were initially screened at three concentrations (100, 10, and 1 μM) in order to estimate the range of the IC<sub>50</sub> value. Those which were able to reduce uPA activity by at least 50% at 100 μM concentration were submitted to an exact IC<sub>50</sub> determination. Final IC<sub>50</sub> values of the most potent inhibitors were the average of three independent experimental results. Additionally, control experiments using commercial inhibitors were included, and they involved: guanidinophenyl fragment (<b>26</b>); uPA Inhibitor II, UK122 (<b>7</b>, Santa Cruz Biotechnology); gabexate mesylate (<b>9</b>, Enzo Life Sciences); and amiloride (<b>10</b>, Selleckchem).<a onclick="showRef(event, 'ref10 ref26 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref10 ref26 ref27 ref28">(10, 26-28)</a></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i123" class="anchor-spacer"></div><h3 class="article-section__title" id="_i123"> Determination of the selectivity for uPA</h3><div class="NLM_p">The inhibitor kinetic assays and determination of the IC<sub>50</sub> values for thrombin, tPA, FXa, plasmin, plasma kallikrein, trypsin, and FVIIa were performed in the same manner as for uPA, using HEPES buffer at pH 8.2 for thrombin, tPA, and FXa, at pH 7.0 for plasmin, at pH 7.4 for plasma kallikrein, trypsin, and HEPES buffer at pH 7.5 (50 mM HEPES, 100 mM NaCl, 5 mM CaCl<sub>2</sub>, 0.1% BSA) for FVIIa. In case of the latter one, enzymatic assay was performed in the presence of tissue factor Innovin (Dade Behring). For each of the enzymes, a specific chromogenic substrate was used. The substrates were obtained from HYPHEN BioMed or Sigma-Aldrich. In the case of thrombin (from human plasma, Sigma), the activated protein C chromogenic substrate Biophen CS-21(66) (pyroGlu-Pro-Arg-pNA-HCl, <i>K</i><sub>m</sub> = 400 μM) was used at 415 μM concentration in assay. In the case of tPA (recombinant human tPA, HYPHEN BioMed), the tPA and broad spectrum chromogenic substrate Biophen CS-05(88) (H-<span class="smallcaps smallerCapital">d</span>-Ile-Pro-<span class="smallcaps smallerCapital">l</span>-Arg-pNA-2HCl, <i>K</i><sub>m</sub> = 1000 μM) was used at 1000 μM concentration in assay. As for factor Xa (purified human factor Xa, HYPHEN BioMed), the factor Xa chromogenic substrate Biophen CS-11(32) (Suc-Ile-Glu(γPip)-Gly-Arg-pNa-HCl) was used at 411 μM concentration in assay. In the case of plasmin (from human plasma, Sigma), the activated protein C chromogenic substrate, Biophen CS-21(66) (pyroGlu-Pro-Arg-pNA-HCl, <i>K</i><sub><i>m</i></sub> = 400 μM) was used at 400 μM concentration in assay. In the case of plasma kallikrein (from human plasma, Sigma), the kallikrein chromogenic substrate, Biophen CS-31(02) (<span class="smallcaps smallerCapital">d</span>-Pro-Phe-Arg-pNA-2HCl, <i>K</i><sub><i>m</i></sub> = 269 μM) was used at 269 μM concentration in assay. In the case of trypsin (from bovine pancreas, Sigma), the trypsin chromogenic substrate, BAPNA (<i>N</i>α-benzoyl-<span class="smallcaps smallerCapital">d</span>,<span class="smallcaps smallerCapital">l</span>-Arg-pNA-HCl, <i>K</i><sub>m</sub> = 1 mM) was used at 425 μM concentration in assay. As for FVIIa (from human plasma, purified, Enzo), the factor VIIa chromogenic substrate (MeSO<sub>2</sub>-Cha-Abu-Arg-pNA) was used at 800 μM concentration in assay.</div><div class="NLM_p last">Selectivity assays included the guanidinophenyl fragment (<b>26</b>), as well as previously reported uPA inhibitors UK-122 (<b>7</b>), gabexate (<b>9</b>), and amiloride (<b>10</b>) as positive controls.<a onclick="showRef(event, 'ref10 ref26 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref10 ref26 ref27 ref28">(10, 26-28)</a> Selectivity data are summarized in <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i124" class="anchor-spacer"></div><h3 class="article-section__title" id="_i124"> Molecular Modeling</h3><div class="NLM_p last">Proposed binding conformations of compounds <b>15a</b>, <b>15b</b>, and <b>25a</b>–<b>f</b> in the binding pocket of uPA were generated starting from the protein crystal structure of human uPA in complex with 1-phenylguanidine (PDB-code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2O8W">2O8W</a><a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29, 30)</a>). Visualization of the crystal structure was done with PyMol,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> and compounds <b>15a</b> and <b>15b</b> were docked in the active site using AutoDock 4.2<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> with standard parameters and after manually removing the 1-phenylguanidine ligand from its crystal structure. Compounds <b>25a</b>–<b>f</b> were generated from the docked structure of compound <b>15a</b> by manually building the <i>N</i>-substituted amide fragment onto the imidazopyridine ring system of compound <b>15a</b> using optimal bond lengths, bond angles, and torsion angles.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i125"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01171">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08206" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08206" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.5b01171" class="ext-link">10.1021/acs.jmedchem.5b01171</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Detailed synthetic procedures and analytical data for the synthesized compounds together with extended inhibitory screening data (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01171/suppl_file/jm5b01171_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01171/suppl_file/jm5b01171_si_001.pdf">jm5b01171_si_001.pdf (348.91 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.5b01171" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47411" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47411" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pieter Van der Veken</span> - <span class="hlFld-Affiliation affiliation">Laboratory
of Medicinal Chemistry (UAMC), Department of Pharmaceutical Sciences, University of Antwerp (UA), Universiteitsplein 1, B-2610 Wilrijk, Antwerp, Belgium</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#d0a0b9b5a4b5a2fea6b1beb4b5a2a6b5bbb5be90a5b1bea4a7b5a2a0b5befeb2b5"><span class="__cf_email__" data-cfemail="1d6d747869786f336b7c7379786f6b787678735d687c73696a786f6d7873337f78">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rafaela Gladysz</span> - <span class="hlFld-Affiliation affiliation">Laboratory
of Medicinal Chemistry (UAMC), Department of Pharmaceutical Sciences, University of Antwerp (UA), Universiteitsplein 1, B-2610 Wilrijk, Antwerp, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yves Adriaenssens</span> - <span class="hlFld-Affiliation affiliation">Laboratory
of Medicinal Chemistry (UAMC), Department of Pharmaceutical Sciences, University of Antwerp (UA), Universiteitsplein 1, B-2610 Wilrijk, Antwerp, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hans De Winter</span> - <span class="hlFld-Affiliation affiliation">Laboratory
of Medicinal Chemistry (UAMC), Department of Pharmaceutical Sciences, University of Antwerp (UA), Universiteitsplein 1, B-2610 Wilrijk, Antwerp, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jurgen Joossens</span> - <span class="hlFld-Affiliation affiliation">Laboratory
of Medicinal Chemistry (UAMC), Department of Pharmaceutical Sciences, University of Antwerp (UA), Universiteitsplein 1, B-2610 Wilrijk, Antwerp, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anne-Marie Lambeir</span> - <span class="hlFld-Affiliation affiliation">Medical Biochemistry, Department
of Pharmaceutical Sciences, University of
Antwerp, Universiteitsplein
1, B-2610 Wilrijk, Antwerp, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Koen Augustyns</span> - <span class="hlFld-Affiliation affiliation">Laboratory
of Medicinal Chemistry (UAMC), Department of Pharmaceutical Sciences, University of Antwerp (UA), Universiteitsplein 1, B-2610 Wilrijk, Antwerp, Belgium</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d133e7805-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i126">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58512" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58512" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Rafaela Gladysz is thankful to the IWT-Vlaanderen (Institute for Innovation by Science and Technology-Flanders) for a Ph.D. grant. The Laboratory of Medicinal Chemistry is a partner of the Antwerp Drug Discovery Network (<a href="http://www.addn.be" class="extLink">www.addn.be</a>). The NMR and purification equipment was financed by the Hercules Foundation. We also acknowledge Filip Lemière (Biomolecular and Analytical Mass Spectrometry, University of Antwerp) for recording the HRMS spectra.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i127" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i127"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i128" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i128"> Abbreviations Used</h2><tr><td class="NLM_term">uPA</td><td class="NLM_def"><p class="first last">urokinase plasminogen activator</p></td></tr><tr><td class="NLM_term">tPA</td><td class="NLM_def"><p class="first last">tissue-type plasminogen activator</p></td></tr><tr><td class="NLM_term">FXa</td><td class="NLM_def"><p class="first last">factor Xa</p></td></tr><tr><td class="NLM_term">PAIs</td><td class="NLM_def"><p class="first last">plasminogen activator inhibitors</p></td></tr><tr><td class="NLM_term">uPAR</td><td class="NLM_def"><p class="first last">urokinase plasminogen activator receptor</p></td></tr><tr><td class="NLM_term">ECM</td><td class="NLM_def"><p class="first last">extracellular matrix</p></td></tr><tr><td class="NLM_term">MMPs</td><td class="NLM_def"><p class="first last">matrix metallopreoteases</p></td></tr><tr><td class="NLM_term">SAS</td><td class="NLM_def"><p class="first last">substrate activity screening</p></td></tr><tr><td class="NLM_term">MSAS</td><td class="NLM_def"><p class="first last">modified substrate activity screening</p></td></tr><tr><td class="NLM_term">GBB</td><td class="NLM_def"><p class="first last">Groebke–Blackburn–Bienaymé reaction</p></td></tr><tr><td class="NLM_term">3CC</td><td class="NLM_def"><p class="first last">three-component coupling reaction</p></td></tr><tr><td class="NLM_term">PDE3</td><td class="NLM_def"><p class="first last">phosphodiesterase 3</p></td></tr><tr><td class="NLM_term">CXCR4</td><td class="NLM_def"><p class="first last">CXC chemokine receptor 4</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i129">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87075" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87075" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 32 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Dass, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmad, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azmi, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarkar, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarkar, F. H.</span><span> </span><span class="NLM_article-title">Evolving Role of uPA/uPAR System in Human Cancers</span> <span class="citation_source-journal">Cancer Treat. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">122</span><span class="NLM_x">–</span> <span class="NLM_lpage">136</span><span class="refDoi"> DOI: 10.1016/j.ctrv.2007.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1016%2Fj.ctrv.2007.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=18162327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtl2jsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2008&pages=122-136&author=K.+Dassauthor=A.+Ahmadauthor=A.+S.+Azmiauthor=S.+H.+Sarkarauthor=F.+H.+Sarkar&title=Evolving+Role+of+uPA%2FuPAR+System+in+Human+Cancers&doi=10.1016%2Fj.ctrv.2007.10.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Evolving role of uPA/uPAR system in human cancers</span></div><div class="casAuthors">Dass, Kathleen; Ahmad, Aamir; Azmi, Asfar S.; Sarkar, Sarah H.; Sarkar, Fazlul H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">122-136</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Summary: Recent advancements in cancer research have led to some major breakthroughs; however, the impact on overall cancer-related death rate remains unacceptable, suggesting that further insight into tumor markers and development of targeted therapies is urgently needed.  The urokinase plasminogen activator (uPA) system represents a family of serine proteases that are involved in the degrdn. of basement membrane and the extracellular matrix, leading to tumor cell invasion and metastasis.  In this review, we have provided an overview of emerging data, from basic research as well as clin. studies, highlighting the evolving role of uPA/uPAR system in tumor progression.  It is currently believed that the expression and activation of uPA plays an important role in tumorigenicity, and high endogenous levels of uPA and uPAR are assocd. with advanced metastatic cancers.  The endogenous inhibitors of this system, PAI-1 and PAI-2, regulate uPA-uPAR activity by either direct inhibition or affecting cell surface expression and internalization.  PAI-1's role in cancers is rather unusual; on one hand, it inhibits uPA-uPAR leading to inhibition of invasion and metastasis and on the other it has been reported to facilitate tumor growth and angiogenesis.  Individual components of uPA/uPAR system are reported to be differentially expressed in cancer tissues compared to normal tissues and, thus, have the potential to be developed as prognostic and/or therapeutic targets.  Therefore, this system represents a highly attractive target that warrants further in-depth studies.  Such studies are likely to contribute towards the development of molecularly-driven targeted therapies in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSD06JySW-rbVg90H21EOLACvtfcHk0lhYa4483cbf1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtl2jsb0%253D&md5=057ddcbbeba4b8d93249eb44eef734f9</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2007.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2007.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DDass%26aufirst%3DK.%26aulast%3DAhmad%26aufirst%3DA.%26aulast%3DAzmi%26aufirst%3DA.%2BS.%26aulast%3DSarkar%26aufirst%3DS.%2BH.%26aulast%3DSarkar%26aufirst%3DF.%2BH.%26atitle%3DEvolving%2520Role%2520of%2520uPA%252FuPAR%2520System%2520in%2520Human%2520Cancers%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2008%26volume%3D34%26spage%3D122%26epage%3D136%26doi%3D10.1016%2Fj.ctrv.2007.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Mekkawy, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pourgholami, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, D. L.</span><span> </span><span class="NLM_article-title">Involvement of Urokinase-Type Plasminogen Activator System in Cancer: An Overview</span> <span class="citation_source-journal">Med. Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">918</span><span class="NLM_x">–</span> <span class="NLM_lpage">956</span><span class="refDoi"> DOI: 10.1002/med.21308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1002%2Fmed.21308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=24549574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1KisrvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=918-956&author=A.+H.+Mekkawyauthor=M.+H.+Pourgholamiauthor=D.+L.+Morris&title=Involvement+of+Urokinase-Type+Plasminogen+Activator+System+in+Cancer%3A+An+Overview&doi=10.1002%2Fmed.21308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of urokinase-type plasminogen activator system in cancer: An overview</span></div><div class="casAuthors">Mekkawy, Ahmed H.; Pourgholami, Mohammad H.; Morris, David L.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">918-956</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Currently, there are several studies supporting the role of urokinase-type plasminogen activator (uPA) system in cancer.  The assocn. of uPA to its receptor triggers the conversion of plasminogen into plasmin.  This process is regulated by the uPA inhibitors (PAI-1 and PAI-2).  Plasmin promotes degrdn. of basement membrane and extracellular matrix (ECM) components as well as activation of ECM latent matrix metalloproteases.  Degrdn. and remodeling of the surrounding tissues is crucial in the early steps of tumor progression by facilitating expansion of the tumor mass, release of tumor growth factors, activation of cytokines as well as induction of tumor cell proliferation, migration, and invasion.  Hence, many tumors showed a correlation between uPA system component levels and tumor aggressiveness and survival.  Therefore, this review summarizes the structure of the uPA system, its contribution to cancer progression, and the clin. relevance of uPA family members in cancer diagnosis.  In addn., the review evaluates the significance of uPA system in the development of cancer-targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqz7UqvJj1hC7Vg90H21EOLACvtfcHk0lht47BNkqhICw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1KisrvE&md5=15d7ad04dd7aac616936f4087e984b55</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1002%2Fmed.21308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21308%26sid%3Dliteratum%253Aachs%26aulast%3DMekkawy%26aufirst%3DA.%2BH.%26aulast%3DPourgholami%26aufirst%3DM.%2BH.%26aulast%3DMorris%26aufirst%3DD.%2BL.%26atitle%3DInvolvement%2520of%2520Urokinase-Type%2520Plasminogen%2520Activator%2520System%2520in%2520Cancer%253A%2520An%2520Overview%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2014%26volume%3D34%26spage%3D918%26epage%3D956%26doi%3D10.1002%2Fmed.21308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Tang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, X.</span><span> </span><span class="NLM_article-title">The Urokinase Plasminogen Activator System in Breast Cancer Invasion and Metastasis</span> <span class="citation_source-journal">Biomed. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">179</span><span class="NLM_x">–</span> <span class="NLM_lpage">182</span><span class="refDoi"> DOI: 10.1016/j.biopha.2012.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1016%2Fj.biopha.2012.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=23201006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhsl2ju7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2013&pages=179-182&author=L.+Tangauthor=X.+Han&title=The+Urokinase+Plasminogen+Activator+System+in+Breast+Cancer+Invasion+and+Metastasis&doi=10.1016%2Fj.biopha.2012.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The urokinase plasminogen activator system in breast cancer invasion and metastasis</span></div><div class="casAuthors">Tang, Linlin; Han, Xiuzhen</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicine & Pharmacotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-182</span>CODEN:
                <span class="NLM_cas:coden">BIPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0753-3322</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  The urokinase plasminogen activator system, which is a serine protease family include urokinase-type plasminogen activator (uPA), the uPA receptor and plasminogen activator inhibitors (PAIs). uPA catalyzes the transformation of plasminogen to its active form plasmin, which is able to degrade the extracellular matrix (ECM) and basement membranes, directly or indirectly through activating pro-matrix metalloproteinases (pro-MMPs), promoting cancer cell metastasis and invasion.  Both uPA and PAI-1 are poor prognosis markers in primary breast cancer.  Evidence has been presented that the uPA system facilitates breast cancer metastasis by several different mechanisms, such as the Ras-ERK pathway and p38 MAPK pathway.  This review focuses on uPA system, summarizes their biol. effects, highlights the mol. mechanism and pathway, and discusses the role of uPA system in the prevention and treatment of human breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVDPyZ5w-UW7Vg90H21EOLACvtfcHk0lht47BNkqhICw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhsl2ju7bL&md5=b46a83ba7db2f8ad27d3fc89e9927f2c</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.biopha.2012.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopha.2012.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DL.%26aulast%3DHan%26aufirst%3DX.%26atitle%3DThe%2520Urokinase%2520Plasminogen%2520Activator%2520System%2520in%2520Breast%2520Cancer%2520Invasion%2520and%2520Metastasis%26jtitle%3DBiomed.%2520Pharmacother.%26date%3D2013%26volume%3D67%26spage%3D179%26epage%3D182%26doi%3D10.1016%2Fj.biopha.2012.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Smith, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span> </span><span class="NLM_article-title">Regulation of Cell Signalling by uPAR</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span><span class="NLM_x">–</span> <span class="NLM_lpage">36</span><span class="refDoi"> DOI: 10.1038/nrm2821</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1038%2Fnrm2821" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=20027185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFymtb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=23-36&author=H.+W.+Smithauthor=C.+J.+Marshall&title=Regulation+of+Cell+Signalling+by+uPAR&doi=10.1038%2Fnrm2821"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of cell signalling by uPAR</span></div><div class="casAuthors">Smith, Harvey W.; Marshall, Chris J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-36</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Urokinase-type plasminogen activator receptor (uPAR) expression is elevated during inflammation and tissue remodelling and in many human cancers, in which it frequently indicates poor prognosis. uPAR regulates proteolysis by binding the extracellular protease urokinase-type plasminogen activator (uPA; also known as urokinase) and also activates many intracellular signalling pathways.  Coordination of extracellular matrix (ECM) proteolysis and cell signalling by uPAR underlies its important function in cell migration, proliferation and survival and makes it an attractive therapeutic target in cancer and inflammatory diseases. uPAR lacks transmembrane and intracellular domains and so requires transmembrane co-receptors for signalling.  Integrins are essential uPAR signalling co-receptors and a second uPAR ligand, the ECM protein vitronectin, is also crucial for this process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvNxm1RoivP7Vg90H21EOLACvtfcHk0liIG-9MgESLwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFymtb7M&md5=cd788f114e3576289c17339bbf636651</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1038%2Fnrm2821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2821%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DH.%2BW.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26atitle%3DRegulation%2520of%2520Cell%2520Signalling%2520by%2520uPAR%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2010%26volume%3D11%26spage%3D23%26epage%3D36%26doi%3D10.1038%2Fnrm2821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Blasi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmeliet, P.</span><span> </span><span class="NLM_article-title">uPAR: A Versatile Signalling Orchestrator</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">932</span><span class="NLM_x">–</span> <span class="NLM_lpage">943</span><span class="refDoi"> DOI: 10.1038/nrm977</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1038%2Fnrm977" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=12461559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BD38XptFKnt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=932-943&author=F.+Blasiauthor=P.+Carmeliet&title=uPAR%3A+A+Versatile+Signalling+Orchestrator&doi=10.1038%2Fnrm977"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">uPAR: A versatile signalling orchestrator</span></div><div class="casAuthors">Blasi, Francesco; Carmeliet, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">932-943</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The plasminogen system has been implicated in clot lysis, wound healing, tissue regeneration, cancer, and many other processes that affect health and disease.  The urokinase receptor uPAR was originally thought to assist the directional invasion of migrating cells, but it is now becoming increasingly evident that this proteinase receptor elicits a plethora of cellular responses that include cellular adhesion, differentiation, proliferation, and migration in a non-proteolytic fashion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0I96h2pJMXbVg90H21EOLACvtfcHk0liIG-9MgESLwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XptFKnt7c%253D&md5=4d6857dcdaa9874fc905e3442d859ccb</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1038%2Fnrm977&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm977%26sid%3Dliteratum%253Aachs%26aulast%3DBlasi%26aufirst%3DF.%26aulast%3DCarmeliet%26aufirst%3DP.%26atitle%3DuPAR%253A%2520A%2520Versatile%2520Signalling%2520Orchestrator%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2002%26volume%3D3%26spage%3D932%26epage%3D943%26doi%3D10.1038%2Fnrm977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5a"><span><span class="NLM_label">(a) </span>Phase I & II with Mesupron; <span class="NLM_publisher-name">Wilex Ag</span>: <span class="NLM_publisher-loc">Munich</span>,<span class="NLM_x"> </span><span class="NLM_year">2010</span><span class="NLM_x">; </span><a href="http://www.wilex.de/portfolio-english/mesupron/phase-i-ii-with-mesu/" class="extLink">http://www.wilex.de/portfolio-english/mesupron/phase-i-ii-with-mesu/</a> (accessed september 10,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Phase+I+%26+II+with+Mesupron%3B+Wilex+Ag%3A+Munich%2C+2010%3B+http%3A%2F%2Fwww.wilex.de%2Fportfolio-english%2Fmesupron%2Fphase-i-ii-with-mesu%2F+%28accessed+september+10%2C+2015%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DPhase%2520I%2520%2526%2520II%2520with%2520Mesupron%26pub%3DWilex%2520Ag%26date%3D2010%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Abbenante, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairlie, D. P.</span><span> </span><span class="NLM_article-title">Protease Inhibitors in the Clinic</span> <span class="citation_source-journal">Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">71</span><span class="NLM_x">–</span> <span class="NLM_lpage">104</span><span class="refDoi"> DOI: 10.2174/1573406053402569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.2174%2F1573406053402569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=16789888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsVWkur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2005&pages=71-104&author=G.+Abbenanteauthor=D.+P.+Fairlie&title=Protease+Inhibitors+in+the+Clinic&doi=10.2174%2F1573406053402569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Protease inhibitors in the clinic</span></div><div class="casAuthors">Abbenante, Giovanni; Fairlie, David P.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">71-104</span>CODEN:
                <span class="NLM_cas:coden">MCEHAJ</span>;
        ISSN:<span class="NLM_cas:issn">1573-4064</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">This review describes the clin. status (based on available information) of exptl. drugs that inhibit enzymes called proteases, or more precisely a sub-class of proteases called peptidases that catalyze the hydrolysis of polypeptide main chain amide bonds.  These peptidases are classified by the key catalytic residue in the active site of the enzyme that effects hydrolysis, namely aspartic, serine, cysteine, metallo or threonine proteases.  In this review the authors show structures for 108 inhibitors of these enzymes and update the clin. disposition of over 100 inhibitors that were considered worthy enough by pharmaceutical, biotechnol. or academic researchers and their financial backers to be trialed in humans as prospective medicines.  The authors outline some of their chem. and pharmacol. characteristics and compare the current status of protease inhibitors in the clinic with what was obsd. about 5 years ago.  The authors assess the progress of protease inhibitors into man, predict their futures, and outline some of the hurdles that were overcome and that still remain for this promising class of new therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg7u79t8OBObVg90H21EOLACvtfcHk0lht8jUh-IqGqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsVWkur8%253D&md5=ba8890c238cceb145a032f0545f521af</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.2174%2F1573406053402569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1573406053402569%26sid%3Dliteratum%253Aachs%26aulast%3DAbbenante%26aufirst%3DG.%26aulast%3DFairlie%26aufirst%3DD.%2BP.%26atitle%3DProtease%2520Inhibitors%2520in%2520the%2520Clinic%26jtitle%3DMed.%2520Chem.%26date%3D2005%26volume%3D1%26spage%3D71%26epage%3D104%26doi%3D10.2174%2F1573406053402569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Heinemann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebert, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laubender, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bevan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mala, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boeck, S.</span><span> </span><span class="NLM_article-title">Phase II Randomised Proof-of-Concept Study of the Urokinase Inhibitor Upamostat (WX-671) in Combination with Gemcitabine Compared with Gemcitabine Alone in Patients with Non-Resectable, Locally Advanced Pancreatic Cancer</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">766</span><span class="NLM_x">–</span> <span class="NLM_lpage">770</span><span class="refDoi"> DOI: 10.1038/bjc.2013.62</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1038%2Fbjc.2013.62" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=23412098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjslWmtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2013&pages=766-770&author=V.+Heinemannauthor=M.+P.+Ebertauthor=R.+P.+Laubenderauthor=P.+Bevanauthor=C.+Malaauthor=S.+Boeck&title=Phase+II+Randomised+Proof-of-Concept+Study+of+the+Urokinase+Inhibitor+Upamostat+%28WX-671%29+in+Combination+with+Gemcitabine+Compared+with+Gemcitabine+Alone+in+Patients+with+Non-Resectable%2C+Locally+Advanced+Pancreatic+Cancer&doi=10.1038%2Fbjc.2013.62"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5cR"><div class="casContent"><span class="casTitleNuber">5c</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II randomized proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer</span></div><div class="casAuthors">Heinemann, V.; Ebert, M. P.; Laubender, R. P.; Bevan, P.; Mala, C.; Boeck, S.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">766-770</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: To evaluate the efficacy and tolerability of the urokinase plasminogen activator (uPA) inhibitor upamostat in combination with gemcitabine in locally advanced pancreatic adenocarcinoma (LAPC).  Methods: Within a prospective multicenter study, LAPC patients were randomly assigned to receive 1000 mg m-2 of gemcitabine IV weekly either alone (arm A) or in combination with 200 mg (arm B) or 400 mg (arm C) oral upamostat daily.  Efficacy endpoints of this proof-of-concept study included response rate, time to first metastasis, progression-free and overall survival (OS).  Results: Of the 95 enrolled patients, 85 were evaluable for response and 93 for safety.  Median OS was 12.5 mo (95% CI 8.2-18.2) in arm C, 9.7 mo (95% CI 8.4-17.1) in arm B and 9.9 mo (95% CI 7.4-12.1) in arm A; corresponding 1-yr survival rates were 50.6%, 40.7% and 33.9%, resp.  More patients achieved a partial remission (confirmed responses by RECIST) with upamostat combination therapy (arm C: 12.9%; arm B: 7.1%; arm A: 3.8%).  Overall, only 12 patients progressed by developing detectable distant metastasis (arm A: 4, arm B: 6, arm C: 2).  The most common adverse events considered to be related to upamostat were asthenia, fever and nausea.  Conclusion: In this proof-of-concept study targeting the uPA system in LAPC, the addn. of upamostat to gemcitabine was tolerated well; similar survival results were obsd. for the three treatment arms.  British Journal of Cancer (2013) 108, 766-770; doi:10.1038/bjc.2013.62 www.bjcancer.com; published online 14 Feb. 2013.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmZfmwPy6jILVg90H21EOLACvtfcHk0lht8jUh-IqGqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjslWmtbo%253D&md5=8cb64bd2fb82944adeaec5327c8b7c47</span></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2013.62&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2013.62%26sid%3Dliteratum%253Aachs%26aulast%3DHeinemann%26aufirst%3DV.%26aulast%3DEbert%26aufirst%3DM.%2BP.%26aulast%3DLaubender%26aufirst%3DR.%2BP.%26aulast%3DBevan%26aufirst%3DP.%26aulast%3DMala%26aufirst%3DC.%26aulast%3DBoeck%26aufirst%3DS.%26atitle%3DPhase%2520II%2520Randomised%2520Proof-of-Concept%2520Study%2520of%2520the%2520Urokinase%2520Inhibitor%2520Upamostat%2520%2528WX-671%2529%2520in%2520Combination%2520with%2520Gemcitabine%2520Compared%2520with%2520Gemcitabine%2520Alone%2520in%2520Patients%2520with%2520Non-Resectable%252C%2520Locally%2520Advanced%2520Pancreatic%2520Cancer%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2013%26volume%3D108%26spage%3D766%26epage%3D770%26doi%3D10.1038%2Fbjc.2013.62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Meyer, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brocks, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graefe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mala, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thäns, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bürgle, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rempel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rotter, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wollenberg, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, S.</span><span> </span><span class="NLM_article-title">The Oral Serine Protease Inhibitor WX-671 - First Experience in Patients with Advanced Head and Neck Carcinoma</span> <span class="citation_source-journal">Breast Care</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">20</span><span class="NLM_x">–</span> <span class="NLM_lpage">24</span><span class="refDoi"> DOI: 10.1159/000151736</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1159%2F000151736" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=20824010" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=20-24&author=J.+E.+Meyerauthor=C.+Brocksauthor=H.+Graefeauthor=C.+Malaauthor=N.+Th%C3%A4nsauthor=M.+B%C3%BCrgleauthor=A.+Rempelauthor=N.+Rotterauthor=B.+Wollenbergauthor=S.+Lang&title=The+Oral+Serine+Protease+Inhibitor+WX-671+-+First+Experience+in+Patients+with+Advanced+Head+and+Neck+Carcinoma&doi=10.1159%2F000151736"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5d&amp;dbid=16384&amp;doi=10.1159%2F000151736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000151736%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DJ.%2BE.%26aulast%3DBrocks%26aufirst%3DC.%26aulast%3DGraefe%26aufirst%3DH.%26aulast%3DMala%26aufirst%3DC.%26aulast%3DTh%25C3%25A4ns%26aufirst%3DN.%26aulast%3DB%25C3%25BCrgle%26aufirst%3DM.%26aulast%3DRempel%26aufirst%3DA.%26aulast%3DRotter%26aufirst%3DN.%26aulast%3DWollenberg%26aufirst%3DB.%26aulast%3DLang%26aufirst%3DS.%26atitle%3DThe%2520Oral%2520Serine%2520Protease%2520Inhibitor%2520WX-671%2520-%2520First%2520Experience%2520in%2520Patients%2520with%2520Advanced%2520Head%2520and%2520Neck%2520Carcinoma%26jtitle%3DBreast%2520Care%26date%3D2008%26volume%3D3%26spage%3D20%26epage%3D24%26doi%3D10.1159%2F000151736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Setyono-Han, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stürzebecher, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmalix, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muehlenweg, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sieuwerts, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timmermans, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magdolen, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klijn, J. G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foekens, J. A.</span><span> </span><span class="NLM_article-title">Suppression of Rat Breast Cancer Metastasis and Reduction of Primary Tumour Growth by the Small Synthetic Urokinase Inhibitor WX-UKI</span> <span class="citation_source-journal">Thromb. Haemostasis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">779</span><span class="NLM_x">–</span> <span class="NLM_lpage">786</span><span class="refDoi"> DOI: 10.1160/TH04-11-0712</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1160%2FTH04-11-0712" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=15841327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjs1ert78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2005&pages=779-786&author=B.+Setyono-Hanauthor=J.+St%C3%BCrzebecherauthor=W.+A.+Schmalixauthor=B.+Muehlenwegauthor=A.+M.+Sieuwertsauthor=M.+Timmermansauthor=V.+Magdolenauthor=M.+Schmittauthor=J.+G.+M.+Klijnauthor=J.+A.+Foekens&title=Suppression+of+Rat+Breast+Cancer+Metastasis+and+Reduction+of+Primary+Tumour+Growth+by+the+Small+Synthetic+Urokinase+Inhibitor+WX-UKI&doi=10.1160%2FTH04-11-0712"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5eR"><div class="casContent"><span class="casTitleNuber">5e</span><div class="casTitle"><span class="NLM_cas:atitle">Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1</span></div><div class="casAuthors">Setyono-Han, Buddy; Stuerzebecher, Joerg; Schmalix, Wolfgang A.; Muehlenweg, Bernd; Sieuwerts, Anieta M.; Timmermans, Mieke; Magdolen, Viktor; Schmitt, Manfred; Klijn, Jan G. M.; Foekens, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis and Haemostasis</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">779-786</span>CODEN:
                <span class="NLM_cas:coden">THHADQ</span>;
        ISSN:<span class="NLM_cas:issn">0340-6245</span>.
    
            (<span class="NLM_cas:orgname">Schattauer GmbH</span>)
        </div><div class="casAbstract">The serine protease uPA (urokinase-type plasminogen activator) and its receptor uPAR (CD87) are often elevated in malignant tumors, hence, inhibition of this tumor-assocd. plasminogen activation system provides an attractive target for therapeutic strategies.  WX-UK1, a deriv. of 3-aminophenylalanine in the L-conformation with inhibitory antiproteolytic properties, was tested for its specificity spectrum using specific chromogenic paranitroanilide peptide substrates.  The corresponding D-enantiomer of WX-UK1 was used as a control.  The antitumor and anti-metastatic (no. of lung foci and wt. of the axillary lymph nodes) properties were studied by s.c. administration of WX-UK1 to Brown Norwegian (BN) rats carrying orthotopically transplanted BN472 rat breast tumors.  WX-UK1 selectively inhibited tumor-related proteases from rats and humans such as uPA, plasmin, or thrombin in the sub or low micromolar range.  The activity was stereoselective as the D-enantiomer of WX-UK1 inhibited uPA and plasmin at approx. 70-fold higher Ki values than the active L-form.  Chronical administration of the L-enantiomer of WX-UK1 impaired primary tumor growth and metastasis of BN472 rat breast cancer in a dose-dependent manner.  The min. inhibitory dosage with maximal effect was between 0.15 and 0.3 mg/kg/day.  The inactive D-enantiomer of WX-UK1 was not active in this respect.  Daily treatment with WX-UK1 for up to 35 days was well tolerated as judged by the unchanged body and organ wt. development.  In conclusion, our results provide evidence that WX-UK1 as a single agent inhibits breast tumor growth and metastasis in vivo, and thus is a promising candidate drug to treat human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoydJhqyuXt0LVg90H21EOLACvtfcHk0lguJI_982DEMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjs1ert78%253D&md5=3a22d68678cce69d209c47e7ea4585cb</span></div><a href="/servlet/linkout?suffix=cit5e&amp;dbid=16384&amp;doi=10.1160%2FTH04-11-0712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1160%252FTH04-11-0712%26sid%3Dliteratum%253Aachs%26aulast%3DSetyono-Han%26aufirst%3DB.%26aulast%3DSt%25C3%25BCrzebecher%26aufirst%3DJ.%26aulast%3DSchmalix%26aufirst%3DW.%2BA.%26aulast%3DMuehlenweg%26aufirst%3DB.%26aulast%3DSieuwerts%26aufirst%3DA.%2BM.%26aulast%3DTimmermans%26aufirst%3DM.%26aulast%3DMagdolen%26aufirst%3DV.%26aulast%3DSchmitt%26aufirst%3DM.%26aulast%3DKlijn%26aufirst%3DJ.%2BG.%2BM.%26aulast%3DFoekens%26aufirst%3DJ.%2BA.%26atitle%3DSuppression%2520of%2520Rat%2520Breast%2520Cancer%2520Metastasis%2520and%2520Reduction%2520of%2520Primary%2520Tumour%2520Growth%2520by%2520the%2520Small%2520Synthetic%2520Urokinase%2520Inhibitor%2520WX-UKI%26jtitle%3DThromb.%2520Haemostasis%26date%3D2005%26volume%3D93%26spage%3D779%26epage%3D786%26doi%3D10.1160%2FTH04-11-0712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Barber, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickinson, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fish, P. V.</span><span> </span><span class="NLM_article-title">Selective Urokinase-Type Plasminogen Activator (uPA) Inhibitors. Part 3:1-Isoquinolinylguanidines</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">3227</span><span class="NLM_x">–</span> <span class="NLM_lpage">3230</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2004.03.094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1016%2Fj.bmcl.2004.03.094" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=3227-3230&author=C.+G.+Barberauthor=R.+P.+Dickinsonauthor=P.+V.+Fish&title=Selective+Urokinase-Type+Plasminogen+Activator+%28uPA%29+Inhibitors.+Part+3%3A1-Isoquinolinylguanidines&doi=10.1016%2Fj.bmcl.2004.03.094"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.03.094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.03.094%26sid%3Dliteratum%253Aachs%26aulast%3DBarber%26aufirst%3DC.%2BG.%26aulast%3DDickinson%26aufirst%3DR.%2BP.%26aulast%3DFish%26aufirst%3DP.%2BV.%26atitle%3DSelective%2520Urokinase-Type%2520Plasminogen%2520Activator%2520%2528uPA%2529%2520Inhibitors.%2520Part%25203%253A1-Isoquinolinylguanidines%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D3227%26epage%3D3230%26doi%3D10.1016%2Fj.bmcl.2004.03.094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Bayliss, M. A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venn, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edgington, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, D. K.</span><span> </span><span class="NLM_article-title">Determination of a Potent Urokinase-Type Plasminogen Activator, UK-356,202, in Plasma at pg/mL Levels Using Column-Switching HPLC and Fluorescence Detection</span> <span class="citation_source-journal">J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">877</span><span class="NLM_x">, </span> <span class="NLM_fpage">121</span><span class="NLM_x">–</span> <span class="NLM_lpage">126</span><span class="refDoi"> DOI: 10.1016/j.jchromb.2008.11.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1016%2Fj.jchromb.2008.11.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=19119083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksVCrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=877&publication_year=2009&pages=121-126&author=M.+A.+J.+Baylissauthor=R.+F.+Vennauthor=A.+M.+Edgingtonauthor=R.+Websterauthor=D.+K.+Walker&title=Determination+of+a+Potent+Urokinase-Type+Plasminogen+Activator%2C+UK-356%2C202%2C+in+Plasma+at+pg%2FmL+Levels+Using+Column-Switching+HPLC+and+Fluorescence+Detection&doi=10.1016%2Fj.jchromb.2008.11.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">Determination of a potent urokinase-type plasminogen activator, UK-356,202, in plasma at pg/mL levels using column-switching HPLC and fluorescence detection</span></div><div class="casAuthors">Bayliss, Mark A. J.; Venn, Richard F.; Edgington, Alan M.; Webster, Robert; Walker, Donald K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">877</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">121-126</span>CODEN:
                <span class="NLM_cas:coden">JCBAAI</span>;
        ISSN:<span class="NLM_cas:issn">1570-0232</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A rapid, sensitive and selective method using column-switching HPLC with fluorescence detection has been developed for the detn. of UK-356,202, a potent urokinase-type plasminogen activator, in human plasma.  A structural isomer of UK-356,202 is used as an internal std.  The lower limit of quantification is 20 pg/mL and the method is linear over a 100-fold concn. range.  UK-356,202 is extd. from plasma simply through the removal of proteins by pptn. with acetonitrile.  The HPLC system comprises three columns and the cycle time is 9.5 min per sample.  The eluate from the extn. column is heart-cut onto a trace enrichment cartridge which is then back-flushed onto a narrow-bore Supelco ABZ+ Plus anal. column.  The method has been used to analyze many thousands of samples from clin. and toxicol. studies support.  Its ruggedness is demonstrated by the use of a single extn. column for the anal. of over 1200 clin. samples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX04bfWXDaVbVg90H21EOLACvtfcHk0lgCHLdssZ0aWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksVCrtg%253D%253D&md5=f2ef941164cb9226d6546015cfe91272</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1016%2Fj.jchromb.2008.11.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jchromb.2008.11.038%26sid%3Dliteratum%253Aachs%26aulast%3DBayliss%26aufirst%3DM.%2BA.%2BJ.%26aulast%3DVenn%26aufirst%3DR.%2BF.%26aulast%3DEdgington%26aufirst%3DA.%2BM.%26aulast%3DWebster%26aufirst%3DR.%26aulast%3DWalker%26aufirst%3DD.%2BK.%26atitle%3DDetermination%2520of%2520a%2520Potent%2520Urokinase-Type%2520Plasminogen%2520Activator%252C%2520UK-356%252C202%252C%2520in%2520Plasma%2520at%2520pg%252FmL%2520Levels%2520Using%2520Column-Switching%2520HPLC%2520and%2520Fluorescence%2520Detection%26jtitle%3DJ.%2520Chromatogr.%2520B%253A%2520Anal.%2520Technol.%2520Biomed.%2520Life%2520Sci.%26date%3D2009%26volume%3D877%26spage%3D121%26epage%3D126%26doi%3D10.1016%2Fj.jchromb.2008.11.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Fish, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barber, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collis, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickinson, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henry, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horne, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huggins, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Gara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCleverty, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntosh, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, R.</span><span> </span><span class="NLM_article-title">Selective Urokinase-Type Plasminogen Activator Inhibitors. 4. 1-(7-Sulfonamidoisoquinolinyl)guanidines</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">2341</span><span class="NLM_x">–</span> <span class="NLM_lpage">2351</span><span class="refDoi"> DOI: 10.1021/jm061066t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm061066t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2341-2351&author=P.+V.+Fishauthor=C.+G.+Barberauthor=D.+G.+Brownauthor=R.+Buttauthor=M.+G.+Collisauthor=R.+P.+Dickinsonauthor=B.+T.+Henryauthor=V.+A.+Horneauthor=J.+P.+Hugginsauthor=E.+Kingauthor=M.+O%27Garaauthor=D.+McClevertyauthor=F.+McIntoshauthor=C.+Phillipsauthor=R.+Webster&title=Selective+Urokinase-Type+Plasminogen+Activator+Inhibitors.+4.+1-%287-Sulfonamidoisoquinolinyl%29guanidines&doi=10.1021%2Fjm061066t"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=10.1021%2Fjm061066t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061066t%26sid%3Dliteratum%253Aachs%26aulast%3DFish%26aufirst%3DP.%2BV.%26aulast%3DBarber%26aufirst%3DC.%2BG.%26aulast%3DBrown%26aufirst%3DD.%2BG.%26aulast%3DButt%26aufirst%3DR.%26aulast%3DCollis%26aufirst%3DM.%2BG.%26aulast%3DDickinson%26aufirst%3DR.%2BP.%26aulast%3DHenry%26aufirst%3DB.%2BT.%26aulast%3DHorne%26aufirst%3DV.%2BA.%26aulast%3DHuggins%26aufirst%3DJ.%2BP.%26aulast%3DKing%26aufirst%3DE.%26aulast%3DO%2527Gara%26aufirst%3DM.%26aulast%3DMcCleverty%26aufirst%3DD.%26aulast%3DMcIntosh%26aufirst%3DF.%26aulast%3DPhillips%26aufirst%3DC.%26aulast%3DWebster%26aufirst%3DR.%26atitle%3DSelective%2520Urokinase-Type%2520Plasminogen%2520Activator%2520Inhibitors.%25204.%25201-%25287-Sulfonamidoisoquinolinyl%2529guanidines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2341%26epage%3D2351%26doi%3D10.1021%2Fjm061066t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Schweinitz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinmetzer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banke, I. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arlt, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stürzebecher, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuster, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geissler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giersiefen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeslawska, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacob, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krüger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stürzebecher, J.</span><span> </span><span class="NLM_article-title">Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x"> (</span><span class="NLM_issue">32</span><span class="NLM_x">) </span> <span class="NLM_fpage">33613</span><span class="NLM_x">–</span> <span class="NLM_lpage">33622</span><span class="refDoi"> DOI: 10.1074/jbc.M314151200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1074%2Fjbc.M314151200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=33613-33622&issue=32&author=A.+Schweinitzauthor=T.+Steinmetzerauthor=I.+J.+Bankeauthor=M.+J.+Arltauthor=A.+St%C3%BCrzebecherauthor=O.+Schusterauthor=A.+Geisslerauthor=H.+Giersiefenauthor=E.+Zeslawskaauthor=U.+Jacobauthor=A.+Kr%C3%BCgerauthor=J.+St%C3%BCrzebecher&title=Design+of+novel+and+selective+inhibitors+of+urokinase-type+plasminogen+activator+with+improved+pharmacokinetic+properties+for+use+as+antimetastatic+agents&doi=10.1074%2Fjbc.M314151200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M314151200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M314151200%26sid%3Dliteratum%253Aachs%26aulast%3DSchweinitz%26aufirst%3DA.%26aulast%3DSteinmetzer%26aufirst%3DT.%26aulast%3DBanke%26aufirst%3DI.%2BJ.%26aulast%3DArlt%26aufirst%3DM.%2BJ.%26aulast%3DSt%25C3%25BCrzebecher%26aufirst%3DA.%26aulast%3DSchuster%26aufirst%3DO.%26aulast%3DGeissler%26aufirst%3DA.%26aulast%3DGiersiefen%26aufirst%3DH.%26aulast%3DZeslawska%26aufirst%3DE.%26aulast%3DJacob%26aufirst%3DU.%26aulast%3DKr%25C3%25BCger%26aufirst%3DA.%26aulast%3DSt%25C3%25BCrzebecher%26aufirst%3DJ.%26atitle%3DDesign%2520of%2520novel%2520and%2520selective%2520inhibitors%2520of%2520urokinase-type%2520plasminogen%2520activator%2520with%2520improved%2520pharmacokinetic%2520properties%2520for%2520use%2520as%2520antimetastatic%2520agents%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26issue%3D32%26spage%3D33613%26epage%3D33622%26doi%3D10.1074%2Fjbc.M314151200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Henneke, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greschus, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korfei, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markart, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahavadi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schermuly, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wygrecka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stürzebecher, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeger, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Günther, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruppert, C.</span><span> </span><span class="NLM_article-title">Inhibition of Urokinase Activity Reduces Primary Tumor Growth and Metastasis Formation in a Murine Lung Carcinoma Model</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">181</span><span class="NLM_x">, </span> <span class="NLM_fpage">611</span><span class="NLM_x">–</span> <span class="NLM_lpage">619</span><span class="refDoi"> DOI: 10.1164/rccm.200903-0342OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1164%2Frccm.200903-0342OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=20056905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFahsLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2010&pages=611-619&author=I.+Hennekeauthor=S.+Greschusauthor=R.+Savaiauthor=M.+Korfeiauthor=P.+Markartauthor=P.+Mahavadiauthor=R.+T.+Schermulyauthor=M.+Wygreckaauthor=J.+St%C3%BCrzebecherauthor=W.+Seegerauthor=A.+G%C3%BCntherauthor=C.+Ruppert&title=Inhibition+of+Urokinase+Activity+Reduces+Primary+Tumor+Growth+and+Metastasis+Formation+in+a+Murine+Lung+Carcinoma+Model&doi=10.1164%2Frccm.200903-0342OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of urokinase activity reduces primary tumor growth and metastasis formation in a murine lung carcinoma model</span></div><div class="casAuthors">Henneke, Ingrid; Greschus, Susanne; Savai, Rajkumar; Korfei, Martina; Markart, Philipp; Mahavadi, Poornima; Schermuly, Ralph T.; Wygrecka, Malgorzata; Stuerzebecher, Joerg; Seeger, Werner; Guenther, Andreas; Ruppert, Clemens</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">611-619</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: Lung cancer is the most common malignancy in humans.  Urokinase (uPA) plays a crucial role in carcinogenesis by facilitating tumor cell invasion and metastasis.  Objectives: We investigated the effect of the highly specific urokinase inhibitor CJ-463 (benzylsulfonyl-D-Ser-Ser-4-amidinobenzylamide) on tumor growth, metastasis formation, and tumor vascularization in the murine Lewis lung carcinoma (LLC) and a human small lung cancer model.  Methods: A quantity of 3 × 106 LLC cells were s.c. injected into the right flank of C57Bl6/N mice, uPA knock out, and uPA receptor knockout mice.  Seven days later mice were randomized to receive i.p. either saline (control group), CJ-463 (10 and 100 mg/kg, twice a day), or its ineffective stereoisomer (10 mg/kg, twice a day).  Tumor vol. was measured every second day and metastasis formation was monitored by volumetric-computed tomog.  Twelve days after onset of treatment mice were killed and tumors were prepd. for histol. examn.  Measurements and Main Results: Treatment with CJ-463 resulted in a significant inhibition of primary tumor growth, with the highest efficacy seen in the 100 mg/kg group.  In addn., histol. anal. of the lung revealed a significant redn. in lung micrometastasis in the 100 mg/kg group.  Similarly, a reduced seeding of tumor cells into the lung after i.v. injection of LLC cells was obsd. in inhibitor-treated mice.  In these mice, treatment with CJ-463 appeared not to significantly alter the relative extent of tumor vascularization.  In vitro, proliferation of LLC cells remained unchanged upon inhibitor treatment.  CJ-463 was found to similarly reduce tumor growth in uPA receptor knockout mice, but was ineffective in uPA knockout mice.  Conclusions: Our results suggest that synthetic low-mol.-wt. uPA-inhibitors offer as novel agents for treatment of lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRonLD45172bVg90H21EOLACvtfcHk0lh0UC_ZpUJctQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFahsLfE&md5=bc34f167070bfd3531eb442c30ab843b</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1164%2Frccm.200903-0342OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200903-0342OC%26sid%3Dliteratum%253Aachs%26aulast%3DHenneke%26aufirst%3DI.%26aulast%3DGreschus%26aufirst%3DS.%26aulast%3DSavai%26aufirst%3DR.%26aulast%3DKorfei%26aufirst%3DM.%26aulast%3DMarkart%26aufirst%3DP.%26aulast%3DMahavadi%26aufirst%3DP.%26aulast%3DSchermuly%26aufirst%3DR.%2BT.%26aulast%3DWygrecka%26aufirst%3DM.%26aulast%3DSt%25C3%25BCrzebecher%26aufirst%3DJ.%26aulast%3DSeeger%26aufirst%3DW.%26aulast%3DG%25C3%25BCnther%26aufirst%3DA.%26aulast%3DRuppert%26aufirst%3DC.%26atitle%3DInhibition%2520of%2520Urokinase%2520Activity%2520Reduces%2520Primary%2520Tumor%2520Growth%2520and%2520Metastasis%2520Formation%2520in%2520a%2520Murine%2520Lung%2520Carcinoma%2520Model%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2010%26volume%3D181%26spage%3D611%26epage%3D619%26doi%3D10.1164%2Frccm.200903-0342OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Frederickson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callaghan, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chessari, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Congreve, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMenamin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vinković, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallis, N. G.</span><span> </span><span class="NLM_article-title">Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">183</span><span class="NLM_x">–</span> <span class="NLM_lpage">186</span><span class="refDoi"> DOI: 10.1021/jm701359z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701359z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=183-186&author=M.+Fredericksonauthor=O.+Callaghanauthor=G.+Chessariauthor=M.+Congreveauthor=S.+R.+Cowanauthor=J.+E.+Matthewsauthor=R.+McMenaminauthor=D.-M.+Smithauthor=M.+Vinkovi%C4%87author=N.+G.+Wallis&title=Fragment-Based+Discovery+of+Mexiletine+Derivatives+as+Orally+Bioavailable+Inhibitors+of+Urokinase-Type+Plasminogen+Activator&doi=10.1021%2Fjm701359z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fjm701359z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701359z%26sid%3Dliteratum%253Aachs%26aulast%3DFrederickson%26aufirst%3DM.%26aulast%3DCallaghan%26aufirst%3DO.%26aulast%3DChessari%26aufirst%3DG.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DCowan%26aufirst%3DS.%2BR.%26aulast%3DMatthews%26aufirst%3DJ.%2BE.%26aulast%3DMcMenamin%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DD.-M.%26aulast%3DVinkovi%25C4%2587%26aufirst%3DM.%26aulast%3DWallis%26aufirst%3DN.%2BG.%26atitle%3DFragment-Based%2520Discovery%2520of%2520Mexiletine%2520Derivatives%2520as%2520Orally%2520Bioavailable%2520Inhibitors%2520of%2520Urokinase-Type%2520Plasminogen%2520Activator%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D183%26epage%3D186%26doi%3D10.1021%2Fjm701359z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Bruncko, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McClellan, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wendt, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sauer, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geyer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalton, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaminski, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weitzberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dellaria, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantei, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nienaber, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinghofer, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rockway, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giranda, V. L.</span><span> </span><span class="NLM_article-title">Naphthamidine Urokinase Plasminogen Activator Inhibitors with Improved Pharmacokinetic Properties</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">93</span><span class="NLM_x">–</span> <span class="NLM_lpage">98</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2004.10.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1016%2Fj.bmcl.2004.10.026" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=93-98&author=M.+Brunckoauthor=W.+J.+McClellanauthor=M.+D.+Wendtauthor=D.+R.+Sauerauthor=A.+Geyerauthor=C.+R.+Daltonauthor=M.+A.+Kaminskiauthor=M.+Weitzbergauthor=J.+Gongauthor=J.+F.+Dellariaauthor=R.+Manteiauthor=X.+Zhaoauthor=V.+L.+Nienaberauthor=K.+Stewartauthor=V.+Klinghoferauthor=J.+Bouskaauthor=T.+W.+Rockwayauthor=V.+L.+Giranda&title=Naphthamidine+Urokinase+Plasminogen+Activator+Inhibitors+with+Improved+Pharmacokinetic+Properties&doi=10.1016%2Fj.bmcl.2004.10.026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.10.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.10.026%26sid%3Dliteratum%253Aachs%26aulast%3DBruncko%26aufirst%3DM.%26aulast%3DMcClellan%26aufirst%3DW.%2BJ.%26aulast%3DWendt%26aufirst%3DM.%2BD.%26aulast%3DSauer%26aufirst%3DD.%2BR.%26aulast%3DGeyer%26aufirst%3DA.%26aulast%3DDalton%26aufirst%3DC.%2BR.%26aulast%3DKaminski%26aufirst%3DM.%2BA.%26aulast%3DWeitzberg%26aufirst%3DM.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DDellaria%26aufirst%3DJ.%2BF.%26aulast%3DMantei%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DNienaber%26aufirst%3DV.%2BL.%26aulast%3DStewart%26aufirst%3DK.%26aulast%3DKlinghofer%26aufirst%3DV.%26aulast%3DBouska%26aufirst%3DJ.%26aulast%3DRockway%26aufirst%3DT.%2BW.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26atitle%3DNaphthamidine%2520Urokinase%2520Plasminogen%2520Activator%2520Inhibitors%2520with%2520Improved%2520Pharmacokinetic%2520Properties%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D93%26epage%3D98%26doi%3D10.1016%2Fj.bmcl.2004.10.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Zhu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gokhale, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munoz, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baek, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bashyam, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Von Hoff, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, H.</span><span> </span><span class="NLM_article-title">Identification of a Novel Inhibitor of Urokinase-Type Plasminogen Activator</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1348</span><span class="NLM_x">–</span> <span class="NLM_lpage">1356</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-06-0520</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1158%2F1535-7163.MCT-06-0520" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=17431113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BD2sXktFams70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=1348-1356&author=M.+Zhuauthor=V.+M.+Gokhaleauthor=L.+Szaboauthor=R.+M.+Munozauthor=H.+Baekauthor=S.+Bashyamauthor=L.+H.+Hurleyauthor=D.+D.+Von+Hoffauthor=H.+Han&title=Identification+of+a+Novel+Inhibitor+of+Urokinase-Type+Plasminogen+Activator&doi=10.1158%2F1535-7163.MCT-06-0520"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a novel inhibitor of urokinase-type plasminogen activator</span></div><div class="casAuthors">Zhu, Ming; Gokhale, Vijay M.; Szabo, Lajos; Munoz, Ruben M.; Baek, Hyounggee; Bashyam, Sridevi; Hurley, Laurence H.; Von Hoff, Daniel D.; Han, Haiyong</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1348-1356</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Urokinase-type plasminogen activator (uPA), a highly restricted serine protease, plays an important role in the regulation of diverse physiol. and pathol. processes.  Strong clin. and exptl. evidence has shown that elevated uPA expression is assocd. with cancer progression, metastasis, and shortened survival in patients.  UPA has been considered as a promising mol. target for development of anticancer drugs.  Here, we report the identification of several new uPA inhibitors using a high-throughput screen from a chem. library.  From these uPA inhibitors, mol. modeling and docking studies identified 4-oxazolidinone as a novel lead pharmacophore.  Optimization of the 4-oxazolidinone pharmacophore resulted in a series of structurally modified compds. with improved potency and selectivity.  One of the 4-oxazolidinone analogs, UK122, showed the highest inhibition of uPA activity.  The IC50 of UK122 in a cell-free indirect uPA assay is 0.2 μmol/L.  This compd. also showed no or little inhibition of other serine proteases such as thrombin, trypsin, plasmin, and the tissue-type plasminogen activator, indicating its high specificity against uPA.  Moreover, UK122 showed little cytotoxicity against CFPAC-1 cells (IC50 >100 μmol/L) but significantly inhibited the migration and invasion of this pancreatic cancer cell line.  Our data show that UK122 could potentially be developed as a new anticancer agent that prevents the invasion and metastasis of pancreatic cancer. [Mol Cancer Ther 2007;6(4):1348-56].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEnj7xwlO_JLVg90H21EOLACvtfcHk0lgYGTuY_Wk2BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXktFams70%253D&md5=8d75c347878e3123db205e78bcaefd26</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0520%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DGokhale%26aufirst%3DV.%2BM.%26aulast%3DSzabo%26aufirst%3DL.%26aulast%3DMunoz%26aufirst%3DR.%2BM.%26aulast%3DBaek%26aufirst%3DH.%26aulast%3DBashyam%26aufirst%3DS.%26aulast%3DHurley%26aufirst%3DL.%2BH.%26aulast%3DVon%2BHoff%26aufirst%3DD.%2BD.%26aulast%3DHan%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520a%2520Novel%2520Inhibitor%2520of%2520Urokinase-Type%2520Plasminogen%2520Activator%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D1348%26epage%3D1356%26doi%3D10.1158%2F1535-7163.MCT-06-0520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Joossens, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Sayed, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surpateanu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van der Veken, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambeir, A.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setyono-Han, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foekens, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmalix, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haemers, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Augustyns, K.</span><span> </span><span class="NLM_article-title">Small, Potent, and Selective Diaryl Phosphonate Inhibitors for Urokinase-Type Plasminogen Activator with in Vivo Antimetastatic Properties</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">6638</span><span class="NLM_x">–</span> <span class="NLM_lpage">6646</span><span class="refDoi"> DOI: 10.1021/jm700962j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm700962j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=6638-6646&author=J.+Joossensauthor=O.+M.+Aliauthor=I.+El-Sayedauthor=G.+Surpateanuauthor=P.+Van+der+Vekenauthor=A.-M.+Lambeirauthor=B.+Setyono-Hanauthor=J.+A.+Foekensauthor=A.+Schneiderauthor=W.+Schmalixauthor=A.+Haemersauthor=K.+Augustyns&title=Small%2C+Potent%2C+and+Selective+Diaryl+Phosphonate+Inhibitors+for+Urokinase-Type+Plasminogen+Activator+with+in+Vivo+Antimetastatic+Properties&doi=10.1021%2Fjm700962j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm700962j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm700962j%26sid%3Dliteratum%253Aachs%26aulast%3DJoossens%26aufirst%3DJ.%26aulast%3DAli%26aufirst%3DO.%2BM.%26aulast%3DEl-Sayed%26aufirst%3DI.%26aulast%3DSurpateanu%26aufirst%3DG.%26aulast%3DVan%2Bder%2BVeken%26aufirst%3DP.%26aulast%3DLambeir%26aufirst%3DA.-M.%26aulast%3DSetyono-Han%26aufirst%3DB.%26aulast%3DFoekens%26aufirst%3DJ.%2BA.%26aulast%3DSchneider%26aufirst%3DA.%26aulast%3DSchmalix%26aufirst%3DW.%26aulast%3DHaemers%26aufirst%3DA.%26aulast%3DAugustyns%26aufirst%3DK.%26atitle%3DSmall%252C%2520Potent%252C%2520and%2520Selective%2520Diaryl%2520Phosphonate%2520Inhibitors%2520for%2520Urokinase-Type%2520Plasminogen%2520Activator%2520with%2520in%2520Vivo%2520Antimetastatic%2520Properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D6638%26epage%3D6646%26doi%3D10.1021%2Fjm700962j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Parry, G.; Mazar, A. P.</span><span> </span><span class="NLM_article-title">Urokinase-type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof</span>. US Patent 8105602,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=G.+Parry&author=A.+P.+Mazar&title=Urokinase-type+plasminogen+activator+receptor+epitope%2C+monoclonal+antibodies+derived+therefrom+and+methods+of+use+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DParry%26aufirst%3DG.%26atitle%3DUrokinase-type%2520plasminogen%2520activator%2520receptor%2520epitope%252C%2520monoclonal%2520antibodies%2520derived%2520therefrom%2520and%2520methods%2520of%2520use%2520thereof%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Xu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donate, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juarez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parry, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meehan, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ugolkov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubrovskyi, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Halloran, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazar, A. P.</span><span> </span><span class="NLM_article-title">Identification of a New Epitope in uPAR as a Target for the Cancer Therapeutic Monoclonal Antibody ATN-658, a Structural Homolog of the uPAR Binding Integrin CD11b (αM)</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">e95349</span><span class="NLM_x">–</span> <span class="NLM_lpage">13</span><span class="refDoi"> DOI: 10.1371/journal.pone.0085349</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1371%2Fjournal.pone.0085349" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e95349-13&issue=1&author=X.+Xuauthor=Y.+Caiauthor=Y.+Weiauthor=F.+Donateauthor=J.+Juarezauthor=G.+Parryauthor=L.+Chenauthor=E.+J.+Meehanauthor=R.+W.+Ahnauthor=A.+Ugolkovauthor=O.+Dubrovskyiauthor=T.+O%27Halloranauthor=M.+Huangauthor=A.+P.+Mazar&title=Identification+of+a+New+Epitope+in+uPAR+as+a+Target+for+the+Cancer+Therapeutic+Monoclonal+Antibody+ATN-658%2C+a+Structural+Homolog+of+the+uPAR+Binding+Integrin+CD11b+%28%CE%B1M%29&doi=10.1371%2Fjournal.pone.0085349"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0085349&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0085349%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DX.%26aulast%3DCai%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DDonate%26aufirst%3DF.%26aulast%3DJuarez%26aufirst%3DJ.%26aulast%3DParry%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DMeehan%26aufirst%3DE.%2BJ.%26aulast%3DAhn%26aufirst%3DR.%2BW.%26aulast%3DUgolkov%26aufirst%3DA.%26aulast%3DDubrovskyi%26aufirst%3DO.%26aulast%3DO%2527Halloran%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DMazar%26aufirst%3DA.%2BP.%26atitle%3DIdentification%2520of%2520a%2520New%2520Epitope%2520in%2520uPAR%2520as%2520a%2520Target%2520for%2520the%2520Cancer%2520Therapeutic%2520Monoclonal%2520Antibody%2520ATN-658%252C%2520a%2520Structural%2520Homolog%2520of%2520the%2520uPAR%2520Binding%2520Integrin%2520CD11b%2520%2528%25CE%25B1M%2529%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26issue%3D1%26spage%3De95349%26epage%3D13%26doi%3D10.1371%2Fjournal.pone.0085349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Chen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gfeller, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buth, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michielin, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leiman, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinis, C.</span><span> </span><span class="NLM_article-title">Improving Binding Affinity and Stability of Peptide Ligands by Substituting Glycines with D-Amino Acids</span> <span class="citation_source-journal">ChemBioChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1316</span><span class="NLM_x">–</span> <span class="NLM_lpage">1322</span><span class="refDoi"> DOI: 10.1002/cbic.201300228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1002%2Fcbic.201300228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=23828687" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVGku7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=1316-1322&author=S.+Chenauthor=D.+Gfellerauthor=S.+A.+Buthauthor=O.+Michielinauthor=P.+G.+Leimanauthor=C.+Heinis&title=Improving+Binding+Affinity+and+Stability+of+Peptide+Ligands+by+Substituting+Glycines+with+D-Amino+Acids&doi=10.1002%2Fcbic.201300228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Improving Binding Affinity and Stability of Peptide Ligands by Substituting Glycines with D-Amino Acids</span></div><div class="casAuthors">Chen, Shiyu; Gfeller, David; Buth, Sergey A.; Michielin, Olivier; Leiman, Petr G.; Heinis, Christian</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1316-1322</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Improving the binding affinity and/or stability of peptide ligands often requires testing of large nos. of variants to identify beneficial mutations.  Herein we propose a type of mutation that promises a high success rate.  In a bicyclic peptide inhibitor of the cancer-related protease urokinase-type plasminogen activator (uPA), we obsd. a glycine residue that has a pos. .vphi. dihedral angle when bound to the target.  We hypothesized that replacing it with a D-amino acid, which favors pos. .vphi. angles, could enhance the binding affinity and/or proteolytic resistance.  Mutation of this specific glycine to D-serine in the bicyclic peptide indeed improved inhibitory activity (1.75-fold) and stability (fourfold).  X-ray-structure anal. of the inhibitors in complex with uPA showed that the peptide backbone conformation was conserved.  Anal. of known cyclic peptide ligands showed that glycine is one of the most frequent amino acids, and that glycines with pos. .vphi. angles are found in many protein-bound peptides.  These results suggest that the glycine-to-D-amino acid mutagenesis strategy could be broadly applied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSvU_PyOWh77Vg90H21EOLACvtfcHk0ljFzkq2ILBW0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVGku7vL&md5=e9ddaa6e0dfe2004d2ed52805ad18835</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201300228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201300228%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.%26aulast%3DGfeller%26aufirst%3DD.%26aulast%3DButh%26aufirst%3DS.%2BA.%26aulast%3DMichielin%26aufirst%3DO.%26aulast%3DLeiman%26aufirst%3DP.%2BG.%26aulast%3DHeinis%26aufirst%3DC.%26atitle%3DImproving%2520Binding%2520Affinity%2520and%2520Stability%2520of%2520Peptide%2520Ligands%2520by%2520Substituting%2520Glycines%2520with%2520D-Amino%2520Acids%26jtitle%3DChemBioChem%26date%3D2013%26volume%3D14%26spage%3D1316%26epage%3D1322%26doi%3D10.1002%2Fcbic.201300228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Roodbeen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paaske, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulder, F. A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreasen, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, K. J.</span><span> </span><span class="NLM_article-title">Bicyclic Peptide Inhibitor of Urokinase-Type Plasminogen Activator: Mode of Action</span> <span class="citation_source-journal">ChemBioChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">2179</span><span class="NLM_x">–</span> <span class="NLM_lpage">2188</span><span class="refDoi"> DOI: 10.1002/cbic.201300335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1002%2Fcbic.201300335" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=24115455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsF2nt77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=2179-2188&author=R.+Roodbeenauthor=B.+Paaskeauthor=L.+Jiangauthor=J.+K.+Jensenauthor=A.+Christensenauthor=J.+T.+Nielsenauthor=M.+Huangauthor=F.+A.+A.+Mulderauthor=N.+C.+Nielsenauthor=P.+A.+Andreasenauthor=K.+J.+Jensen&title=Bicyclic+Peptide+Inhibitor+of+Urokinase-Type+Plasminogen+Activator%3A+Mode+of+Action&doi=10.1002%2Fcbic.201300335"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Bicyclic Peptide Inhibitor of Urokinase-Type Plasminogen Activator: Mode of Action</span></div><div class="casAuthors">Roodbeen, Renee; Paaske, Berit; Jiang, Longguang; Jensen, Jan K.; Christensen, Anni; Nielsen, Jakob T.; Huang, Mingdong; Mulder, Frans A. A.; Nielsen, Niels Chr.; Andreasen, Peter A.; Jensen, Knud J.</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2179-2188</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The development of protease inhibitors for pharmacol. intervention has taken a new turn using peptide-based inhibitors.  Here, the authors report the rational design of bicyclic peptide inhibitors of the serine protease urokinase-type plasminogen activator (uPA), based on the established monocyclic peptide, upain-2.  It was successfully converted to a bicyclic peptide, without loss of inhibitory properties.  The aim was to produce a peptide cyclized by an amide bond with an addnl. stabilizing across-the-ring covalent bond.  The authors expected this bicyclic peptide to exhibit a lower entropic burden upon binding.  Two bicyclic peptides were synthesized with affinities similar to that of upain-2, and their binding energetics were evaluated by isothermal titrn. calorimetry.  Indeed, compared to upain-2, the bicyclic peptides showed reduced loss of entropy upon binding to uPA.  The authors also studied the soln. structures of the bicyclic peptide by NMR spectroscopy to map possible conformations.  An x-ray structure of the bicyclic-peptide-uPA complex confirmed an interaction similar to that for the previous upain-1/upain-2-uPA complexes.  These phys. studies of the peptide-protease interactions will aid future designs of bicyclic peptide protease inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3Sy6oFrgO87Vg90H21EOLACvtfcHk0ljFzkq2ILBW0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsF2nt77I&md5=fd3049e453450a0a5fef5f3ecd25c9b9</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201300335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201300335%26sid%3Dliteratum%253Aachs%26aulast%3DRoodbeen%26aufirst%3DR.%26aulast%3DPaaske%26aufirst%3DB.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DJensen%26aufirst%3DJ.%2BK.%26aulast%3DChristensen%26aufirst%3DA.%26aulast%3DNielsen%26aufirst%3DJ.%2BT.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DMulder%26aufirst%3DF.%2BA.%2BA.%26aulast%3DNielsen%26aufirst%3DN.%2BC.%26aulast%3DAndreasen%26aufirst%3DP.%2BA.%26aulast%3DJensen%26aufirst%3DK.%2BJ.%26atitle%3DBicyclic%2520Peptide%2520Inhibitor%2520of%2520Urokinase-Type%2520Plasminogen%2520Activator%253A%2520Mode%2520of%2520Action%26jtitle%3DChemBioChem%26date%3D2013%26volume%3D14%26spage%3D2179%26epage%3D2188%26doi%3D10.1002%2Fcbic.201300335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Gladysz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cleenewerck, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joossens, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambeir, A.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Augustyns, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van der Veken, P.</span><span> </span><span class="NLM_article-title">Repositioning the Substrate Activity Screening (SAS) Approach as a Fragment-Based Method for Identification of Weak Binders</span> <span class="citation_source-journal">ChemBioChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">2238</span><span class="NLM_x">–</span> <span class="NLM_lpage">2247</span><span class="refDoi"> DOI: 10.1002/cbic.201402192</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1002%2Fcbic.201402192" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=25154878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVSqtb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=2238-2247&author=R.+Gladyszauthor=M.+Cleenewerckauthor=J.+Joossensauthor=A.-M.+Lambeirauthor=K.+Augustynsauthor=P.+Van+der+Veken&title=Repositioning+the+Substrate+Activity+Screening+%28SAS%29+Approach+as+a+Fragment-Based+Method+for+Identification+of+Weak+Binders&doi=10.1002%2Fcbic.201402192"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Repositioning the Substrate Activity Screening (SAS) Approach as a Fragment-Based Method for Identification of Weak Binders</span></div><div class="casAuthors">Gladysz, Rafaela; Cleenewerck, Matthias; Joossens, Jurgen; Lambeir, Anne-Marie; Augustyns, Koen; Van der Veken, Pieter</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2238-2247</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Fragment-based drug discovery (FBDD) has evolved into an established approach for "hit" identification.  Typically, most applications of FBDD depend on specialised cost- and time-intensive biophys. techniques.  The substrate activity screening (SAS) approach has been proposed as a relatively cheap and straightforward alternative for identification of fragments for enzyme inhibitors.  We have investigated SAS for the discovery of inhibitors of oncol. target urokinase (uPA).  Although our results support the key hypotheses of SAS, we also encountered a no. of unreported limitations.  In response, we propose an efficient modified methodol.: "MSAS" (modified substrate activity screening).  MSAS circumvents the limitations of SAS and broadens its scope by providing addnl. fragments and more coherent SAR data.  As well as presenting and validating MSAS, this study expands existing SAR knowledge for the S1 pocket of uPA and reports new reversible and irreversible uPA inhibitor scaffolds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxGqDxLUMmCLVg90H21EOLACvtfcHk0lhEzyuV_PNQgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVSqtb3N&md5=9af3469f29276dc79343e1469b13ce95</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201402192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201402192%26sid%3Dliteratum%253Aachs%26aulast%3DGladysz%26aufirst%3DR.%26aulast%3DCleenewerck%26aufirst%3DM.%26aulast%3DJoossens%26aufirst%3DJ.%26aulast%3DLambeir%26aufirst%3DA.-M.%26aulast%3DAugustyns%26aufirst%3DK.%26aulast%3DVan%2Bder%2BVeken%26aufirst%3DP.%26atitle%3DRepositioning%2520the%2520Substrate%2520Activity%2520Screening%2520%2528SAS%2529%2520Approach%2520as%2520a%2520Fragment-Based%2520Method%2520for%2520Identification%2520of%2520Weak%2520Binders%26jtitle%3DChemBioChem%26date%3D2014%26volume%3D15%26spage%3D2238%26epage%3D2247%26doi%3D10.1002%2Fcbic.201402192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Groebke, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehlin, F.</span><span> </span><span class="NLM_article-title">Synthesis of Imidazo[1,2-<i>a</i>] Annulated Pyridines, Pyrazines and Pyrimidines by a Novel Three-Component Condensation</span> <span class="citation_source-journal">Synlett</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">1998</span><span class="NLM_x">, </span> <span class="NLM_fpage">661</span><span class="NLM_x">–</span> <span class="NLM_lpage">663</span><span class="refDoi"> DOI: 10.1055/s-1998-1721</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1055%2Fs-1998-1721" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1998&publication_year=1998&pages=661-663&author=K.+Groebkeauthor=L.+Weberauthor=F.+Mehlin&title=Synthesis+of+Imidazo%5B1%2C2-a%5D+Annulated+Pyridines%2C+Pyrazines+and+Pyrimidines+by+a+Novel+Three-Component+Condensation&doi=10.1055%2Fs-1998-1721"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1055%2Fs-1998-1721&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1998-1721%26sid%3Dliteratum%253Aachs%26aulast%3DGroebke%26aufirst%3DK.%26aulast%3DWeber%26aufirst%3DL.%26aulast%3DMehlin%26aufirst%3DF.%26atitle%3DSynthesis%2520of%2520Imidazo%255B1%252C2-a%255D%2520Annulated%2520Pyridines%252C%2520Pyrazines%2520and%2520Pyrimidines%2520by%2520a%2520Novel%2520Three-Component%2520Condensation%26jtitle%3DSynlett%26date%3D1998%26volume%3D1998%26spage%3D661%26epage%3D663%26doi%3D10.1055%2Fs-1998-1721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Blackburn, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleming, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiosaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, S.</span><span> </span><span class="NLM_article-title">Parallel Synthesis of 3-aminoimidazo[1,2-<i>a</i>]pyridines and Pyrazines by a New Three-Component Condensation</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">3635</span><span class="NLM_x">–</span> <span class="NLM_lpage">3638</span><span class="refDoi"> DOI: 10.1016/S0040-4039(98)00653-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1016%2FS0040-4039%2898%2900653-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADyaK1cXjtlWrtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1998&pages=3635-3638&author=C.+Blackburnauthor=B.+Guanauthor=P.+Flemingauthor=K.+Shiosakiauthor=S.+Tsai&title=Parallel+Synthesis+of+3-aminoimidazo%5B1%2C2-a%5Dpyridines+and+Pyrazines+by+a+New+Three-Component+Condensation&doi=10.1016%2FS0040-4039%2898%2900653-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Parallel synthesis of 3-aminoimidazo[1,2-a]pyridines and pyrazines by a new three-component condensation</span></div><div class="casAuthors">Blackburn, Christopher; Guan, Bing; Fleming, Paul; Shiosaki, Kazumi; Tsai, Shirling</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3635-3638</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A three-component condensation reaction between 2-aminopyridine, an aldehyde and an isonitrile catalyzed by scandium triflate affords derivs. of 3-aminoimidazo[1,2-a]pyridine; aminopyrazine reacts similarly.  A library of heterocycles, prepd. in high yield by parallel synthesis and purifn. on an ion-exchange resin, was subjected to further reaction at the amino group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrndWK-azaOEbVg90H21EOLACvtfcHk0lhEzyuV_PNQgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjtlWrtLs%253D&md5=dfdddf23bcb1051d2ff6375f9f2616f5</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2898%2900653-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252898%252900653-4%26sid%3Dliteratum%253Aachs%26aulast%3DBlackburn%26aufirst%3DC.%26aulast%3DGuan%26aufirst%3DB.%26aulast%3DFleming%26aufirst%3DP.%26aulast%3DShiosaki%26aufirst%3DK.%26aulast%3DTsai%26aufirst%3DS.%26atitle%3DParallel%2520Synthesis%2520of%25203-aminoimidazo%255B1%252C2-a%255Dpyridines%2520and%2520Pyrazines%2520by%2520a%2520New%2520Three-Component%2520Condensation%26jtitle%3DTetrahedron%2520Lett.%26date%3D1998%26volume%3D39%26spage%3D3635%26epage%3D3638%26doi%3D10.1016%2FS0040-4039%2898%2900653-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Bienaymé, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouzid, K.</span><span> </span><span class="NLM_article-title">A New Heterocyclic Multicomponent Reaction For the Combinatorial Synthesis of Fused 3-Aminoimidazoles</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">2234</span><span class="NLM_x">–</span> <span class="NLM_lpage">2237</span><span class="refDoi"> DOI: 10.1002/(SICI)1521-3773(19980904)37:16<2234::AID-ANIE2234>3.3.CO;2-I</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1002%2F%28SICI%291521-3773%2819980904%2937%3A16%3C2234%3A%3AAID-ANIE2234%3E3.3.CO%3B2-I" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1998&pages=2234-2237&author=H.+Bienaym%C3%A9author=K.+Bouzid&title=A+New+Heterocyclic+Multicomponent+Reaction+For+the+Combinatorial+Synthesis+of+Fused+3-Aminoimidazoles&doi=10.1002%2F%28SICI%291521-3773%2819980904%2937%3A16%3C2234%3A%3AAID-ANIE2234%3E3.3.CO%3B2-I"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291521-3773%2819980904%2937%3A16%3C2234%3A%3AAID-ANIE2234%3E3.3.CO%3B2-I&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291521-3773%252819980904%252937%253A16%253C2234%253A%253AAID-ANIE2234%253E3.3.CO%253B2-I%26sid%3Dliteratum%253Aachs%26aulast%3DBienaym%25C3%25A9%26aufirst%3DH.%26aulast%3DBouzid%26aufirst%3DK.%26atitle%3DA%2520New%2520Heterocyclic%2520Multicomponent%2520Reaction%2520For%2520the%2520Combinatorial%2520Synthesis%2520of%2520Fused%25203-Aminoimidazoles%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D1998%26volume%3D37%26spage%3D2234%26epage%3D2237%26doi%3D10.1002%2F%28SICI%291521-3773%2819980904%2937%3A16%3C2234%3A%3AAID-ANIE2234%3E3.3.CO%3B2-I" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bagdi, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santra, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monir, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajra, A.</span><span> </span><span class="NLM_article-title">Synthesis of imidazo[1,2-<i>a</i>]pyridines: A Decade Update</span> <span class="citation_source-journal">Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1555</span><span class="NLM_x">–</span> <span class="NLM_lpage">1575</span><span class="refDoi"> DOI: 10.1039/C4CC08495K</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1039%2FC4CC08495K" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=25407981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVyiu7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2015&pages=1555-1575&author=A.+K.+Bagdiauthor=S.+Santraauthor=K.+Monirauthor=A.+Hajra&title=Synthesis+of+imidazo%5B1%2C2-a%5Dpyridines%3A+A+Decade+Update&doi=10.1039%2FC4CC08495K"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18aR"><div class="casContent"><span class="casTitleNuber">18a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of imidazo[1,2-a]pyridines: a decade update</span></div><div class="casAuthors">Bagdi, Avik Kumar; Santra, Sougata; Monir, Kamarul; Hajra, Alakananda</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1555-1575</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Imidazopyridine is one of the important fused bicyclic 5-6 heterocycles and it is recognized as a "drug prejudice" scaffold due to its wide range of applications in medicinal chem.  This moiety is also useful in material science because of its structural character.  Synthesis of this moiety from the easily available chems. is desirable due to its tremendous use in the various branches of chem.  Here we report a review on the synthesis of this scaffold employing different strategies such as condensation, multicomponent reactions, oxidative coupling, tandem reactions, aminooxygenation, and hydroamination reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYesaxznoq0bVg90H21EOLACvtfcHk0linFkO2tVdDJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVyiu7%252FI&md5=4437aa97b3b269d776fe04f847460194</span></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.1039%2FC4CC08495K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4CC08495K%26sid%3Dliteratum%253Aachs%26aulast%3DBagdi%26aufirst%3DA.%2BK.%26aulast%3DSantra%26aufirst%3DS.%26aulast%3DMonir%26aufirst%3DK.%26aulast%3DHajra%26aufirst%3DA.%26atitle%3DSynthesis%2520of%2520imidazo%255B1%252C2-a%255Dpyridines%253A%2520A%2520Decade%2520Update%26jtitle%3DChem.%2520Commun.%26date%3D2015%26volume%3D51%26spage%3D1555%26epage%3D1575%26doi%3D10.1039%2FC4CC08495K" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Devi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rawal, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, V.</span><span> </span><span class="NLM_article-title">Diversity-Oriented Synthesis of Fused-Imidazole Derivatives via Groebke–Blackburn–Bienayme Reaction: A Review</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">183</span><span class="NLM_x">–</span> <span class="NLM_lpage">232</span><span class="refDoi"> DOI: 10.1016/j.tet.2014.10.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1016%2Fj.tet.2014.10.032" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2015&pages=183-232&author=N.+Deviauthor=R.+K.+Rawalauthor=V.+Singh&title=Diversity-Oriented+Synthesis+of+Fused-Imidazole+Derivatives+via+Groebke%E2%80%93Blackburn%E2%80%93Bienayme+Reaction%3A+A+Review&doi=10.1016%2Fj.tet.2014.10.032"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2014.10.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2014.10.032%26sid%3Dliteratum%253Aachs%26aulast%3DDevi%26aufirst%3DN.%26aulast%3DRawal%26aufirst%3DR.%2BK.%26aulast%3DSingh%26aufirst%3DV.%26atitle%3DDiversity-Oriented%2520Synthesis%2520of%2520Fused-Imidazole%2520Derivatives%2520via%2520Groebke%25E2%2580%2593Blackburn%25E2%2580%2593Bienayme%2520Reaction%253A%2520A%2520Review%26jtitle%3DTetrahedron%26date%3D2015%26volume%3D71%26spage%3D183%26epage%3D232%26doi%3D10.1016%2Fj.tet.2014.10.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Crestani, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Möhler, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, U.</span><span> </span><span class="NLM_article-title">Mechanism of action of the hypnotic zolpidem <i>in vivo</i></span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x">, </span> <span class="NLM_fpage">1251</span><span class="NLM_x">–</span> <span class="NLM_lpage">1254</span><span class="refDoi"> DOI: 10.1038/sj.bjp.0703717</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1038%2Fsj.bjp.0703717" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=11090095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BD3cXovFygt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2000&pages=1251-1254&author=F.+Crestaniauthor=J.+R.+Martinauthor=H.+M%C3%B6hlerauthor=U.+Rudolph&title=Mechanism+of+action+of+the+hypnotic+zolpidem+in+vivo&doi=10.1038%2Fsj.bjp.0703717"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18cR"><div class="casContent"><span class="casTitleNuber">18c</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of action of the hypnotic zolpidem in vivo</span></div><div class="casAuthors">Crestani, Florence; Martin, James R.; Mohler, Hanns; Rudolph, Uwe</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1251-1254</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Zolpidem is a widely used hypnotic agent acting at the GABAA receptor benzodiazepine site.  On recombinant receptors, zolpidem displays a high affinity to α1-GABAA receptors, an intermediate affinity to α2- and α3-GABAA receptors and fails to bind to α5-GABAA receptors.  However, it is not known which receptor subtype is essential for mediating the sedative-hypnotic action in vivo.  Studying α1(H101R) mice, which possess zolpidem-insensitive α1-GABAA receptors, we show that the sedative action of zolpidem is exclusively mediated by α1-GABAA receptors.  Similarly, the activity of zolpidem against pentylenetetrazole-induced tonic convulsions is also completely mediated by α1-GABAA receptors.  These results establish that the sedative-hypnotic and anticonvulsant activities of zolpidem are due to its action on α1-GABAA receptors and not on α2- or α3-GABAA receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw0ldi7hhL07Vg90H21EOLACvtfcHk0lj6GdsIqa5fYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXovFygt7o%253D&md5=f1d50d8f6e1ee6e1781068d02cd301de</span></div><a href="/servlet/linkout?suffix=cit18c&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0703717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0703717%26sid%3Dliteratum%253Aachs%26aulast%3DCrestani%26aufirst%3DF.%26aulast%3DMartin%26aufirst%3DJ.%2BR.%26aulast%3DM%25C3%25B6hler%26aufirst%3DH.%26aulast%3DRudolph%26aufirst%3DU.%26atitle%3DMechanism%2520of%2520action%2520of%2520the%2520hypnotic%2520zolpidem%2520in%2520vivo%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2000%26volume%3D131%26spage%3D1251%26epage%3D1254%26doi%3D10.1038%2Fsj.bjp.0703717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Mizushige, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yukiiri, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, H.</span><span> </span><span class="NLM_article-title">Olprinone: A Phosphodiesterase III Inhibitor with Positive Inotropic and Vasodilator Effects</span> <span class="citation_source-journal">Cardiovasc. Drug Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">163</span><span class="NLM_x">–</span> <span class="NLM_lpage">174</span><span class="refDoi"> DOI: 10.1111/j.1527-3466.2002.tb00085.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1111%2Fj.1527-3466.2002.tb00085.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=12397365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BD38XovVWnsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=163-174&author=K.+Mizushigeauthor=T.+Uedaauthor=K.+Yukiiriauthor=H.+Suzuki&title=Olprinone%3A+A+Phosphodiesterase+III+Inhibitor+with+Positive+Inotropic+and+Vasodilator+Effects&doi=10.1111%2Fj.1527-3466.2002.tb00085.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18dR"><div class="casContent"><span class="casTitleNuber">18d</span><div class="casTitle"><span class="NLM_cas:atitle">Olprinone: a phosphodiesterase III inhibitor with positive inotropic and vasodilator effects</span></div><div class="casAuthors">Mizushige, Katsufumi; Ueda, Takashi; Yukiiri, Kazushi; Suzuki, Hitoshi</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Drug Reviews</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">163-174</span>CODEN:
                <span class="NLM_cas:coden">CDREEA</span>;
        ISSN:<span class="NLM_cas:issn">0897-5957</span>.
    
            (<span class="NLM_cas:orgname">Neva Press</span>)
        </div><div class="casAbstract">A review.  Olprinone is a newly developed phosphodiesterase III inhibitor characterized by several properties.  First, olprinone has pos. inotropic and vasodilator actions and improves myocardial mech. efficiency.  Second, olprinone augments cerebral blood flow by a direct vasodilatory effect on cerebral arteries.  The cerebrovascular reactivity to olprinone is marked in patients with impaired cerebral circulation.  Third, olprinone selectively improves carotid artery distensibility, which may be attributable to differences in the arterial structural components or the reactivity of smooth muscle cells to olprinone.  Fourth, olprinone improves inadequate redistribution of brain perfusion and may prevent cerebral metabolic abnormalities in heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpErFNpkZl4ibVg90H21EOLACvtfcHk0lj6GdsIqa5fYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovVWnsrg%253D&md5=79bb45d7a8667d38d0bf1ce79cd90ff2</span></div><a href="/servlet/linkout?suffix=cit18d&amp;dbid=16384&amp;doi=10.1111%2Fj.1527-3466.2002.tb00085.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1527-3466.2002.tb00085.x%26sid%3Dliteratum%253Aachs%26aulast%3DMizushige%26aufirst%3DK.%26aulast%3DUeda%26aufirst%3DT.%26aulast%3DYukiiri%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DH.%26atitle%3DOlprinone%253A%2520A%2520Phosphodiesterase%2520III%2520Inhibitor%2520with%2520Positive%2520Inotropic%2520and%2520Vasodilator%2520Effects%26jtitle%3DCardiovasc.%2520Drug%2520Rev.%26date%3D2002%26volume%3D20%26spage%3D163%26epage%3D174%26doi%3D10.1111%2Fj.1527-3466.2002.tb00085.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Boggs, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elitzin, V. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gudmundsson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharp, M. J.</span><span> </span><span class="NLM_article-title">CXCR4 Antagonist (GSK812397)</span> <span class="citation_source-journal">Synfacts</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">2010</span><span class="NLM_x">, </span> <span class="NLM_fpage">0011</span><span class="refDoi"> DOI: 10.1055/s-0029-1218261</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1055%2Fs-0029-1218261" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2010&publication_year=2010&pages=0011&author=S.+Boggsauthor=V.+I.+Elitzinauthor=K.+Gudmundssonauthor=M.+T.+Martinauthor=M.+J.+Sharp&title=CXCR4+Antagonist+%28GSK812397%29&doi=10.1055%2Fs-0029-1218261"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18e&amp;dbid=16384&amp;doi=10.1055%2Fs-0029-1218261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0029-1218261%26sid%3Dliteratum%253Aachs%26aulast%3DBoggs%26aufirst%3DS.%26aulast%3DElitzin%26aufirst%3DV.%2BI.%26aulast%3DGudmundsson%26aufirst%3DK.%26aulast%3DMartin%26aufirst%3DM.%2BT.%26aulast%3DSharp%26aufirst%3DM.%2BJ.%26atitle%3DCXCR4%2520Antagonist%2520%2528GSK812397%2529%26jtitle%3DSynfacts%26date%3D2010%26volume%3D2010%26spage%3D0011%26doi%3D10.1055%2Fs-0029-1218261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Hartman, G. D.; Weinstock, L. M.</span><span> </span><span class="NLM_article-title">Thiazoles from Ethyl Isocyanoacetate and Thiono Esters: Ethyl Thiazole-4-Carboxylate</span>.  <span class="citation_source-book">Organic Syntheses</span>; <span class="NLM_publisher-name">John Wiley & Sons</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">1988</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">6</span>, p  <span class="NLM_fpage">620</span>, <span class="refDoi"> DOI: 10.1002/0471264180.os059.26</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1002%2F0471264180.os059.26" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1988&pages=620&author=G.+D.+Hartman&author=L.+M.+Weinstock&title=Organic+Syntheses"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2F0471264180.os059.26&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F0471264180.os059.26%26sid%3Dliteratum%253Aachs%26aulast%3DHartman%26aufirst%3DG.%2BD.%26atitle%3DThiazoles%2520from%2520Ethyl%2520Isocyanoacetate%2520and%2520Thiono%2520Esters%253A%2520Ethyl%2520Thiazole-4-Carboxylate%26btitle%3DOrganic%2520Syntheses%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%26date%3D1988%26volume%3D6%26spage%3D620%26doi%3D10.1002%2F0471264180.os059.26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Obrecht, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ugi, I.</span><span> </span><span class="NLM_article-title">Isocyanide Synthesis with Phosphoryl Chloride and Diisopropylamine</span> <span class="citation_source-journal">Synthesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">1985</span><span class="NLM_x">, </span> <span class="NLM_fpage">400</span><span class="refDoi"> DOI: 10.1055/s-1985-31216</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1055%2Fs-1985-31216" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1985&publication_year=1985&pages=400&author=R.+Obrechtauthor=R.+Herrmannauthor=I.+Ugi&title=Isocyanide+Synthesis+with+Phosphoryl+Chloride+and+Diisopropylamine&doi=10.1055%2Fs-1985-31216"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1055%2Fs-1985-31216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1985-31216%26sid%3Dliteratum%253Aachs%26aulast%3DObrecht%26aufirst%3DR.%26aulast%3DHerrmann%26aufirst%3DR.%26aulast%3DUgi%26aufirst%3DI.%26atitle%3DIsocyanide%2520Synthesis%2520with%2520Phosphoryl%2520Chloride%2520and%2520Diisopropylamine%26jtitle%3DSynthesis%26date%3D1985%26volume%3D1985%26spage%3D400%26doi%3D10.1055%2Fs-1985-31216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Dömling, A.</span><span> </span><span class="NLM_article-title">Recent Developments in Isocyanide Based Multicomponent Reactions in Applied Chemistry</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">17</span><span class="NLM_x">–</span> <span class="NLM_lpage">89</span><span class="refDoi"> DOI: 10.1021/cr0505728</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr0505728" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A280%3ADC%252BD28%252FhslyntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2006&pages=17-89&author=A.+D%C3%B6mling&title=Recent+Developments+in+Isocyanide+Based+Multicomponent+Reactions+in+Applied+Chemistry&doi=10.1021%2Fcr0505728"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments in isocyanide based multicomponent reactions in applied chemistry</span></div><div class="casAuthors">Domling Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Chemical reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-89</span>
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRtCMEx7SbgjiM8MEzWGjS9fW6udTcc2eaXaVIX87eVPbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28%252FhslyntA%253D%253D&md5=33b233fa9ca718d7e0e6db6fee49e5fd</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fcr0505728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr0505728%26sid%3Dliteratum%253Aachs%26aulast%3DD%25C3%25B6mling%26aufirst%3DA.%26atitle%3DRecent%2520Developments%2520in%2520Isocyanide%2520Based%2520Multicomponent%2520Reactions%2520in%2520Applied%2520Chemistry%26jtitle%3DChem.%2520Rev.%26date%3D2006%26volume%3D106%26spage%3D17%26epage%3D89%26doi%3D10.1021%2Fcr0505728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">DiMauro, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, J. M.</span><span> </span><span class="NLM_article-title">Rapid Synthesis of 3-Amino-imidazopyridines by a Microwave-Assisted Four-Component Coupling in One Pot</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">1013</span><span class="NLM_x">–</span> <span class="NLM_lpage">1016</span><span class="refDoi"> DOI: 10.1021/jo0622072</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo0622072" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlKjsr%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2007&pages=1013-1016&author=E.+F.+DiMauroauthor=J.+M.+Kennedy&title=Rapid+Synthesis+of+3-Amino-imidazopyridines+by+a+Microwave-Assisted+Four-Component+Coupling+in+One+Pot&doi=10.1021%2Fjo0622072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid synthesis of 3-amino-imidazopyridines by a microwave-assisted four-component coupling in one pot</span></div><div class="casAuthors">DiMauro, Erin F.; Kennedy, Joseph M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1013-1016</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The rapid and efficient synthesis of various 2,6-disubstituted-3-amino-imidazopyridines, e.g., I, using a microwave-assisted one-pot cyclization/Suzuki coupling approach was described.  The utility of a 2-aminopyridine-5-boronic acid pinacol ester as a robust and versatile building block for the synthesis of diverse compd. libraries was emphasized.  The boronate functional group was remarkably tolerant to the Lewis acid catalyzed cyclizations, and the subsequent Pd(0)-catalyzed Suzuki coupling reactions proceeded cleanly in the presence of magnesium salts.  This work highlighted the vast potential of microwave-assisted, metal-catalyzed, multicomponent reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpr8UZw-6qpPLVg90H21EOLACvtfcHk0ljsvK49yp6OcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlKjsr%252FF&md5=14f67b20d79fe674129cf82522211c28</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjo0622072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0622072%26sid%3Dliteratum%253Aachs%26aulast%3DDiMauro%26aufirst%3DE.%2BF.%26aulast%3DKennedy%26aufirst%3DJ.%2BM.%26atitle%3DRapid%2520Synthesis%2520of%25203-Amino-imidazopyridines%2520by%2520a%2520Microwave-Assisted%2520Four-Component%2520Coupling%2520in%2520One%2520Pot%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2007%26volume%3D72%26spage%3D1013%26epage%3D1016%26doi%3D10.1021%2Fjo0622072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Lyon, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kercher, T. S.</span><span> </span><span class="NLM_article-title">Glyoxylic Acid and MP-Glyoxylate: Efficient Formaldehyde Equivalents in the 3-CC of 2-Aminoazines, Aldehydes, and Isonitriles</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">4989</span><span class="NLM_x">–</span> <span class="NLM_lpage">4992</span><span class="refDoi"> DOI: 10.1021/ol0478234</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol0478234" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=4989-4992&author=M.+A.+Lyonauthor=T.+S.+Kercher&title=Glyoxylic+Acid+and+MP-Glyoxylate%3A+Efficient+Formaldehyde+Equivalents+in+the+3-CC+of+2-Aminoazines%2C+Aldehydes%2C+and+Isonitriles&doi=10.1021%2Fol0478234"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fol0478234&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol0478234%26sid%3Dliteratum%253Aachs%26aulast%3DLyon%26aufirst%3DM.%2BA.%26aulast%3DKercher%26aufirst%3DT.%2BS.%26atitle%3DGlyoxylic%2520Acid%2520and%2520MP-Glyoxylate%253A%2520Efficient%2520Formaldehyde%2520Equivalents%2520in%2520the%25203-CC%2520of%25202-Aminoazines%252C%2520Aldehydes%252C%2520and%2520Isonitriles%26jtitle%3DOrg.%2520Lett.%26date%3D2004%26volume%3D6%26spage%3D4989%26epage%3D4992%26doi%3D10.1021%2Fol0478234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Kiesewetter, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scholten, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirn, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hedrick, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waymouth, R. M.</span><span> </span><span class="NLM_article-title">Cyclic Guanidine Organic Catalysts: What Is Magic about Triazabicyclodecene?</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">9490</span><span class="NLM_x">–</span> <span class="NLM_lpage">9496</span><span class="refDoi"> DOI: 10.1021/jo902369g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo902369g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVKhs7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2009&pages=9490-9496&author=M.+K.+Kiesewetterauthor=M.+D.+Scholtenauthor=N.+Kirnauthor=R.+L.+Weberauthor=J.+L.+Hedrickauthor=R.+M.+Waymouth&title=Cyclic+Guanidine+Organic+Catalysts%3A+What+Is+Magic+about+Triazabicyclodecene%3F&doi=10.1021%2Fjo902369g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclic guanidine organic catalysts: What is magic about triazabicyclodecene?</span></div><div class="casAuthors">Kiesewetter, Matthew K.; Scholten, Marc D.; Kirn, Nicole; Weber, Ryan L.; Hedrick, James L.; Waymouth, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9490-9496</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The bicyclic guanidine 1,5,7-triazabicyclo[4.4.0]dec-5-ene (TBD) is an effective organocatalyst for the formation of amides from esters and primary amines.  Mechanistic and kinetic studies support a nucleophilic mechanism where TBD reacts reversibly with esters to generate an acyl-TBD intermediate that acylates amines to generate the amides.  Comparative studies of the analogous bicyclic guanidine 1,4,6-triazabicyclo[3.3.0]oct-4-ene (TBO) reveal it to be a much less active acylation catalyst than TBD.  Theor. and mechanistic studies imply that the higher reactivity of TBD is a consequence of both its higher basicity and nucleophilicity than TBO and the high reactivity of the acyl-TBD intermediate, which is sterically prevented from adopting a planar amide structure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9dztZtVWNcrVg90H21EOLACvtfcHk0ljR-lwvyXyhAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVKhs7nP&md5=0f263f5a0f48749b17ed6bbd486e7f32</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjo902369g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo902369g%26sid%3Dliteratum%253Aachs%26aulast%3DKiesewetter%26aufirst%3DM.%2BK.%26aulast%3DScholten%26aufirst%3DM.%2BD.%26aulast%3DKirn%26aufirst%3DN.%26aulast%3DWeber%26aufirst%3DR.%2BL.%26aulast%3DHedrick%26aufirst%3DJ.%2BL.%26aulast%3DWaymouth%26aufirst%3DR.%2BM.%26atitle%3DCyclic%2520Guanidine%2520Organic%2520Catalysts%253A%2520What%2520Is%2520Magic%2520about%2520Triazabicyclodecene%253F%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2009%26volume%3D74%26spage%3D9490%26epage%3D9496%26doi%3D10.1021%2Fjo902369g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Joossens, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van der Veken, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surpateanu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambeir, A.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Sayed, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Augustyns, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haemers, A.</span><span> </span><span class="NLM_article-title">Diphenyl Phosphonate Inhibitors for the Urokinase-Type Plasminogen Activator: Optimization of the P4 Position</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">5785</span><span class="NLM_x">–</span> <span class="NLM_lpage">5793</span><span class="refDoi"> DOI: 10.1021/jm060622g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060622g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5785-5793&author=J.+Joossensauthor=P.+Van+der+Vekenauthor=G.+Surpateanuauthor=A.-M.+Lambeirauthor=I.+El-Sayedauthor=O.+M.+Aliauthor=K.+Augustynsauthor=A.+Haemers&title=Diphenyl+Phosphonate+Inhibitors+for+the+Urokinase-Type+Plasminogen+Activator%3A+Optimization+of+the+P4+Position&doi=10.1021%2Fjm060622g"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm060622g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060622g%26sid%3Dliteratum%253Aachs%26aulast%3DJoossens%26aufirst%3DJ.%26aulast%3DVan%2Bder%2BVeken%26aufirst%3DP.%26aulast%3DSurpateanu%26aufirst%3DG.%26aulast%3DLambeir%26aufirst%3DA.-M.%26aulast%3DEl-Sayed%26aufirst%3DI.%26aulast%3DAli%26aufirst%3DO.%2BM.%26aulast%3DAugustyns%26aufirst%3DK.%26aulast%3DHaemers%26aufirst%3DA.%26atitle%3DDiphenyl%2520Phosphonate%2520Inhibitors%2520for%2520the%2520Urokinase-Type%2520Plasminogen%2520Activator%253A%2520Optimization%2520of%2520the%2520P4%2520Position%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5785%26epage%3D5793%26doi%3D10.1021%2Fjm060622g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Sperl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacob, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arroyo de Prada, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stürzebecher, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilhelm, O. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bode, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magdolen, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huber, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moroder, L.</span><span> </span><span class="NLM_article-title">(4-Aminomethyl)Phenylguanidine Derivatives As Nonpeptidic Highly Selective Inhibitors of Human Urokinase</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">5113</span><span class="NLM_x">–</span> <span class="NLM_lpage">5118</span><span class="refDoi"> DOI: 10.1073/pnas.97.10.5113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1073%2Fpnas.97.10.5113" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2000&pages=5113-5118&author=S.+Sperlauthor=U.+Jacobauthor=N.+Arroyo+de+Pradaauthor=J.+St%C3%BCrzebecherauthor=O.+G.+Wilhelmauthor=W.+Bodeauthor=V.+Magdolenauthor=R.+Huberauthor=L.+Moroder&title=%284-Aminomethyl%29Phenylguanidine+Derivatives+As+Nonpeptidic+Highly+Selective+Inhibitors+of+Human+Urokinase&doi=10.1073%2Fpnas.97.10.5113"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1073%2Fpnas.97.10.5113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.97.10.5113%26sid%3Dliteratum%253Aachs%26aulast%3DSperl%26aufirst%3DS.%26aulast%3DJacob%26aufirst%3DU.%26aulast%3DArroyo%2Bde%2BPrada%26aufirst%3DN.%26aulast%3DSt%25C3%25BCrzebecher%26aufirst%3DJ.%26aulast%3DWilhelm%26aufirst%3DO.%2BG.%26aulast%3DBode%26aufirst%3DW.%26aulast%3DMagdolen%26aufirst%3DV.%26aulast%3DHuber%26aufirst%3DR.%26aulast%3DMoroder%26aufirst%3DL.%26atitle%3D%25284-Aminomethyl%2529Phenylguanidine%2520Derivatives%2520As%2520Nonpeptidic%2520Highly%2520Selective%2520Inhibitors%2520of%2520Human%2520Urokinase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2000%26volume%3D97%26spage%3D5113%26epage%3D5118%26doi%3D10.1073%2Fpnas.97.10.5113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span>Inhibitor Expert (Inhibitors, Compound Libraries; <span class="NLM_publisher-name">Selleck Chemicals</span>: <span class="NLM_publisher-loc">Houston, TX</span>,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">; </span><a href="http://www.selleckchem.com" class="extLink">http://www.selleckchem.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Inhibitor+Expert+%28Inhibitors%2C+Compound+Libraries%3B+Selleck+Chemicals%3A+Houston%2C+TX%2C+2013%3B+http%3A%2F%2Fwww.selleckchem.com."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DInhibitor%2520Expert%2520%2528Inhibitors%252C%2520Compound%2520Libraries%26pub%3DSelleck%2520Chemicals%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span>Enzo Life Sciences; <span class="NLM_publisher-name">Enzo Life Sciences, Inc.</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span><a href="http://www.enzolifesciences.com" class="extLink">http://www.enzolifesciences.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Enzo+Life+Sciences%3B+Enzo+Life+Sciences%2C+Inc.%2C+2015%3B+http%3A%2F%2Fwww.enzolifesciences.com."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DEnzo%2520Life%2520Sciences%26pub%3DEnzo%2520Life%2520Sciences%252C%2520Inc%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Zhao, G.; Yuan, C.; Jiang, L.; Huang, Z.; Huang, M.</span> (submitted for publication).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Zhao%2C+G.%3B+Yuan%2C+C.%3B+Jiang%2C+L.%3B+Huang%2C+Z.%3B+Huang%2C+M.+%28submitted+for+publication%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DG." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Berman, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westbrook, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhat, T. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissig, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shindyalov, I. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourne, P. E.</span><span> </span><span class="NLM_article-title">The Protein Data Bank</span> <span class="citation_source-journal">Nucleic Acids Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">242</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1093%2Fnar%2F28.1.235" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10592235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhvVKjt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2000&pages=235-242&author=H.+M.+Bermanauthor=J.+Westbrookauthor=Z.+Fengauthor=G.+Gillilandauthor=T.+N.+Bhatauthor=H.+Weissigauthor=I.+N.+Shindyalovauthor=P.+E.+Bourne&title=The+Protein+Data+Bank"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">The Protein Data Bank</span></div><div class="casAuthors">Berman, Helen M.; Westbrook, John; Feng, Zukang; Gilliland, Gary; Bhat, T. N.; Weissig, Helge; Shindyalov, Ilya N.; Bourne, Philip E.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">235-242</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The Protein Data Bank (PDB; http://www.rcsb.org/pdb/)is the single worldwide archive of structural data of biol. macromols.  This paper describes the goals of the PDB, the systems in place for data deposition and access, how to obtain further information, and near-term plans for the future development of the resource.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpStGCxT8QzirVg90H21EOLACvtfcHk0liMS7sebGOtqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhvVKjt7w%253D&md5=227fb393f754be2be375ab727bfd05dc</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1093%2Fnar%2F28.1.235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252F28.1.235%26sid%3Dliteratum%253Aachs%26aulast%3DBerman%26aufirst%3DH.%2BM.%26aulast%3DWestbrook%26aufirst%3DJ.%26aulast%3DFeng%26aufirst%3DZ.%26aulast%3DGilliland%26aufirst%3DG.%26aulast%3DBhat%26aufirst%3DT.%2BN.%26aulast%3DWeissig%26aufirst%3DH.%26aulast%3DShindyalov%26aufirst%3DI.%2BN.%26aulast%3DBourne%26aufirst%3DP.%2BE.%26atitle%3DThe%2520Protein%2520Data%2520Bank%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2000%26volume%3D28%26spage%3D235%26epage%3D242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span>PyMol: The PyMOL Molecular Graphics System, <span class="NLM_edition">version 1.5.0.4</span>; <span class="NLM_publisher-name">Schrödinger LLC</span>; <a href="http://www.pymol.org" class="extLink">http://www.pymol.org</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=PyMol%3A+The+PyMOL+Molecular+Graphics+System%2C+version+1.5.0.4%3B+Schr%C3%B6dinger+LLC%3B+http%3A%2F%2Fwww.pymol.org."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520PyMOL%2520Molecular%2520Graphics%2520System%26pub%3DSchr%25C3%25B6dinger%2520LLC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Morris, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindstrom, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanner, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belew, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodsell, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. J.</span><span> </span><span class="NLM_article-title">Autodock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexiblity</span> <span class="citation_source-journal">J. Comput. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">2785</span><span class="NLM_x">–</span> <span class="NLM_lpage">2791</span><span class="refDoi"> DOI: 10.1002/jcc.21256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1002%2Fjcc.21256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=19399780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1GitrnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=2785-2791&author=G.+M.+Morrisauthor=R.+Hueyauthor=W.+Lindstromauthor=M.+F.+Sannerauthor=R.+K.+Belewauthor=D.+S.+Goodsellauthor=A.+J.+Olson&title=Autodock4+and+AutoDockTools4%3A+Automated+Docking+with+Selective+Receptor+Flexiblity&doi=10.1002%2Fjcc.21256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">AutoDock and AutoDockTools: Automated docking with selective receptor flexibility</span></div><div class="casAuthors">Morris, Garrett M.; Huey, Ruth; Lindstrom, William; Sanner, Michel F.; Belew, Richard K.; Goodsell, David S.; Olson, Arthur J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2785-2791</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">We describe the testing and release of AutoDock4 and the accompanying graphical user interface AutoDockTools.  AutoDock4 incorporates limited flexibility in the receptor.  Several tests are reported here, including a redocking expt. with 188 diverse ligand-protein complexes and a cross-docking expt. using flexible sidechains in 87 HIV protease complexes.  We also report its utility in anal. of covalently bound ligands, using both a grid-based docking method and a modification of the flexible sidechain technique. © 2009 Wiley Periodicals, Inc.  J Comput Chem, 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqktE6WAo4GEbVg90H21EOLACvtfcHk0liCChvkF97YDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1GitrnK&md5=679ce22fc50e9291c9aa16e7a1855845</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fjcc.21256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.21256%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DG.%2BM.%26aulast%3DHuey%26aufirst%3DR.%26aulast%3DLindstrom%26aufirst%3DW.%26aulast%3DSanner%26aufirst%3DM.%2BF.%26aulast%3DBelew%26aufirst%3DR.%2BK.%26aulast%3DGoodsell%26aufirst%3DD.%2BS.%26aulast%3DOlson%26aufirst%3DA.%2BJ.%26atitle%3DAutodock4%2520and%2520AutoDockTools4%253A%2520Automated%2520Docking%2520with%2520Selective%2520Receptor%2520Flexiblity%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2009%26volume%3D30%26spage%3D2785%26epage%3D2791%26doi%3D10.1002%2Fjcc.21256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4a','cit4b'],'ref5':['cit5a','cit5b','cit5c','cit5d','cit5e'],'ref6':['cit6a','cit6b','cit6c'],'ref7':['cit7a','cit7b'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12a','cit12b'],'ref13':['cit13a','cit13b'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18a','cit18b','cit18c','cit18d','cit18e'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 20 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Frédéric Vuillermet, Joanick Bourret, <span class="NLM_string-name hlFld-ContribAuthor">Guillaume Pelletier</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Imidazo[1,2-a]pyridines: Triflic Anhydride-Mediated Annulation of 2H-Azirines with 2-Chloropyridines. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>86 </em>
                                    (1)
                                     , 388-402. <a href="https://doi.org/10.1021/acs.joc.0c02148" title="DOI URL">https://doi.org/10.1021/acs.joc.0c02148</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c02148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c02148%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Bof%252BImidazo%25255B1%25252C2-a%25255Dpyridines%25253A%252BTriflic%252BAnhydride-Mediated%252BAnnulation%252Bof%252B2H-Azirines%252Bwith%252B2-Chloropyridines%26aulast%3DVuillermet%26aufirst%3DFr%25C3%25A9d%25C3%25A9ric%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D05092020%26date%3D03122020%26volume%3D86%26issue%3D1%26spage%3D388%26epage%3D402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Qiu-Xing He, Yao-Feng Liang, Chang Xu, Xiao-Kun Yao, Hua Cao, <span class="NLM_string-name hlFld-ContribAuthor">Hua-Gang Yao</span>. </span><span class="cited-content_cbyCitation_article-title">Highly Regioselective, Acid-Catalyzed, Three-Component Cascade Reaction for the Synthesis of 2-aminopyridine-Decorated Imidazo[1,2-a]pyridine. </span><span class="cited-content_cbyCitation_journal-name">ACS Combinatorial Science</span><span> <strong>2019,</strong> <em>21 </em>
                                    (3)
                                     , 149-153. <a href="https://doi.org/10.1021/acscombsci.8b00149" title="DOI URL">https://doi.org/10.1021/acscombsci.8b00149</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscombsci.8b00149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscombsci.8b00149%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Combinatorial%2520Science%26atitle%3DHighly%252BRegioselective%25252C%252BAcid-Catalyzed%25252C%252BThree-Component%252BCascade%252BReaction%252Bfor%252Bthe%252BSynthesis%252Bof%252B2-aminopyridine-Decorated%252BImidazo%25255B1%25252C2-a%25255Dpyridine%26aulast%3DHe%26aufirst%3DQiu-Xing%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D2019%26date%3D28092018%26date%3D07012019%26date%3D22012019%26date%3D17012019%26volume%3D21%26issue%3D3%26spage%3D149%26epage%3D153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="NLM_string-name hlFld-ContribAuthor">Peter M. Fischer</span>. </span><span class="cited-content_cbyCitation_article-title">Design of Small-Molecule Active-Site Inhibitors of the S1A Family Proteases as Procoagulant and Anticoagulant Drugs. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (9)
                                     , 3799-3822. <a href="https://doi.org/10.1021/acs.jmedchem.7b00772" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00772</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00772&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00772%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Bof%252BSmall-Molecule%252BActive-Site%252BInhibitors%252Bof%252Bthe%252BS1A%252BFamily%252BProteases%252Bas%252BProcoagulant%252Band%252BAnticoagulant%252BDrugs%26aulast%3DFischer%26aufirst%3DPeter%2BM.%26date%3D2018%26date%3D2017%26date%3D2017%26date%3D25052017%26date%3D09112017%26date%3D26102017%26volume%3D61%26issue%3D9%26spage%3D3799%26epage%3D3822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuai  Lu</span>, <span class="hlFld-ContribAuthor ">Xinju  Zhu</span>, <span class="hlFld-ContribAuthor ">Ke  Li</span>, <span class="hlFld-ContribAuthor ">Yu-Jing  Guo</span>, <span class="hlFld-ContribAuthor ">Meng-Dan  Wang</span>, <span class="hlFld-ContribAuthor ">Xue-Mei  Zhao</span>, <span class="hlFld-ContribAuthor ">Xin-Qi  Hao</span>, and <span class="hlFld-ContribAuthor ">Mao-Ping  Song</span>  . </span><span class="cited-content_cbyCitation_article-title">Reactivity of p-Toluenesulfonylmethyl Isocyanide: Iron-Involved C–H Tosylmethylation of Imidazopyridines in Nontoxic Media. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2016,</strong> <em>81 </em>
                                    (18)
                                     , 8370-8377. <a href="https://doi.org/10.1021/acs.joc.6b01552" title="DOI URL">https://doi.org/10.1021/acs.joc.6b01552</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.6b01552&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.6b01552%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DReactivity%252Bof%252Bp-Toluenesulfonylmethyl%252BIsocyanide%25253A%252BIron-Involved%252BC%2525E2%252580%252593H%252BTosylmethylation%252Bof%252BImidazopyridines%252Bin%252BNontoxic%252BMedia%26aulast%3DLu%26aufirst%3DShuai%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D28062016%26date%3D06092016%26date%3D16092016%26date%3D25082016%26volume%3D81%26issue%3D18%26spage%3D8370%26epage%3D8377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel M.  Dupont</span>, <span class="hlFld-ContribAuthor ">Nils  Bjerregaard</span>, <span class="hlFld-ContribAuthor ">Ben  Verpaalen</span>, <span class="hlFld-ContribAuthor ">Peter A.  Andreasen</span>, and <span class="hlFld-ContribAuthor ">Jan K.  Jensen</span>  . </span><span class="cited-content_cbyCitation_article-title">Building a Molecular Trap for a Serine Protease from Aptamer and Peptide Modules. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2016,</strong> <em>27 </em>
                                    (4)
                                     , 918-926. <a href="https://doi.org/10.1021/acs.bioconjchem.6b00007" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.6b00007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.6b00007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.6b00007%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DBuilding%252Ba%252BMolecular%252BTrap%252Bfor%252Ba%252BSerine%252BProtease%252Bfrom%252BAptamer%252Band%252BPeptide%252BModules%26aulast%3DDupont%26aufirst%3DDaniel%2BM.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D05012016%26date%3D26022016%26date%3D11032016%26date%3D20042016%26date%3D01032016%26volume%3D27%26issue%3D4%26spage%3D918%26epage%3D926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dipika  Konwar</span>, <span class="hlFld-ContribAuthor ">Utpal  Bora</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Developments in Transition‐Metal‐Catalyzed Regioselective Functionalization of Imidazo[1, 2‐
              a
              ]pyridine. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2021,</strong> <em>6 </em>
                                    (11)
                                     , 2716-2744. <a href="https://doi.org/10.1002/slct.202100144" title="DOI URL">https://doi.org/10.1002/slct.202100144</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.202100144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.202100144%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DRecent%252BDevelopments%252Bin%252BTransition%2525E2%252580%252590Metal%2525E2%252580%252590Catalyzed%252BRegioselective%252BFunctionalization%252Bof%252BImidazo%25255B1%25252C%252B2%2525E2%252580%252590%252Ba%252B%25255Dpyridine%26aulast%3DKonwar%26aufirst%3DDipika%26date%3D2021%26date%3D2021%26volume%3D6%26issue%3D11%26spage%3D2716%26epage%3D2744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Blake J. M.  Baker</span>, <span class="hlFld-ContribAuthor ">William J.  Kerr</span>, <span class="hlFld-ContribAuthor ">David M.  Lindsay</span>, <span class="hlFld-ContribAuthor ">Vipulkumar K.  Patel</span>, <span class="hlFld-ContribAuthor ">Darren L.  Poole</span>. </span><span class="cited-content_cbyCitation_article-title">A sustainable and scalable multicomponent continuous flow process to access fused imidazoheterocycle pharmacophores. </span><span class="cited-content_cbyCitation_journal-name">Green Chemistry</span><span> <strong>2021,</strong> <em>23 </em>
                                    (1)
                                     , 280-287. <a href="https://doi.org/10.1039/D0GC03675G" title="DOI URL">https://doi.org/10.1039/D0GC03675G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0GC03675G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0GC03675G%26sid%3Dliteratum%253Aachs%26jtitle%3DGreen%2520Chemistry%26atitle%3DA%252Bsustainable%252Band%252Bscalable%252Bmulticomponent%252Bcontinuous%252Bflow%252Bprocess%252Bto%252Baccess%252Bfused%252Bimidazoheterocycle%252Bpharmacophores%26aulast%3DBaker%26aufirst%3DBlake%2BJ.%2BM.%26date%3D2021%26date%3D2021%26volume%3D23%26issue%3D1%26spage%3D280%26epage%3D287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qiuyao  Huang</span>, <span class="hlFld-ContribAuthor ">Hui  Dong</span>, <span class="hlFld-ContribAuthor ">Bingbing  Li</span>, <span class="hlFld-ContribAuthor ">Wenhao  Hu</span>, <span class="hlFld-ContribAuthor ">Yuanxiang  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Rhodium catalyzed direct C3-ethoxycarbonylmethylation of imidazo[1,2-a]pyridines with ethyl diazoacetate. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2020,</strong> <em>76 </em>
                                    (10)
                                     , 130998. <a href="https://doi.org/10.1016/j.tet.2020.130998" title="DOI URL">https://doi.org/10.1016/j.tet.2020.130998</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2020.130998&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2020.130998%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DRhodium%252Bcatalyzed%252Bdirect%252BC3-ethoxycarbonylmethylation%252Bof%252Bimidazo%25255B1%25252C2-a%25255Dpyridines%252Bwith%252Bethyl%252Bdiazoacetate%26aulast%3DHuang%26aufirst%3DQiuyao%26date%3D2020%26volume%3D76%26issue%3D10%26spage%3D130998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">André  Boltjes</span>, <span class="hlFld-ContribAuthor ">Alexander  Dömling</span>. </span><span class="cited-content_cbyCitation_article-title">The Groebke-Blackburn-Bienaymé Reaction. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>2019 </em>
                                    (42)
                                     , 7007-7049. <a href="https://doi.org/10.1002/ejoc.201901124" title="DOI URL">https://doi.org/10.1002/ejoc.201901124</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201901124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201901124%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DThe%252BGroebke-Blackburn-Bienaym%2525C3%2525A9%252BReaction%26aulast%3DBoltjes%26aufirst%3DAndr%25C3%25A9%26date%3D2019%26date%3D2019%26volume%3D2019%26issue%3D42%26spage%3D7007%26epage%3D7049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rafaela  Gladysz</span>, <span class="hlFld-ContribAuthor ">Johannes  Vrijdag</span>, <span class="hlFld-ContribAuthor ">Dries  Van Rompaey</span>, <span class="hlFld-ContribAuthor ">Anne‐Marie  Lambeir</span>, <span class="hlFld-ContribAuthor ">Koen  Augustyns</span>, <span class="hlFld-ContribAuthor ">Hans  De Winter</span>, <span class="hlFld-ContribAuthor ">Pieter  Van der Veken</span>. </span><span class="cited-content_cbyCitation_article-title">Efforts towards an On‐Target Version of the Groebke–Blackburn–Bienaymé (GBB) Reaction for Discovery of Druglike Urokinase (uPA) Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemistry – A European Journal</span><span> <strong>2019,</strong> <em>25 </em>
                                    (53)
                                     , 12380-12393. <a href="https://doi.org/10.1002/chem.201901917" title="DOI URL">https://doi.org/10.1002/chem.201901917</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.201901917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.201901917%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520A%2520European%2520Journal%26atitle%3DEfforts%252Btowards%252Ban%252BOn%2525E2%252580%252590Target%252BVersion%252Bof%252Bthe%252BGroebke%2525E2%252580%252593Blackburn%2525E2%252580%252593Bienaym%2525C3%2525A9%252B%252528GBB%252529%252BReaction%252Bfor%252BDiscovery%252Bof%252BDruglike%252BUrokinase%252B%252528uPA%252529%252BInhibitors%26aulast%3DGladysz%26aufirst%3DRafaela%26date%3D2019%26date%3D2019%26volume%3D25%26issue%3D53%26spage%3D12380%26epage%3D12393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mingming  Luan</span>, <span class="hlFld-ContribAuthor ">Mingwan  Shi</span>, <span class="hlFld-ContribAuthor ">Wei  Pan</span>, <span class="hlFld-ContribAuthor ">Na  Li</span>, <span class="hlFld-ContribAuthor ">Bo  Tang</span>. </span><span class="cited-content_cbyCitation_article-title">A gold–selenium-bonded nanoprobe for real-time
              in situ
              imaging of the upstream and downstream relationship between uPA and MMP-9 in cancer cells. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2019,</strong> <em>55 </em>
                                    (41)
                                     , 5817-5820. <a href="https://doi.org/10.1039/C9CC01454C" title="DOI URL">https://doi.org/10.1039/C9CC01454C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9CC01454C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9CC01454C%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DA%252Bgold%2525E2%252580%252593selenium-bonded%252Bnanoprobe%252Bfor%252Breal-time%252Bin%252Bsitu%252Bimaging%252Bof%252Bthe%252Bupstream%252Band%252Bdownstream%252Brelationship%252Bbetween%252BuPA%252Band%252BMMP-9%252Bin%252Bcancer%252Bcells%26aulast%3DLuan%26aufirst%3DMingming%26date%3D2019%26date%3D2019%26volume%3D55%26issue%3D41%26spage%3D5817%26epage%3D5820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yeon Joo  Kim</span>, <span class="hlFld-ContribAuthor ">Dae Young  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Electrochemical oxidative selenylation of imidazo[1,2–a]pyridines with diselenides. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2019,</strong> <em>60 </em>
                                    (10)
                                     , 739-742. <a href="https://doi.org/10.1016/j.tetlet.2019.02.001" title="DOI URL">https://doi.org/10.1016/j.tetlet.2019.02.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2019.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2019.02.001%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DElectrochemical%252Boxidative%252Bselenylation%252Bof%252Bimidazo%25255B1%25252C2%2525E2%252580%252593a%25255Dpyridines%252Bwith%252Bdiselenides%26aulast%3DKim%26aufirst%3DYeon%2BJoo%26date%3D2019%26volume%3D60%26issue%3D10%26spage%3D739%26epage%3D742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jan  Mican</span>, <span class="hlFld-ContribAuthor ">Martin  Toul</span>, <span class="hlFld-ContribAuthor ">David  Bednar</span>, <span class="hlFld-ContribAuthor ">Jiri  Damborsky</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Biology and Protein Engineering of Thrombolytics. </span><span class="cited-content_cbyCitation_journal-name">Computational and Structural Biotechnology Journal</span><span> <strong>2019,</strong> <em>17 </em>, 917-938. <a href="https://doi.org/10.1016/j.csbj.2019.06.023" title="DOI URL">https://doi.org/10.1016/j.csbj.2019.06.023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.csbj.2019.06.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.csbj.2019.06.023%26sid%3Dliteratum%253Aachs%26jtitle%3DComputational%2520and%2520Structural%2520Biotechnology%2520Journal%26atitle%3DStructural%252BBiology%252Band%252BProtein%252BEngineering%252Bof%252BThrombolytics%26aulast%3DMican%26aufirst%3DJan%26date%3D2019%26volume%3D17%26spage%3D917%26epage%3D938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guojie  Yin</span>, <span class="hlFld-ContribAuthor ">Mei  Zhu</span>, <span class="hlFld-ContribAuthor ">Weijun  Fu</span>. </span><span class="cited-content_cbyCitation_article-title">Visible-light-induced photocatalytic difluoroacetylation of imidazopyridines via direct and regioselective C H functionalization. </span><span class="cited-content_cbyCitation_journal-name">Journal of Fluorine Chemistry</span><span> <strong>2017,</strong> <em>199 </em>, 14-19. <a href="https://doi.org/10.1016/j.jfluchem.2017.04.005" title="DOI URL">https://doi.org/10.1016/j.jfluchem.2017.04.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jfluchem.2017.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jfluchem.2017.04.005%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Fluorine%2520Chemistry%26atitle%3DVisible-light-induced%252Bphotocatalytic%252Bdifluoroacetylation%252Bof%252Bimidazopyridines%252Bvia%252Bdirect%252Band%252Bregioselective%252BC%252BH%252Bfunctionalization%26aulast%3DYin%26aufirst%3DGuojie%26date%3D2017%26volume%3D199%26spage%3D14%26epage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guojie  Yin</span>, <span class="hlFld-ContribAuthor ">Mei  Zhu</span>, <span class="hlFld-ContribAuthor ">Weijun  Fu</span>. </span><span class="cited-content_cbyCitation_article-title">Visible-light mediated regioselective (phenylsulfonyl)difluoromethylation of fused imidazoles with iododifluoromethyl phenyl sulfone. </span><span class="cited-content_cbyCitation_journal-name">Heterocyclic Communications</span><span> <strong>2017,</strong> <em>23 </em>
                                    (4)
                                     <a href="https://doi.org/10.1515/hc-2017-0101" title="DOI URL">https://doi.org/10.1515/hc-2017-0101</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1515/hc-2017-0101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1515%2Fhc-2017-0101%26sid%3Dliteratum%253Aachs%26jtitle%3DHeterocyclic%2520Communications%26atitle%3DVisible-light%252Bmediated%252Bregioselective%252B%252528phenylsulfonyl%252529difluoromethylation%252Bof%252Bfused%252Bimidazoles%252Bwith%252Biododifluoromethyl%252Bphenyl%252Bsulfone%26aulast%3DYin%26aufirst%3DGuojie%26date%3D2017%26volume%3D23%26issue%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthias  Cleenewerck</span>, <span class="hlFld-ContribAuthor ">Mandy O.J.  Grootaert</span>, <span class="hlFld-ContribAuthor ">Rafaela  Gladysz</span>, <span class="hlFld-ContribAuthor ">Yves  Adriaenssens</span>, <span class="hlFld-ContribAuthor ">Ria  Roelandt</span>, <span class="hlFld-ContribAuthor ">Jurgen  Joossens</span>, <span class="hlFld-ContribAuthor ">Anne-Marie  Lambeir</span>, <span class="hlFld-ContribAuthor ">Guido R.Y.  De Meyer</span>, <span class="hlFld-ContribAuthor ">Wim  Declercq</span>, <span class="hlFld-ContribAuthor ">Koen  Augustyns</span>, <span class="hlFld-ContribAuthor ">Wim  Martinet</span>, <span class="hlFld-ContribAuthor ">Pieter  Van der Veken</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibitor screening and enzymatic activity determination for autophagy target Atg4B using a gel electrophoresis-based assay. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>123 </em>, 631-638. <a href="https://doi.org/10.1016/j.ejmech.2016.07.073" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.07.073</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.07.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.07.073%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DInhibitor%252Bscreening%252Band%252Benzymatic%252Bactivity%252Bdetermination%252Bfor%252Bautophagy%252Btarget%252BAtg4B%252Busing%252Ba%252Bgel%252Belectrophoresis-based%252Bassay%26aulast%3DCleenewerck%26aufirst%3DMatthias%26date%3D2016%26volume%3D123%26spage%3D631%26epage%3D638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Meng-Ming  Xing</span>, <span class="hlFld-ContribAuthor ">Ming  Xin</span>, <span class="hlFld-ContribAuthor ">Chao  Shen</span>, <span class="hlFld-ContribAuthor ">Jian-Rong  Gao</span>, <span class="hlFld-ContribAuthor ">Jian-Hong  Jia</span>, <span class="hlFld-ContribAuthor ">Yu-Jin  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Iodine-promoted oxidative coupling reaction: a simple and efficient process to access imidazo[1,2-a]pyridines from 2-aminopyridines and chalcones. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2016,</strong> <em>72 </em>
                                    (29)
                                     , 4201-4204. <a href="https://doi.org/10.1016/j.tet.2016.05.052" title="DOI URL">https://doi.org/10.1016/j.tet.2016.05.052</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2016.05.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2016.05.052%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DIodine-promoted%252Boxidative%252Bcoupling%252Breaction%25253A%252Ba%252Bsimple%252Band%252Befficient%252Bprocess%252Bto%252Baccess%252Bimidazo%25255B1%25252C2-a%25255Dpyridines%252Bfrom%252B2-aminopyridines%252Band%252Bchalcones%26aulast%3DXing%26aufirst%3DMeng-Ming%26date%3D2016%26volume%3D72%26issue%3D29%26spage%3D4201%26epage%3D4204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Natalia A.  Keiko</span>, <span class="hlFld-ContribAuthor ">Nadezhda V.  Vchislo</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of imidazo[1,2-a]pyridines from α,β-unsaturated aldehydes (microreview). </span><span class="cited-content_cbyCitation_journal-name">Chemistry of Heterocyclic Compounds</span><span> <strong>2016,</strong> <em>52 </em>
                                    (4)
                                     , 222-224. <a href="https://doi.org/10.1007/s10593-016-1867-x" title="DOI URL">https://doi.org/10.1007/s10593-016-1867-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10593-016-1867-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10593-016-1867-x%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520of%2520Heterocyclic%2520Compounds%26atitle%3DSynthesis%252Bof%252Bimidazo%25255B1%25252C2-a%25255Dpyridines%252Bfrom%252B%2525CE%2525B1%25252C%2525CE%2525B2-unsaturated%252Baldehydes%252B%252528microreview%252529%26aulast%3DKeiko%26aufirst%3DNatalia%2BA.%26date%3D2016%26date%3D2016%26volume%3D52%26issue%3D4%26spage%3D222%26epage%3D224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rafaela  Gladysz</span>, <span class="hlFld-ContribAuthor ">Anne-Marie  Lambeir</span>, <span class="hlFld-ContribAuthor ">Jurgen  Joossens</span>, <span class="hlFld-ContribAuthor ">Koen  Augustyns</span>, <span class="hlFld-ContribAuthor ">Pieter  Van der Veken</span>. </span><span class="cited-content_cbyCitation_article-title">Substrate Activity Screening (SAS) and Related Approaches in Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2016,</strong> <em>11 </em>
                                    (5)
                                     , 467-476. <a href="https://doi.org/10.1002/cmdc.201500569" title="DOI URL">https://doi.org/10.1002/cmdc.201500569</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201500569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201500569%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DSubstrate%252BActivity%252BScreening%252B%252528SAS%252529%252Band%252BRelated%252BApproaches%252Bin%252BMedicinal%252BChemistry%26aulast%3DGladysz%26aufirst%3DRafaela%26date%3D2016%26date%3D2016%26volume%3D11%26issue%3D5%26spage%3D467%26epage%3D476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shucheng  Wang</span>, <span class="hlFld-ContribAuthor ">Xuhu  Huang</span>, <span class="hlFld-ContribAuthor ">Zemei  Ge</span>, <span class="hlFld-ContribAuthor ">Xin  Wang</span>, <span class="hlFld-ContribAuthor ">Runtao  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Metal-free C-3 alkylation of imidazopyridines with xanthates and convenient access to alpidem and zolpidem. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2016,</strong> <em>6 </em>
                                    (68)
                                     , 63532-63535. <a href="https://doi.org/10.1039/C6RA09046J" title="DOI URL">https://doi.org/10.1039/C6RA09046J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6RA09046J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6RA09046J%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DMetal-free%252BC-3%252Balkylation%252Bof%252Bimidazopyridines%252Bwith%252Bxanthates%252Band%252Bconvenient%252Baccess%252Bto%252Balpidem%252Band%252Bzolpidem%26aulast%3DWang%26aufirst%3DShucheng%26date%3D2016%26date%3D2016%26volume%3D6%26issue%3D68%26spage%3D63532%26epage%3D63535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/medium/jm-2015-01171e_0021.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/large/jm-2015-01171e_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01171&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/medium/jm-2015-01171e_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/large/jm-2015-01171e_0001.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Reported inhibitors of uPA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/large/jm-2015-01171e_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01171&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/medium/jm-2015-01171e_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/large/jm-2015-01171e_0002.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Inhibitory activities of the reference compounds against uPA determined under the assay conditions of this manuscript.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/large/jm-2015-01171e_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01171&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/medium/jm-2015-01171e_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/large/jm-2015-01171e_0003.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Overview of the strategy followed for the preparation of potent uPA inhibitors with an imidazopyridine scaffold.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/large/jm-2015-01171e_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01171&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/medium/jm-2015-01171e_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/large/jm-2015-01171e_0005.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Steps Leading to the Monosubstituted Scaffold-Based Inhibitors <b>14h</b>, <b>15a</b>–<b>g</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/large/jm-2015-01171e_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01171&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) ethyl formate, TEA, 55 °C, 24 h, 55–90%; (b) POCl<sub>3</sub>, DIPA, DCM, 60–85%; (c) pyridin-2-amine, glyoxylic acid monohydrate, HClO<sub>4</sub> (cat.), MeOH, rt, 24 h, 38–66%; (d) TFA/DCM (1:1), rt, 1 h, 95–100%.</p></p></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/medium/jm-2015-01171e_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/large/jm-2015-01171e_0004.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Predicted binding mode of compounds <b>15a</b> (light brown) and <b>15b</b> (yellow) in the active site of uPA (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2O8W">2O8W</a>). Proposed hydrogen bonds between ligands and labeled protein residues are indicated by yellow dashed lines. Both compounds overlay quite well and show an almost identical binding pattern.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/large/jm-2015-01171e_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01171&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/medium/jm-2015-01171e_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/large/jm-2015-01171e_0023.jpeg" id="rightTab-GRAPHIC-d133e737-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Helicopter view of uPA’s active site (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2O8W">2O8W</a>) showing the proposed binding mode of compound <b>15a</b> (a), compound <b>25a</b> (b), and compounds <b>25b</b>–<b>f</b> (c). The protein surface is colored white, while the surface generated by residue Ser-195 is colored red, and the surface generated by residues Ser-190, Asp-189, and Gly-219 is colored green. Putative hydrogen bonds are shown as dashed yellow lines. Docking of compound <b>25a</b> (b) reveals an additional hydrogen bond between the ligand and the hydroxyl group of Tyr-151 (colored blue). The R<sup>4</sup> group (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>) of compound <b>25a</b> is colored green and has been docked using idealized geometrical bond and torsion angles.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/large/jm-2015-01171e_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01171&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/medium/jm-2015-01171e_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/large/jm-2015-01171e_0006.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Analogues Modified at the 2-Position <b>17a</b>–<b>k</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/large/jm-2015-01171e_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01171&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) HClO<sub>4</sub> (cat.), MeOH, rt, 24 h, 22–86%; (b) TFA/DCM (1:1), rt, 1 h, 94–100%.</p></p></figure><figure data-id="sch3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/medium/jm-2015-01171e_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/large/jm-2015-01171e_0007.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Analogues <b>22a</b>–<b>i</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/large/jm-2015-01171e_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01171&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) HClO<sub>4</sub> (cat.), MeOH, rt, 24 h, 25–68% (in case of compound <b>21d</b> (i) methyl 2-aminopyridine-4-carboxylate, TBD, DMF, 120 °C, 20 h, 52.5%, (ii) HClO<sub>4</sub> (cat.), MeOH, rt, 24 h, 60%); compound <b>21h</b> (i) methyl 6-aminonicotinate, TBD, DMF, 120 °C, 24 h, 42%, (ii) HClO<sub>4</sub> (cat), MeOH, rt, 24 h, 47%); (b) TFA/DCM (1:1), rt, 1 h, 94–100% (in case of compound <b>22c</b> (i) NaOH (2 M), DCM/MeOH (9:1), 12 h, rt, 69%, (ii) TFA/DCM (1:1), rt, 1 h, 93%).</p></p></figure><figure data-id="sch4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/medium/jm-2015-01171e_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/large/jm-2015-01171e_0008.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of the Amide-Substituted Analogues <b>25a</b>–<b>f</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01171/20151204/images/large/jm-2015-01171e_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01171&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) TBD, toluene, 110 °C, 20 h, 86–97% (in case of compound <b>20a</b> TBD, DMF, 120 °C, 20 h, 52.5%); (b) glyoxylic acid monohydrate, isocyanide <b>13a</b>, HClO<sub>4</sub> (cat.), MeOH, rt, 6 h, 42–61%; (c) TFA/DCM (1:1), rt, 1 h, 96–100%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i129">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56723" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56723" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 32 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Dass, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmad, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azmi, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarkar, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarkar, F. H.</span><span> </span><span class="NLM_article-title">Evolving Role of uPA/uPAR System in Human Cancers</span> <span class="citation_source-journal">Cancer Treat. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">122</span><span class="NLM_x">–</span> <span class="NLM_lpage">136</span><span class="refDoi"> DOI: 10.1016/j.ctrv.2007.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1016%2Fj.ctrv.2007.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=18162327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtl2jsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2008&pages=122-136&author=K.+Dassauthor=A.+Ahmadauthor=A.+S.+Azmiauthor=S.+H.+Sarkarauthor=F.+H.+Sarkar&title=Evolving+Role+of+uPA%2FuPAR+System+in+Human+Cancers&doi=10.1016%2Fj.ctrv.2007.10.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Evolving role of uPA/uPAR system in human cancers</span></div><div class="casAuthors">Dass, Kathleen; Ahmad, Aamir; Azmi, Asfar S.; Sarkar, Sarah H.; Sarkar, Fazlul H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">122-136</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Summary: Recent advancements in cancer research have led to some major breakthroughs; however, the impact on overall cancer-related death rate remains unacceptable, suggesting that further insight into tumor markers and development of targeted therapies is urgently needed.  The urokinase plasminogen activator (uPA) system represents a family of serine proteases that are involved in the degrdn. of basement membrane and the extracellular matrix, leading to tumor cell invasion and metastasis.  In this review, we have provided an overview of emerging data, from basic research as well as clin. studies, highlighting the evolving role of uPA/uPAR system in tumor progression.  It is currently believed that the expression and activation of uPA plays an important role in tumorigenicity, and high endogenous levels of uPA and uPAR are assocd. with advanced metastatic cancers.  The endogenous inhibitors of this system, PAI-1 and PAI-2, regulate uPA-uPAR activity by either direct inhibition or affecting cell surface expression and internalization.  PAI-1's role in cancers is rather unusual; on one hand, it inhibits uPA-uPAR leading to inhibition of invasion and metastasis and on the other it has been reported to facilitate tumor growth and angiogenesis.  Individual components of uPA/uPAR system are reported to be differentially expressed in cancer tissues compared to normal tissues and, thus, have the potential to be developed as prognostic and/or therapeutic targets.  Therefore, this system represents a highly attractive target that warrants further in-depth studies.  Such studies are likely to contribute towards the development of molecularly-driven targeted therapies in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSD06JySW-rbVg90H21EOLACvtfcHk0liXk2PaL1NyEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtl2jsb0%253D&md5=057ddcbbeba4b8d93249eb44eef734f9</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2007.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2007.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DDass%26aufirst%3DK.%26aulast%3DAhmad%26aufirst%3DA.%26aulast%3DAzmi%26aufirst%3DA.%2BS.%26aulast%3DSarkar%26aufirst%3DS.%2BH.%26aulast%3DSarkar%26aufirst%3DF.%2BH.%26atitle%3DEvolving%2520Role%2520of%2520uPA%252FuPAR%2520System%2520in%2520Human%2520Cancers%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2008%26volume%3D34%26spage%3D122%26epage%3D136%26doi%3D10.1016%2Fj.ctrv.2007.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Mekkawy, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pourgholami, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, D. L.</span><span> </span><span class="NLM_article-title">Involvement of Urokinase-Type Plasminogen Activator System in Cancer: An Overview</span> <span class="citation_source-journal">Med. Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">918</span><span class="NLM_x">–</span> <span class="NLM_lpage">956</span><span class="refDoi"> DOI: 10.1002/med.21308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1002%2Fmed.21308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=24549574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1KisrvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=918-956&author=A.+H.+Mekkawyauthor=M.+H.+Pourgholamiauthor=D.+L.+Morris&title=Involvement+of+Urokinase-Type+Plasminogen+Activator+System+in+Cancer%3A+An+Overview&doi=10.1002%2Fmed.21308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of urokinase-type plasminogen activator system in cancer: An overview</span></div><div class="casAuthors">Mekkawy, Ahmed H.; Pourgholami, Mohammad H.; Morris, David L.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">918-956</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Currently, there are several studies supporting the role of urokinase-type plasminogen activator (uPA) system in cancer.  The assocn. of uPA to its receptor triggers the conversion of plasminogen into plasmin.  This process is regulated by the uPA inhibitors (PAI-1 and PAI-2).  Plasmin promotes degrdn. of basement membrane and extracellular matrix (ECM) components as well as activation of ECM latent matrix metalloproteases.  Degrdn. and remodeling of the surrounding tissues is crucial in the early steps of tumor progression by facilitating expansion of the tumor mass, release of tumor growth factors, activation of cytokines as well as induction of tumor cell proliferation, migration, and invasion.  Hence, many tumors showed a correlation between uPA system component levels and tumor aggressiveness and survival.  Therefore, this review summarizes the structure of the uPA system, its contribution to cancer progression, and the clin. relevance of uPA family members in cancer diagnosis.  In addn., the review evaluates the significance of uPA system in the development of cancer-targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqz7UqvJj1hC7Vg90H21EOLACvtfcHk0liXk2PaL1NyEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1KisrvE&md5=15d7ad04dd7aac616936f4087e984b55</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1002%2Fmed.21308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21308%26sid%3Dliteratum%253Aachs%26aulast%3DMekkawy%26aufirst%3DA.%2BH.%26aulast%3DPourgholami%26aufirst%3DM.%2BH.%26aulast%3DMorris%26aufirst%3DD.%2BL.%26atitle%3DInvolvement%2520of%2520Urokinase-Type%2520Plasminogen%2520Activator%2520System%2520in%2520Cancer%253A%2520An%2520Overview%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2014%26volume%3D34%26spage%3D918%26epage%3D956%26doi%3D10.1002%2Fmed.21308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Tang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, X.</span><span> </span><span class="NLM_article-title">The Urokinase Plasminogen Activator System in Breast Cancer Invasion and Metastasis</span> <span class="citation_source-journal">Biomed. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">179</span><span class="NLM_x">–</span> <span class="NLM_lpage">182</span><span class="refDoi"> DOI: 10.1016/j.biopha.2012.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1016%2Fj.biopha.2012.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=23201006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhsl2ju7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2013&pages=179-182&author=L.+Tangauthor=X.+Han&title=The+Urokinase+Plasminogen+Activator+System+in+Breast+Cancer+Invasion+and+Metastasis&doi=10.1016%2Fj.biopha.2012.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The urokinase plasminogen activator system in breast cancer invasion and metastasis</span></div><div class="casAuthors">Tang, Linlin; Han, Xiuzhen</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicine & Pharmacotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-182</span>CODEN:
                <span class="NLM_cas:coden">BIPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0753-3322</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  The urokinase plasminogen activator system, which is a serine protease family include urokinase-type plasminogen activator (uPA), the uPA receptor and plasminogen activator inhibitors (PAIs). uPA catalyzes the transformation of plasminogen to its active form plasmin, which is able to degrade the extracellular matrix (ECM) and basement membranes, directly or indirectly through activating pro-matrix metalloproteinases (pro-MMPs), promoting cancer cell metastasis and invasion.  Both uPA and PAI-1 are poor prognosis markers in primary breast cancer.  Evidence has been presented that the uPA system facilitates breast cancer metastasis by several different mechanisms, such as the Ras-ERK pathway and p38 MAPK pathway.  This review focuses on uPA system, summarizes their biol. effects, highlights the mol. mechanism and pathway, and discusses the role of uPA system in the prevention and treatment of human breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVDPyZ5w-UW7Vg90H21EOLACvtfcHk0lhNlgbU5BqrSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhsl2ju7bL&md5=b46a83ba7db2f8ad27d3fc89e9927f2c</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.biopha.2012.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopha.2012.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DL.%26aulast%3DHan%26aufirst%3DX.%26atitle%3DThe%2520Urokinase%2520Plasminogen%2520Activator%2520System%2520in%2520Breast%2520Cancer%2520Invasion%2520and%2520Metastasis%26jtitle%3DBiomed.%2520Pharmacother.%26date%3D2013%26volume%3D67%26spage%3D179%26epage%3D182%26doi%3D10.1016%2Fj.biopha.2012.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Smith, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span> </span><span class="NLM_article-title">Regulation of Cell Signalling by uPAR</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span><span class="NLM_x">–</span> <span class="NLM_lpage">36</span><span class="refDoi"> DOI: 10.1038/nrm2821</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1038%2Fnrm2821" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=20027185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFymtb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=23-36&author=H.+W.+Smithauthor=C.+J.+Marshall&title=Regulation+of+Cell+Signalling+by+uPAR&doi=10.1038%2Fnrm2821"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of cell signalling by uPAR</span></div><div class="casAuthors">Smith, Harvey W.; Marshall, Chris J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-36</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Urokinase-type plasminogen activator receptor (uPAR) expression is elevated during inflammation and tissue remodelling and in many human cancers, in which it frequently indicates poor prognosis. uPAR regulates proteolysis by binding the extracellular protease urokinase-type plasminogen activator (uPA; also known as urokinase) and also activates many intracellular signalling pathways.  Coordination of extracellular matrix (ECM) proteolysis and cell signalling by uPAR underlies its important function in cell migration, proliferation and survival and makes it an attractive therapeutic target in cancer and inflammatory diseases. uPAR lacks transmembrane and intracellular domains and so requires transmembrane co-receptors for signalling.  Integrins are essential uPAR signalling co-receptors and a second uPAR ligand, the ECM protein vitronectin, is also crucial for this process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvNxm1RoivP7Vg90H21EOLACvtfcHk0lhNlgbU5BqrSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFymtb7M&md5=cd788f114e3576289c17339bbf636651</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1038%2Fnrm2821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2821%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DH.%2BW.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26atitle%3DRegulation%2520of%2520Cell%2520Signalling%2520by%2520uPAR%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2010%26volume%3D11%26spage%3D23%26epage%3D36%26doi%3D10.1038%2Fnrm2821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Blasi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmeliet, P.</span><span> </span><span class="NLM_article-title">uPAR: A Versatile Signalling Orchestrator</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">932</span><span class="NLM_x">–</span> <span class="NLM_lpage">943</span><span class="refDoi"> DOI: 10.1038/nrm977</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1038%2Fnrm977" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=12461559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BD38XptFKnt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=932-943&author=F.+Blasiauthor=P.+Carmeliet&title=uPAR%3A+A+Versatile+Signalling+Orchestrator&doi=10.1038%2Fnrm977"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">uPAR: A versatile signalling orchestrator</span></div><div class="casAuthors">Blasi, Francesco; Carmeliet, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">932-943</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The plasminogen system has been implicated in clot lysis, wound healing, tissue regeneration, cancer, and many other processes that affect health and disease.  The urokinase receptor uPAR was originally thought to assist the directional invasion of migrating cells, but it is now becoming increasingly evident that this proteinase receptor elicits a plethora of cellular responses that include cellular adhesion, differentiation, proliferation, and migration in a non-proteolytic fashion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0I96h2pJMXbVg90H21EOLACvtfcHk0lhNlgbU5BqrSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XptFKnt7c%253D&md5=4d6857dcdaa9874fc905e3442d859ccb</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1038%2Fnrm977&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm977%26sid%3Dliteratum%253Aachs%26aulast%3DBlasi%26aufirst%3DF.%26aulast%3DCarmeliet%26aufirst%3DP.%26atitle%3DuPAR%253A%2520A%2520Versatile%2520Signalling%2520Orchestrator%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2002%26volume%3D3%26spage%3D932%26epage%3D943%26doi%3D10.1038%2Fnrm977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_label">(a) </span>Phase I & II with Mesupron; <span class="NLM_publisher-name">Wilex Ag</span>: <span class="NLM_publisher-loc">Munich</span>,<span class="NLM_x"> </span><span class="NLM_year">2010</span><span class="NLM_x">; </span><a href="http://www.wilex.de/portfolio-english/mesupron/phase-i-ii-with-mesu/" class="extLink">http://www.wilex.de/portfolio-english/mesupron/phase-i-ii-with-mesu/</a> (accessed september 10,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Phase+I+%26+II+with+Mesupron%3B+Wilex+Ag%3A+Munich%2C+2010%3B+http%3A%2F%2Fwww.wilex.de%2Fportfolio-english%2Fmesupron%2Fphase-i-ii-with-mesu%2F+%28accessed+september+10%2C+2015%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DPhase%2520I%2520%2526%2520II%2520with%2520Mesupron%26pub%3DWilex%2520Ag%26date%3D2010%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Abbenante, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairlie, D. P.</span><span> </span><span class="NLM_article-title">Protease Inhibitors in the Clinic</span> <span class="citation_source-journal">Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">71</span><span class="NLM_x">–</span> <span class="NLM_lpage">104</span><span class="refDoi"> DOI: 10.2174/1573406053402569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.2174%2F1573406053402569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=16789888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsVWkur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2005&pages=71-104&author=G.+Abbenanteauthor=D.+P.+Fairlie&title=Protease+Inhibitors+in+the+Clinic&doi=10.2174%2F1573406053402569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Protease inhibitors in the clinic</span></div><div class="casAuthors">Abbenante, Giovanni; Fairlie, David P.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">71-104</span>CODEN:
                <span class="NLM_cas:coden">MCEHAJ</span>;
        ISSN:<span class="NLM_cas:issn">1573-4064</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">This review describes the clin. status (based on available information) of exptl. drugs that inhibit enzymes called proteases, or more precisely a sub-class of proteases called peptidases that catalyze the hydrolysis of polypeptide main chain amide bonds.  These peptidases are classified by the key catalytic residue in the active site of the enzyme that effects hydrolysis, namely aspartic, serine, cysteine, metallo or threonine proteases.  In this review the authors show structures for 108 inhibitors of these enzymes and update the clin. disposition of over 100 inhibitors that were considered worthy enough by pharmaceutical, biotechnol. or academic researchers and their financial backers to be trialed in humans as prospective medicines.  The authors outline some of their chem. and pharmacol. characteristics and compare the current status of protease inhibitors in the clinic with what was obsd. about 5 years ago.  The authors assess the progress of protease inhibitors into man, predict their futures, and outline some of the hurdles that were overcome and that still remain for this promising class of new therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg7u79t8OBObVg90H21EOLACvtfcHk0lhNlgbU5BqrSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsVWkur8%253D&md5=ba8890c238cceb145a032f0545f521af</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.2174%2F1573406053402569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1573406053402569%26sid%3Dliteratum%253Aachs%26aulast%3DAbbenante%26aufirst%3DG.%26aulast%3DFairlie%26aufirst%3DD.%2BP.%26atitle%3DProtease%2520Inhibitors%2520in%2520the%2520Clinic%26jtitle%3DMed.%2520Chem.%26date%3D2005%26volume%3D1%26spage%3D71%26epage%3D104%26doi%3D10.2174%2F1573406053402569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Heinemann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebert, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laubender, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bevan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mala, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boeck, S.</span><span> </span><span class="NLM_article-title">Phase II Randomised Proof-of-Concept Study of the Urokinase Inhibitor Upamostat (WX-671) in Combination with Gemcitabine Compared with Gemcitabine Alone in Patients with Non-Resectable, Locally Advanced Pancreatic Cancer</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">766</span><span class="NLM_x">–</span> <span class="NLM_lpage">770</span><span class="refDoi"> DOI: 10.1038/bjc.2013.62</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1038%2Fbjc.2013.62" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=23412098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjslWmtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2013&pages=766-770&author=V.+Heinemannauthor=M.+P.+Ebertauthor=R.+P.+Laubenderauthor=P.+Bevanauthor=C.+Malaauthor=S.+Boeck&title=Phase+II+Randomised+Proof-of-Concept+Study+of+the+Urokinase+Inhibitor+Upamostat+%28WX-671%29+in+Combination+with+Gemcitabine+Compared+with+Gemcitabine+Alone+in+Patients+with+Non-Resectable%2C+Locally+Advanced+Pancreatic+Cancer&doi=10.1038%2Fbjc.2013.62"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5cR"><div class="casContent"><span class="casTitleNuber">5c</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II randomized proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer</span></div><div class="casAuthors">Heinemann, V.; Ebert, M. P.; Laubender, R. P.; Bevan, P.; Mala, C.; Boeck, S.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">766-770</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: To evaluate the efficacy and tolerability of the urokinase plasminogen activator (uPA) inhibitor upamostat in combination with gemcitabine in locally advanced pancreatic adenocarcinoma (LAPC).  Methods: Within a prospective multicenter study, LAPC patients were randomly assigned to receive 1000 mg m-2 of gemcitabine IV weekly either alone (arm A) or in combination with 200 mg (arm B) or 400 mg (arm C) oral upamostat daily.  Efficacy endpoints of this proof-of-concept study included response rate, time to first metastasis, progression-free and overall survival (OS).  Results: Of the 95 enrolled patients, 85 were evaluable for response and 93 for safety.  Median OS was 12.5 mo (95% CI 8.2-18.2) in arm C, 9.7 mo (95% CI 8.4-17.1) in arm B and 9.9 mo (95% CI 7.4-12.1) in arm A; corresponding 1-yr survival rates were 50.6%, 40.7% and 33.9%, resp.  More patients achieved a partial remission (confirmed responses by RECIST) with upamostat combination therapy (arm C: 12.9%; arm B: 7.1%; arm A: 3.8%).  Overall, only 12 patients progressed by developing detectable distant metastasis (arm A: 4, arm B: 6, arm C: 2).  The most common adverse events considered to be related to upamostat were asthenia, fever and nausea.  Conclusion: In this proof-of-concept study targeting the uPA system in LAPC, the addn. of upamostat to gemcitabine was tolerated well; similar survival results were obsd. for the three treatment arms.  British Journal of Cancer (2013) 108, 766-770; doi:10.1038/bjc.2013.62 www.bjcancer.com; published online 14 Feb. 2013.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmZfmwPy6jILVg90H21EOLACvtfcHk0liBBdxDfkCnPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjslWmtbo%253D&md5=8cb64bd2fb82944adeaec5327c8b7c47</span></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2013.62&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2013.62%26sid%3Dliteratum%253Aachs%26aulast%3DHeinemann%26aufirst%3DV.%26aulast%3DEbert%26aufirst%3DM.%2BP.%26aulast%3DLaubender%26aufirst%3DR.%2BP.%26aulast%3DBevan%26aufirst%3DP.%26aulast%3DMala%26aufirst%3DC.%26aulast%3DBoeck%26aufirst%3DS.%26atitle%3DPhase%2520II%2520Randomised%2520Proof-of-Concept%2520Study%2520of%2520the%2520Urokinase%2520Inhibitor%2520Upamostat%2520%2528WX-671%2529%2520in%2520Combination%2520with%2520Gemcitabine%2520Compared%2520with%2520Gemcitabine%2520Alone%2520in%2520Patients%2520with%2520Non-Resectable%252C%2520Locally%2520Advanced%2520Pancreatic%2520Cancer%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2013%26volume%3D108%26spage%3D766%26epage%3D770%26doi%3D10.1038%2Fbjc.2013.62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Meyer, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brocks, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graefe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mala, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thäns, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bürgle, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rempel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rotter, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wollenberg, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, S.</span><span> </span><span class="NLM_article-title">The Oral Serine Protease Inhibitor WX-671 - First Experience in Patients with Advanced Head and Neck Carcinoma</span> <span class="citation_source-journal">Breast Care</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">20</span><span class="NLM_x">–</span> <span class="NLM_lpage">24</span><span class="refDoi"> DOI: 10.1159/000151736</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1159%2F000151736" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=20824010" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=20-24&author=J.+E.+Meyerauthor=C.+Brocksauthor=H.+Graefeauthor=C.+Malaauthor=N.+Th%C3%A4nsauthor=M.+B%C3%BCrgleauthor=A.+Rempelauthor=N.+Rotterauthor=B.+Wollenbergauthor=S.+Lang&title=The+Oral+Serine+Protease+Inhibitor+WX-671+-+First+Experience+in+Patients+with+Advanced+Head+and+Neck+Carcinoma&doi=10.1159%2F000151736"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5d&amp;dbid=16384&amp;doi=10.1159%2F000151736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000151736%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DJ.%2BE.%26aulast%3DBrocks%26aufirst%3DC.%26aulast%3DGraefe%26aufirst%3DH.%26aulast%3DMala%26aufirst%3DC.%26aulast%3DTh%25C3%25A4ns%26aufirst%3DN.%26aulast%3DB%25C3%25BCrgle%26aufirst%3DM.%26aulast%3DRempel%26aufirst%3DA.%26aulast%3DRotter%26aufirst%3DN.%26aulast%3DWollenberg%26aufirst%3DB.%26aulast%3DLang%26aufirst%3DS.%26atitle%3DThe%2520Oral%2520Serine%2520Protease%2520Inhibitor%2520WX-671%2520-%2520First%2520Experience%2520in%2520Patients%2520with%2520Advanced%2520Head%2520and%2520Neck%2520Carcinoma%26jtitle%3DBreast%2520Care%26date%3D2008%26volume%3D3%26spage%3D20%26epage%3D24%26doi%3D10.1159%2F000151736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Setyono-Han, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stürzebecher, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmalix, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muehlenweg, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sieuwerts, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timmermans, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magdolen, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klijn, J. G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foekens, J. A.</span><span> </span><span class="NLM_article-title">Suppression of Rat Breast Cancer Metastasis and Reduction of Primary Tumour Growth by the Small Synthetic Urokinase Inhibitor WX-UKI</span> <span class="citation_source-journal">Thromb. Haemostasis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">779</span><span class="NLM_x">–</span> <span class="NLM_lpage">786</span><span class="refDoi"> DOI: 10.1160/TH04-11-0712</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1160%2FTH04-11-0712" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=15841327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjs1ert78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2005&pages=779-786&author=B.+Setyono-Hanauthor=J.+St%C3%BCrzebecherauthor=W.+A.+Schmalixauthor=B.+Muehlenwegauthor=A.+M.+Sieuwertsauthor=M.+Timmermansauthor=V.+Magdolenauthor=M.+Schmittauthor=J.+G.+M.+Klijnauthor=J.+A.+Foekens&title=Suppression+of+Rat+Breast+Cancer+Metastasis+and+Reduction+of+Primary+Tumour+Growth+by+the+Small+Synthetic+Urokinase+Inhibitor+WX-UKI&doi=10.1160%2FTH04-11-0712"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5eR"><div class="casContent"><span class="casTitleNuber">5e</span><div class="casTitle"><span class="NLM_cas:atitle">Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1</span></div><div class="casAuthors">Setyono-Han, Buddy; Stuerzebecher, Joerg; Schmalix, Wolfgang A.; Muehlenweg, Bernd; Sieuwerts, Anieta M.; Timmermans, Mieke; Magdolen, Viktor; Schmitt, Manfred; Klijn, Jan G. M.; Foekens, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis and Haemostasis</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">779-786</span>CODEN:
                <span class="NLM_cas:coden">THHADQ</span>;
        ISSN:<span class="NLM_cas:issn">0340-6245</span>.
    
            (<span class="NLM_cas:orgname">Schattauer GmbH</span>)
        </div><div class="casAbstract">The serine protease uPA (urokinase-type plasminogen activator) and its receptor uPAR (CD87) are often elevated in malignant tumors, hence, inhibition of this tumor-assocd. plasminogen activation system provides an attractive target for therapeutic strategies.  WX-UK1, a deriv. of 3-aminophenylalanine in the L-conformation with inhibitory antiproteolytic properties, was tested for its specificity spectrum using specific chromogenic paranitroanilide peptide substrates.  The corresponding D-enantiomer of WX-UK1 was used as a control.  The antitumor and anti-metastatic (no. of lung foci and wt. of the axillary lymph nodes) properties were studied by s.c. administration of WX-UK1 to Brown Norwegian (BN) rats carrying orthotopically transplanted BN472 rat breast tumors.  WX-UK1 selectively inhibited tumor-related proteases from rats and humans such as uPA, plasmin, or thrombin in the sub or low micromolar range.  The activity was stereoselective as the D-enantiomer of WX-UK1 inhibited uPA and plasmin at approx. 70-fold higher Ki values than the active L-form.  Chronical administration of the L-enantiomer of WX-UK1 impaired primary tumor growth and metastasis of BN472 rat breast cancer in a dose-dependent manner.  The min. inhibitory dosage with maximal effect was between 0.15 and 0.3 mg/kg/day.  The inactive D-enantiomer of WX-UK1 was not active in this respect.  Daily treatment with WX-UK1 for up to 35 days was well tolerated as judged by the unchanged body and organ wt. development.  In conclusion, our results provide evidence that WX-UK1 as a single agent inhibits breast tumor growth and metastasis in vivo, and thus is a promising candidate drug to treat human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoydJhqyuXt0LVg90H21EOLACvtfcHk0liBBdxDfkCnPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjs1ert78%253D&md5=3a22d68678cce69d209c47e7ea4585cb</span></div><a href="/servlet/linkout?suffix=cit5e&amp;dbid=16384&amp;doi=10.1160%2FTH04-11-0712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1160%252FTH04-11-0712%26sid%3Dliteratum%253Aachs%26aulast%3DSetyono-Han%26aufirst%3DB.%26aulast%3DSt%25C3%25BCrzebecher%26aufirst%3DJ.%26aulast%3DSchmalix%26aufirst%3DW.%2BA.%26aulast%3DMuehlenweg%26aufirst%3DB.%26aulast%3DSieuwerts%26aufirst%3DA.%2BM.%26aulast%3DTimmermans%26aufirst%3DM.%26aulast%3DMagdolen%26aufirst%3DV.%26aulast%3DSchmitt%26aufirst%3DM.%26aulast%3DKlijn%26aufirst%3DJ.%2BG.%2BM.%26aulast%3DFoekens%26aufirst%3DJ.%2BA.%26atitle%3DSuppression%2520of%2520Rat%2520Breast%2520Cancer%2520Metastasis%2520and%2520Reduction%2520of%2520Primary%2520Tumour%2520Growth%2520by%2520the%2520Small%2520Synthetic%2520Urokinase%2520Inhibitor%2520WX-UKI%26jtitle%3DThromb.%2520Haemostasis%26date%3D2005%26volume%3D93%26spage%3D779%26epage%3D786%26doi%3D10.1160%2FTH04-11-0712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Barber, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickinson, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fish, P. V.</span><span> </span><span class="NLM_article-title">Selective Urokinase-Type Plasminogen Activator (uPA) Inhibitors. Part 3:1-Isoquinolinylguanidines</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">3227</span><span class="NLM_x">–</span> <span class="NLM_lpage">3230</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2004.03.094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1016%2Fj.bmcl.2004.03.094" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=3227-3230&author=C.+G.+Barberauthor=R.+P.+Dickinsonauthor=P.+V.+Fish&title=Selective+Urokinase-Type+Plasminogen+Activator+%28uPA%29+Inhibitors.+Part+3%3A1-Isoquinolinylguanidines&doi=10.1016%2Fj.bmcl.2004.03.094"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.03.094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.03.094%26sid%3Dliteratum%253Aachs%26aulast%3DBarber%26aufirst%3DC.%2BG.%26aulast%3DDickinson%26aufirst%3DR.%2BP.%26aulast%3DFish%26aufirst%3DP.%2BV.%26atitle%3DSelective%2520Urokinase-Type%2520Plasminogen%2520Activator%2520%2528uPA%2529%2520Inhibitors.%2520Part%25203%253A1-Isoquinolinylguanidines%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D3227%26epage%3D3230%26doi%3D10.1016%2Fj.bmcl.2004.03.094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Bayliss, M. A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venn, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edgington, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, D. K.</span><span> </span><span class="NLM_article-title">Determination of a Potent Urokinase-Type Plasminogen Activator, UK-356,202, in Plasma at pg/mL Levels Using Column-Switching HPLC and Fluorescence Detection</span> <span class="citation_source-journal">J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">877</span><span class="NLM_x">, </span> <span class="NLM_fpage">121</span><span class="NLM_x">–</span> <span class="NLM_lpage">126</span><span class="refDoi"> DOI: 10.1016/j.jchromb.2008.11.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1016%2Fj.jchromb.2008.11.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=19119083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksVCrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=877&publication_year=2009&pages=121-126&author=M.+A.+J.+Baylissauthor=R.+F.+Vennauthor=A.+M.+Edgingtonauthor=R.+Websterauthor=D.+K.+Walker&title=Determination+of+a+Potent+Urokinase-Type+Plasminogen+Activator%2C+UK-356%2C202%2C+in+Plasma+at+pg%2FmL+Levels+Using+Column-Switching+HPLC+and+Fluorescence+Detection&doi=10.1016%2Fj.jchromb.2008.11.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">Determination of a potent urokinase-type plasminogen activator, UK-356,202, in plasma at pg/mL levels using column-switching HPLC and fluorescence detection</span></div><div class="casAuthors">Bayliss, Mark A. J.; Venn, Richard F.; Edgington, Alan M.; Webster, Robert; Walker, Donald K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">877</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">121-126</span>CODEN:
                <span class="NLM_cas:coden">JCBAAI</span>;
        ISSN:<span class="NLM_cas:issn">1570-0232</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A rapid, sensitive and selective method using column-switching HPLC with fluorescence detection has been developed for the detn. of UK-356,202, a potent urokinase-type plasminogen activator, in human plasma.  A structural isomer of UK-356,202 is used as an internal std.  The lower limit of quantification is 20 pg/mL and the method is linear over a 100-fold concn. range.  UK-356,202 is extd. from plasma simply through the removal of proteins by pptn. with acetonitrile.  The HPLC system comprises three columns and the cycle time is 9.5 min per sample.  The eluate from the extn. column is heart-cut onto a trace enrichment cartridge which is then back-flushed onto a narrow-bore Supelco ABZ+ Plus anal. column.  The method has been used to analyze many thousands of samples from clin. and toxicol. studies support.  Its ruggedness is demonstrated by the use of a single extn. column for the anal. of over 1200 clin. samples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX04bfWXDaVbVg90H21EOLACvtfcHk0lg906T7_opJXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksVCrtg%253D%253D&md5=f2ef941164cb9226d6546015cfe91272</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1016%2Fj.jchromb.2008.11.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jchromb.2008.11.038%26sid%3Dliteratum%253Aachs%26aulast%3DBayliss%26aufirst%3DM.%2BA.%2BJ.%26aulast%3DVenn%26aufirst%3DR.%2BF.%26aulast%3DEdgington%26aufirst%3DA.%2BM.%26aulast%3DWebster%26aufirst%3DR.%26aulast%3DWalker%26aufirst%3DD.%2BK.%26atitle%3DDetermination%2520of%2520a%2520Potent%2520Urokinase-Type%2520Plasminogen%2520Activator%252C%2520UK-356%252C202%252C%2520in%2520Plasma%2520at%2520pg%252FmL%2520Levels%2520Using%2520Column-Switching%2520HPLC%2520and%2520Fluorescence%2520Detection%26jtitle%3DJ.%2520Chromatogr.%2520B%253A%2520Anal.%2520Technol.%2520Biomed.%2520Life%2520Sci.%26date%3D2009%26volume%3D877%26spage%3D121%26epage%3D126%26doi%3D10.1016%2Fj.jchromb.2008.11.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Fish, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barber, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collis, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickinson, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henry, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horne, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huggins, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Gara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCleverty, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntosh, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, R.</span><span> </span><span class="NLM_article-title">Selective Urokinase-Type Plasminogen Activator Inhibitors. 4. 1-(7-Sulfonamidoisoquinolinyl)guanidines</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">2341</span><span class="NLM_x">–</span> <span class="NLM_lpage">2351</span><span class="refDoi"> DOI: 10.1021/jm061066t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm061066t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2341-2351&author=P.+V.+Fishauthor=C.+G.+Barberauthor=D.+G.+Brownauthor=R.+Buttauthor=M.+G.+Collisauthor=R.+P.+Dickinsonauthor=B.+T.+Henryauthor=V.+A.+Horneauthor=J.+P.+Hugginsauthor=E.+Kingauthor=M.+O%27Garaauthor=D.+McClevertyauthor=F.+McIntoshauthor=C.+Phillipsauthor=R.+Webster&title=Selective+Urokinase-Type+Plasminogen+Activator+Inhibitors.+4.+1-%287-Sulfonamidoisoquinolinyl%29guanidines&doi=10.1021%2Fjm061066t"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=10.1021%2Fjm061066t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061066t%26sid%3Dliteratum%253Aachs%26aulast%3DFish%26aufirst%3DP.%2BV.%26aulast%3DBarber%26aufirst%3DC.%2BG.%26aulast%3DBrown%26aufirst%3DD.%2BG.%26aulast%3DButt%26aufirst%3DR.%26aulast%3DCollis%26aufirst%3DM.%2BG.%26aulast%3DDickinson%26aufirst%3DR.%2BP.%26aulast%3DHenry%26aufirst%3DB.%2BT.%26aulast%3DHorne%26aufirst%3DV.%2BA.%26aulast%3DHuggins%26aufirst%3DJ.%2BP.%26aulast%3DKing%26aufirst%3DE.%26aulast%3DO%2527Gara%26aufirst%3DM.%26aulast%3DMcCleverty%26aufirst%3DD.%26aulast%3DMcIntosh%26aufirst%3DF.%26aulast%3DPhillips%26aufirst%3DC.%26aulast%3DWebster%26aufirst%3DR.%26atitle%3DSelective%2520Urokinase-Type%2520Plasminogen%2520Activator%2520Inhibitors.%25204.%25201-%25287-Sulfonamidoisoquinolinyl%2529guanidines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2341%26epage%3D2351%26doi%3D10.1021%2Fjm061066t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Schweinitz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinmetzer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banke, I. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arlt, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stürzebecher, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuster, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geissler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giersiefen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeslawska, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacob, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krüger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stürzebecher, J.</span><span> </span><span class="NLM_article-title">Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x"> (</span><span class="NLM_issue">32</span><span class="NLM_x">) </span> <span class="NLM_fpage">33613</span><span class="NLM_x">–</span> <span class="NLM_lpage">33622</span><span class="refDoi"> DOI: 10.1074/jbc.M314151200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1074%2Fjbc.M314151200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=33613-33622&issue=32&author=A.+Schweinitzauthor=T.+Steinmetzerauthor=I.+J.+Bankeauthor=M.+J.+Arltauthor=A.+St%C3%BCrzebecherauthor=O.+Schusterauthor=A.+Geisslerauthor=H.+Giersiefenauthor=E.+Zeslawskaauthor=U.+Jacobauthor=A.+Kr%C3%BCgerauthor=J.+St%C3%BCrzebecher&title=Design+of+novel+and+selective+inhibitors+of+urokinase-type+plasminogen+activator+with+improved+pharmacokinetic+properties+for+use+as+antimetastatic+agents&doi=10.1074%2Fjbc.M314151200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M314151200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M314151200%26sid%3Dliteratum%253Aachs%26aulast%3DSchweinitz%26aufirst%3DA.%26aulast%3DSteinmetzer%26aufirst%3DT.%26aulast%3DBanke%26aufirst%3DI.%2BJ.%26aulast%3DArlt%26aufirst%3DM.%2BJ.%26aulast%3DSt%25C3%25BCrzebecher%26aufirst%3DA.%26aulast%3DSchuster%26aufirst%3DO.%26aulast%3DGeissler%26aufirst%3DA.%26aulast%3DGiersiefen%26aufirst%3DH.%26aulast%3DZeslawska%26aufirst%3DE.%26aulast%3DJacob%26aufirst%3DU.%26aulast%3DKr%25C3%25BCger%26aufirst%3DA.%26aulast%3DSt%25C3%25BCrzebecher%26aufirst%3DJ.%26atitle%3DDesign%2520of%2520novel%2520and%2520selective%2520inhibitors%2520of%2520urokinase-type%2520plasminogen%2520activator%2520with%2520improved%2520pharmacokinetic%2520properties%2520for%2520use%2520as%2520antimetastatic%2520agents%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26issue%3D32%26spage%3D33613%26epage%3D33622%26doi%3D10.1074%2Fjbc.M314151200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Henneke, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greschus, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korfei, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markart, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahavadi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schermuly, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wygrecka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stürzebecher, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeger, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Günther, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruppert, C.</span><span> </span><span class="NLM_article-title">Inhibition of Urokinase Activity Reduces Primary Tumor Growth and Metastasis Formation in a Murine Lung Carcinoma Model</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">181</span><span class="NLM_x">, </span> <span class="NLM_fpage">611</span><span class="NLM_x">–</span> <span class="NLM_lpage">619</span><span class="refDoi"> DOI: 10.1164/rccm.200903-0342OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1164%2Frccm.200903-0342OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=20056905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFahsLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2010&pages=611-619&author=I.+Hennekeauthor=S.+Greschusauthor=R.+Savaiauthor=M.+Korfeiauthor=P.+Markartauthor=P.+Mahavadiauthor=R.+T.+Schermulyauthor=M.+Wygreckaauthor=J.+St%C3%BCrzebecherauthor=W.+Seegerauthor=A.+G%C3%BCntherauthor=C.+Ruppert&title=Inhibition+of+Urokinase+Activity+Reduces+Primary+Tumor+Growth+and+Metastasis+Formation+in+a+Murine+Lung+Carcinoma+Model&doi=10.1164%2Frccm.200903-0342OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of urokinase activity reduces primary tumor growth and metastasis formation in a murine lung carcinoma model</span></div><div class="casAuthors">Henneke, Ingrid; Greschus, Susanne; Savai, Rajkumar; Korfei, Martina; Markart, Philipp; Mahavadi, Poornima; Schermuly, Ralph T.; Wygrecka, Malgorzata; Stuerzebecher, Joerg; Seeger, Werner; Guenther, Andreas; Ruppert, Clemens</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">611-619</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: Lung cancer is the most common malignancy in humans.  Urokinase (uPA) plays a crucial role in carcinogenesis by facilitating tumor cell invasion and metastasis.  Objectives: We investigated the effect of the highly specific urokinase inhibitor CJ-463 (benzylsulfonyl-D-Ser-Ser-4-amidinobenzylamide) on tumor growth, metastasis formation, and tumor vascularization in the murine Lewis lung carcinoma (LLC) and a human small lung cancer model.  Methods: A quantity of 3 × 106 LLC cells were s.c. injected into the right flank of C57Bl6/N mice, uPA knock out, and uPA receptor knockout mice.  Seven days later mice were randomized to receive i.p. either saline (control group), CJ-463 (10 and 100 mg/kg, twice a day), or its ineffective stereoisomer (10 mg/kg, twice a day).  Tumor vol. was measured every second day and metastasis formation was monitored by volumetric-computed tomog.  Twelve days after onset of treatment mice were killed and tumors were prepd. for histol. examn.  Measurements and Main Results: Treatment with CJ-463 resulted in a significant inhibition of primary tumor growth, with the highest efficacy seen in the 100 mg/kg group.  In addn., histol. anal. of the lung revealed a significant redn. in lung micrometastasis in the 100 mg/kg group.  Similarly, a reduced seeding of tumor cells into the lung after i.v. injection of LLC cells was obsd. in inhibitor-treated mice.  In these mice, treatment with CJ-463 appeared not to significantly alter the relative extent of tumor vascularization.  In vitro, proliferation of LLC cells remained unchanged upon inhibitor treatment.  CJ-463 was found to similarly reduce tumor growth in uPA receptor knockout mice, but was ineffective in uPA knockout mice.  Conclusions: Our results suggest that synthetic low-mol.-wt. uPA-inhibitors offer as novel agents for treatment of lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRonLD45172bVg90H21EOLACvtfcHk0lg906T7_opJXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFahsLfE&md5=bc34f167070bfd3531eb442c30ab843b</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1164%2Frccm.200903-0342OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200903-0342OC%26sid%3Dliteratum%253Aachs%26aulast%3DHenneke%26aufirst%3DI.%26aulast%3DGreschus%26aufirst%3DS.%26aulast%3DSavai%26aufirst%3DR.%26aulast%3DKorfei%26aufirst%3DM.%26aulast%3DMarkart%26aufirst%3DP.%26aulast%3DMahavadi%26aufirst%3DP.%26aulast%3DSchermuly%26aufirst%3DR.%2BT.%26aulast%3DWygrecka%26aufirst%3DM.%26aulast%3DSt%25C3%25BCrzebecher%26aufirst%3DJ.%26aulast%3DSeeger%26aufirst%3DW.%26aulast%3DG%25C3%25BCnther%26aufirst%3DA.%26aulast%3DRuppert%26aufirst%3DC.%26atitle%3DInhibition%2520of%2520Urokinase%2520Activity%2520Reduces%2520Primary%2520Tumor%2520Growth%2520and%2520Metastasis%2520Formation%2520in%2520a%2520Murine%2520Lung%2520Carcinoma%2520Model%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2010%26volume%3D181%26spage%3D611%26epage%3D619%26doi%3D10.1164%2Frccm.200903-0342OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Frederickson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callaghan, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chessari, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Congreve, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMenamin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vinković, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallis, N. G.</span><span> </span><span class="NLM_article-title">Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">183</span><span class="NLM_x">–</span> <span class="NLM_lpage">186</span><span class="refDoi"> DOI: 10.1021/jm701359z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701359z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=183-186&author=M.+Fredericksonauthor=O.+Callaghanauthor=G.+Chessariauthor=M.+Congreveauthor=S.+R.+Cowanauthor=J.+E.+Matthewsauthor=R.+McMenaminauthor=D.-M.+Smithauthor=M.+Vinkovi%C4%87author=N.+G.+Wallis&title=Fragment-Based+Discovery+of+Mexiletine+Derivatives+as+Orally+Bioavailable+Inhibitors+of+Urokinase-Type+Plasminogen+Activator&doi=10.1021%2Fjm701359z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fjm701359z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701359z%26sid%3Dliteratum%253Aachs%26aulast%3DFrederickson%26aufirst%3DM.%26aulast%3DCallaghan%26aufirst%3DO.%26aulast%3DChessari%26aufirst%3DG.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DCowan%26aufirst%3DS.%2BR.%26aulast%3DMatthews%26aufirst%3DJ.%2BE.%26aulast%3DMcMenamin%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DD.-M.%26aulast%3DVinkovi%25C4%2587%26aufirst%3DM.%26aulast%3DWallis%26aufirst%3DN.%2BG.%26atitle%3DFragment-Based%2520Discovery%2520of%2520Mexiletine%2520Derivatives%2520as%2520Orally%2520Bioavailable%2520Inhibitors%2520of%2520Urokinase-Type%2520Plasminogen%2520Activator%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D183%26epage%3D186%26doi%3D10.1021%2Fjm701359z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Bruncko, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McClellan, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wendt, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sauer, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geyer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalton, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaminski, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weitzberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dellaria, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantei, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nienaber, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinghofer, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rockway, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giranda, V. L.</span><span> </span><span class="NLM_article-title">Naphthamidine Urokinase Plasminogen Activator Inhibitors with Improved Pharmacokinetic Properties</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">93</span><span class="NLM_x">–</span> <span class="NLM_lpage">98</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2004.10.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1016%2Fj.bmcl.2004.10.026" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=93-98&author=M.+Brunckoauthor=W.+J.+McClellanauthor=M.+D.+Wendtauthor=D.+R.+Sauerauthor=A.+Geyerauthor=C.+R.+Daltonauthor=M.+A.+Kaminskiauthor=M.+Weitzbergauthor=J.+Gongauthor=J.+F.+Dellariaauthor=R.+Manteiauthor=X.+Zhaoauthor=V.+L.+Nienaberauthor=K.+Stewartauthor=V.+Klinghoferauthor=J.+Bouskaauthor=T.+W.+Rockwayauthor=V.+L.+Giranda&title=Naphthamidine+Urokinase+Plasminogen+Activator+Inhibitors+with+Improved+Pharmacokinetic+Properties&doi=10.1016%2Fj.bmcl.2004.10.026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.10.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.10.026%26sid%3Dliteratum%253Aachs%26aulast%3DBruncko%26aufirst%3DM.%26aulast%3DMcClellan%26aufirst%3DW.%2BJ.%26aulast%3DWendt%26aufirst%3DM.%2BD.%26aulast%3DSauer%26aufirst%3DD.%2BR.%26aulast%3DGeyer%26aufirst%3DA.%26aulast%3DDalton%26aufirst%3DC.%2BR.%26aulast%3DKaminski%26aufirst%3DM.%2BA.%26aulast%3DWeitzberg%26aufirst%3DM.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DDellaria%26aufirst%3DJ.%2BF.%26aulast%3DMantei%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DNienaber%26aufirst%3DV.%2BL.%26aulast%3DStewart%26aufirst%3DK.%26aulast%3DKlinghofer%26aufirst%3DV.%26aulast%3DBouska%26aufirst%3DJ.%26aulast%3DRockway%26aufirst%3DT.%2BW.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26atitle%3DNaphthamidine%2520Urokinase%2520Plasminogen%2520Activator%2520Inhibitors%2520with%2520Improved%2520Pharmacokinetic%2520Properties%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D93%26epage%3D98%26doi%3D10.1016%2Fj.bmcl.2004.10.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Zhu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gokhale, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munoz, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baek, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bashyam, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Von Hoff, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, H.</span><span> </span><span class="NLM_article-title">Identification of a Novel Inhibitor of Urokinase-Type Plasminogen Activator</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1348</span><span class="NLM_x">–</span> <span class="NLM_lpage">1356</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-06-0520</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1158%2F1535-7163.MCT-06-0520" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=17431113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BD2sXktFams70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=1348-1356&author=M.+Zhuauthor=V.+M.+Gokhaleauthor=L.+Szaboauthor=R.+M.+Munozauthor=H.+Baekauthor=S.+Bashyamauthor=L.+H.+Hurleyauthor=D.+D.+Von+Hoffauthor=H.+Han&title=Identification+of+a+Novel+Inhibitor+of+Urokinase-Type+Plasminogen+Activator&doi=10.1158%2F1535-7163.MCT-06-0520"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a novel inhibitor of urokinase-type plasminogen activator</span></div><div class="casAuthors">Zhu, Ming; Gokhale, Vijay M.; Szabo, Lajos; Munoz, Ruben M.; Baek, Hyounggee; Bashyam, Sridevi; Hurley, Laurence H.; Von Hoff, Daniel D.; Han, Haiyong</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1348-1356</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Urokinase-type plasminogen activator (uPA), a highly restricted serine protease, plays an important role in the regulation of diverse physiol. and pathol. processes.  Strong clin. and exptl. evidence has shown that elevated uPA expression is assocd. with cancer progression, metastasis, and shortened survival in patients.  UPA has been considered as a promising mol. target for development of anticancer drugs.  Here, we report the identification of several new uPA inhibitors using a high-throughput screen from a chem. library.  From these uPA inhibitors, mol. modeling and docking studies identified 4-oxazolidinone as a novel lead pharmacophore.  Optimization of the 4-oxazolidinone pharmacophore resulted in a series of structurally modified compds. with improved potency and selectivity.  One of the 4-oxazolidinone analogs, UK122, showed the highest inhibition of uPA activity.  The IC50 of UK122 in a cell-free indirect uPA assay is 0.2 μmol/L.  This compd. also showed no or little inhibition of other serine proteases such as thrombin, trypsin, plasmin, and the tissue-type plasminogen activator, indicating its high specificity against uPA.  Moreover, UK122 showed little cytotoxicity against CFPAC-1 cells (IC50 >100 μmol/L) but significantly inhibited the migration and invasion of this pancreatic cancer cell line.  Our data show that UK122 could potentially be developed as a new anticancer agent that prevents the invasion and metastasis of pancreatic cancer. [Mol Cancer Ther 2007;6(4):1348-56].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEnj7xwlO_JLVg90H21EOLACvtfcHk0lhfYvfb98sC_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXktFams70%253D&md5=8d75c347878e3123db205e78bcaefd26</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0520%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DGokhale%26aufirst%3DV.%2BM.%26aulast%3DSzabo%26aufirst%3DL.%26aulast%3DMunoz%26aufirst%3DR.%2BM.%26aulast%3DBaek%26aufirst%3DH.%26aulast%3DBashyam%26aufirst%3DS.%26aulast%3DHurley%26aufirst%3DL.%2BH.%26aulast%3DVon%2BHoff%26aufirst%3DD.%2BD.%26aulast%3DHan%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520a%2520Novel%2520Inhibitor%2520of%2520Urokinase-Type%2520Plasminogen%2520Activator%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D1348%26epage%3D1356%26doi%3D10.1158%2F1535-7163.MCT-06-0520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Joossens, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Sayed, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surpateanu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van der Veken, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambeir, A.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setyono-Han, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foekens, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmalix, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haemers, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Augustyns, K.</span><span> </span><span class="NLM_article-title">Small, Potent, and Selective Diaryl Phosphonate Inhibitors for Urokinase-Type Plasminogen Activator with in Vivo Antimetastatic Properties</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">6638</span><span class="NLM_x">–</span> <span class="NLM_lpage">6646</span><span class="refDoi"> DOI: 10.1021/jm700962j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm700962j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=6638-6646&author=J.+Joossensauthor=O.+M.+Aliauthor=I.+El-Sayedauthor=G.+Surpateanuauthor=P.+Van+der+Vekenauthor=A.-M.+Lambeirauthor=B.+Setyono-Hanauthor=J.+A.+Foekensauthor=A.+Schneiderauthor=W.+Schmalixauthor=A.+Haemersauthor=K.+Augustyns&title=Small%2C+Potent%2C+and+Selective+Diaryl+Phosphonate+Inhibitors+for+Urokinase-Type+Plasminogen+Activator+with+in+Vivo+Antimetastatic+Properties&doi=10.1021%2Fjm700962j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm700962j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm700962j%26sid%3Dliteratum%253Aachs%26aulast%3DJoossens%26aufirst%3DJ.%26aulast%3DAli%26aufirst%3DO.%2BM.%26aulast%3DEl-Sayed%26aufirst%3DI.%26aulast%3DSurpateanu%26aufirst%3DG.%26aulast%3DVan%2Bder%2BVeken%26aufirst%3DP.%26aulast%3DLambeir%26aufirst%3DA.-M.%26aulast%3DSetyono-Han%26aufirst%3DB.%26aulast%3DFoekens%26aufirst%3DJ.%2BA.%26aulast%3DSchneider%26aufirst%3DA.%26aulast%3DSchmalix%26aufirst%3DW.%26aulast%3DHaemers%26aufirst%3DA.%26aulast%3DAugustyns%26aufirst%3DK.%26atitle%3DSmall%252C%2520Potent%252C%2520and%2520Selective%2520Diaryl%2520Phosphonate%2520Inhibitors%2520for%2520Urokinase-Type%2520Plasminogen%2520Activator%2520with%2520in%2520Vivo%2520Antimetastatic%2520Properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D6638%26epage%3D6646%26doi%3D10.1021%2Fjm700962j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Parry, G.; Mazar, A. P.</span><span> </span><span class="NLM_article-title">Urokinase-type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof</span>. US Patent 8105602,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=G.+Parry&author=A.+P.+Mazar&title=Urokinase-type+plasminogen+activator+receptor+epitope%2C+monoclonal+antibodies+derived+therefrom+and+methods+of+use+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DParry%26aufirst%3DG.%26atitle%3DUrokinase-type%2520plasminogen%2520activator%2520receptor%2520epitope%252C%2520monoclonal%2520antibodies%2520derived%2520therefrom%2520and%2520methods%2520of%2520use%2520thereof%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Xu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donate, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juarez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parry, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meehan, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ugolkov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubrovskyi, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Halloran, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazar, A. P.</span><span> </span><span class="NLM_article-title">Identification of a New Epitope in uPAR as a Target for the Cancer Therapeutic Monoclonal Antibody ATN-658, a Structural Homolog of the uPAR Binding Integrin CD11b (αM)</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">e95349</span><span class="NLM_x">–</span> <span class="NLM_lpage">13</span><span class="refDoi"> DOI: 10.1371/journal.pone.0085349</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1371%2Fjournal.pone.0085349" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e95349-13&issue=1&author=X.+Xuauthor=Y.+Caiauthor=Y.+Weiauthor=F.+Donateauthor=J.+Juarezauthor=G.+Parryauthor=L.+Chenauthor=E.+J.+Meehanauthor=R.+W.+Ahnauthor=A.+Ugolkovauthor=O.+Dubrovskyiauthor=T.+O%27Halloranauthor=M.+Huangauthor=A.+P.+Mazar&title=Identification+of+a+New+Epitope+in+uPAR+as+a+Target+for+the+Cancer+Therapeutic+Monoclonal+Antibody+ATN-658%2C+a+Structural+Homolog+of+the+uPAR+Binding+Integrin+CD11b+%28%CE%B1M%29&doi=10.1371%2Fjournal.pone.0085349"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0085349&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0085349%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DX.%26aulast%3DCai%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DDonate%26aufirst%3DF.%26aulast%3DJuarez%26aufirst%3DJ.%26aulast%3DParry%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DMeehan%26aufirst%3DE.%2BJ.%26aulast%3DAhn%26aufirst%3DR.%2BW.%26aulast%3DUgolkov%26aufirst%3DA.%26aulast%3DDubrovskyi%26aufirst%3DO.%26aulast%3DO%2527Halloran%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DMazar%26aufirst%3DA.%2BP.%26atitle%3DIdentification%2520of%2520a%2520New%2520Epitope%2520in%2520uPAR%2520as%2520a%2520Target%2520for%2520the%2520Cancer%2520Therapeutic%2520Monoclonal%2520Antibody%2520ATN-658%252C%2520a%2520Structural%2520Homolog%2520of%2520the%2520uPAR%2520Binding%2520Integrin%2520CD11b%2520%2528%25CE%25B1M%2529%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26issue%3D1%26spage%3De95349%26epage%3D13%26doi%3D10.1371%2Fjournal.pone.0085349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Chen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gfeller, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buth, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michielin, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leiman, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinis, C.</span><span> </span><span class="NLM_article-title">Improving Binding Affinity and Stability of Peptide Ligands by Substituting Glycines with D-Amino Acids</span> <span class="citation_source-journal">ChemBioChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1316</span><span class="NLM_x">–</span> <span class="NLM_lpage">1322</span><span class="refDoi"> DOI: 10.1002/cbic.201300228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1002%2Fcbic.201300228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=23828687" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVGku7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=1316-1322&author=S.+Chenauthor=D.+Gfellerauthor=S.+A.+Buthauthor=O.+Michielinauthor=P.+G.+Leimanauthor=C.+Heinis&title=Improving+Binding+Affinity+and+Stability+of+Peptide+Ligands+by+Substituting+Glycines+with+D-Amino+Acids&doi=10.1002%2Fcbic.201300228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Improving Binding Affinity and Stability of Peptide Ligands by Substituting Glycines with D-Amino Acids</span></div><div class="casAuthors">Chen, Shiyu; Gfeller, David; Buth, Sergey A.; Michielin, Olivier; Leiman, Petr G.; Heinis, Christian</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1316-1322</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Improving the binding affinity and/or stability of peptide ligands often requires testing of large nos. of variants to identify beneficial mutations.  Herein we propose a type of mutation that promises a high success rate.  In a bicyclic peptide inhibitor of the cancer-related protease urokinase-type plasminogen activator (uPA), we obsd. a glycine residue that has a pos. .vphi. dihedral angle when bound to the target.  We hypothesized that replacing it with a D-amino acid, which favors pos. .vphi. angles, could enhance the binding affinity and/or proteolytic resistance.  Mutation of this specific glycine to D-serine in the bicyclic peptide indeed improved inhibitory activity (1.75-fold) and stability (fourfold).  X-ray-structure anal. of the inhibitors in complex with uPA showed that the peptide backbone conformation was conserved.  Anal. of known cyclic peptide ligands showed that glycine is one of the most frequent amino acids, and that glycines with pos. .vphi. angles are found in many protein-bound peptides.  These results suggest that the glycine-to-D-amino acid mutagenesis strategy could be broadly applied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSvU_PyOWh77Vg90H21EOLACvtfcHk0liTc5NrmPWY_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVGku7vL&md5=e9ddaa6e0dfe2004d2ed52805ad18835</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201300228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201300228%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.%26aulast%3DGfeller%26aufirst%3DD.%26aulast%3DButh%26aufirst%3DS.%2BA.%26aulast%3DMichielin%26aufirst%3DO.%26aulast%3DLeiman%26aufirst%3DP.%2BG.%26aulast%3DHeinis%26aufirst%3DC.%26atitle%3DImproving%2520Binding%2520Affinity%2520and%2520Stability%2520of%2520Peptide%2520Ligands%2520by%2520Substituting%2520Glycines%2520with%2520D-Amino%2520Acids%26jtitle%3DChemBioChem%26date%3D2013%26volume%3D14%26spage%3D1316%26epage%3D1322%26doi%3D10.1002%2Fcbic.201300228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Roodbeen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paaske, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulder, F. A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreasen, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, K. J.</span><span> </span><span class="NLM_article-title">Bicyclic Peptide Inhibitor of Urokinase-Type Plasminogen Activator: Mode of Action</span> <span class="citation_source-journal">ChemBioChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">2179</span><span class="NLM_x">–</span> <span class="NLM_lpage">2188</span><span class="refDoi"> DOI: 10.1002/cbic.201300335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1002%2Fcbic.201300335" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=24115455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsF2nt77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=2179-2188&author=R.+Roodbeenauthor=B.+Paaskeauthor=L.+Jiangauthor=J.+K.+Jensenauthor=A.+Christensenauthor=J.+T.+Nielsenauthor=M.+Huangauthor=F.+A.+A.+Mulderauthor=N.+C.+Nielsenauthor=P.+A.+Andreasenauthor=K.+J.+Jensen&title=Bicyclic+Peptide+Inhibitor+of+Urokinase-Type+Plasminogen+Activator%3A+Mode+of+Action&doi=10.1002%2Fcbic.201300335"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Bicyclic Peptide Inhibitor of Urokinase-Type Plasminogen Activator: Mode of Action</span></div><div class="casAuthors">Roodbeen, Renee; Paaske, Berit; Jiang, Longguang; Jensen, Jan K.; Christensen, Anni; Nielsen, Jakob T.; Huang, Mingdong; Mulder, Frans A. A.; Nielsen, Niels Chr.; Andreasen, Peter A.; Jensen, Knud J.</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2179-2188</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The development of protease inhibitors for pharmacol. intervention has taken a new turn using peptide-based inhibitors.  Here, the authors report the rational design of bicyclic peptide inhibitors of the serine protease urokinase-type plasminogen activator (uPA), based on the established monocyclic peptide, upain-2.  It was successfully converted to a bicyclic peptide, without loss of inhibitory properties.  The aim was to produce a peptide cyclized by an amide bond with an addnl. stabilizing across-the-ring covalent bond.  The authors expected this bicyclic peptide to exhibit a lower entropic burden upon binding.  Two bicyclic peptides were synthesized with affinities similar to that of upain-2, and their binding energetics were evaluated by isothermal titrn. calorimetry.  Indeed, compared to upain-2, the bicyclic peptides showed reduced loss of entropy upon binding to uPA.  The authors also studied the soln. structures of the bicyclic peptide by NMR spectroscopy to map possible conformations.  An x-ray structure of the bicyclic-peptide-uPA complex confirmed an interaction similar to that for the previous upain-1/upain-2-uPA complexes.  These phys. studies of the peptide-protease interactions will aid future designs of bicyclic peptide protease inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3Sy6oFrgO87Vg90H21EOLACvtfcHk0lh24c2jRMVfUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsF2nt77I&md5=fd3049e453450a0a5fef5f3ecd25c9b9</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201300335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201300335%26sid%3Dliteratum%253Aachs%26aulast%3DRoodbeen%26aufirst%3DR.%26aulast%3DPaaske%26aufirst%3DB.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DJensen%26aufirst%3DJ.%2BK.%26aulast%3DChristensen%26aufirst%3DA.%26aulast%3DNielsen%26aufirst%3DJ.%2BT.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DMulder%26aufirst%3DF.%2BA.%2BA.%26aulast%3DNielsen%26aufirst%3DN.%2BC.%26aulast%3DAndreasen%26aufirst%3DP.%2BA.%26aulast%3DJensen%26aufirst%3DK.%2BJ.%26atitle%3DBicyclic%2520Peptide%2520Inhibitor%2520of%2520Urokinase-Type%2520Plasminogen%2520Activator%253A%2520Mode%2520of%2520Action%26jtitle%3DChemBioChem%26date%3D2013%26volume%3D14%26spage%3D2179%26epage%3D2188%26doi%3D10.1002%2Fcbic.201300335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Gladysz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cleenewerck, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joossens, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambeir, A.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Augustyns, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van der Veken, P.</span><span> </span><span class="NLM_article-title">Repositioning the Substrate Activity Screening (SAS) Approach as a Fragment-Based Method for Identification of Weak Binders</span> <span class="citation_source-journal">ChemBioChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">2238</span><span class="NLM_x">–</span> <span class="NLM_lpage">2247</span><span class="refDoi"> DOI: 10.1002/cbic.201402192</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1002%2Fcbic.201402192" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=25154878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVSqtb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=2238-2247&author=R.+Gladyszauthor=M.+Cleenewerckauthor=J.+Joossensauthor=A.-M.+Lambeirauthor=K.+Augustynsauthor=P.+Van+der+Veken&title=Repositioning+the+Substrate+Activity+Screening+%28SAS%29+Approach+as+a+Fragment-Based+Method+for+Identification+of+Weak+Binders&doi=10.1002%2Fcbic.201402192"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Repositioning the Substrate Activity Screening (SAS) Approach as a Fragment-Based Method for Identification of Weak Binders</span></div><div class="casAuthors">Gladysz, Rafaela; Cleenewerck, Matthias; Joossens, Jurgen; Lambeir, Anne-Marie; Augustyns, Koen; Van der Veken, Pieter</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2238-2247</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Fragment-based drug discovery (FBDD) has evolved into an established approach for "hit" identification.  Typically, most applications of FBDD depend on specialised cost- and time-intensive biophys. techniques.  The substrate activity screening (SAS) approach has been proposed as a relatively cheap and straightforward alternative for identification of fragments for enzyme inhibitors.  We have investigated SAS for the discovery of inhibitors of oncol. target urokinase (uPA).  Although our results support the key hypotheses of SAS, we also encountered a no. of unreported limitations.  In response, we propose an efficient modified methodol.: "MSAS" (modified substrate activity screening).  MSAS circumvents the limitations of SAS and broadens its scope by providing addnl. fragments and more coherent SAR data.  As well as presenting and validating MSAS, this study expands existing SAR knowledge for the S1 pocket of uPA and reports new reversible and irreversible uPA inhibitor scaffolds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxGqDxLUMmCLVg90H21EOLACvtfcHk0lh24c2jRMVfUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVSqtb3N&md5=9af3469f29276dc79343e1469b13ce95</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201402192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201402192%26sid%3Dliteratum%253Aachs%26aulast%3DGladysz%26aufirst%3DR.%26aulast%3DCleenewerck%26aufirst%3DM.%26aulast%3DJoossens%26aufirst%3DJ.%26aulast%3DLambeir%26aufirst%3DA.-M.%26aulast%3DAugustyns%26aufirst%3DK.%26aulast%3DVan%2Bder%2BVeken%26aufirst%3DP.%26atitle%3DRepositioning%2520the%2520Substrate%2520Activity%2520Screening%2520%2528SAS%2529%2520Approach%2520as%2520a%2520Fragment-Based%2520Method%2520for%2520Identification%2520of%2520Weak%2520Binders%26jtitle%3DChemBioChem%26date%3D2014%26volume%3D15%26spage%3D2238%26epage%3D2247%26doi%3D10.1002%2Fcbic.201402192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Groebke, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehlin, F.</span><span> </span><span class="NLM_article-title">Synthesis of Imidazo[1,2-<i>a</i>] Annulated Pyridines, Pyrazines and Pyrimidines by a Novel Three-Component Condensation</span> <span class="citation_source-journal">Synlett</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">1998</span><span class="NLM_x">, </span> <span class="NLM_fpage">661</span><span class="NLM_x">–</span> <span class="NLM_lpage">663</span><span class="refDoi"> DOI: 10.1055/s-1998-1721</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1055%2Fs-1998-1721" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1998&publication_year=1998&pages=661-663&author=K.+Groebkeauthor=L.+Weberauthor=F.+Mehlin&title=Synthesis+of+Imidazo%5B1%2C2-a%5D+Annulated+Pyridines%2C+Pyrazines+and+Pyrimidines+by+a+Novel+Three-Component+Condensation&doi=10.1055%2Fs-1998-1721"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1055%2Fs-1998-1721&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1998-1721%26sid%3Dliteratum%253Aachs%26aulast%3DGroebke%26aufirst%3DK.%26aulast%3DWeber%26aufirst%3DL.%26aulast%3DMehlin%26aufirst%3DF.%26atitle%3DSynthesis%2520of%2520Imidazo%255B1%252C2-a%255D%2520Annulated%2520Pyridines%252C%2520Pyrazines%2520and%2520Pyrimidines%2520by%2520a%2520Novel%2520Three-Component%2520Condensation%26jtitle%3DSynlett%26date%3D1998%26volume%3D1998%26spage%3D661%26epage%3D663%26doi%3D10.1055%2Fs-1998-1721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Blackburn, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleming, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiosaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, S.</span><span> </span><span class="NLM_article-title">Parallel Synthesis of 3-aminoimidazo[1,2-<i>a</i>]pyridines and Pyrazines by a New Three-Component Condensation</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">3635</span><span class="NLM_x">–</span> <span class="NLM_lpage">3638</span><span class="refDoi"> DOI: 10.1016/S0040-4039(98)00653-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1016%2FS0040-4039%2898%2900653-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADyaK1cXjtlWrtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1998&pages=3635-3638&author=C.+Blackburnauthor=B.+Guanauthor=P.+Flemingauthor=K.+Shiosakiauthor=S.+Tsai&title=Parallel+Synthesis+of+3-aminoimidazo%5B1%2C2-a%5Dpyridines+and+Pyrazines+by+a+New+Three-Component+Condensation&doi=10.1016%2FS0040-4039%2898%2900653-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Parallel synthesis of 3-aminoimidazo[1,2-a]pyridines and pyrazines by a new three-component condensation</span></div><div class="casAuthors">Blackburn, Christopher; Guan, Bing; Fleming, Paul; Shiosaki, Kazumi; Tsai, Shirling</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3635-3638</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A three-component condensation reaction between 2-aminopyridine, an aldehyde and an isonitrile catalyzed by scandium triflate affords derivs. of 3-aminoimidazo[1,2-a]pyridine; aminopyrazine reacts similarly.  A library of heterocycles, prepd. in high yield by parallel synthesis and purifn. on an ion-exchange resin, was subjected to further reaction at the amino group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrndWK-azaOEbVg90H21EOLACvtfcHk0ljeJ4RavNAQFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjtlWrtLs%253D&md5=dfdddf23bcb1051d2ff6375f9f2616f5</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2898%2900653-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252898%252900653-4%26sid%3Dliteratum%253Aachs%26aulast%3DBlackburn%26aufirst%3DC.%26aulast%3DGuan%26aufirst%3DB.%26aulast%3DFleming%26aufirst%3DP.%26aulast%3DShiosaki%26aufirst%3DK.%26aulast%3DTsai%26aufirst%3DS.%26atitle%3DParallel%2520Synthesis%2520of%25203-aminoimidazo%255B1%252C2-a%255Dpyridines%2520and%2520Pyrazines%2520by%2520a%2520New%2520Three-Component%2520Condensation%26jtitle%3DTetrahedron%2520Lett.%26date%3D1998%26volume%3D39%26spage%3D3635%26epage%3D3638%26doi%3D10.1016%2FS0040-4039%2898%2900653-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Bienaymé, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouzid, K.</span><span> </span><span class="NLM_article-title">A New Heterocyclic Multicomponent Reaction For the Combinatorial Synthesis of Fused 3-Aminoimidazoles</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">2234</span><span class="NLM_x">–</span> <span class="NLM_lpage">2237</span><span class="refDoi"> DOI: 10.1002/(SICI)1521-3773(19980904)37:16<2234::AID-ANIE2234>3.3.CO;2-I</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1002%2F%28SICI%291521-3773%2819980904%2937%3A16%3C2234%3A%3AAID-ANIE2234%3E3.3.CO%3B2-I" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1998&pages=2234-2237&author=H.+Bienaym%C3%A9author=K.+Bouzid&title=A+New+Heterocyclic+Multicomponent+Reaction+For+the+Combinatorial+Synthesis+of+Fused+3-Aminoimidazoles&doi=10.1002%2F%28SICI%291521-3773%2819980904%2937%3A16%3C2234%3A%3AAID-ANIE2234%3E3.3.CO%3B2-I"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291521-3773%2819980904%2937%3A16%3C2234%3A%3AAID-ANIE2234%3E3.3.CO%3B2-I&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291521-3773%252819980904%252937%253A16%253C2234%253A%253AAID-ANIE2234%253E3.3.CO%253B2-I%26sid%3Dliteratum%253Aachs%26aulast%3DBienaym%25C3%25A9%26aufirst%3DH.%26aulast%3DBouzid%26aufirst%3DK.%26atitle%3DA%2520New%2520Heterocyclic%2520Multicomponent%2520Reaction%2520For%2520the%2520Combinatorial%2520Synthesis%2520of%2520Fused%25203-Aminoimidazoles%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D1998%26volume%3D37%26spage%3D2234%26epage%3D2237%26doi%3D10.1002%2F%28SICI%291521-3773%2819980904%2937%3A16%3C2234%3A%3AAID-ANIE2234%3E3.3.CO%3B2-I" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bagdi, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santra, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monir, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajra, A.</span><span> </span><span class="NLM_article-title">Synthesis of imidazo[1,2-<i>a</i>]pyridines: A Decade Update</span> <span class="citation_source-journal">Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1555</span><span class="NLM_x">–</span> <span class="NLM_lpage">1575</span><span class="refDoi"> DOI: 10.1039/C4CC08495K</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1039%2FC4CC08495K" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=25407981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVyiu7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2015&pages=1555-1575&author=A.+K.+Bagdiauthor=S.+Santraauthor=K.+Monirauthor=A.+Hajra&title=Synthesis+of+imidazo%5B1%2C2-a%5Dpyridines%3A+A+Decade+Update&doi=10.1039%2FC4CC08495K"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18aR"><div class="casContent"><span class="casTitleNuber">18a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of imidazo[1,2-a]pyridines: a decade update</span></div><div class="casAuthors">Bagdi, Avik Kumar; Santra, Sougata; Monir, Kamarul; Hajra, Alakananda</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1555-1575</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Imidazopyridine is one of the important fused bicyclic 5-6 heterocycles and it is recognized as a "drug prejudice" scaffold due to its wide range of applications in medicinal chem.  This moiety is also useful in material science because of its structural character.  Synthesis of this moiety from the easily available chems. is desirable due to its tremendous use in the various branches of chem.  Here we report a review on the synthesis of this scaffold employing different strategies such as condensation, multicomponent reactions, oxidative coupling, tandem reactions, aminooxygenation, and hydroamination reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYesaxznoq0bVg90H21EOLACvtfcHk0ljeJ4RavNAQFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVyiu7%252FI&md5=4437aa97b3b269d776fe04f847460194</span></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.1039%2FC4CC08495K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4CC08495K%26sid%3Dliteratum%253Aachs%26aulast%3DBagdi%26aufirst%3DA.%2BK.%26aulast%3DSantra%26aufirst%3DS.%26aulast%3DMonir%26aufirst%3DK.%26aulast%3DHajra%26aufirst%3DA.%26atitle%3DSynthesis%2520of%2520imidazo%255B1%252C2-a%255Dpyridines%253A%2520A%2520Decade%2520Update%26jtitle%3DChem.%2520Commun.%26date%3D2015%26volume%3D51%26spage%3D1555%26epage%3D1575%26doi%3D10.1039%2FC4CC08495K" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Devi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rawal, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, V.</span><span> </span><span class="NLM_article-title">Diversity-Oriented Synthesis of Fused-Imidazole Derivatives via Groebke–Blackburn–Bienayme Reaction: A Review</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">183</span><span class="NLM_x">–</span> <span class="NLM_lpage">232</span><span class="refDoi"> DOI: 10.1016/j.tet.2014.10.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1016%2Fj.tet.2014.10.032" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2015&pages=183-232&author=N.+Deviauthor=R.+K.+Rawalauthor=V.+Singh&title=Diversity-Oriented+Synthesis+of+Fused-Imidazole+Derivatives+via+Groebke%E2%80%93Blackburn%E2%80%93Bienayme+Reaction%3A+A+Review&doi=10.1016%2Fj.tet.2014.10.032"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2014.10.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2014.10.032%26sid%3Dliteratum%253Aachs%26aulast%3DDevi%26aufirst%3DN.%26aulast%3DRawal%26aufirst%3DR.%2BK.%26aulast%3DSingh%26aufirst%3DV.%26atitle%3DDiversity-Oriented%2520Synthesis%2520of%2520Fused-Imidazole%2520Derivatives%2520via%2520Groebke%25E2%2580%2593Blackburn%25E2%2580%2593Bienayme%2520Reaction%253A%2520A%2520Review%26jtitle%3DTetrahedron%26date%3D2015%26volume%3D71%26spage%3D183%26epage%3D232%26doi%3D10.1016%2Fj.tet.2014.10.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Crestani, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Möhler, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, U.</span><span> </span><span class="NLM_article-title">Mechanism of action of the hypnotic zolpidem <i>in vivo</i></span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x">, </span> <span class="NLM_fpage">1251</span><span class="NLM_x">–</span> <span class="NLM_lpage">1254</span><span class="refDoi"> DOI: 10.1038/sj.bjp.0703717</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1038%2Fsj.bjp.0703717" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=11090095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BD3cXovFygt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2000&pages=1251-1254&author=F.+Crestaniauthor=J.+R.+Martinauthor=H.+M%C3%B6hlerauthor=U.+Rudolph&title=Mechanism+of+action+of+the+hypnotic+zolpidem+in+vivo&doi=10.1038%2Fsj.bjp.0703717"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18cR"><div class="casContent"><span class="casTitleNuber">18c</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of action of the hypnotic zolpidem in vivo</span></div><div class="casAuthors">Crestani, Florence; Martin, James R.; Mohler, Hanns; Rudolph, Uwe</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1251-1254</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Zolpidem is a widely used hypnotic agent acting at the GABAA receptor benzodiazepine site.  On recombinant receptors, zolpidem displays a high affinity to α1-GABAA receptors, an intermediate affinity to α2- and α3-GABAA receptors and fails to bind to α5-GABAA receptors.  However, it is not known which receptor subtype is essential for mediating the sedative-hypnotic action in vivo.  Studying α1(H101R) mice, which possess zolpidem-insensitive α1-GABAA receptors, we show that the sedative action of zolpidem is exclusively mediated by α1-GABAA receptors.  Similarly, the activity of zolpidem against pentylenetetrazole-induced tonic convulsions is also completely mediated by α1-GABAA receptors.  These results establish that the sedative-hypnotic and anticonvulsant activities of zolpidem are due to its action on α1-GABAA receptors and not on α2- or α3-GABAA receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw0ldi7hhL07Vg90H21EOLACvtfcHk0ljeJ4RavNAQFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXovFygt7o%253D&md5=f1d50d8f6e1ee6e1781068d02cd301de</span></div><a href="/servlet/linkout?suffix=cit18c&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0703717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0703717%26sid%3Dliteratum%253Aachs%26aulast%3DCrestani%26aufirst%3DF.%26aulast%3DMartin%26aufirst%3DJ.%2BR.%26aulast%3DM%25C3%25B6hler%26aufirst%3DH.%26aulast%3DRudolph%26aufirst%3DU.%26atitle%3DMechanism%2520of%2520action%2520of%2520the%2520hypnotic%2520zolpidem%2520in%2520vivo%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2000%26volume%3D131%26spage%3D1251%26epage%3D1254%26doi%3D10.1038%2Fsj.bjp.0703717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Mizushige, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yukiiri, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, H.</span><span> </span><span class="NLM_article-title">Olprinone: A Phosphodiesterase III Inhibitor with Positive Inotropic and Vasodilator Effects</span> <span class="citation_source-journal">Cardiovasc. Drug Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">163</span><span class="NLM_x">–</span> <span class="NLM_lpage">174</span><span class="refDoi"> DOI: 10.1111/j.1527-3466.2002.tb00085.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1111%2Fj.1527-3466.2002.tb00085.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=12397365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BD38XovVWnsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=163-174&author=K.+Mizushigeauthor=T.+Uedaauthor=K.+Yukiiriauthor=H.+Suzuki&title=Olprinone%3A+A+Phosphodiesterase+III+Inhibitor+with+Positive+Inotropic+and+Vasodilator+Effects&doi=10.1111%2Fj.1527-3466.2002.tb00085.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18dR"><div class="casContent"><span class="casTitleNuber">18d</span><div class="casTitle"><span class="NLM_cas:atitle">Olprinone: a phosphodiesterase III inhibitor with positive inotropic and vasodilator effects</span></div><div class="casAuthors">Mizushige, Katsufumi; Ueda, Takashi; Yukiiri, Kazushi; Suzuki, Hitoshi</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Drug Reviews</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">163-174</span>CODEN:
                <span class="NLM_cas:coden">CDREEA</span>;
        ISSN:<span class="NLM_cas:issn">0897-5957</span>.
    
            (<span class="NLM_cas:orgname">Neva Press</span>)
        </div><div class="casAbstract">A review.  Olprinone is a newly developed phosphodiesterase III inhibitor characterized by several properties.  First, olprinone has pos. inotropic and vasodilator actions and improves myocardial mech. efficiency.  Second, olprinone augments cerebral blood flow by a direct vasodilatory effect on cerebral arteries.  The cerebrovascular reactivity to olprinone is marked in patients with impaired cerebral circulation.  Third, olprinone selectively improves carotid artery distensibility, which may be attributable to differences in the arterial structural components or the reactivity of smooth muscle cells to olprinone.  Fourth, olprinone improves inadequate redistribution of brain perfusion and may prevent cerebral metabolic abnormalities in heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpErFNpkZl4ibVg90H21EOLACvtfcHk0lgrgcoGAdwr-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovVWnsrg%253D&md5=79bb45d7a8667d38d0bf1ce79cd90ff2</span></div><a href="/servlet/linkout?suffix=cit18d&amp;dbid=16384&amp;doi=10.1111%2Fj.1527-3466.2002.tb00085.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1527-3466.2002.tb00085.x%26sid%3Dliteratum%253Aachs%26aulast%3DMizushige%26aufirst%3DK.%26aulast%3DUeda%26aufirst%3DT.%26aulast%3DYukiiri%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DH.%26atitle%3DOlprinone%253A%2520A%2520Phosphodiesterase%2520III%2520Inhibitor%2520with%2520Positive%2520Inotropic%2520and%2520Vasodilator%2520Effects%26jtitle%3DCardiovasc.%2520Drug%2520Rev.%26date%3D2002%26volume%3D20%26spage%3D163%26epage%3D174%26doi%3D10.1111%2Fj.1527-3466.2002.tb00085.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Boggs, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elitzin, V. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gudmundsson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharp, M. J.</span><span> </span><span class="NLM_article-title">CXCR4 Antagonist (GSK812397)</span> <span class="citation_source-journal">Synfacts</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">2010</span><span class="NLM_x">, </span> <span class="NLM_fpage">0011</span><span class="refDoi"> DOI: 10.1055/s-0029-1218261</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1055%2Fs-0029-1218261" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2010&publication_year=2010&pages=0011&author=S.+Boggsauthor=V.+I.+Elitzinauthor=K.+Gudmundssonauthor=M.+T.+Martinauthor=M.+J.+Sharp&title=CXCR4+Antagonist+%28GSK812397%29&doi=10.1055%2Fs-0029-1218261"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18e&amp;dbid=16384&amp;doi=10.1055%2Fs-0029-1218261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0029-1218261%26sid%3Dliteratum%253Aachs%26aulast%3DBoggs%26aufirst%3DS.%26aulast%3DElitzin%26aufirst%3DV.%2BI.%26aulast%3DGudmundsson%26aufirst%3DK.%26aulast%3DMartin%26aufirst%3DM.%2BT.%26aulast%3DSharp%26aufirst%3DM.%2BJ.%26atitle%3DCXCR4%2520Antagonist%2520%2528GSK812397%2529%26jtitle%3DSynfacts%26date%3D2010%26volume%3D2010%26spage%3D0011%26doi%3D10.1055%2Fs-0029-1218261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Hartman, G. D.; Weinstock, L. M.</span><span> </span><span class="NLM_article-title">Thiazoles from Ethyl Isocyanoacetate and Thiono Esters: Ethyl Thiazole-4-Carboxylate</span>.  <span class="citation_source-book">Organic Syntheses</span>; <span class="NLM_publisher-name">John Wiley & Sons</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">1988</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">6</span>, p  <span class="NLM_fpage">620</span>, <span class="refDoi"> DOI: 10.1002/0471264180.os059.26</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1002%2F0471264180.os059.26" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1988&pages=620&author=G.+D.+Hartman&author=L.+M.+Weinstock&title=Organic+Syntheses"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2F0471264180.os059.26&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F0471264180.os059.26%26sid%3Dliteratum%253Aachs%26aulast%3DHartman%26aufirst%3DG.%2BD.%26atitle%3DThiazoles%2520from%2520Ethyl%2520Isocyanoacetate%2520and%2520Thiono%2520Esters%253A%2520Ethyl%2520Thiazole-4-Carboxylate%26btitle%3DOrganic%2520Syntheses%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%26date%3D1988%26volume%3D6%26spage%3D620%26doi%3D10.1002%2F0471264180.os059.26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Obrecht, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ugi, I.</span><span> </span><span class="NLM_article-title">Isocyanide Synthesis with Phosphoryl Chloride and Diisopropylamine</span> <span class="citation_source-journal">Synthesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">1985</span><span class="NLM_x">, </span> <span class="NLM_fpage">400</span><span class="refDoi"> DOI: 10.1055/s-1985-31216</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1055%2Fs-1985-31216" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1985&publication_year=1985&pages=400&author=R.+Obrechtauthor=R.+Herrmannauthor=I.+Ugi&title=Isocyanide+Synthesis+with+Phosphoryl+Chloride+and+Diisopropylamine&doi=10.1055%2Fs-1985-31216"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1055%2Fs-1985-31216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1985-31216%26sid%3Dliteratum%253Aachs%26aulast%3DObrecht%26aufirst%3DR.%26aulast%3DHerrmann%26aufirst%3DR.%26aulast%3DUgi%26aufirst%3DI.%26atitle%3DIsocyanide%2520Synthesis%2520with%2520Phosphoryl%2520Chloride%2520and%2520Diisopropylamine%26jtitle%3DSynthesis%26date%3D1985%26volume%3D1985%26spage%3D400%26doi%3D10.1055%2Fs-1985-31216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Dömling, A.</span><span> </span><span class="NLM_article-title">Recent Developments in Isocyanide Based Multicomponent Reactions in Applied Chemistry</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">17</span><span class="NLM_x">–</span> <span class="NLM_lpage">89</span><span class="refDoi"> DOI: 10.1021/cr0505728</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr0505728" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A280%3ADC%252BD28%252FhslyntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2006&pages=17-89&author=A.+D%C3%B6mling&title=Recent+Developments+in+Isocyanide+Based+Multicomponent+Reactions+in+Applied+Chemistry&doi=10.1021%2Fcr0505728"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments in isocyanide based multicomponent reactions in applied chemistry</span></div><div class="casAuthors">Domling Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Chemical reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-89</span>
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRtCMEx7SbgjiM8MEzWGjS9fW6udTcc2eZ7bKGz_tzt2bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28%252FhslyntA%253D%253D&md5=33b233fa9ca718d7e0e6db6fee49e5fd</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fcr0505728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr0505728%26sid%3Dliteratum%253Aachs%26aulast%3DD%25C3%25B6mling%26aufirst%3DA.%26atitle%3DRecent%2520Developments%2520in%2520Isocyanide%2520Based%2520Multicomponent%2520Reactions%2520in%2520Applied%2520Chemistry%26jtitle%3DChem.%2520Rev.%26date%3D2006%26volume%3D106%26spage%3D17%26epage%3D89%26doi%3D10.1021%2Fcr0505728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">DiMauro, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, J. M.</span><span> </span><span class="NLM_article-title">Rapid Synthesis of 3-Amino-imidazopyridines by a Microwave-Assisted Four-Component Coupling in One Pot</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">1013</span><span class="NLM_x">–</span> <span class="NLM_lpage">1016</span><span class="refDoi"> DOI: 10.1021/jo0622072</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo0622072" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlKjsr%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2007&pages=1013-1016&author=E.+F.+DiMauroauthor=J.+M.+Kennedy&title=Rapid+Synthesis+of+3-Amino-imidazopyridines+by+a+Microwave-Assisted+Four-Component+Coupling+in+One+Pot&doi=10.1021%2Fjo0622072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid synthesis of 3-amino-imidazopyridines by a microwave-assisted four-component coupling in one pot</span></div><div class="casAuthors">DiMauro, Erin F.; Kennedy, Joseph M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1013-1016</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The rapid and efficient synthesis of various 2,6-disubstituted-3-amino-imidazopyridines, e.g., I, using a microwave-assisted one-pot cyclization/Suzuki coupling approach was described.  The utility of a 2-aminopyridine-5-boronic acid pinacol ester as a robust and versatile building block for the synthesis of diverse compd. libraries was emphasized.  The boronate functional group was remarkably tolerant to the Lewis acid catalyzed cyclizations, and the subsequent Pd(0)-catalyzed Suzuki coupling reactions proceeded cleanly in the presence of magnesium salts.  This work highlighted the vast potential of microwave-assisted, metal-catalyzed, multicomponent reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpr8UZw-6qpPLVg90H21EOLACvtfcHk0lh9c77OatU-UQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlKjsr%252FF&md5=14f67b20d79fe674129cf82522211c28</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjo0622072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0622072%26sid%3Dliteratum%253Aachs%26aulast%3DDiMauro%26aufirst%3DE.%2BF.%26aulast%3DKennedy%26aufirst%3DJ.%2BM.%26atitle%3DRapid%2520Synthesis%2520of%25203-Amino-imidazopyridines%2520by%2520a%2520Microwave-Assisted%2520Four-Component%2520Coupling%2520in%2520One%2520Pot%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2007%26volume%3D72%26spage%3D1013%26epage%3D1016%26doi%3D10.1021%2Fjo0622072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Lyon, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kercher, T. S.</span><span> </span><span class="NLM_article-title">Glyoxylic Acid and MP-Glyoxylate: Efficient Formaldehyde Equivalents in the 3-CC of 2-Aminoazines, Aldehydes, and Isonitriles</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">4989</span><span class="NLM_x">–</span> <span class="NLM_lpage">4992</span><span class="refDoi"> DOI: 10.1021/ol0478234</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol0478234" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=4989-4992&author=M.+A.+Lyonauthor=T.+S.+Kercher&title=Glyoxylic+Acid+and+MP-Glyoxylate%3A+Efficient+Formaldehyde+Equivalents+in+the+3-CC+of+2-Aminoazines%2C+Aldehydes%2C+and+Isonitriles&doi=10.1021%2Fol0478234"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fol0478234&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol0478234%26sid%3Dliteratum%253Aachs%26aulast%3DLyon%26aufirst%3DM.%2BA.%26aulast%3DKercher%26aufirst%3DT.%2BS.%26atitle%3DGlyoxylic%2520Acid%2520and%2520MP-Glyoxylate%253A%2520Efficient%2520Formaldehyde%2520Equivalents%2520in%2520the%25203-CC%2520of%25202-Aminoazines%252C%2520Aldehydes%252C%2520and%2520Isonitriles%26jtitle%3DOrg.%2520Lett.%26date%3D2004%26volume%3D6%26spage%3D4989%26epage%3D4992%26doi%3D10.1021%2Fol0478234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Kiesewetter, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scholten, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirn, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hedrick, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waymouth, R. M.</span><span> </span><span class="NLM_article-title">Cyclic Guanidine Organic Catalysts: What Is Magic about Triazabicyclodecene?</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">9490</span><span class="NLM_x">–</span> <span class="NLM_lpage">9496</span><span class="refDoi"> DOI: 10.1021/jo902369g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo902369g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVKhs7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2009&pages=9490-9496&author=M.+K.+Kiesewetterauthor=M.+D.+Scholtenauthor=N.+Kirnauthor=R.+L.+Weberauthor=J.+L.+Hedrickauthor=R.+M.+Waymouth&title=Cyclic+Guanidine+Organic+Catalysts%3A+What+Is+Magic+about+Triazabicyclodecene%3F&doi=10.1021%2Fjo902369g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclic guanidine organic catalysts: What is magic about triazabicyclodecene?</span></div><div class="casAuthors">Kiesewetter, Matthew K.; Scholten, Marc D.; Kirn, Nicole; Weber, Ryan L.; Hedrick, James L.; Waymouth, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9490-9496</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The bicyclic guanidine 1,5,7-triazabicyclo[4.4.0]dec-5-ene (TBD) is an effective organocatalyst for the formation of amides from esters and primary amines.  Mechanistic and kinetic studies support a nucleophilic mechanism where TBD reacts reversibly with esters to generate an acyl-TBD intermediate that acylates amines to generate the amides.  Comparative studies of the analogous bicyclic guanidine 1,4,6-triazabicyclo[3.3.0]oct-4-ene (TBO) reveal it to be a much less active acylation catalyst than TBD.  Theor. and mechanistic studies imply that the higher reactivity of TBD is a consequence of both its higher basicity and nucleophilicity than TBO and the high reactivity of the acyl-TBD intermediate, which is sterically prevented from adopting a planar amide structure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9dztZtVWNcrVg90H21EOLACvtfcHk0lh9c77OatU-UQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVKhs7nP&md5=0f263f5a0f48749b17ed6bbd486e7f32</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjo902369g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo902369g%26sid%3Dliteratum%253Aachs%26aulast%3DKiesewetter%26aufirst%3DM.%2BK.%26aulast%3DScholten%26aufirst%3DM.%2BD.%26aulast%3DKirn%26aufirst%3DN.%26aulast%3DWeber%26aufirst%3DR.%2BL.%26aulast%3DHedrick%26aufirst%3DJ.%2BL.%26aulast%3DWaymouth%26aufirst%3DR.%2BM.%26atitle%3DCyclic%2520Guanidine%2520Organic%2520Catalysts%253A%2520What%2520Is%2520Magic%2520about%2520Triazabicyclodecene%253F%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2009%26volume%3D74%26spage%3D9490%26epage%3D9496%26doi%3D10.1021%2Fjo902369g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Joossens, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van der Veken, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surpateanu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambeir, A.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Sayed, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Augustyns, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haemers, A.</span><span> </span><span class="NLM_article-title">Diphenyl Phosphonate Inhibitors for the Urokinase-Type Plasminogen Activator: Optimization of the P4 Position</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">5785</span><span class="NLM_x">–</span> <span class="NLM_lpage">5793</span><span class="refDoi"> DOI: 10.1021/jm060622g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060622g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5785-5793&author=J.+Joossensauthor=P.+Van+der+Vekenauthor=G.+Surpateanuauthor=A.-M.+Lambeirauthor=I.+El-Sayedauthor=O.+M.+Aliauthor=K.+Augustynsauthor=A.+Haemers&title=Diphenyl+Phosphonate+Inhibitors+for+the+Urokinase-Type+Plasminogen+Activator%3A+Optimization+of+the+P4+Position&doi=10.1021%2Fjm060622g"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm060622g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060622g%26sid%3Dliteratum%253Aachs%26aulast%3DJoossens%26aufirst%3DJ.%26aulast%3DVan%2Bder%2BVeken%26aufirst%3DP.%26aulast%3DSurpateanu%26aufirst%3DG.%26aulast%3DLambeir%26aufirst%3DA.-M.%26aulast%3DEl-Sayed%26aufirst%3DI.%26aulast%3DAli%26aufirst%3DO.%2BM.%26aulast%3DAugustyns%26aufirst%3DK.%26aulast%3DHaemers%26aufirst%3DA.%26atitle%3DDiphenyl%2520Phosphonate%2520Inhibitors%2520for%2520the%2520Urokinase-Type%2520Plasminogen%2520Activator%253A%2520Optimization%2520of%2520the%2520P4%2520Position%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5785%26epage%3D5793%26doi%3D10.1021%2Fjm060622g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Sperl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacob, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arroyo de Prada, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stürzebecher, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilhelm, O. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bode, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magdolen, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huber, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moroder, L.</span><span> </span><span class="NLM_article-title">(4-Aminomethyl)Phenylguanidine Derivatives As Nonpeptidic Highly Selective Inhibitors of Human Urokinase</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">5113</span><span class="NLM_x">–</span> <span class="NLM_lpage">5118</span><span class="refDoi"> DOI: 10.1073/pnas.97.10.5113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1073%2Fpnas.97.10.5113" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2000&pages=5113-5118&author=S.+Sperlauthor=U.+Jacobauthor=N.+Arroyo+de+Pradaauthor=J.+St%C3%BCrzebecherauthor=O.+G.+Wilhelmauthor=W.+Bodeauthor=V.+Magdolenauthor=R.+Huberauthor=L.+Moroder&title=%284-Aminomethyl%29Phenylguanidine+Derivatives+As+Nonpeptidic+Highly+Selective+Inhibitors+of+Human+Urokinase&doi=10.1073%2Fpnas.97.10.5113"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1073%2Fpnas.97.10.5113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.97.10.5113%26sid%3Dliteratum%253Aachs%26aulast%3DSperl%26aufirst%3DS.%26aulast%3DJacob%26aufirst%3DU.%26aulast%3DArroyo%2Bde%2BPrada%26aufirst%3DN.%26aulast%3DSt%25C3%25BCrzebecher%26aufirst%3DJ.%26aulast%3DWilhelm%26aufirst%3DO.%2BG.%26aulast%3DBode%26aufirst%3DW.%26aulast%3DMagdolen%26aufirst%3DV.%26aulast%3DHuber%26aufirst%3DR.%26aulast%3DMoroder%26aufirst%3DL.%26atitle%3D%25284-Aminomethyl%2529Phenylguanidine%2520Derivatives%2520As%2520Nonpeptidic%2520Highly%2520Selective%2520Inhibitors%2520of%2520Human%2520Urokinase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2000%26volume%3D97%26spage%3D5113%26epage%3D5118%26doi%3D10.1073%2Fpnas.97.10.5113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span>Inhibitor Expert (Inhibitors, Compound Libraries; <span class="NLM_publisher-name">Selleck Chemicals</span>: <span class="NLM_publisher-loc">Houston, TX</span>,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">; </span><a href="http://www.selleckchem.com" class="extLink">http://www.selleckchem.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Inhibitor+Expert+%28Inhibitors%2C+Compound+Libraries%3B+Selleck+Chemicals%3A+Houston%2C+TX%2C+2013%3B+http%3A%2F%2Fwww.selleckchem.com."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DInhibitor%2520Expert%2520%2528Inhibitors%252C%2520Compound%2520Libraries%26pub%3DSelleck%2520Chemicals%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span>Enzo Life Sciences; <span class="NLM_publisher-name">Enzo Life Sciences, Inc.</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span><a href="http://www.enzolifesciences.com" class="extLink">http://www.enzolifesciences.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Enzo+Life+Sciences%3B+Enzo+Life+Sciences%2C+Inc.%2C+2015%3B+http%3A%2F%2Fwww.enzolifesciences.com."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DEnzo%2520Life%2520Sciences%26pub%3DEnzo%2520Life%2520Sciences%252C%2520Inc%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Zhao, G.; Yuan, C.; Jiang, L.; Huang, Z.; Huang, M.</span> (submitted for publication).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Zhao%2C+G.%3B+Yuan%2C+C.%3B+Jiang%2C+L.%3B+Huang%2C+Z.%3B+Huang%2C+M.+%28submitted+for+publication%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DG." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Berman, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westbrook, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhat, T. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissig, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shindyalov, I. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourne, P. E.</span><span> </span><span class="NLM_article-title">The Protein Data Bank</span> <span class="citation_source-journal">Nucleic Acids Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">242</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1093%2Fnar%2F28.1.235" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10592235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhvVKjt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2000&pages=235-242&author=H.+M.+Bermanauthor=J.+Westbrookauthor=Z.+Fengauthor=G.+Gillilandauthor=T.+N.+Bhatauthor=H.+Weissigauthor=I.+N.+Shindyalovauthor=P.+E.+Bourne&title=The+Protein+Data+Bank"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">The Protein Data Bank</span></div><div class="casAuthors">Berman, Helen M.; Westbrook, John; Feng, Zukang; Gilliland, Gary; Bhat, T. N.; Weissig, Helge; Shindyalov, Ilya N.; Bourne, Philip E.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">235-242</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The Protein Data Bank (PDB; http://www.rcsb.org/pdb/)is the single worldwide archive of structural data of biol. macromols.  This paper describes the goals of the PDB, the systems in place for data deposition and access, how to obtain further information, and near-term plans for the future development of the resource.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpStGCxT8QzirVg90H21EOLACvtfcHk0lhehtzgHbxgqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhvVKjt7w%253D&md5=227fb393f754be2be375ab727bfd05dc</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1093%2Fnar%2F28.1.235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252F28.1.235%26sid%3Dliteratum%253Aachs%26aulast%3DBerman%26aufirst%3DH.%2BM.%26aulast%3DWestbrook%26aufirst%3DJ.%26aulast%3DFeng%26aufirst%3DZ.%26aulast%3DGilliland%26aufirst%3DG.%26aulast%3DBhat%26aufirst%3DT.%2BN.%26aulast%3DWeissig%26aufirst%3DH.%26aulast%3DShindyalov%26aufirst%3DI.%2BN.%26aulast%3DBourne%26aufirst%3DP.%2BE.%26atitle%3DThe%2520Protein%2520Data%2520Bank%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2000%26volume%3D28%26spage%3D235%26epage%3D242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span>PyMol: The PyMOL Molecular Graphics System, <span class="NLM_edition">version 1.5.0.4</span>; <span class="NLM_publisher-name">Schrödinger LLC</span>; <a href="http://www.pymol.org" class="extLink">http://www.pymol.org</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=PyMol%3A+The+PyMOL+Molecular+Graphics+System%2C+version+1.5.0.4%3B+Schr%C3%B6dinger+LLC%3B+http%3A%2F%2Fwww.pymol.org."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520PyMOL%2520Molecular%2520Graphics%2520System%26pub%3DSchr%25C3%25B6dinger%2520LLC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Morris, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindstrom, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanner, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belew, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodsell, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. J.</span><span> </span><span class="NLM_article-title">Autodock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexiblity</span> <span class="citation_source-journal">J. Comput. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">2785</span><span class="NLM_x">–</span> <span class="NLM_lpage">2791</span><span class="refDoi"> DOI: 10.1002/jcc.21256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=10.1002%2Fjcc.21256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=19399780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1GitrnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=2785-2791&author=G.+M.+Morrisauthor=R.+Hueyauthor=W.+Lindstromauthor=M.+F.+Sannerauthor=R.+K.+Belewauthor=D.+S.+Goodsellauthor=A.+J.+Olson&title=Autodock4+and+AutoDockTools4%3A+Automated+Docking+with+Selective+Receptor+Flexiblity&doi=10.1002%2Fjcc.21256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">AutoDock and AutoDockTools: Automated docking with selective receptor flexibility</span></div><div class="casAuthors">Morris, Garrett M.; Huey, Ruth; Lindstrom, William; Sanner, Michel F.; Belew, Richard K.; Goodsell, David S.; Olson, Arthur J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2785-2791</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">We describe the testing and release of AutoDock4 and the accompanying graphical user interface AutoDockTools.  AutoDock4 incorporates limited flexibility in the receptor.  Several tests are reported here, including a redocking expt. with 188 diverse ligand-protein complexes and a cross-docking expt. using flexible sidechains in 87 HIV protease complexes.  We also report its utility in anal. of covalently bound ligands, using both a grid-based docking method and a modification of the flexible sidechain technique. © 2009 Wiley Periodicals, Inc.  J Comput Chem, 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqktE6WAo4GEbVg90H21EOLACvtfcHk0lhehtzgHbxgqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1GitrnK&md5=679ce22fc50e9291c9aa16e7a1855845</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fjcc.21256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.21256%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DG.%2BM.%26aulast%3DHuey%26aufirst%3DR.%26aulast%3DLindstrom%26aufirst%3DW.%26aulast%3DSanner%26aufirst%3DM.%2BF.%26aulast%3DBelew%26aufirst%3DR.%2BK.%26aulast%3DGoodsell%26aufirst%3DD.%2BS.%26aulast%3DOlson%26aufirst%3DA.%2BJ.%26atitle%3DAutodock4%2520and%2520AutoDockTools4%253A%2520Automated%2520Docking%2520with%2520Selective%2520Receptor%2520Flexiblity%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2009%26volume%3D30%26spage%3D2785%26epage%3D2791%26doi%3D10.1002%2Fjcc.21256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2O8W" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2O8W','PDB','2O8W'); return false;">PDB: 2O8W</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i125"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01171">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_18188"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.5b01171">10.1021/acs.jmedchem.5b01171</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Detailed synthetic procedures and analytical data for the synthesized compounds together with extended inhibitory screening data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01171/suppl_file/jm5b01171_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01171/suppl_file/jm5b01171_si_001.pdf">jm5b01171_si_001.pdf (348.91 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.5b01171&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.5b01171%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2015.58.issue-23%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.5b01171" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799760a3e111252","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
